Detailed Schedule - Tuesday, April 8

Transcription

13_14AM_Tue_Layout 1 3/11/14 12:43 PM Page 429
TUESDAY, APRIL 8
AT-A-GLANCE
All sessions eligible for CME credit
unless otherwise noted.
7:00 a.m.-8:00 a.m.
Special Session
431
7:00 a.m.-8:00 a.m.
Meet-the-Expert Sessions
432-435
8:00 a.m.-12:00 p.m.
Poster Sessions
436-471
8:00 a.m.-12:00 p.m.
Late-Breaking Poster Sessions
472
8:15 a.m.-10:15 a.m.
Plenary Session
473
8:30 a.m.-2:00 p.m.
Science Ed Professional Advancement Session
474
10:30 a.m.-12:00 p.m.
NCI/NIH-Sponsored Session
475
10:30 a.m.-12:30 p.m.
Clinical Trials Symposium
476
10:30 a.m.-12:30 p.m.
Current Concepts in Diagnostics
and Therapeutics Research
477
10:30 a.m.-12:30 p.m.
Current Concepts in Epidemiology
and Prevention Research
478
10:30 a.m.-12:30 p.m.
Current Concepts in Organ Site Research
479-480
10:30 a.m.-12:30 p.m.
Major Symposia
481-484
10:30 a.m.-12:30 p.m.
485
10:30 a.m.-12:30 p.m.
AMC Professional Advancement Session
486
10:30 a.m.-12:30 p.m.
Pancreatic Cancer Action Network
Special Session
487-488
10:30 a.m.-12:30 p.m.
Regulatory Science and Policy Session
489
10:30 a.m.-12:30 p.m.
PCWG Special Session
490
12:00 p.m.-1:30 p.m.
491-492
1:00 p.m.-2:00 p.m.
Career Conversations
493
1:00 p.m.-2:30 p.m.
AMC Professional Advancement Session
494
1:00 p.m.-3:00 p.m.
Clinical Trials Minisymposium
495
April 5-9, 2014 • San Diego, CA
429
TUESDAY, APRIL 8
AT-A-GLANCE
All sessions eligible for CME credit
unless otherwise noted.
1:00 p.m.-3:00 p.m.
Current Concepts in Diagnostics
and Therapeutics Research
496
1:00 p.m.-3:00 p.m.
Current Concepts in Organ Site Research
497-499
1:00 p.m.-3:00 p.m.
Major Symposia
500-503
1:00 p.m.-3:00 p.m.
504
1:00 p.m.-5:00 p.m.
Poster Sessions
505-539
1:00 p.m.-5:00 p.m.
Late-Breaking Poster Sessions
540
1:30 p.m.-3:30 p.m.
541
2:30 p.m.-3:30 p.m.
Career Conversations
542
2:30 p.m.-3:30 p.m.
Meet the Mentor: Undergraduate Focus
542
3:00 p.m.-4:00 p.m.
AACR CICR Award Lecture
543
3:00 p.m.-4:00 p.m.
AACR-ACS Award Lecture
544
3:00 p.m.-5:00 p.m.
Major Symposium
545
3:00 p.m.-5:00 p.m.
Clinical Trials Minisymposium
546
3:00 p.m.-5:00 p.m.
Late-Breaking Minisymposium
547
3:00 p.m.-5:00 p.m.
Major Symposium
548
3:00 p.m.-5:00 p.m.
Minisymposia
549-553
3:00 p.m.-5:00 p.m.
554
3:30 p.m.-4:30 p.m.
Meet the Director of CRCHD
555
3:30 p.m.-5:30 p.m.
556
4:00 p.m.-5:00 p.m.
AACR Burchenal Award Lecture
557
4:00 p.m.-5:00 p.m.
AACR Rosenthal Award Lecture
558
5:00 p.m.-6:30 p.m.
Forums
559-560
5:00 p.m.-6:30 p.m.
RAS Interactome Session
561
6:00 p.m.-8:30 p.m.
CIMM Town Meeting
562
430
AACR ANNUAL MEETING 2014
SPECIAL SESSION
Tuesday, 7:00 a.m.-8:00 a.m.
(not eligible for CME credit)
Room 1, San Diego Convention Center
imPatient-Driven Science: Engaging a Restless Public in Research
Moderator: Susan M. Love, Dr. Susan Love Research Foundation, Santa Monica, CA
The Love Army of Women (AOW) has existed for five and a half years. It was designed to
accelerate translational research by facilitating the recruitment of women to participate in studies
aimed at identifying the causes of breast cancer. The response from the public has been strong;
however, much of the scientific community appears reluctant to engage the public in their work.
Meanwhile, the patient/public population has become increasingly impatient with the rate of
clinically relevant discoveries from cancer research.
In an effort to directly engage its membership with research, the Dr. Susan Love Research
Foundation (DSLRF) launched the Health of Women Study in October 2012. This online study
represents a cohort of women and men with and without breast cancer. The DSLRF has since
gathered crowdsourced questions, allowing people the opportunity to highlight topics that they
feel require further investigation, such as what are the underlying mechanisms causing breast
cancer and how can we best eliminate treatment-associated toxicities and side effects. The
DSLRF found that while patients are grateful for their survival, there is a consensus that more
research is needed to document and understand the long-lasting effects of breast cancer
treatment regimes. As a first effort in the fall of 2013, the DSLRF, along with similar advocacy
groups, launched a collaborative project focused on gathering topics and questions from breast
cancer patients of all ages, genders, and stages with the hope of documenting the true cost of the
cure, the collateral damage experienced by patients, while simultaneously stimulating a greater
public interest in the research process.
Panel:
Carla V. Finkielstein, Virginia Polytechnic Institute and State University, Blacksburg, VA
Christine Fischetti, Dr. Susan Love Research Foundation, Santa Monica, CA
Karla Lancaster, Dr. Susan Love Research Foundation, Santa Monica, CA
Harikrishna Nakshatri, Indiana University Simon Cancer Center, Indianapolis, IN
Michele Rakoff, Breast Cancer Care and Research Fund, Los Angeles, CA
431
MEET-THE-EXPERT SESSIONS
Room 28A-C, San Diego Convention Center
Alcohol and Cancer: Modest
Cardiovascular Disease Benefits but
Many Cancer and Other Risks
Cancer Cell Migration, Invasion,
and Metastasis
Susan M. Gapstur, American Cancer Society, Atlanta, GA
While drinking low to moderate amounts of alcohol is
linked to a reduced risk of heart disease, drinking too
much alcohol increases risk of high blood pressure,
heart failure, sudden death, and stroke. Moreover,
alcohol drinking is a cause of cancers at eight different
anatomic sites, including breast cancer, the most
commonly diagnosed cancer among women in the U.S.
and worldwide. However, the scientific evidence linking
alcohol to several other cancer sites is limited. My recent
research has focused on examining associations of
alcohol drinking with cancer sites where the evidence is
limited using data collected from the Cancer Prevention
Study-II, a large cohort of U.S. men and women followed
for cancer mortality since 1982, and from a subset of this
cohort followed for cancer incidence since 1992. Data
from this cohort allow us to examine associations with
different alcohol beverage types and to disentangle the
effects cigarette smoking from that of alcohol drinking.
Room 6B, San Diego Convention Center
Antibody Therapy for Cancer: Targeting
the Tumor and Targeting the Host
Ronald Levy, Stanford University, Stanford, CA
Sara A. Courtneidge, Sanford-Burnham Medical
Research Institute, La Jolla, CA
Cell invasion plays a central role in a wide variety of
biological phenomena, and is the cause of tumor growth
and metastasis. Understanding the biochemical
mechanisms that control cell invasion is one of the major
goals of our laboratory. Podosomes and invadopodia are
specialized cellular structures present in cells with
physiological or pathological invasive behaviors. These
transient structures are localized at the ventral cell
surface, contain an array of different proteins, and
facilitate cell-substrate adhesion as well as the local
proteolytic activity necessary for extracellular matrix
remodeling and subsequent cellular invasion. We have
shown that the adaptor proteins and Src substrates Tks4
and Tks5 are required for podosome and invadopodia
formation, for cell migration during development, for
cancer cell invasion in vitro, and for tumor growth in vivo.
Inhibitors of podosome and invadopodia formation might
have utility in the treatment of vascular diseases and
cancer. We have developed a high content, cell-based
high-throughput screening assay to quantify
podosome/invadopodia formation, and screened a
diversity set of small-molecule inhibitors as well as a
library of siRNAs targeting the entire kinome. The
mechanisms by which select compounds and kinases
regulate invadopodia formation are the subject of our
current investigations.
Great advances have been made using monoclonal
antibodies and their derivatives for the treatment of
cancer. These agents have changed the standard of care
of a number of malignancies, including lymphoma,
leukemia, breast, colon, and head and neck cancer, with
regression of tumor and extension of life having been
achieved. These agents have been great commercial
successes. However, very few patients with these
diseases are being cured. Most recently, antibodies have
been developed that target the host immune system in
various ways to enhance the power of antibodies
targeted against the tumor, as well as the power of other
antitumor therapies. We can look forward to a time when
highly effective combinations of antibodies and small
targeted molecules will result in a greater number of
patients being cured.
432
Tuesday, 7:00 a.m.-8:00 a.m.
Room 29A-D, San Diego Convention Center
Cancer Genome Landscapes
Through Tissue and Blood-Based
Molecular Analyses
Colorectal Cancer Risk Factors: Does
Molecular Subtype Matter?
Victor E. Velculescu, Johns Hopkins Kimmel
Comprehensive Cancer Center, Baltimore, MD
Analyses of cancer genomes have revealed mechanisms
underlying tumorigenesis and new avenues for
therapeutic intervention. In this session, I will discuss
lessons learned through the characterization of cancer
genome landscapes, challenges in translating these
analyses to the clinic, and new technologies that have
emerged to analyze molecular alterations in the
circulation of cancer patients as cell-free tumor DNA.
These approaches have important implications for
noninvasive detection and monitoring of human cancer,
therapeutic stratification, and identification of
mechanisms of resistance to targeted therapies.
Paul J. Limburg, Mayo Clinic College of Medicine,
Rochester, MN
Colorectal cancer (CRC) is a leading cause of malignant
death in the United States. Although environmental
factors appear to be important in modulating CRC risk,
the associated cellular targets and carcinogenic
pathways remain incompletely defined. Using data and
tissue resources from the prospective Iowa Women’s
Health Study (IWHS), our transdisciplinary investigative
team has been evaluating candidate lifestyle, hormonal,
and dietary factors that may be plausibly linked to
distinct, molecularly defined CRC subtypes. Emerging
data in this field will be reviewed to share insights
regarding exposure modification, early detection,
chemoprevention, and other potential prevention
strategies.
Ballroom 20D, San Diego Convention Center
Cancer Pharmacogenomics: Strategies
and Challenges
Mark J. Ratain, University of Chicago, Chicago, IL
Germline variation influences the response of an
individual to drug treatments, both in toxicity and
efficacy. Understanding this variation has the potential to
make antineoplastic therapy safer and more effective by
determining selection and dosing of drugs for an
individual patient. The session will discuss
methodological issues in germline cancer
pharmacogenomics, including genotyping, phenotyping,
and statistical analysis. Specific published studies will
also be discussed that illustrate methodological
challenges.
Disordered Histone Methylation in
Hematological and Other Malignancies
Jonathan D. Licht, Northwestern University Lurie
Comprehensive Cancer Center, Chicago, IL
Advances in genome sequencing revealed that recurrent
mutations in chromatin regulators, including histone
methyltransferases (HMTs) and histone demethylases,
are prominent. These mutations may yield global,
genome-wide dysfunction of chromatin, strongly
affecting gene regulation. The balance between histone
3 lysine 27 trimethylation (H3K27me3), associated with
gene silencing and H3K4 methylation, linked to gene
activation, is critical for normal gene expression.
Activation of enhancers is associated with the placement
of the H3K4 monomethyl mark and H3K27 acetylation,
created by a complex including MLL2, MLL3, UTX, and
SWI SNF components and CBP or p300, all of which
may be mutated in malignancy. The repressive PRC2
complex contains a H3K27-specifc HMT, EZH2. Loss of
function mutations of EZH2 or partner proteins leads to
global loss of H3K27me3, while gain of function
mutations of lymphoma increases H3K27me3. We will
discuss how mutations of epigenetic modulators may
drive malignancy and offer new therapeutic targets.
433
MEET-THE-EXPERT SESSIONS
Room 6A, San Diego Convention Center
Extending Genomic Profiling Towards
Direct Medical Applications: From Bark
to Bedside
Jeffrey M. Trent, Translational Genomics Research
Institute, Phoenix, AZ
While targeted therapies revolutionize treatment of
advanced cancers, strategies are needed to overcome
therapeutic resistance and identify even more effective
treatment options. Multidimensional
genomics/knowledge recovery strategies may extend
molecularly directed therapy to a broader spectrum of
patients. Rigorous clinical evaluation in multiple patient
populations, the development of significant
infrastructure, deployment of novel analytics, and
inclusion of targeted investigational agents directly allow
genomics enabled medicine into cancer clinical trials.
Recognizing the nascent, and frequently tumor-specific
nature of current “rules” linking drugs to genomic
profiles, significant efforts are refining drug matching
through iterative learning including patient-derived
tumorgrafts, cell lines, and leveraging network
information in drug-matching algorithms. Importantly, the
compressed disease course and commonality of
genomic “drivers” allow novel adaptive trial designs in
canine cancer patients. These studies will be discussed
within a framework where novel computational platforms
automatically query collective prior knowledge integrated
with in vitro, in silico, and clinical outcomes.
anhydrase IX and glycogen metabolism, where marked
synergy was shown. These approaches are applicable to
most types of cancer. Additional work on RNA
sequencing of tumors and cell lines has revealed many
new hypoxia-regulated targets and the extent of the
modifications, including long noncoding RNAs,
microRNAs, and antisense RNAs. Recent data on their
clinical relevance will be discussed.
Room 6CF, San Diego Convention Center
Interpreting Genomic and HighThroughput Screening Data to Identify
Novel Druggable Pathways in Cancer
Michael A. Dyer, St. Jude Children’s Research Hospital,
Memphis, TN
Over the past 5 years, Next-Gen sequencing efforts have
generated an extensive catalog of germline and somatic
mutations that occur in diverse cancer types. Now we
face the challenge of using those data to make betterinformed decisions about therapeutic interventions. This
session will focus on the genomic landscape of pediatric
solid tumors and the recurrently mutated, druggable
signaling pathways that support those tumors. I will
assess current efforts in clinical genomics to interpret
tumor-mutation data to direct therapy and unbiased drug
screening in primary tumor cells in culture. This work will
be presented in the context of a comprehensive
translational research roadmap.
The Hypoxia Transcriptome and
Antiangiogenesis Therapy:
Synthetic Lethality Recruited for
Therapeutic Effect
Adrian L. Harris, University of Oxford, Oxford,
United Kingdom
There are still no biomarkers for the effect on this
antiangiogenic therapy and one of the limiting factors is
the induction of hypoxia, which induces many genes
which are pro-tumorigenic. Through window-ofopportunity studies in breast cancer patients treated with
bevacizumab, one may evaluate the genes induced by
hypoxia to assess whether they produce new
therapeutic potential. Examples will be given of carbonic
434
Tuesday, 7:00 a.m.-8:00 a.m.
Lung Cancer Genomics
Tumor-Host Dialogue During
Progression and Therapeutic
Resistance: A Perspective from the
Vascular Niche
Roman K. Thomas, University of Cologne, Cologne,
Germany
Major sequencing efforts have enabled systematic
discovery of recurrent genomic alterations in the major
subtypes of lung cancer. Some of these alterations are
therapeutically relevant; others are useful for a
refinement of histopathological diagnoses. In my session
I will discuss basic concepts of genomic sequencing of
tumor specimens as well as recent discoveries in lung
adenocarcinomas, squamous cell lung cancer, and small
cell lung cancer. I will focus in particular on genomic
alterations that might have therapeutic implications and
that are currently being explored clinically. Finally, I will
discuss the application of genome analysis technologies
for diagnostic purposes. In summary, I will provide an
overview on the state of the art of lung cancer genomics
with a particular focus on clinically relevant findings and
technological developments.
Targeting Physical Forces to Enhance
Cancer Treatment
Rakesh K. Jain, Massachusetts General Hospital,
Boston, MA
Gabriele Bergers, University of California,
San Francisco, CA
Cancers are heterogeneous entities in which tumor cell
populations as well as distinct host cell constituents
form a dynamic and interactive tumor community that is
pivotal not only for the genesis and progression of a
tumor but also for the tumor’s ability to resist therapeutic
elimination. Our major focus over the last years has been
to expose the heterotypical signals of the tumor-host
dialogue – with an emphasis on the vascular niche and
its various cell constituents – that regulate tumor
survival, stem cell maintenance, tumor invasion, and
neovascularization. As any standard or targeted cancer
therapy will provoke responses from the entire tumor
community to fight the attempts of tumor eradication, it
is the sum of all of these responses that will dictate the
efficiency and endurance of a treatment modality. In
order to balance these responses, it is our intention to
identify combinatorial treatment modalities that interfere
with these compensatory feedback loops and help to
develop an adequate polytherapy that is tailored to more
successfully impede therapeutic resistance and prolong
survival.
As tumors grow, they generate physical forces. These
forces may fuel tumor progression and metastasis, and
impair the efficacy of various treatments. Our hypothesis
is that alleviating these forces should enhance treatment.
I will discuss two types of physical forces: pressure
exerted by the interstitial fluid (interstitial fluid pressure
[IFP]) and by the solid components of tumors and
surrounding tissue (compressive and tensile solid
stresses), and explain why solid stress – and not
elevated IFP – can collapse a leaky tumor vessel. I will
summarize recent data on agents – including FDAapproved antihypertensive drugs – that can reopen
tumor vessels and improve the distribution and efficacy
of therapeutics in desmoplastic tumors. Therapies based
on this emerging concept are now entering clinical trials
in pancreatic ductal adenocarcinoma – a disease with a
particularly grim prognosis – and have the potential to
improve the treatment of cancer beyond what is
currently possible via “vascular normalization” using
antiangiogenic agents.
435
POSTER SESSION
Hall A-E, Poster Section 2 • Tuesday, 8:00 a.m.-12:00 p.m.
Tumor Biology 27
Poster
Section
2
2
Angiogenesis 3: Translation to Therapeutics
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
436
2979 Effects of VEGF inhibition on skin ulcer induced by
administration of cytotoxic anticancer drugs. Tatsu Shimoyama,
Kiyoshi Ogura, Yuusuke Kanemasa, Shigeo Yamaguti, Eisaku Sasaki,
Yasushi Omuro, Takeshi Sawada, Fumiaki Koizumi, Yoshiharu
Maeda.
2980 Maximizing the efficacy of anti-angiogenesis cancer
therapy: A multi-targeting strategy by tyrosine kinase inhibitors.
Youya Nakazawa, Satoshi Kawano, Junji Matsui, Yasuhiro Funahashi,
Osamu Tohyama, Hiroki Muto, Takayuki Nakagawa, Tomohiro
Matsushima.
2981 Combination therapy of oncolytic herpes virus HF10
and bevacizumab against experimental model of human breast
carcinoma xenograft. Gewen Tan, Hideki Kasuya, Tevfik Tolga
Sahin, Toshio Shikano, Suguru Yamada, Akiyuki Kanzaki, Kazuo
Yamamura, Tsutomu Fujii, Hiro-yuki Sugimoto, Shuji Nomoto, Yoko
Nishikawa, Maki Tanaka, Naoko Tsurumaru, Shin Takeda, Akimasa
Nakao, Yasuhiro Kodera.
2982 Macrophages modulate adaptive resistance to
antiangiogenic therapy. Heather J. Dalton, Sunila Pradeep,
Guillermo N. Armaiz-Pena, Rebecca Previs, Ashley Davis, Rajesha
Rupaimoole, Behrouz Zand, Yared Hailemichael, Willem W. Overwijk,
Gabriel Lopez-Berestein, Anil K. Sood.
2983 Bisphosphonates: new strategies for targeting
angiogenesis in ovarian cancer. Heather J. Dalton, Nicole M.
Reusser, Alexander Zien, David Jackson, Rebecca Previs, Rajesha
Rupaimoole, Behrouz Zand, Gabriel Lopez-Berestein, Robert L.
Coleman, Anil K. Sood.
2984 Normalization of tumor vasculature by antiangiogenesis therapy in metastatic tumor: A clinical study to
determine the timing and effect. Yen-Shen Lu, Bang-Bin Chen,
Ching-Hung Lin, Wei-Wu Chen, Pei-Fang Wu, Ann-Lii Cheng, Tiffany
Ting-Fang Shih.
2985 In vivo evaluation of regorafenib and liposomaldoxorubicin in a panel of low passage uterine START-PDX tumor
models. Justin Meade, Michael J. Wick, Teresa Vaught, Lizette
Gamez, Roger Chavez, Anthony Tolcher, Drew Rasco, Amita Patnaik,
Allan J. White, Kyriakos Papadopoulos.
2986 Novel vascular targeting strategy using pegylated
liposomal doxorubicin to increase drug accumulation to tumor
site and therapeutic efficacy. Kenji Yokoi, Tomonori Tanei, Yuki
Saito, Mauro Ferrari.
2987 Evaluation of CTLA-4 blockage with sequential
metronomic chemotherapy for the treatment of preclinical
breast cancer. Karla Parra, Chantal Vidal, Paloma Valenzuela, Sarah
Jallad, Georgialina Rodriguez, Mitchell S. Felder, Natzidielly Lerma,
Guido Bocci, Urban Emmenegger, Robert A. Kirken, Giulio Francia.
2988 Microenvironmental distribution of trastuzumab is
heterogeneous and decreases sharply when administered
following a single dose of bevacizumab in Her2ⴙve xenografts
and metastases models. Jennifer H. Baker, Alastair H. Kyle, Stefan
A. Reinsberg, Firas Moosvi, Jordan Cran, Urs Hafeli, Katayoun
Saatchi, Andrew I. Minchinton.
2989 High-dose, intermittent sunitinib as an alternative
treatment strategy. Maria Rovithi, Richard R. de Haas, Richard J.
Honeywell, Johannes Voortman, Arjan W. Griffioen, Mariette Labots,
Anne M. Luik, Godefridus J. Peters, Henk J. Broxterman, Henk M.
Verheul.
2990 Notch1 monoclonal antibody inhibits tumor growth and
modulates angiogenesis. Heidi Okamura, Theresa Proia, Alisa Bell,
Qing Liu, Zakir Siddiquee, Jie Lin, Jeno Gyuris.
2991 Triple combination of Bevacizumab, Anti-DLL4 (delta
like ligand 4) and Trebananib gives enhanced therapeutic
effects in three xenograft tumor models. Bethany Mattson, Jodi
Moriguchi, H. Toni Jun, Angela Coxon, Dave Cordover, Steve
Kaufman, Jon Oliner, Charlie Starnes.
2992 Zoledronic acid inhibits angiogenesis through Rac1
inactivation in ovarian cancer. VIANEY GONZALEZ-VILLASANA,
Cristian Rodriguez-Aguayo, Enrique Fuentes-Mattei, Sunila Pradeep,
Cristina Ivan, Anil K. Sood, Gabriel Lopez-Berestein.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
2993 Dll4 inhibition plus aflibercept markedly reduces
ovarian tumor burden and ascites. Jie Huang, Wei Hu, Heather J.
Dalton, Justin Bottsford-Miller, Robert L. Coleman, Robert B. Jaffe,
Anil K. Sood.
2994 Cediranib affects tumor progression and survival of
mice bearing patient derived ovarian carcinoma xenografts
(EOC-PDX). Alessandra Decio, Marta Cesca, Francesca Bizzaro,
Dorina Belotti, Raffaella Giavazzi.
2995 Metronomic albumin-bound paclitaxel and topotecan
has potent antitumor activity in ovarian cancer. Ashley N. Davis,
Yvonne G. Lin-Liu, Rebecca A. Previs, Heather J. Dalton, Behrouz
Zand, Justin Bottsford-Miller, Robert Coleman, Anil K. Sood.
2996 Sunitinib withdrawal uncovers complementary
stromal- and tumor-mediated mechanisms of resistance and
rebound growth in metastatic mouse models. Michalis Mastri,
Amanda Tracz, Christina R. Lee, Derya Deveci, John M. Ebos.
2997 Vessel co-option in colorectal cancer liver metastases
mediates resistance to VEGF-targeted therapy. Sophia Frentzas,
Victoria L. Thompson, Peter B. Vermeulen, Shane Foo, Gina Brown,
David Cunningham, Andrew R. Reynolds.
2998 Akt-activated endothelium constitute the niche for
residual disease and resistance to bevacizumab in ovarian
cancer. Bella Samia Guerrouahen, Jennifer Pasquier, Nadine Abou
Kaoud, Marie-Claude Beauchamp, Mahtab Maleki, Pegah Ghiabi,
Raphael Lis, Ahmed Saleh, Walter H. Gotlieb, Shahin Rafii, Arash
Rafii.
2999 Interleukin-8 mediates resistance to anti-VEGF therapy
in ovarian cancer. Bharat Kumar Devapatla, Ankur Sharma,
Sukyung Woo.
3000 Angiogenic recovery under chronic exposure to
sunitinib is associated with vasculogenic mimicry in renal cell
carcinoma. Annemilai Tijeras-Raballand, Célia Dos Santos, Maria
Serova, Matthieu Martinet, Sandrine Faivre, Armand de Gramont, Eric
Raymond.
3001 Angiogenesis-related cytokine secretion pattern in
tumor interstitial fluid and its relationship with VEGF expression
and metastatic profile. Louis Dore-Savard, Esak Lee, Aleksander S.
Popel, Zaver M. Bhujwalla.
3002 ID3 expression and oxidative DNA damage are
associated with growth of benign and malignant vascular
lesions. Quentin H. Felty, Jayanta K. Das.
3003 Targeting nucleolin - a potential strategy to overcome
stroma-mediated bevacizumab resistance in lung cancer. Ângela
Valério-Fernandes, Nuno Fonseca, Vera Moura, Ana Ladeirinha,
Teresa Ferreira, Ana Alarcão, Lina Carvalho, Sérgio Simões, João N.
Moreira.
3004 VEGFR2 expression and vascular phenotyping
demonstrate different patterns of tumor angiogenesis in human
gastric and breast cancers. Timothy R. Holzer, Beverly L. Falcon,
Angie D. Fulford, Sook A. McDonald, Andy L. Ray, Patrick Finnegan,
Mark T. Uhlik, Laura E. Benjamin, Andrew E. Schade, Aejaz Nasir.
3005 Vascular endothelial growth factor A - a systematic
review and meta-analysis of expression patterns in breast
cancer. Arthur Adams, Jeroen Vermeulen, Peter Zuithoff, Elsken Van
der Wall, Laetitia Lamberts, Elisabeth de Vries, Johannes de Jong,
Gooitzen Van Dam, Paul J. van Diest, Willem P. Mali, Sjoerd G. Elias.
3006 Serum insulin growth factor/insulin growth factor
receptor1 (IGF-I, IGF-I-1R) and VEGF-A as prognostic factors and
surrogate biomarkers in triple negative breast cancer patients
(TNBC). Abdel-Rahman N. Zekri, Abeer Bahnassy.
3007 Heterogeneity of vascular endothelial growth factor
receptors 1, 2, and 3 in primary human colorectal
adenocarcinoma. Timothy R. Holzer, Leslie A. O’Neill, Drew M.
Nedderman, Angie D. Fulford, Beverly L. Falcon, Mark T. Uhlik, Laura
E. Benjamin, Andrew E. Schade, Aejaz Nasir.
3008 Effects of HSPG on inhibition of chemokine-induced
angiogenesis. Donghong Ju, Cecelia Speyer, David Gorski, Mary A.
Kosir.
POSTER SESSION
Tumor Biology 28
Cancer Stem Cell Niche and Metastasis
Poster
Section
Poster Abstract
Board Number
1.
3009
Membrane pseudokinase PTK7 regulates
metastasis. Vladislav Golubkov, Yong Zhang, Natalie
Prigozhina, Robert M. Hoffman, Alex Strongin.
2.
3010
The role of NF-kappaB in mammary tumor
initiation. Whitney Barham, Oleg Tikhomirov, Lianyi Chen,
Ryan Ortega, Halina Onishko, Linda Connelly, Fiona E. Yull.
3.
3011
Differential expressions of lysophospholipid
receptors (LPRs) in benign and malignant tissues from
various human system/organs. Chunyi Wang, Samantha
Redfield, Jinghe Mao, Yinyuan Mo, Xinchun Zhou.
4.
3012
Converging effectors of airway lineage
specification and metastasis in lung cancer. Don X.
Nguyen.
Poster Abstract
Board Number
13.
3021
Roles of EMT on stem cell properties of
prostate stem and cancer cells during castrationresistant prostate cancer progression. Shu Lin, Evelyn
Kono, Joyce Yamashiro, Sean Lee, Owen Witte, Andrew
Goldstein, Robert E. Reiter.
14.
3022
PAR-2 activation is required for cancer stem
cells maintenance through upregulation of POSTN.
Yiming Ma, Hongying Wang.
15.
3023
The characterisation of hyaluronan-related
enzymes in breast cancer cell subpopulations. Vera
Evtimov, Tracey Brown.
16.
3024
Cancer stem-like cells in ovarian clear cell
carcinoma are enriched in ALDH-high population
associated with the accelerated scavenging system of
reactive oxygen species. Tomoko Mizuno, Noriko Suzuki,
Minako Mori, Hiroshi Makino, Tatsuro Furui, Naoki Ito, Akio
Yamamoto, Kennichiro Morishige.
5.
3013
Different tumor-initiating cells from a IDH1 wt
glioblastoma patient. Akio Soeda, Akira Hara, Takahiro
Kunisada, Toru Iwama.
6.
3014
Hyaluronan-mediated motility receptor
maintains stemness and tumorigenic potential of
glioblastoma stem cells. Jessica Tilghman, John Laterra,
Mingyao Ying.
17.
3015
Annexin A3 is selectively expressed in MET-like
as compared to EMT-like breast cancer stem cells. Deol
S. Yadwinder, Sean McDermott, David M. Lubman, Jenny C.
Chang, Song Nie, Yang Cong, Alice Turdo, Ebrahim Azizi,
Tahra K. Luther, Shawn G. Clouthier, Max Wicha.
3025
HER2/Stat3 signaling mediated radioresistance
in U87 glioma cancer cells through suppressed
apoptosis and enhanced glycolysis. Lili Qin, Ming Fan,
Jian Jian Li.
18.
3016
Characterization of cancer stem-like cells
derived from mouse induced pluripotent stem cells
transformed by tumor-derived exosomes/microvesicles.
Yan Ting, Junko Masuda, Akifumi Mizutani, Ling Chen,
Tsukasa Shigehiro, Shuichi Matsuda, Tomonari Kasai,
Takayuki Kudoh, Hiroshi Murakami, Mary J. Hendrix, Luigi
Strizzi, David S. Salomon, Li Fu, Masaharu Seno.
3026
Cancer stem cells maintain a hierarchy of
differentiation by creating their niche. Akifumi Mizutani,
Shuichi Matsuda, Ting Yan, Marta Prieto-Vila, Ling Chen,
Ayano Satoh, Tomonari Kasai, Junko Masuda, Takyuki
Kudoh, Hiroshi Murakami, Li Fu, David S. Salomon,
Masaharu Seno.
19.
3027
Stromal cells-derived paracrine factors promote
dedifferentiation of human lung carcinoma cells into
cancer stem cells. Carlos F. Rodrigues, Inês P. Rodrigues,
Mariana Val, Lina Carvalho, Artur Paiva, Anatoly Zhitkovich,
Isabel M. Carreira, Mª Carmen Alpoim.
20.
3028
Optical imaging of cancer stem-like cells in
cervical cancer. Kazuhiko Hayashi, Keisuke Tamari,
Yoshihiro Kano, Shimpei Nishikawa, Takahito Fukusumi,
Masaaki Miyo, Kozo Noguchi, Hisataka Ogawa, Atsushi
Hamabe, Masamitsu Konno, Yuji Seo, Hideshi Ishii, Yuichiro
Doki, Masaki Mori, Kazuhiko Ogawa.
21.
3029
MKP1-mediated survival of HER2 positive breast
cancer stem cells. Demet Candas, Chung-Ling Lu, Ming
Fan, Frank Chuang, Colleen Sweeney, Alexander Borowsky,
Jian Jian Li.
22.
3030
Correlation of circulating tumor cells (CTCs)
expressing stemness and EMT phenotypes with
immunosuppressive cells in metastatic breast cancer
patients. Despoina Aggouraki, Maria Papadaki, Eleni K.
Vetsika, Anna Koutoulaki, Athanasios Kotsakis, Galatea
Kallergi, Sofia Agelaki, Dimitris Mavroudis, Vassilis
Georgoulias.
23.
3031
HMGA2 promotes invasion and stemness in
glioblastoma. Harpreet Kaur, Marianne Hütt, Xing-gang
Mao, Brent A. Orr, Charles G. Eberhart, Eric H. Raabe.
7.
8.
9.
10.
11.
12.
3017
A spontaneous developmental lineage plasticity
that underlies the response of prostate cancer cells to
androgen deprivation. Josselin Caradec*, Amy Lubik*,
Mannan Nouri, Na Li, Jennifer Bishop, Martin Gleave, Ralph
Buttyan.
3018
SHIP2 plays an oncogenic role in breast cancer
stem cells through JNK/vimentin activation and its
phosphatase activity. Chiung-Hui Fu, Ruey-Jen Lin, John
Yu, Wen-Wei Chang, Guo-Shiou Liao, Wen-Ying Chang,
Ling-Ming Tseng, Yi-Fang Tsai, Jyh-Cherng Yu, Alice L. Yu.
3019
Aberrant NF-␬B and Notch pathways promote
CD133ⴙ cancer stem cells in human primary cutaneous
squamous cell carcinoma. Xinxin Quan, Nga Voong,
Weiping Chen, Jamie Coupar, Steven Lee, David W.
Petersen, Daniel C. Edelman, Paul S. Meltzer, Andrew
Montemarano, Martin Braun, Jonathan Vogel, Carter Van
Waes, Zhong Chen.
3020
Patient-derived xenograft (PDX) models to study
the role of breast cancer stem cells in metastasis
formation. Christophe Ginestier, Danae Lartigue, Olivier
Cabaud, Aurelie Malzac, Julien Wicinski, Emmanuelle
Josselin, Pascal Finetti, Jose Adelaide, Francois Bertucci,
Max Chaffanet, Daniel Birnbaum, Emmanuelle CharafeJauffret.
April 5–9, 2014 • San Diego, CA
3
3
437
POSTER SESSION
Tumor Biology 29
Poster
Section
4
4
Cancer Stem Cell Phenotype and Function 2
Poster Abstract
Board Number
1.
3032
The effect of a tankyrase inhibitor on the small
intestine tissue homeostasis. Jens Henrik Norum, Ellen
Skarpen, Andreas Brech, Raoul Kuiper, Jo Waaler, Stefan
Krauss, Therese Sørlie.
2.
3033
An alveolar-restricted stem cell population in
the mammary luminal lineage revealed by lineage
tracing serves as cells of origin of heterogeneous
mammary tumors. Maaike van Bragt, Luwei Tao, Zhe Li.
3.
4.
3035
Cripto/GRP78 signaling promotes the stem cell
phenotype in normal and neoplastic mammary epithelial
cells. Benjamin T. Spike, Jonathan A. Kelber, Evan Booker,
Madhuri Kalathur, Rose Rodewald, Julia Lipianskaya, Justin
La, Marielle He, Tracy Wright, Richard Klemke, Geoffrey
Wahl, Peter C. Gray.
5.
3036
Basal stem cells contribute to squamous cell
carcinomas in the oral cavity. Xiao-Han Tang, Theresa
Scognamiglio, Lorraine Gudas.
6.
3037
Adipokines modulate human mammary stem
cell self-renewal through mTOR. Ray Esper, Dame
MIchael, Zora Djuric, William Smith, Max Wicha, Dean
Brenner.
7.
3038
Intra-testicular transplantation of purified
autologous stem cells for treatment of chemotherapyinduced male infertility. Adeeb M. AlZoubi.
8.
3039
The MELK/FOXM1 axis is a master regulator of
proneural to mesenchymal transition (PMT) in glioma
stem cells by controlling EZH2 transcriptional activity.
Kaushal Joshi, Sunghak Kim, Jeongwu Lee, Ronald Waclaw,
Lisa Salcini, Ichiro Nakano.
9.
3040
Forced astroglial differentiation depletes
glioblastoma stem cells. Raffaella Spina, Dillon M. Voss,
Andrew E. Sloan, Eli E. Bar.
10.
3041
GPR56 promotes the adhesion of glioma stemlike cells to the perivascular niche and regulates cell
fate. Marta Moreno, Stefanie Giera, Xianhua Piao, Nuria de
la Iglesia.
11.
3042
Therapeutic targeting of distinct subsets of
cancer stem cells within triple negative breast cancers.
Diana Azzam, Shaun Brothers, Claes Wahlestedt, Joyce
Slingerland.
12.
13.
14.
438
3034
Integrin ␣v␤3 drives Slug activation and
stemness in the pregnant and neoplastic mammary
gland. Jay S. Desgrosellier, Jacqueline Lesperance, Laetitia
Seguin, Sanford J. Shattil, David A. Cheresh.
3043
Mesenchymal phenoptype of metastasizing
primary human colorectal TIC is maintained through
epigenetic silencing of miR-200. Christopher M.
Hoffmann, Klara M. Giessler, Claudia R. Ball, Taronish D.
Dubash, Sebastian M. Dieter, Sarah Bergmann, Wilko
Weichert, Christof Von Kalle, Martin Schneider, Constance
Baer, Christoph Plass, Manfred Schmidt, Hanno Glimm.
3044
Cancer associated fibroblasts-derived HGF
regulates cancer stem cell-like properties in
hepatocellular carcinoma. Yuen Ting Lau, Jessica Lo,
Irene Oi Lin Ng, Terence Kin Wah Lee.
3045
Defining an elusive multiple myeloma stem cell
population in mice. Joshua Kellner, Yunpeng Hua, Bei Liu,
Zihai Li.
Poster Abstract
Board Number
15.
3046
Lin28B mediated IKK-␤ sustains the stemness
of breast cancer stem cell via regulating Wnt/TCF4 and
miR-34a/LEF1 signaling pathway. Chong Chen, Lipeng
Bai, Fengqi Cao, Yan Liu, Junling Xie, Wei Wang, Qin Si,
Jian Yang, Antao Chang, Rong Xiang, Yunping Luo.
16.
3047
Hypoxia leads to deregulation of
PI3K/AKT/mTOR signaling in prostate cancer stem cells.
Maximilian Marhold, Erwin Tomasich, Zuzana Pernicová,
Radek Fedr, Karel Soucek, Andreas Spittler, Michael Krainer,
Peter Horak.
17.
3048
OMP-59R5 (Anti-Notch2/3) inhibits tumor
growth and reduces cancer stem cell frequency in
patient derived SCLC xenografts. Marcus M. Fischer,
Jalpa Shah, Jennifer Cain, Belinda Cancilla, James W.
Evans, Christopher L. Murriel, Tracy Tang, Jie Wei, WanChing Yen, Chun Zhang, Austin Gurney, John Lewicki, Ann
M. Kapoun, Timothy Hoey.
18.
3049
Regulation of cancer cell stemness by delta-like
1 homolog (Drosophila) and prohibitins. Qun Lin, Asma
Begum, Chenye Yu, Ming-Yeah Hu, Yuri Kim, Zhong Yun.
19.
3050
Human rectal carcinoid tumors highly express
DCLK1, a putative cancer stem cell marker. Yu Ikezono,
Hironori Koga, Mitsuhiko Abe, Takafumi Yoshida, Toru
Nakamura, Jun Akiba, Hirohisa Yano, Osamu Tsuruta, Takuji
Torimura, Michio Sata.
20.
3051
Genome-wide microarray expression and
genomic alteration by array-CGH analysis in
neuroblastoma stem-like cells. Raquel Ordoñez, Gabriel
Gallo, Soledad Martínez, Sheila Legarra, Noémie Pata-Merci,
Justine Guegan, Giselle Danglot, Xing Fan, Juan A. Rey,
Alain Bernheim, Javier S. Castresana.
21.
3052
Genomic, transcriptomic, and epigenomic
analyses of gastric cancer stem cells. Seon-Young Kim,
Su-Jin Baek, Myoung-Eun Han, Hee-Jin Kim, Jeong-Hwan
Kim, Sae-Ock Oh.
22.
3053
Epigenetic control of cell phenotypes in the
stem cell compartments of human prostate and prostate
cancer: implications for enhancement of prostate cancer
therapies. Norman J. Maitland, Davide Pellacani, Jayant K.
Rane, Fiona M. Frame, Anne T. Collins.
23.
3054
Snail-induced epithelial-mesenchymal transition
generates the properties of cancer stem cells in head
and neck cancer cells. Ichiro Ota, Takashi Masui, Shinji
Mikami, Toshiaki Yamanaka, Hiroshi Hosoi.
24.
3055
Potential role of cyclin D1 in regulation of liver
cancer stem cells. Wei Xia, Xiao Qi Wang.
25.
3056
Human ovarian cancer stem cells: In vitro
cultivation and characterization. Tatsuya Ishiguro,
Hirokazu Ohata, Hitoshi Nakagama, Koji Okamoto, Kenichi
Tanaka, Takayuki Enomoto.
26.
3057
Unstable phenotype of human colon cancer
tumor initiating cells. Taronish D. Dubash, Christopher M.
Hoffmann, Felix Oppel, Klara Giessler, Sarah Bergmann,
Sebastian M. Dieter, Wilko Weichert, Martin Schneider,
Manfred Schmidt, Christof von Kalle, Hanno Glimm, Claudia
R. Ball.
POSTER SESSION
Tumor Biology 30
Isolation of Circulating and Disseminated Tumor Cells
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
3058
Bone marrow hematopoietic stem cell niche
activation and mobilization fosters the metastatic niche.
Amber J. Giles, Meera Murgai, Yorleny Vicioso, Steven
Highfil, Crystal Mackall, Leonard Wexler, David Lyden,
Rosandra N. Kaplan.
3059
Detection and characterization of circulating
tumor cells by imaging flow cytometry. Barry Dent,
Rachel L. O’Donnell, Laura F. Ogle, Emma D. Rourke,
Hamsavardhini P. Ramesh, Maddie Moat, Nick Hayes, Ujjal
K. Mallick, Felicity E. May, Helen L. Reeves, Nicola J.
Curtain, Richard J. Edmondson, Alan V. Boddy, Ruth
Plummer, David Jamieson.
3060
Circulating tumor cells from small cell lung
cancer patients are tumorigenic. Christopher J. Morrow,
Cassandra L. Hodgkinson, Yaoyong Li, Robert Metcalf,
Dominic Rothwell, Francesca Trapani, Radoslaw Polanski,
Debbie Burt, Kathryn Simpson, Karen Morris, Stuart Pepper,
Daisuke Nonaka, Alastair Greystole, Paul Kelly, Matthew
Krebs, Jenny Antonello, Mahmood Ayub, Suzanne Faulkner,
Lynsey Priest, Louise Carter, Catriona Tate, Crispin J. Miller,
Fiona Blackhall, Ged Brady, Caroline Dive.
3061
A novel flow cytometry-based cell capture
platform for the detection, capture and molecular
characterization of circulating tumor cells. Yasuhiro Koh,
Masaru Watanabe, Takeshi Sawada, Hirotsugu Kenmotsu,
Masakuni Serizawa, Masayuki Ishige, Kazuo Takeda,
Nobuyuki Yamamoto, Toshiaki Takahashi, Fumiaki Koizumi.
3062
Isolation and characterization of circulating
tumor cells (CTCs) from peripheral blood specimens of
patients with advanced solid tumor malignancies (using
ApoStream™ instrumentation). Priya Balasubramanian,
Lihua Wang, Scott M. Lawrence, Tony Navas, Shivaani
Kummar, Melinda Hollingshead, Francis Owusu, Ralph E.
Parchment, Joseph E. Tomaszewski, James H. Doroshow,
Robert J. Kinders.
3063
Molecular characterization of individual
circulating tumor cells by RNA sequencing. Jaymala
Patel, Brad Foulk, Vipul Bhargava, Denis A. Smirnov.
3064
Importance of circulating tumor cells in newly
diagnosed colorectal cancer. Guus van Dalum, Marco R.
de Groot, Gerrit-Jan Stam, Loes F. Scholten, Walter J.
Mastboom, Istvan Vermes, Arjan G. Tibbe, Leon W.
Terstappen.
3065
Single cell isolation and DNA analysis from
circulating tumor cells using a self sorting nanowell
plate. Joost F. Swennenhuis, Arjan G. Tibbe, Michiel
Stevens, Hien Duy Tong, Cees J. van Rijn, Leon W.
Terstappen.
3066
Establishment of a new method for the
selection and detection of circulating tumor cells in
metastatic breast cancer patients. Maren Bredemeier,
Bahriye Aktas, Jenny Wagner, Doreen Schellbach, Rainer
Kimmig, Sabine Kasimir-Bauer.
3067
PIK3CA hotspot mutations are present at a
relatively high frequency in CTCs of operable and
metastatic breast cancer patients. Athina N. Markou,
Sofia Farkona, Christina Schiza, Antonia Eftathiou, Nikolaos
Malamos, Vassilis Georgoulias, Evi Lianidou.
3068
Multiparameter analysis including the
measurement of a mesenchymal marker and the
detection of EGFR mutation of negatively enriched blood
samples from patients with non-small cell lung cancer.
Takeshi Sawada, Masaru Watanabe, Misaki Ono, Yuu
Fujimura, Shintaro Kanda, Hidehito Horinouchi, Yutaka
Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Tomohide
Tamura, Yasuhiro Koh, Fumiaki Koizumi.
Poster Abstract
Board Number
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
3069
Radial flow microfluidic device for highthroughput affinity-based isolation of circulating tumor
cells. Vasudha Murlidhar, Rishindra M. Reddy, Mina Zeinali,
Svetlana Grabauskiene, Mostafa Ghannad-Rezaie, Max S.
Wicha, Diane M. Simeone, Nithya Ramnath, Sunitha
Nagrath.
3070
Capture, isolation, and mutational analysis of
single pancreatic circulating tumor cells using
NanoVelcro technology. Jacob S. Ankeny, Shuang Hou,
Millicent Lin, Matthew Frias, Hank OuYang, Min Song,
Matthew M. Rochefort, Mark D. Girgis, Hsian-Rong Tseng,
James S. Tomlinson.
3071
Size-based isolation of circulating tumor cells
(CTCs) in mouse tumor models. Katarina Kolostova, Robert
M. Hoffman, Ali Maawy, Yong Zhang, Vladimir Bobek.
3072
High-recovery multiplex analysis of circulating
tumor cells by density-based enrichment, automated
platform immunofluorescence staining, and digital
microscopy. Daniel Campton, Arturo Ramirez, Joshua
Nordberg, Anthony Blau, Jackie Stilwell, Eric Kaldjian.
3073
Detection and isolation of circulating tumor
cells in ovarian cancer: Principles and methods. ShinWha Lee, Ha-Young Lee, Jin-Young Mo, Byung Chul Kim,
Eun Hye Kim, Yong-Man Kim.
3074
Detection and enumeration of circulating tumor
cells using imaging flow cytometery. Shobana
Vaidyanathan, Don Weldon, David Basiji, Philip Morrissey.
3075
Ex-vivo expansion of circulating tumor cells in
early lung cancer using a microfluidic model. Jennifer
Zhuo Zhang, Hiroe Shiratsuchi, Jules Lin, Guoan Chen,
Rishindra M. Reddy, Ebrahim Azizi, Shamileh Fouladdel,
Andrew C. Chang, Lin Lin, Diane M. Simeone, Max S.
Wicha, David G. Beer, Nithya Ramnath, Sunitha Nagrath.
3076
A fully automated q-PCR-based circulating
tumor cell analysis using the Alere TM q-Analyzer test
platform. Stephan Hubold, Ivan Loncarevic, Jana Thiele,
Maren Bredemeier, Heidi Klemm, Heike Klabunde, Danny
Michel, Rainer Kimmig, Siegfried Hauch, Bahriye Aktas,
Eugen Ermantraut, Sabine Kasimir-Bauer.
3077
Label free prostate cancer cell isolation from
blood by acoustic standing wave technology acoustophoresis. Cecilia Magnusson, Per Augustsson,
Benedikta Haflidadottir, Andreas Lenshof, Yvonne Ceder,
Thomas Laurell, Hans Lilja.
3078
Isolation and in vitro culturing of human
circulating tumor cells. Vladimir Bobek, Katarina Kolostova.
3079
Characterization of the molecular heterogeneity
of circulating tumor cells in metastatic prostate cancer.
Christophe Massard, Marianne Oulhen, Alexander Valent,
Sylvestre Lemoulec, Karim Fizazi, Philippe Vielh, Françoise
Farace.
3080
Comparison of CellSearch with polymeric
microfluidic devices for CTC isolation using EpCAMnegative tumor cell lines of malignant pleural
mesothelioma. Yasuhiro Chikaishi, Tomoko So, Masaru
Takenaka, Soichi Oka, Ayako Hirai, Takashi Iwanami,
Hidehiko Shimokawa, Kazue Yoneda, Yoshika Nagata,
Hidetaka Uramoto, Takeshi Ohnaga, Fumihiro Tanaka.
3081
Isolation and identification of circulating tumor
cells in renal cell carcinoma . Peixuan Zhu, Thai Ho, Erik
P. Castle, Richard W. Joseph, Melissa L. Stanton, Shuhong
Li, Daniel Adams, Olga V. Makarova, Platte T. Amstutz, ChaMei Tang.
3082
Isolation and identification of disseminated
tumor cells from bone marrow. Peixuan Zhu, Daniel
Adams, Rebecca L. Aft, Sreeraj G. Pillai, Mark A. Watson,
Shuhong Li, Olga V. Makarova, Platte T. Amstutz, Cha-Mei
Tang.
Poster
Section
5
5
439
POSTER SESSION
Tumor Biology 31
Poster
Section
6
6
Pediatric Cancers 2
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
10.
11.
12.
3094 Epigenetic classification of ependymal brain tumors across
age groups. Hendrik Witt, Martin Sill, Khalida Wani, Steve Mack, David
Capper, Stephanie Heim, Pascal Johann, Sally Lambert, Marina Rhyzova,
Volker Hovestadt, Theophilos Tzaridis, Kristian Pajtler, Sebastian Bender,
Till Milde, Paul A. Northcott, Andreas E. Kulozik, Olaf Witt, Peter Lichter,
V. P. Collins, Andreas von Deimling, Marcel Kool, Michael D. Taylor,
Martin Hasselblatt, David T. Jones, Andrey Korshunov, Ken Aldape, Stefan
Pfister.
13.
3095
14.
440
3083 The genetic landscape of Ph-like acute lymphoblastic
leukemia. Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner,
Jinghui Zhang, Richard C. Harvey, Yung-Li Yang, Guangchun Song,
Jing Ma, Shann-Ching Chen, Jinjun Cheng, Natalia Santiago-Morales,
Ilaria Iacobucci, Meenakshi Devidas, I-Ming Chen, Shalini Reshmi,
Michael Rusch, Pankaj Gupta, Naomi J. Winick, William L. Carroll,
Nyla A. Heerema, Andrew J. Carroll, Elizabeth A. Raetz, Guido
Marcucci, Clara D. Bloomfield, Wendy Stock, Steven M. Kornblau,
Elisabeth Paietta, Ching-Hon Pui, Sima Jeha, James Downing,
Daniela S. Gerhard, Julie M. Gastier-Foster, Mignon L. Loh, Cheryl
Willman, Stephen P. Hunger, Charles G. Mullighan.
3084 Epigenetic deregulation in H3.3-K27M mutant pediatric
high-grade gliomas. Sebastian Bender, Yujie Tang, Anders M.
Lindroth, Volker Hovestadt, Marc Zapatka, David T. Jones, Marcel
Kool, Paul A. Northcott, Dominik Sturm, Peter Lichter, Christoph
Plass, Yoon-Jae Cho.
3085 Tenascin C is a canonical Wnt target gene in Ewing
sarcoma and its expression is potentiated by R-spondin.
Elisabeth A. Pedersen, Christopher A. Scannell, Rajasree Menon,
Elizabeth R. Lawlor.
3086 The genetic landscape of the childhood liver cancer
hepatoblastoma. Roland Kappler, Melanie Eichenmüller, Franziska
Trippel, Tim M. Strom, Dietrich von Schweinitz.
3087 Whole genome sequencing of rhabdoid tumors of the
kidney. Hye-Jung E. Chun, Kelsey Zhu, Jenny Q. Qian, Karen L.
Mungall, Yussanne Ma, Yong-Jun Zhao, Andrew J. Mungall, Richard
A. Moore, Jacquie E. Schein, Daniela S. Gerhard, Elizabeth J.
Perlman, Marco A. Marra.
3088 Biallelic DICER1 mutations in sporadic
pleuropulmonary blastoma. Masafumi Seki, Kenichi Yoshida, Yuichi
Shiraishi, Yusuke Sato, Teppei Shimamura, Riki Nishimura, Kenichi
Chiba, Hiroko Tanaka, Keisuke Kato, Motohiro Kato, Ryoji Hanada,
Yuko Nomura, Myoung-Ja Park, Toshiaki Ishida, Akira Oka, Satoru
Miyano, Yasuhide Hayashi, Seishi Ogawa.
3089 (Epi)genetic profiling enables molecular reclassification of CNS-primitive neuroectodermal tumors. Dominik
Sturm, Paul A. Northcott, David T. Jones, Andrey Korshunov, Daniel
Picard, Peter Lichter, Annie Huang, Stefan M. Pfister, Marcel Kool.
3090 Targeting glutamine metabolism as a therapeutic
strategy in MYC-driven medulloblastoma. Allison R. Hanaford,
Charles G. Eberhart, Eric H. Raabe.
3092 PTEN mutations correlate with relapse risk in pediatric
T-cell lymphoblastic lymphoma patients - validation of whole
exome sequencing results. Bettina R. Bonn, Andreas Huge, Marius
Rohde, Martin Zimmermann, Reinhard Voss, Wilhelm Woessmann,
Lorenz Trümper, Claudia Rossig, Heribert Juergens, Jochen
Seggewiss, Birgit Burkhardt.
3093 Unravelling the biology of aggressive and therapyresistant embryonal tumors with multilayered rosettes (ETMR).
Marcel Kool, Natalie Jäger, Dominik Sturm, David T. Jones, Volker
Hoverstadt, Ivo Buchhalter, Pascal Johann, Christin Schmidt, Marina
Ryzhova, Paul A. Northcott, Pablo Landgraf, Marc Remke, Michael D.
Taylor, Martin Hasselblatt, Ulrich Schüller, Annie Huang, Marie-Laure
Yaspo, Andreas von Deimling, Roland Eils, Peter Lichter, Andrey
Korshunov, Stefan M. Pfister.
Notch-induced choroid plexus tumor arises from
epithelial progenitor and depends on sonic hedgehog signaling
for growth. Haotian Zhao, Li Li, Katie Picotte.
3096 Obinutuzumab (GA101) significantly induces
antiproliferative effects and programmed cell death, and
significantly downregulates cell signaling pathways in primary
mediastinal B-cell lymphoma (PMBL): Obinutuzumab may be a
future potential targeted agent for treatment of PMBL.
Changhong Yin, Timmy O’Connell, Janet Ayello, Carmella van de
Ven, Sanghoon Lee, Mitchell Cairo.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3097 TSLP regulates expression of genes involved in cell
survival in a preclinical xenograft model of CRLF2 B-ALL. Olivia
L. Francis, Ruijun Su, Shannalee R. Martinez, Ineavely Baez, TerryAnn Milford, Ross Fisher, Christopher L. Morris, Xiaobing Zhang,
Valeri Filippov, Sinisa Dovat, Kimberly J. Payne.
3098 Canonical Wnt signaling is activated during the
initiation of the migratory phenotype of Ewing’s sarcoma family
of tumors (ESFT). Lucy A. Shaw, Andrew P. Gaffney, Helen L.
Payne, Susan A. Burchill.
3099 Dual targeting of mTOR and Notch disrupts growth
and promotes apoptosis in diffuse intrinsic pontine glioma.
Isabella C. Taylor, Marianne Hutt-Cabezas, Melanie Weingart, Kathy
Warren, Howard Chang, Javad Nazarian, Charles G. Eberhart, Eric H.
Raabe.
3100 Glial origin for MYCN-driven medulloblastoma and
targeted prosenescence therapies. Sara M. Bolin, Jasmine Lau,
Justin Chen, Vasil Savov, Anders I. Persson, Sanna-Maria Hede,
William A. Weiss, Fredrik Swartling.
3101 Precise matching of medulloblastoma mouse models
to their human counterparts. Julia Pöschl, Sebastian Stark, Philipp
Neumann, Susanne Gröbner, David Jones, Paul Northcott, Peter
Lichter, Stefan Pfister, Marcel Kool, Ulrich Schüller.
3102 Genomic alterations in biopsy samples predict the
chemosensitivity of pediatric osteosarcoma. Shintaro Iwata,
Tsukasa Yonemoto, Hajime Kageyama, Hiroto Kamoda, Sana Yokoi,
Hiroki Nagase, Akira Nakagawara, Takeshi Ishii, Miki Ohira.
3103 IGF2BP1 and MYCN cooperate in an oncogenic
feedback loop, in high-risk neuroblastoma. Jessica L. Bell,
Turlapati Raseswari, Tao Liu, Bernard Atmadibrata, Daniel Carter,
Glenn Marshall, Knut Krohn, Stefan Hüttelmaier.
3104 PAX3-FOXO1 increases fibroblast reprogramming
efficiency and drives self-renewal in alveolar
rhabdomyosarcoma. Beat W. Schafer, Elisa Casanova, Sampoorna
Satheesha, Melanie Müller, Paolo Cinelli, Paolo Cinelli.
3105 Neuropeptide Y Y5 receptor in neuroblastoma
chemoresistance. Emily Trinh, Magdalena Czarnecka, Sung-Hyeok
Hong, Congyi Lu, Samantha Martin, Susana Galli, Ewa IzyckaSwieszewska, Anna Kuan-Celarier, David Christian, Meredith Horton,
Jason U. Tilan, Joanna B. Kitlinska.
3106 The HoxD locus: its contribution to the osteogenic
phenotype and malignancy of Ewing sarcoma. Kristina von
Heyking, Laura Roth, Miriam Ertl, Stefan Burdach, Günther H.
Richter.
3107 The role of LIN28 in atypical teratoid rhabdoid tumor
(ATRT) pathogenesis. Ji Hoon Phi, Seung Ah Choi, Yong Hwy Kim,
Young-Hoon Kim, Chul-Kee Park, Kyu-Chang Wang, Seung-Ki Kim.
3108 Copy number variation analysis in neuroblastoma
through next generation sequencing data and SNP-microarray.
Susanne Fransson, Malin Östenssson, Anna Djos, Niloufar
Javanmardi, Per Kogner, Tommy Martinsson.
3109 ALK as a valid therapeutic target for the treatment of
rhabdomyosarcoma. Monika Wierdl, Lyudmila Tsurkan, Viktor
Tollemar, Lying Chi, Elizabeth Stewart, Michael A. Dyer, Philip M.
Potter.
3110 Targeting the Wnt/PCP signaling through ROCK - a
new neuroblastoma drug target. Cecilia Dyberg, David Forsberg,
Panos Papachristou, Jessika Lannerholm-Palm, Bjorn Helge Haug,
Baldur Sveinbjörnsson, Hugo Lagercrantz, Per Kogner, John inge
Johnsen, Malin Wickstrom.
3111 Identification of genes that frequently exhibit copy
number alterations in pediatric ependymomas. Christopher A.
Hamm, Fabricio F. Costa, Jared M. Bischof, Elio F. Vanin, Maria de
F. Bonaldo, Steve Iannaccone, Veena Rajaram, David George,
Tadanori Tomita, Stewart Goldman, Lawrence J. Jennings, Richard J.
Gilbertson, Marcelo B. Soares.
3112 Transcription activator-like effector nucleases
(TALENs) mediated silencing of Bruton’s tyrosine kinase (BTK)
inhibits phosphorylation of Erk in Burkitt lymphoma. Sanghoon
Lee, Changhong Yin, Timmy O’Connell, Janet Ayello, Carmella van de
Ven, Mitchell S. Cairo.
POSTER SESSION
Tumor Biology 32
Preclinical Studies in Model Organisms
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
3113 Phenformin has anti-tumorigenic effects in human
ovarian cancer cells and in a genetically engineered mouse
model of serous ovarian cancer. Amanda L. Jackson, Xiaoyun Han,
Joshua E. Kilgore, Chunxiao Zhou, Liza Makowski, Victoria BaeJump.
3114 Targeting MET in preclinical models to support the
clinical development of Volitinib in NSCLC. Celina D’Cruz, Melanie
Frigault, Ammar Adam, Minhui Shen, Garry Beran, Evan Barry, Paul
Gavine, Yongxin Ren, Shiming Fan, Feng Zhou, Weiguo Qing, Mike
Zinda, Weiguo Su, Edwin Clark.
3115 Calcitriol effects on breast cancer tumorgrafts. Maria
Lucia H. Katayama, Victor Celso N. Fonseca-Filho, Eduardo C. Lyra,
Durvanei A. Maria, Ricardo A. Basso, Suely Nonogaki, Juliana M.
Guerra, Simone Maistro, João Carlos S. Goes, Maria Aparecida A.
Koike Folgueira.
3116 AG-221 offers a survival advantage in a primary
human IDH2 mutant AML xenograft model. Kate Ellwood-Yen,
Fang Wang, Jeremy Travins, Yue Chen, Hua Yang, Kim Straley, Sung
Choe, Marion Dorsch, Sam Agresta, David Schenkein, Scott Biller,
Michael Su.
3117 BET bromodomain inhibition triggers apoptosis of NF1associated malignant peripheral nerve sheath tumors through
Bim induction. Amish J. Patel, Chung-Ping Liao, Zhiguo Chen,
Chiachi Liu, Yong Wang, Lu Q. Le.
3118 Chemokine-targeted colorectal cancer: improved
models of human primary tumor formation, liver metastasis and
chemoresistance. Huanhuan J. Chen, Jian Sun, Harry Hou, Winfried
Edelmann, Xiling Shen, Steven M. Lipkin.
3119 Predicting drug resistance in metastatic renal cell
carcinoma: Personalized medicine by xenografting patient
tumors into chicken embryos. Clarisse Mazzola, Chantalle Willie,
Connor D. MacMillan, Ann F. Chambers, James B. Brugarolas,
Nicholas Power, Hon S. Leong.
3120 RUNX2 rescues the inhibitory effect of FGFR-2
silencing and increases the metastatic potential of IBH-6 human
breast cancer xenografts. Cecilia Pérez Piñero, María May, Isabel
A. Lüthy, Claudia Lanari.
3121 Evaluation of novel combinations of PI3K-mTOR
inhibitors with dacomitinib (dac) or chemotherapy in PTENdeficient genomically characterized patient-derived tumor
xenografts (gPTX). Irene Brana, Nhu-An Pham, Lucia Kim, Shingo
Sakashita, Ming Li, Christine Ng, Yuhui Wang, Peter Loparco, Jose
R. Sierra, Lisa Wang, Lillian L. Siu, Ming S. Tsao.
3122 Combination effect of metformin with gemcitabine for
gemcitabine-resistant pancreatic adenocarcinoma. Keiichi Suzuki,
Osamu Takeuchi, Masayoshi Osaku, Yoshinori Yamada.
3123 Modeling anti-leukemic therapy by patient derived
AML xenografts with distinct phenotypes/geneotypes. Jinping
Liu, Xiaoyu An, Na Wang, Di Wang, Liang Huang, Ran Wu, Jie Cai,
Jean-Pierre Wery, Henry Li.
3124 Xenograft models for development of new drugs
targeting fibroblast growth factor receptor (FGFR). Lan Zhang,
Juan Zhang, Qian Shi.
3125 Fisetin inhibits p90RSK/YB-1 signaling and
downregulates chemoresistance associated P-glycoprotein in
A375 melanoma cells. Deeba N. Syed, Rahul K. Lall, Mohammad
Imran Khan, Maria Shabbir, Hasan Mukhtar.
3126 Renca RCC syngeneic model to evaluate efficacy of
novel antisense oligonucleotides targeting TGF-␤ isoforms.
Hanna Korhonen, Julie-Orlane Redon, Damien France, Guillaume
Serin, Francis Bichat, Frank Jaschinski, Katja Wosikowski, Michel
Janicot.
3127 The effect of Guizhi Fuling Wan(GFW)on bladder tumor
growth in a mouse model. Chi-Chen Lu, Ling-Huei Tseng, Syue-Yi
Chen, Jiann-Der Wu, Shu-Fen Wu, Michael W.Y. Chan, Yu-Wei Leu,
Cheng-Da Hsu.
3128 Efficacy of diethyldihydroxyhomospermine against
human pancreatic adenocarcinoma using orthotopic
implantation of human pancreatic L3.6pl cells into the pancreas
of nude mice. Ajit K. Shah, Michael T. Cullen, Cheryl H. Baker.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3129 A platform to assess multiple therapy options
simultaneously in a patient’s own tumor. Richard Klinghoffer,
Alicia Moreno-Gonzalez, Michael Carleton, Jason Frazier, Marc
Grenley, Ilona Tretyak, Nathan Hedin, Joyoti Dey, Joseph Casalini,
Beryl Hatton, Sally Ditzler, James Olson, Daniel Pierce, Ellen
Filvaroff, Nathan Caffo.
3130 Zoledronic acid inhibits proliferation and metastasis of
human pancreatic cancer in the patient-derived orthotopic
xenograft (PDOX) model by targeting tumor-educated
macrophages. Yukihiko Hiroshima, Mohamed K. Hassenein, Rhiana
Menen, Matthew H. Katz, Jason B. Fleming, Sho Sato, Takashi
Murakami, Mako Yamamoto, Fuminari Uehara, Shinji Miwa, Shuya
Yano, Masashi Momiyama, Ali Maawy, Takashi Chishima, Kuniya
Tanaka, Michael Bouvet, Itaru Endo, Robert M. Hoffman.
3131 Recurrence of cervical cancer following PR agonist
withdrawal in mice. Fabiola Mehta, Salil Ojha, Sang-Hyuk Chung.
3132 Nigella sativa oil affects lung cancer growth and
modulates anti-oxidant enzymes in a mouse xenograft model.
Kevin Gallagher, Syed Jafri, Reinhold Munker, Glenn Mills, Jennifer
Minadeo, Heather Kleiner - Hancock, Misty Prince, Ludmila Gavriliuc,
Shubnum Chaudhery, Catherine Chaudoir, Runhua Shi.
3133 The anti-tumor effects of acetazolamide and
sulforaphane on bronchial carcinoids: Preclinical modeling and
mechanism. Reza Bayat Mokhtari, Syed S. Islam, Narges Baluch,
Karen Aitken, Sushil Kumar, Hai-Ling Margaret Cheng, Mehrdad
Yazdanpanah, Khosrow Adeli, Yuanxiang Zhou, Ernest Cutz, Herman
Yeger.
3134 Crizotinib inhibits tumor growth and metabolic
inactivation of gemcitabine in new patient derived orthotopic
pancreatic tumors with c-Met overexpression: A step toward
personalized treatment in pancreatic cancer. Amir Avan, Viola
Caretti, Niccola Funel, Elena Galvani, Mina Maftouh, Richard J.
Honeywell, Tonny Lagerweij, Daniela Campani, Henk M. Verheul,
Gerrit J. Schuurhuis, Ugo Boggi, Godefridus J. Peters, Thomas
Würdinger, Elisa Giovannetti.
3135 Pre-treatment p-EGFR levels in tumors from a
genetically engineered mouse model of BRAFV600E colorectal
cancer predict response to combined BRAF/EGFR inhibition. Erin
M. Coffee, Ryan B. Corcoran, Jeffrey A. Engelman.
3136 X᎑MAN™ isogenic DualXenoTM models with KRAS
mutation predicts the effect of anti-EGFR agents. Yanmei Sun,
Songling Zhang, Nan Li, Holly Astley, Rebecca Foster, Christine
Schofield, Chris Chris Torrance, Jinying Ning, Qian Shi.
3137 Combined inhibition of MEK and PI3 kinase signaling
results in improved survival in a preclinical orthotopic model for
human glioblastoma multiforme. Rajaa El Meskini, Anthony
Iacovelli, Alan Kulaga, Michelle Gumprecht, Philip Martin, Maureen
Baran, Deborah Householder, Terry Van Dyke, Zoe Weaver Ohler.
3138 IL-6/Stat3 signaling is an indispensable modulator of
oncogene-induced cellular senescence. Jan Pencik, Michaela
Schlederer, Melanie Hassler, Wolfgang Gruber, Fritz Aberger, Richard
Kennedy, Stephen Walker, Stephan Rose-John, Valeria Poli, Robert
Eferl, Harald Esterbauer, Osman Aksoy, Merima Herac, Peter Mazal,
Andrea Haitel, Martin Susani, Richard Moriggl, Zoran Culig, Lukas
Kenner.
3139 Nurr1, a novel target of 1,1-bis(3’-indolyl)-1-(pchlorophenyl) methane for inhibition of the initiation and
progression of skin cancer tumorigenesis. Ravi Doddapaneni,
Cedar Boakye, Punit Shah, Apurva R. Patel, Chandraiah Godugu,
Stephen Safe, Santosh Katiyar, Mandip Sachdeva.
3140 Context specific effects of the BRAFV600E mutation on
hematopoiesis identifies novel models of BRAF mutant
hematopoietic disorders. Eunhee Kim, Stephen S. Chung, Jae H.
Park, Young Rock Chung, Piro Lito, Julie Feldstein, Wenhuo Hu,
Wendy Beguilin, Sebastien Monette, Cihangir Duy, Raajit Rampal,
Leon Telis, Minal Patel, Min Kyung Kim, Ari M. Melnick, Neal Rosen,
Martin S. Tallman, Christopher Y. Park, Omar Abdel-Wahab.
3141 Epithelial-to-mesenchymal transition and therapy
resistance in BRCA1-associated breast cancer. Martine Van
Miltenburg, Jos Jonkers.
3142 Derivation and analysis of preclinical models of human
her-2 positive breast cancer. Paloma A. Valenzuela, Sarah N.
Jallad, Karla Parra, Natzidielly Lerma, Irving Miramontes, Alejandra
Gallegos, Ping Xu, William Cruz-Munoz, Shan Man, Robert S. Kerbel,
Giulio Francia.
7
7
441
POSTER SESSION
Tumor Biology 33
Poster
Section
8
8
Tumor Motility and Invasion 1
Poster Abstract
Board Number
1.
3143
Sodium butyrate induced cellular senescence,
inhibited invasion and modulated cellular metabolism in
glioblastoma cells. Hidemitsu Nakagawa, Masahiro
Shindou, Satoru Sasagawa, Kazuyuki Itoh.
2.
3144
PDZ-RhoGEF/␤-arrestin-1 interaction mediates
endothelin A receptor-induced RhoA activation and cell
motility in ovarian tumor cells. Piera Tocci, Roberta
Cianfrocca, Elisa Semprucci, Valeriana Di Castro, Anna
Bagnato, Laura Rosanò.
3.
3145
eIF4E, an adverse prognostic marker of
melanoma patient survival, increases melanoma cell
invasion. Shahram Khosravi, Gholamreza S. Ardekani,
Magdalena Martinka, Christopher J. Ong.
4.
3146
Rac1 accumulates in the nucleus at the
invasive front of colorectal cancer through promoting
cell motility. Shinsuke Funakoshi, Hiromasa Takaishi,
Ayano Niibe-Kabashima, Tomohiro Suzuki, Gen Sakai,
Motoko Izumiya, Masayuki Adachi, Yasuo Hamamoto,
Hajime Higuchi, Akinori Hashiguchi, Nobuhiro Tsukada,
Takanori Kanai.
5.
3147
Low oxygen-driven expression of KrasV12
controls a switch between lung tumor growth and
migration. Anette C. Schafer, Jerry W. Shay, Gaudenz
Danuser.
7.
3149
Targeting ERBB2-induced, lysosome-mediated
invasion. Tuula Kallunki, Ditte M. Brix, Bo Rafn, Knut
Kristoffer Bundgaard Clemmensen, Sofie Hagel Andersen,
Noona Ambartsumian, Marja Jäättelä.
8.
3150
Exploring the role of Rap1Gap in the
progression from DCIS to invasive breast carcinoma.
Seema Shah, Kingsley Osuala, Shihong Mao, Quanwen Li,
Bonnie Sloane, Stephen Krawetz, Raymond R. Mattingly.
9.
3151
Muc1/Cin85 complex is a new molecular target
for control of cancer invasion and metastasis. Sandra
Cascio, Joshua Sciurba, Rebecca Hughey, Carlos Camacho,
Olivera Finn.
10.
3152
Integrin ␣6␤1 dependent collective cell
migration in prostate cancer metastasis. Cynthia S.
Rubenstein, Jaime Gard, Raymond B. Nagle, Terry H.
Landowski, Anne E. Cress.
11.
3153
Slit-2 directs the migration of primary cultured
human GBM tumor initiating cells. Hugo GuerreroCazares, Vivian Capilla-Gonzalez, Emily A. Lavell, Alejandro
Ruiz-Valls, Linda Chen, Gabrielle Drummond, Sural
Ranamukhaarachchi, Alfredo Quinones-Hinojosa.
12.
13.
442
3154
RSK2-mediated phosphorylation of stathmin
promotes microtubule polymerization, providing a proinvasive advantage to metastatic cancer cells. Gina
Alesi, Dan Li, Lingtao Jin, Georgia Z. Chen, Dong M. Shin,
Fadlo Khuri, Sumin Kang.
3155
Tks adaptor proteins and invadopodia formation
in the growth and metastasis of melanoma. Shinji Iizuka,
Christine M. Gould, Matthew D. Buschman, Diaz Begoña,
Christopher Abdullah, Sara Courtneidge.
Poster Abstract
Board Number
14.
3156
Autocrine signaling through release of ATP and
activation of P2X7 receptor promotes migration of
human lung cancer cells. Erina Takai, Mitsutoshi
Tsukimoto, Hitoshi Harada, Miki Hiasa, Yoshinori Moriyama,
Shuji Kojima.
15.
3157
An Rgnef (p190RhoGEF/Arhgef28) signaling axis
regulates ovarian cancer progression. Nichol L. Miller,
Isabelle Tancioni, Sean Uryu, Elizabeth G. Kleinschmidt,
Denise C. Connolly, David D. Schlaepfer.
16.
3158
Identifying novel genes critical to invasion in
head and neck squamous cell carcinoma. Sangeeta K.
Jayakar, Olivier D. Loudig, Margaret Brandwein-Gensler,
Ryung S. Kim, Michael B. Prystowsky, Jeffrey E. Segall,
Thomas J. Belbin.
17.
3159
ZAR2 transcriptionally represses the ATPase
ATP6V0A4 to negatively regulate invasiveness of breast
cancer cells. Smita Misra, Gautam Chaudhuri.
18.
3160
ROCK inhibition promotes microtentacle
formation and reattachment of breast cancer cells.
Lekhana Bhandary, Michele I. Vitolo, Rebecca A. Bettes,
Monica S. Charpentier, Amanda E. Boggs, Jana Slovic,
Keyata Thompson, Stuart S. Martin.
19.
3161
Non-cell autonomous regulation of collective
invasion be an epigenetically distinct subpopulation of
tumor cells. Amanda Prechtl, Jill Westcott, Tuyen Dang,
Erin Maine, Gray Pearson.
20.
3162
Differential mechanisms utilized by pancreatic
tumor cells and associated fibroblasts to remodel
stroma during metastatic invasion. Hong Cao, Robbin
Eppinga, Eugene Krueger, Jing Chen, Gina Razidlo, Mark A.
McNiven.
21.
3163
Transendothelial migration of uveal melanoma
cells. Michael D. Onken, Olivia L. Mooren, Jinmei Li, John
A. Cooper.
22.
3164
Cancer cell adhesion and degradome interact to
metastasize. Asif Rizwan, Menglin Cheng, Balaji
Krishnamachary, Lu Jiang, Zaver Bhujwalla, Glunde Kristine.
23.
3165
Docosahexaenoic acid attenuates survival and
progression in subtype-specific breast cancer by
modifying Myc activity. Michael Mouradian, Palvinder K.
Bains, Amy M. Chattin, Ronald S. Pardini.
24.
3166
Rab11 regulates E-cadherin expression and
induces cell transformation in colorectal carcinoma.
Yuan-Chiang Chung, Wan-Chen Wei, Shin-Han Huang, ChiMin Shih, Chih-Ping Hsu, King-Jen Chang, Wei-Ting Chao.
25.
3167
Myosin-Va involvement in malignant properties
of melanoma cells. Anelisa Ramao, Carmen Lucia S.
Pontes, Enilza M. Espreafico.
POSTER SESSION
Carcinogenesis 3
Environmental and Viral Carcinogenesis
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
3168
Tumor cells express genome-derived DNA in
the cytosol. Yu J. Shen, Nina Le Bert, Christine X. Koo, Ho
S. Samantha, Ken J. Ishii, David H. Raulet, Stephan Gasser.
3169
APOBEC-mediated cytosine deamination is a
prominent mutagenic mechanism in human
papillomavirus-driven cancer. Stephen Henderson, Ankur
Chakravarthy, Xiaoping Su, Chris Boshoff, Tim R. Fenton.
3170
Alternative NF-␬B pathway activation enhanced
by deficient TRAF3 in human papillomavirus (HPV)associated head and neck cancer. Jialing Zhang, Hui
Cheng, Xinping Yang, Emine Guven Maiorov, Ozlem Keskin,
Attila Gursoy, Ruth Nussinov, Zhong Chen, Carter Van Waes.
3171
Overexpression of a cancer stem cell marker
doublecortin-like kinase (DCLK1) leads to activation of
inflammatory cascade during development of virusinduced hepatocellular carcinoma. Naushad Ali,
Parthasarathy Chandrakesan, Mark Huycke, Sanam Husain,
Allison F. Gillaspy, Randal May, William L. Berry, Sripathi
Sureban, Dongfeng Qu, Nathaniel Weygant, Michael S.
Bronze, Danny N. Dhanasekaran, Courtney W. Houchen.
3172
Detection of viral HPV DNA in sporadic
colorectal cancers in relation to CpG island methylator
phenotype (CIMP). Raul D. Bernabe-Dones, Wesley
Villavicencio-Torres, Cristina Munoz-Masso, Yaritza Reyes
-Medina, Lorena Marcano-Bonilla, Hector PerezCantalapiedra, Sharon Fonseca-Williams, Mercedes Y.
Lacourt-Ventura, Yasuhiro Yamamura, Nayra Rodriguez,
Marcia R. Cruz-Correa.
3173
HPV integration and methylation patterns in
cervical intraepithelial neoplasia and invasive cervical
cancer via HPV capture and high-throughput
sequencing. Marissa Iden, Samantha Fye, Yi-Wen Huang,
Pengyuan Liu, Janet S. Rader.
3174
The host genomic environment of the provirus
determines the abundance of BLV-infected clones.
Nicolas Gillet, Alix de Brogniez, Nathalie Renotte, Geronimo
Gutierrez, Irene Alvarez, Karina Trono, Luc Willems.
3175
The splice variant of the human papillomavirus
16 E6 protein, E6*, displays anti-tumor properties in
vivo. Whitney Evans, Maria Filippova, Robert Aragon, Valeri
Filippov, Mark Reeves, Penelope Duerksen-Hughes.
3176
The EGFR pathway as the Achilles’ heel for
human papillomavirus-induced tumors: EGFR/MAPK
pathway inhibitors exhibit antiviral activities and limit
tumor growth in vivo. Anastacia M. Griego, Pamela
Barraza, Chelin Hu, Agnieszka Dziduszko, Brianna K.
Crowley, Helen J. Hathaway, Julie E. Bauman, Michelle A.
Ozbun.
3177
Hepatitis C virus transcriptionally
downregulates miR-181c for promotion of hepatocyte
growth towards hepatocellular carcinoma. Ratna B. Ray,
Anupam Mukherjee, Shubham Shrivastava, Ranjit Ray.
3178
Rack1 protects N-terminal phosphorylated cJun from Fbw7-mediated degradation. Jinhui Zhang,
Feng Zhu, Xiang Li, Yanming Xu, Cong Peng, Shengqing Li,
Yong-Yeon Cho, Ke Yao, Tatyana A. Zykova, Ann M. Bode,
Zigang Dong.
3179
Redox signaling to nuclear respiratory factor-1
proteins by reactive oxygen species contributes to the
estrogen-induced breast tumor development. Deodutta
Roy, Quentin Felty, Victor Okoh.
3180
Gastrokine 1 inhibits Helicobacter pylori CagAinduced gastric carcinogenesis. Junghwan Yoon,
WonSang Park, Won Seok Choi.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
3181
Effects of benzo(a)pyrene-7,8-dione and
cadmium on Akt/protein kinase B, MAPK and p53MDM2 activity in primary human bronchial/tracheal
epithelial cells. Jibanananda Mishra, Berrin Serdar.
3182
Tobacco smoke induces pulmonary
neuroendocrine alterations in vivo. Wei Xie, Zhaofeng
Liang, Ying Yin, Chunfeng Xie, Hao Geng, Li Zhao, Rui Wu,
Xiaoting Li, Feifei Deng, Jieshu Wu, Shanshan Geng,
Mingming Zhu, Jianyun Zhu, Weiwei Zhu, Cong Huang,
Caiyun Zhong.
3183
Modulation of NLRP3 by chemotherapeutics:
Potential application in mesothelioma treatment. Arti
Shukla, Catherine Westbom, Joyce Thompson, Maximilian
MacPherson, Stacie Beuschel.
3184
Differential expression of viral agents in
lymphoma tissues of patients with ABC Diffuse Large
B-cell Lymphoma from high and low endemic infectious
disease region. Ali Moshfegh, Therese Högfeldt, Crystal
Jaing, Joachim Lundahl, Anders Osterborg, Kevin Mc
Loughlin, Shea N. Gardner, Baback Gharizadeh, Anna
Porwit, Abeer A. Bahnassy, Abdel-Rahman N. Zekri, Hussein
M. Khaled, Hakan Mellstedt.
3185
Sub-lethal autolysis in livers of mice given
phthalate esters precedes development of hepatic
lesions. Julia H. Carter, Steven Vogelpohl, Mary Kay Tucker,
Robert Tagher.
3186
Transplacental arsenic exposure modifies the
number of hair follicle keratinocytes stem cells and
alters their cell-cycle control. Paula L. Miliani de Marval,
Sun Hye Kim, Marcelo L. Rodriguez-Puebla.
3187
Genomic abnormalities in air pollution-related
lung cancer. Guang-Biao Zhou, Xian-Jun Yu, Li-Chuan Wu,
Yun-Chao Huang, Gao-Feng Li, Zhe-Sheng Wen, Sai-Juan
Chen, Yi Cao, Sheng-Yue Wang, Min-Jun Yang, Zhu Chen.
3188
Evaluation of clonal origin of malignant
mesothelioma/polyclonal origin of malignant
mesothelioma. Sabahattin Comertpay, Rosanna Mezzapelle,
Mika Tanji, Oriana Strianese, Harvey I. Pass, Tracey Weigel,
Joseph Friedberg, Paul Sugarbaker, Thomas Krausz, Ena
Wang, Giovanni Gaudino, Haining Yang, Amy Powers,
Barbara Parsons, Sandra Pastorino, Michele Carbone.
3189
Morphological and molecular study of cellchrysotile interaction in two different cell lines. Luana R.
Ricardi, Paula Rezende-Teixeira, Marcelo Medina de Souza,
Glaucia M. Machado-Santelli.
3190
Activation of autophagy, a key event in
cadmium-induced prostate carcinogenesis. Joe Luevano,
Suman Suman, Trinath P. Das, Jim Moselhy, Chendil
Damodaran.
3191
Elevation of tumor-promoting cytokines in mice
exposed to the environmental contaminant tributyltin.
Shanieek Lawrence, Samuel T. Pellom, Tasia Hurd-Brown,
Anil Shanker, Margaret Whalen.
3192
The environmental estrogen bisphenol A (BPA)
regulates mammary gland stem cells. Cydney Nichols,
Xiangming Ding, Gustavo Miranda-Carboni, Susan A. Krum.
3192A
Senescence may play an important role in
explaining the mechanisms of increased radiosensitivity
of HPV- and EBV-associated HNSCC. Arunkumar
Anandharaj, Oleksandr Ekshyyan, Xiaohua Rong, Dylan
Hartel, Brandon Bauerle, Sean Nathan, Lynn Harrison, Rona
Scott, Runhua Shi, Cherie-Ann O. Nathan.
9
9
443
POSTER SESSION
Chemistry 5
Poster
Section
10
10
Natural Products
Poster Abstract
Board Number
3206
Mistletoe extract inhibits the proliferation of
human hepatocellular carcinoma cells by induction of
apoptosis and down regulation of c-MYC. Xiaoping Ding,
Carrie Cartwright, Lin Tan, Richard Lee, Peiying Yang.
15.
3207
Curcumin induces pancreatic cancer cell death
by targeting IAPs. Carlos J. Diaz Osterman, Malyn M.
Asuncion Valenzuela, Heather R. Ferguson Bennit, Salma
Khan, Nathan R. Wall.
16.
3208
Identification and characterization of a small
molecule involved in the downregulation of RET
transcription in MTC. Vishnu Muthuraj Kumarasamy, YoonJoo Shin, Daekyu Sun.
17.
3209
The anticancer effects of chemically derived
natural products. Jerry T. Thornthwaite, Brandon England,
Spencer England, Michelle Clarke, Lee Roland, Hare Shah.
18.
3210
Supercritical extract of Azadirachta indica in
chemoprevention of colon cancer. Roxanne Khoogar, Keya
Mukhophadyay, Jay Morris, Girish Soman, Michael
Wargovich.
19.
3211
Citral is the major component of ginger-derived
terpenes to mediate p53-dependent apoptosis in cancer
cells. Lucas Fass, Mildred Felder, Manish S. Patankar,
Arvinder K. Kapur.
20.
3212
Ganoderma lucidum (Reishi) chemosensitizes
EGFR-overexpressing inflammatory breast cancer cells
to erlotinib. Ivette Suárez-Arroyo, Michael Moraskie, Luis A.
Cubano, Michelle M. Martínez-Montemayor.
21.
3213
Rosehip (Rosa canina) extracts prevent MAPK
and AKT-mediated cell proliferation in African American
triple-negative breast cancer cells. Patrice Cagle, Tonisha
Coburn, Patrick M. Martin.
22.
3214
C-seco taxanes with 7, 9-linkages exhibit better
activity in drug-resistant tumor cells. Yong Tang, Pei Cai,
Javier Rodríguez-Salarisch, J. Fernando Díaz, Weishuo Fang.
23.
3215
Role of pterostilbene on proliferation, invasion,
and migration in ovarian and uterine cancer cells. Gina
Lowe, Wei Wen, Cai Roberts, James Finlay, Carlotta Glackin,
Ernest Han, Thanh H. Dellinger.
24.
3216
Anti-proliferative properties of Euphorbia
mauritanica medicinal plant against breast cancer.
Mpho S. Choene, Lesetja R. Motadi.
25.
3217
Capsaicin inhibits proliferation and
chemosensitizes gastric carcinoma cells to 5Fluorouracil. Gorkem Kismali, Merve Alpay, Ogunc Meral,
Funda Kosova, Dilek Ulker Cakir, Tevhide Sel.
26.
3204
Screening of extracts from
ethnopharmacologically selected peruvian plants in
human hepatocarcinoma cell line Hep3B. Jean Edouard
Gairin, Cedric Lavergne, Maelle Carraz, Valérie Jullian,
Geneviève Bourdy, Michel Wright.
3218
Zyflamend, a multi-herbal product, selectively
inhibits the growth of triple negative breast cancer cells
in vitro. Angelica M. Gutierrez-Barrera, Banu K. Arun,
Peiying Yang, Carrie Cartwright.
27.
3205
Structural analysis of cardiac glycosides to
determine the basis for tumoristatic activity. Vivek
Kaushik, Yogesh Kaulkarni, Clayton Wright, George
O’Doherty, Neelam Azad, Anand Iyer.
3219
Synergistic effect between Ganoderma lucidum
(Reishi) and lapatinib in HER2ⴙ inflammatory breast
cancer cells. Yismeilin Feliz-Mosquea, Ivette Suárez-Arroyo,
Luis A. Cubano, Michelle M. Martínez-Montemayor.
28.
3220
Lichen derived polyphenols as potential
anticancer drugs. Gajendra Shrestha, Michael Xiao, Richard
Robison, Larry L. St. Clair, Kim O’Neill.
3193
Apoptotic effect of a single compound derived
from natural product in Gefitinib-resistant non-small
cell lung cancer cells. Xing-Xing Fan, Maria P. Wong, ZhiWei Cao, Na Li, Jin-Lin Wu, Hua Zhou, Zhi-Hong Jiang,
Liang Liu, Elaine L. Leung.
2.
3194
Platycodin D induces growth arrest and cell
cycle arrest by activating MDM2 and interacting with
FOXO3a in prostate cancer. Hongxia Xu, Rui Zhou,
Zongliang Lu, Kai Liu.
3.
3195
Transient duration of action is the primary
mechanism responsible for the unique biology of
bryostatin 1. Noemi Kedei, Aleksandra M. Michalowski,
Peter M. Blumberg.
3196
Antitumor effect of a Compound A, a derivative
of a naturally occurring rotenoid deguelin, by inhibition
of ATP binding to heat shock protein 90. Su-Chan Lee,
Ju-Sung Lee, Seung-Yeob Hyun, Hoon Choi, Hongchan An,
Kyu-Won Kim, Young-Ger Suh, Ho-Young Lee.
5.
3197
Gedunin inactivates the co-chaperone p23
causing cancer cell death by apoptosis. Chaitanya A.
Patwardhan, Laura B. Peterson, Brian Blagg, Ahmed Chadli.
6.
3198
Extract from Scutellaria baicalensis Georgi
inhibits prostate cancer growth in bone. Chaoqian Li,
Hongwei Guo, Yi Lu, Jinlu Dai, Evan Keller, Jian Zhang.
7.
8.
9.
10.
11.
12.
13.
444
14.
1.
4.
Poster Abstract
Board Number
3199
Pterostilbene supresses prostate cancer
progression in transgenic mice model. Liangfen Zhang,
Swati Dhar, Agnes M. Rimando, Avinash Kumar, Janice
Lage, Jack R. Lewin, Xu Zhang, Anait S. Levenson.
3200
The effect of a sesquiterpenoid from Tussilago
farfara on cellular proliferation via the Wnt/␤-catenin
signaling pathway in colon cancer Short title: Anti
cancer effect of tussilagone. Jae-Ha Ryu, Hua Li, Hwa Jin
Lee, Woo-Young Kim.
3201
Parthenolide ameliorates experimental colitis
associated colon cancer by inhibition of NF-kB
signaling. Se Lim Kim, Sang-Wook Kim, Seong Hun Kim, In
Hee Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim.
3202
Deciphering the targets and mechanism of
action of the natural product Tonantzitlolone in clear
cell renal cell carcinomas. Carole Sourbier, Brad
Scroggins, Philip Z. Mannes, John A. Beutler, W. Marston
Linehan, Len Neckers.
3203
Honokiol inhibits growth and migration of renal
cell carcinoma. Shujie Cheng, Matt Welty, Isaac Eliaz,
Victor Castillo, Daniel Sliva.
POSTER SESSION
Chemistry 6
Structural and Biophysical Approaches to Understanding Complex Biological
Pathways
Poster Abstract
Board Number
1.
3221
Covalent inhibitors of S100B (SBiXs) in
malignant melanoma. Michael C. Cavalier.
2.
3222
Structural evaluation of several antitumor
Tencon variants. Rosa Cardoso, Shalom Goldberg, Jinquan
Luo, Alexander Barnakov, Edward Swift, Steven Jacobs,
Gary Gilliland.
3.
3223
EGFR targeted iron-oxide nanoparticles for
photodynamic therapy in head and neck cancer.
Dongsheng Wang, xulei qin, guoqing qian, luma halig,
baowei fei, zhengjia chen, zhuo G. chen, nabil F. saba,
dong M. shin, hong xu, andrew Y. wang.
4.
3224
High affinity interaction of K-Ras4B
hypervariable region with Ras active site. Tanmay S.
Chavan, Hyunbum Jang, Lyuba Khavrutskii, Benjamin C.
Freed, Liv Johannessen, Sergey G. Tarasov, Sherwin J.
Abraham, Vadim Gaponenko, Ruth Nussinov, Nadya
Tarasova.
5.
3225
LEDGF IBD domain represents therapeutic
target for MLL leukemia and HIV. Tomasz Cierpicki,
Marcelo J. Murai, Jonathan Pollock, Trupta Purohit, Shihan
He, Adam Yokom, Jay L. Hess, Andrew G. Muntean, Jolanta
Grembecka.
Poster Abstract
Board Number
10.
3230
Genome-wide localization of anti-cancer drugs.
Lars Anders, Matthew G. Guenther, Jun Qi, Zi Peng Fan,
Jason J. Marineau, Peter B. Rahl, Jakob Lovén, Alla A.
Sigova, William B. Smith, Tong Ihn Lee, James E. Bradner,
Richard A. Young.
11.
3231
A homing peptide for targeting macrophages in
glioblastoma. Pille Säälik, Kadri Toome, Kuldar Kõiv,
Dinorah Friedmann-Morvinski, Inder Verma, Gabriele
Bergers, Nina Obad Obad, Rolf Bjerkvig, Erkki Ruoslahti,
Tambet Teesalu.
12.
3232
Optimization of a potent stapled helix peptide
that binds to Replication Protein A. Alex G. Waterson,
Andreas O. Frank, Bhavatarini Vandgamudi, Michael D.
Feldkamp, Elaine M. Souza-Fagundes, Jessica W. Luzwick,
David Cortez, Edward T. Olejniczak, Olivia W. Rossanese,
Walter J. Chazin, Stephen W. Fesik.
13.
3233
Targeting system xc- in breast cancer cells:
Development of novel therapeutics. Jennifer Fazzari,
Hanxin Lin, Katja Linher-Melville, Gurmit Singh.
14.
3234
Covalent capture of protein binding partners
using an azide-tagged, photo-reactive stapled alpha
helical p53 peptide. Amanda L. Whiting, Joe J. Mitala,
Kathryn M. Headley, Joe Reilly, Bethanie L. Morrison, Kevin
A. Murray, Federico Bernal.
6.
3226
GALNT6 stabilizes GRP78 protein by O-type
glycosylation. Jae-Hyun Park, Suyoun Chung, Jiaying Lin,
Koji Ueda, Toyomasa Katagiri, Yusuke Nakamura.
7.
3227
JNK2 oligomerization regulates its activation
through non-canonical pathways. Tamer S. Kaoud, Austin
F. Riggs, Kevin N. Dalby.
15.
3235
Identification of the potential inhibitors of DNA
polymerase kappa. Christopher B. Sullivan, Irina G. Minko,
Kinrin Yamanaka, Amanda K. McCullough, Stephen Lloyd.
8.
3228
Characterization of a novel, orally bioavailable,
potent and highly selective small molecule inhibitor of
PERK: A tool to probe the biphasic concentrationdependent induction of ER stress in models of multiple
myeloma and B-cell lymphoma. Ian Stansfield, Yannick
Ligny, Yvan Simonnet, Christophe Demestre, Nathalie
Amblard, Christophe Meyer, Tamara Geerts, Jeroen Van de
Ven, Ilse Van den Wyngaert, Peter Vermeulen, Inge Beerden,
Danielle Peeters, Johnny Liebregts, Kurt Van Baelen, Cedric
Simillion, Boudewijn Janssen, Tinne Verhulst, Norbert Esser,
James Bischoff, Lieven Meerpoel, Matthias Versele.
16.
3236
Development of a novel cross-linking strategy
to identify distinct proteasome subtypes. Kimberly C.
Carmony, Do-Min Lee, Lalit K. Sharma, Jieun Park, KyungBo Kim, Wooin Lee.
17.
3237
Characterization of CM-572 and CM-769: novel
irreversible modulators of sigma-2 receptor function.
Hilary E. Nicholson, Pei Ling Chia, Anthony Comeau,
Christophe Mesangeau, Christopher McCurdy, Wayne D.
Bowen.
18.
3238
The transmembrane domain of prostate-specific
membrane antigen: its role in oligomerization and
activation in prostate cancer and nonprostatic
neovasculature. Brianna S. Berg, Brandan M. Cook, Nathan
Beattie, Cliff E. Berkman, Jonel P. Saludes.
9.
3229
Managing stress: Discovery of inhibitors of the
atypical kinase eEF2K and the class III PI3K, VPS34.
Matthias Versele, Claire Moore, Christopher G. Proud, Cindy
Rockx, Inez Van de Weyer, Kurt Van Baelen, Stephanie
Blencke, Sebastian K. Wanndinger, Gaston Diels, Didier
Berthelot, Marcel Viellevoye, Bruno Schoentjes, Berthold
Wroblowski, Lieven Meerpoel, William N. Hait.
Poster
Section
11
11
445
POSTER SESSION
Prevention Research 5
Poster
Section
12
12
Cancer Prevention Targets and Trials
Poster Abstract
Board Number
2.
3240
Proximal human aberrant crypt foci as
surrogate markers of colorectal cancer risk. David A.
Drew, Matthew P. Hanley, Allen Mo, Gyuhyeong Goh, Nicole
A. Horelik, Thomas J. Devers, Joel Levine, Richard G.
Stevens, James J. Grady, Daniel W. Rosenberg.
4.
3242
Colorectal cancer screening pilot - comparative
effectiveness research using two screening modalities.
Giske Ursin, Anita Jørgensen, Ole Petter Børmer, Thomas de
Lange, Per K. Sandvei, Christian Thorjussen, Geir Hoff.
5.
6.
3244
Supplementation with selenium-enriched yeast
but not selenomethionine reduces oxidative stress in
healthy men in a randomized clinical trial. Matt G. Kaag,
John P. Richie, Arun Das, Ana Calcagnotto, Raghu Sinha,
Wanda Neidig, Jiangang Liao, Eugene J. Lengreich, Arthur
Berg, Terryl J. Hartman, Amy Ciccarella, Aaron Baker, Telih
Boyiri, Susan Goodin, Robert S. DiPaola, Karam El-Bayoumy.
7.
3245
Multivitamins and cancer in the Physicians’
Health Study II: Expanded analyses and insights. Howard
D. Sesso, William G. Christen, Vadim Bubes, JoAnn E.
Manson, Robert J. Glynn, Julie E. Buring, J. M. Gaziano.
8.
3246
Mapping of functional protein pathway
modulations in non-sun exposed skin of healthy
volunteers using solar simulated light: A new model for
pharmacodynamic testing of skin cancer
chemopreventive drugs. Steven P. Stratton, Clara CurielLewandrowski, Janine G. Einspahr, Valerie Calvert,
Chengcheng Hu, Yira Bermudez, David S. Alberts, George T.
Bowden, Emanuel F. Petricoin.
9.
446
3243
A pilot study comparing breast cancer risk
scores using models with and without breast density
among women of different race/ethnicities undergoing
breast screening in the University of California, Irvine
Athena Breast Health Network cohort. Hannah Lui Park,
Stephanie M. Tran, Jennifer Lee, Deborah Goodman,
Argyrios Ziogas, Richard Kelly, Kathryn M. Larsen, Andrea
Alvarez, Chris Tannous, Julie Strope, Wendy Lynch, Hoda
Anton-Culver.
3247
SAMe versus placebo for the reduction of
serum AFP in patients with hepatitis C cirrhosis and
moderately elevated AFP: A randomized, placebocontrolled, double-blind phase II trial. Timothy Morgan,
Frank L. Meyskens, John Hoefs, Ke-Qin Hu, Tarek
Hassanein, Thomas D. Boyer, Neville R. Pimstone, Kathy
Osann, Rachel Gonzalez, L M. Rodriguez.
10.
3248
Pilot study on the bioactivity of vitamin D in the
skin after oral supplementation. Clara CurielLewandrowski, Jean Tang, Janine Einspahr, Yira Bermudez,
Chiu-Hsieh Hsu, Melika Rezaee, Alex Lee, Joe Tangrea,
Howard Parnes, David Alberts, H-H. S. Chow.
11.
3249
Differential impact of body mass index (BMI) on
absolute and percent breast density; implications
regarding their use as breast cancer risk (BCR)
biomarkers. Susann Schetter, Terryl Hartman, Jason Liao,
John P. Richie, Bogdan Prokopczyk, Cynthia Dubrock, Carina
Signori, Christopher Hamilton, Laurence M. Demers, Karam
El-Bayoumy, Andrea Manni.
Poster Abstract
Board Number
12.
3250
Survival of patients with incident lung cancer
following screening by computed tomography in the
National Lung Screening Trial. Matthew B. Schabath,
Pierre P. Massion, Zachary J. Thompson, Yoganand
Balagurunathan, Dmitry Goldof, Steven A. Eschrich, Robert
J. Gillies.
13.
3251
Assessing risk markers for oral cancer
recurrence. Denise M. Laronde, Lewei Zhang, P. Michele
Williams, Bertrand Chan, Jay H. Park, Catherine F. Poh,
Miriam P. Rosin.
14.
3252
A regulatory variant in CYP2E1 affects the risk
of lung squamous cell carcinoma. Lei Cao, Jia Lin, Bing
He, Hongge Wang, Juan Rao, Yingwen Liu, Xuemei Zhang.
15.
3253
Id4 and FKBP52 interaction regulates androgen
receptor activity in normal prostate and prostate cancer.
Jugal B. Joshi.
16.
3254
Inhaled buformin for lymphangioleiomyomatosis
and early (airway confined) lung cancer. Steven Lehrer,
Peter H. Rheinstein, James L. Mulshine.
17.
3255
Single oral dose pharmacokinetics of cancer
chemopreventive phytochemicals from Angelica gigas
Nakai in men and women. Jinhui Zhang, Li Li, Thomas W.
Hale, Wayne Chee, Chengguo Xing, Cheng Jiang, Junxuan
Lü.
18.
3256
Variation in treatment of severe oral dysplasia:
Knowledge translation in the COOLS trial points to a
pressing concern. Miriam P. Rosin, Kitty K. Corbett, Huijun
Jiang, Tarinee Lubpairee, Catherine F. Poh, Lewei Zhang.
19.
3257
ERC/mesothelin is expressed in human gastric
cancer tissues and cell lines. Tomoaki Ito, Kazunori
Kajino, Masaaki Abe, Koichi Sato, Hiroshi Maekawa,
Mutsumi Sakurada, Hajime Orita, Ryo Wada, Yoshiaki
Kajiyama, Okio Hino.
20.
3258
Targeting premalignant lesions for early breast
cancer detection and intervention. Aman P. Mann,
Ramana Kotamraju, Tambet Teesalu, Erkki Ruoslahti.
21.
3259
Evaluation of the aromatase inhibition potential
of standardized grape extract. Janet E. Olson, Summer V.
Allen, Vera J. Suman, Tanya L. Hoskin, Celine M. Vachon,
James N. Ingle.
22.
3260
Male pattern baldness increases the risk of
aggressive prostate cancer: A prospective analysis of
the Prostate, Lung, Colorectal and Ovarian (PLCO)
Cancer Screening Trial. Cindy Ke Zhou, Ruth M. Pfeiffer,
Sean D. Cleary, Heather J. Hoffman, Paul H. Levine, Lisa W.
Chu, Ann W. Hsing, Michael B. Cook.
23.
3261
Gestational protein malnutrition impairs c-myc
and p63 protein expression, increases prostatic
intraepithelial neoplasia incidence and prostatitis
aggressiveness in adult male offspring subjected to
hormonal handling. Jaqueline C. Rinaldi, Sergio L.
Felisbino, Reneè L. Amorim, Wellerson R. Scarano, Wagner
J. Favaro, Luis A. Justulin.
POSTER SESSION
Epidemiology 9
Molecular and Genetic Epidemiology of Breast, Ovarian, and Cervical Cancers
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
3262 Windows of susceptibility to endocrine disruptors and
gene expression in mammary tissue. Kalpana Gopalakrishnan,
Qian Li, Yula Ma, Luca Lambertini, Jia Chen, Susan L. Teitelbaum,
Fabiana Manservisi, Fiorella Belpoggi, Luciano Bua, Laura Falcioni.
3263 Association of high obesity with PAM50 breast cancer
intrinsic subtypes and gene expression. Marilyn L. Kwan, Candyce
H. Kroenke, Carol Sweeney, Philip S. Bernard, Erin Weltzien,
Adrienne Castillo, Rachel E. Factor, Kaylynn Shakespear, Inga J.
Stijleman, Charles P. Quesenberry, Laurel A. Habel, Lawrence H.
Kushi, Bette J. Caan.
3264 IGF-axis protein expression and survival in Native
Hawaiian breast cancer patients. Brenda Y. Hernandez, Lynne R.
Wilkens, Loic Le Marchand, David Horio, Clayton D. Chong, Lenora
W. Loo.
3265 Dual specificity phosphatase 4 gene expression in
triple negative breast cancer. Michelle L. Baglia, Qiuyin Cai, Ying
Zheng, Jie Wu, Yinghao Su, Fei Ye, Ping-Ping Bao, Hui Cai, Zhiguo
Zhao, Wei Zheng, Wei Lu, Xiao-Ou Shu.
3266 Expression quantitative trait locus analysis of triple
negative breast cancer. Kristen S. Purrington, Drakoulis
Yannoukakos, Jane Carpenter, Heli Nevanlinna, Angela Cox, Gianluca
Severi, Christine Ambrosone, Amanda E. Toland, Andrew K. Godwin,
Hiltrud Brauch, Peter A. Fasching, Penelope Miron, Jenny ChangClaude, Nicholas G. Martin, Grant W. Montgomery, Vessela
Kristensen, Hoda Anton-Culver, Paul Goodfellow, Janet E. Olson,
Hugues Sicotte, Naresh Prodduturi, Daniel W. Visscher, Jeanette E.
Eckel-Passow, S. Keith Anderson, Seth Slettedahl, Curtis Olswold,
Xianshu Wang, V. Shane Pankratz, Susan Slager, Wei Zheng, Arto
Mannermaa, Ute Hamann, Diana M. Eccles, Celine M. Vachon,
Fergus J. Couch.
3267 Targeted DNA and RNA sequencing identifies breast
cancer risk variants associated with differential expression of
CASP8 and CFLAR/CASP10. Nicola J. Camp, Wei-Yu Lin, Alex
Bigelow, Marina A. Parry, Tim Mosbruger, George Burghel,
Venkatesh Rajamanickam, Sushilaben H. Rigas, Rachel Cosby, Dan
Connley, Guoying Wang, Tresa George, Rosalie Waller, Lisa A.
Cannon-Albright, Brandt Jones, Rob Sargent, Malcolm W. Reed,
Angela Cox.
3268 Differences in expression of lncRNAs in breast tumor,
adjacent normal-appearing breast tissue, and normal breast
tissue from healthy donors. Erin Wagner, Yunlong Liu, Bryan
Schneider, Anna Maria Storniolo, Jiali Han, Chunyan He.
3269 QTLs in breast tumor and breast normal adjacent FFPE
specimens from the Nurses’ Health Study. Alejandro QuirozZarate, Benjamin J. Harshfield, Rong Hu, Nick Knoblauch, Andrew H.
Beck, Vincent Carey, Susan E. Hankinson, Rulla M. Tamimi, David J.
Hunter, John Quackenbush, Aditi Hazra.
3270 Gene expression profiling of breast tumors from
African American and Caucasian women: Are molecular
differences meaningful. Allyson L. Valente, Craig D. Shriver, Rachel
E. Ellsworth.
3271 The association between germline genetic variants in
the PI3K-AKT-mTOR pathway and breast cancer disease free
survival. Mala Pande, Melissa Bondy, Kim-Anh Do, Aysegul A.
Sahin, Jun Ying, Gordon B. Mills, Patricia Thompson, Abenaa
Brewster.
3272 Association between estrogen-metabolizing genetic
risk scores and breast cancer risk. Shaneda N. Warren Andersen,
Guoliang Li, Qiuyin Cai, Alicia Beeghly-Fadiel, Martha J. Shrubsole,
Xiao-Ou Shu, Wei Zheng.
3273 Genetic variation in obesity-related genes and breast
cancer risk in the Seoul Breast Cancer Study. Seokang Chung,
Nan Song, Hyuna Sung, Sue K. Park, Wonshik Han, Dong-Young
Noh, Sei-Hyun Ahn, Keun-Young Yoo, Daehee Kang, Ji-Yeob Choi.
3274 SNP-SNP interaction analyses of NQO1 and NF-␬B
signaling pathway genes on breast cancer survival and
treatment outcome. Maral Jamshidi, Rainer Fagerholm, Sofia Khan,
Kristiina Aittomäki, Carl Blomqvist, Marjanka K. Schmidt, Heli
Nevanlinna, BCAC: Breast Cancer Association Consortium.
3275 Genome-wide association study of childhood body
fatness as a risk factor of breast cancer. Sara Lindstrom, Jingmei
Li, Hongyan Huang, Constance Chen, David J. Hunter, Per Hall, Peter
Kraft, Rulla Tamimi.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
3276 Identifying cross-phenotype inflammatory effects in
cancer. Keston Aquino-Michaels, Vasya Trubetskoy, Hae Kyung Im,
Nancy Cox.
3277 A low plasma mitchondrial DNA copy number is
associated with increased breast cancer risk. Bharat
Thyagarajan, Helene Barcelo, Kristin E. Anderson, Karen Swenson,
Heather Nelson, Myron D. Gross.
3278 The effect of cold ischemia time on protein expression
in breast cancer tissues. Galina F. Khramtsova, Andrey I.
Khramtsov, Lise Sveen, Abayomi Odetunde, Oyinlolu Olorunsogo
Adeyanju, Olufunmilayo I. Olopade, Oluwasola A. Olayiwola.
3279 Dense and non-dense mammographic area and risk of
breast cancer by age and tumor characteristics. Kimberly A.
Bertrand, Christopher G. Scott, Rulla M. Tamimi, Matthew R. Jensen,
V. S. Pankratz, Aaron Norman, John Shepherd, Yunn-Yi Chen, Karla
Kerlikowske, Celine M. Vachon.
3280 Interaction between genetic variants in mTOR and
body size on breast cancer risk in African-American and
European-American women. Ting-Yuan D. Cheng, Jyoti Shankar,
Gary Zirpoli, Song Yao, Michelle Roberts, Chi-Chen Hong, Elisa V.
Bandera, Christine B. Ambrosone.
3281 TGF␤ pathway alteration, body mass index, physical
activity and breast cancer outcomes: the Shanghai Breast
Cancer Survival Study. Yinghao Su, Wei Zheng, Hui Cai, Ying
Zheng, Qingchao Qiu, Wei Lu, Xiao-Ou Shu, Qiuyin Cai.
3282 Determination of cancer susceptibility in probands
with breast and ovarian cancer. Kasmintan A. Schrader, Kara N.
Maxwell, Joseph Vijai, Steven Hart, Tinu Thomas, Bradley
Wubbenhorst, Lucia Guidugli, Robert Klein, Marina Corines, Liying
Zhang, Susan Neuhausen, Jeffrey Weitzel, Namrata Gupta, Larry
Norton, Clifford Hudis, Gad Getz, Mark Daly, Steven Lipkin, David
Altshuler, Fergus Couch, Katherine Nathanson, Kenneth Offit.
3283 GWAS identifies risk variants for mucinous ovarian
carcinoma. Linda E. Kelemen, Jonathan Tyrer, Catherine M. Phelan,
Susan J. Ramus, Andrew Berchuck, Simon A. Gayther, Ellen L.
Goode, Celeste L. Pearce, Joellen M. Schildkraut, Georiga ChenevixTrench, Alvaro N. Monteiro, Marc T. Goodman, Thomas A. Sellers,
Paul P. Pharoah.
3284 Genome-wide association study identifies new
susceptibility loci of epithelial ovarian cancer in Han Chinese.
Lian Li, Kexin Chen, Rongyu Zang, Quen Hao, Zhibin Hu, Dongxin
Lin, Ding Ma, Weihua Jia, Hongbing Shen, Qingyi Wei.
3285 Functional analysis of the 9p22 locus implicates the
transcriptional regulation of BNC2 as a mechanism in ovarian
cancer predisposition . Melissa A. Buckley, Howard C. Shen,
Gustavo A. Mendoza-Fandino, Nicholas T. Woods, Anxhela Gjyshi,
Juliet French, Kate Lawrenson, Honglin Song, Jonathan Tyrer, Renato
S. Carvalho, Alexandra Valle, Ann Chen, Sean Yoder, Gregory Bloom,
Ya-Yu Tsai, Ally Yang, Timothy R. Hughes, Xiaotao Qu, Mine Cicek,
Melissa Larson, Ellen Goode, Brooke Fridley, Susan Ramus, Georgia
Chenevix-Trench, Paul Pharoah, Thomas A. Sellers, Simon Gayther,
Alvaro N. Monteiro, Ovarian Cancer Association Consortium.
3286 Identification of genetic loci associated with ovarian
cancer prognosis. Sharon E. Johnatty, Jonathan Tyrer, Jonathan
Beesley, Bo Gao, Yi Lu, Stuart MacGregor, Anna deFazio, Paul
Pharoah, Ellen Goode, Georgia Chenevix-Trench.
3287 Mutational analysis of serous ovarian cancer using Ion
Torrent sequencing. Salome Masghati, Oliver Dorigo, Chintda
Santisvkulvong.
3288 Integration of GWAS, gene expression and protein
interaction data identifies a HOX-centric gene network
associated with serous ovarian cancer risk. Siddhartha Kar,
Jonathan Tyrer, Thomas Sellers, Simon Gayther, Paul Pharoah,
Ovarian Cancer Association Consortium.
3289 Elevation of oxidative expression proteins in human
ovarian epithelial carcinoma. Sharifeh Mehrabi, Shakeria Cohen,
Felix O. Aikhionbare.
3290 Glucose-regulated protein 58 modulates ␤-catenin
protein stability in cervical adenocarcinoma. Chia-Jung Liao,
Syuan-ling Lin, Tzu-Hao Wang, Kwang-Huei Lin.
Poster
Section
13
13
447
POSTER SESSION
Molecular and Cellular Biology 39
Poster
Section
14
14
448
Cell Signaling 1: Breast, Prostate, and Lung Cancer
Poster Abstract
Board Number
1.
3291
Geranylgeranylation signals to the hippo
pathway for breast cancer cell proliferation and
migration. Wenyi Mi, Qiong Lin, Chandra Childress,
Wannian Yang.
2.
3292
Epsin promotes breast cancer progression and
metastasis by controlling nf-␬b activation. Xiaofeng Cai,
Hong Chen.
3.
3293
Leptin induces breast cancer metastasis
through a Neuropilin-1 (NRP-1)/OBR complex. Zakia
Belaid-Choucair, Julie Dam, Nicolas Goudin, Odile Filhole,
Claude Cochet, Yves lepelletier, Tereza Coman, Geneviève
Courtois, Alain Colige, Marie-Paule Defresne, Ralf Jockers,
Olivier Hermine.
4.
3294
Notch signaling is regulated by vacuolar
ATPase in triple negative breast cancer. Sahithi
Pamarthy, Kenneth D. Beaman.
5.
3295
S6 kinase signaling in prognosis and tamoxifen
response in two randomized breast cancer cohorts.
Josefine Bostner, Elin Karlsson, Cecilia Bivik, Gizeh PerezTenorio, Tommy Fornander, Olle Stål.
6.
3296
Tumor suppressive effects of tristetraprolin
expression in metastatic breast cancer. Christina R.
Ross, Gerald M. Wilson.
7.
3297
PTEN loss enhances amphiregulin-specific
signaling and gene expression in triple-negative breast
cancer. Christiana Kappler, Robert Wilson, Bridget
Varughese, Stephen P. Ethier.
8.
3298
Identifying a function for DHHC20 in breast
cancer. Kristin B. Runkle, Samantha Terkowski, Ewa
Stypulkowski, Eric Witze.
9.
3299
Maternal embryonic leucine zipper kinase is
critical for the growth and migration of triple negative
breast cancer cells. Nidhi Batra, Corey Speers, Ivan Uray,
Abhijit Mazumdar, Anna Tsimelzon, Susan Hilsenbeck,
Gordon Mills, Powel Brown.
Poster Abstract
Board Number
16.
3306
Aberrant expression of ribosomal protein p1
and its pseudogene in breast tumors. Yoo J. Han,
Olufunmilayo I. Olopade.
17.
3307
Angiomotin regulates the Hippo pathway to
increase prostate cancer cell growth. Angelica Ortiz, Hao
Zeng, Sue-Hwa Lin.
18.
3308
A-kinase anchoring protein 2 is required for
calcitonin receptor-stimulated invasion of prostate
cancer cells. Ahmed Aljameeli, Arvind Thakkar, Shibu
Thomas, Girish V. Shah.
19.
3309
Castration-resistant prostate cancer (CRPC)
growth is mediated through gamma-aminobutyric acid a
receptor (GABAAR). Weijuan Wu.
20.
3310
N-cadherin promotes docetaxel resistance
through upregulated TLR4 signaling in castration
resistant prostate cancers. Tatsuya Shimomura, Evelyn
Kono, Chau P. Tran, Joyce Yamashiro, Shu Lin, Sean
Hyung-Kwon Lee, Zev A. Wainberg, Robert E. Reiter.
21.
3311
The cholesterol/ 27-hydroxycholesterol axis is a
novel therapeutic target in castrate resistant prostate
cancer. Mahmoud A. Alfaqih, Erik R. Nelson, Rachid Safi,
Jeff Jasper, Ching-yi Chang, Stephen J. Freedland, Donald
P. McDonnell.
22.
3312
The antibiotic salinomycin cotargets two pivotal
pathways in prostate cancer. Nooshin Mirkheshti, Chung
Song, Bandana Chatterjee.
23.
3313
17␤-Estradiol-ER␤ axis confers proliferation
and migration through IGF-1R-dependent expression of
TMPRSS2 in castration-resistant PC-3 cells. Hogyoung
Kim, Amrita Datta, Zakaria Y. Abd Elmageed, Asim B. AbdelMageed.
24.
3314
Co-regulation of srGAP1 by Wnt and androgen
receptor signaling in castration resistant prostate
cancer. Noriko N. Yokoyama, Toshinori Sakai, Zheng Sun,
Shujuan Shao, Jiaoti Huang, Bang H. Hoang, Xiaolin Zi.
25.
3315
RON-mediated hijacking of AR signaling in
androgen-independent prostate cancer. Izhar S. Batth,
Peng Meng, Roble Bedolla, Robert E. Reddick, Addanki P.
Kumar.
26.
3316
Characterizing mechanisms of resistance to
androgen deprivation in prostate cancer. Ginevra Botta,
Judit Jane-Valbuena, Terence Wong, John Doench, Levi A.
Garraway.
27.
3317
The cytosolic domain of a disintegrin and
metalloprotease (ADAM)-15 promotes proliferation of
non-small cell lung cancer (NSCLC). Hsin-Han Hou,
Chong-Jen Yu.
10.
3300
Estrogen stimulates cell cycle progression
dependent on Src kinase activity and IMP1 stabilization
of myc mRNA in estrogen receptor-positive breast
cancer cells. Christopher Abdullah, Hasan Korkaya, Sara A.
Courtneidge.
11.
3301
Inhibition of the secretory pathway calcium
ATPase 1 (SPCA1) in MDA-MB-231 breast cancer cells
and the effect on protein expression. Jane M. Lee, Diana
G. Ross, Gregory R. Monteith, Sarah J. Roberts-Thomson.
12.
3302
CD146, a suppressor of breast cancer, is a
novel target of CD44-signaling. Mohamed E. Abdraboh,
Andrew D. Hollenbach, Madhwa HG Raj, Allal Ouhtit.
13.
3303
Engineering of highly controlled in vitro coculture model to study the mesenchymal stem cells
mediated signaling in breast cancer cells. Amita Daverey,
Allison Drain, Karleen Crone, Srivatsan Kidambi.
28.
3318
Using synthetic lethal screening to identify
therapeutic targets for innately platinum resistant lung
cancer. Kieren D. Marini, Fernando J. Rossello, Luciano G.
Martelotto, D. Neil Watkins.
14.
3304
17␤-hydroxysteroid dehydrogenase type 1 is
under negative regulation from miR-210 and 518c in
breast cancer. Erik Hilborn, Alexander Hung, Agneta
Jansson Jansson.
29.
3319
PKC␦ switches from a pro-apoptotic to a prosurvival signal in K-ras “dependent” lung cancer. Mary
E. Reyland, Angela M. Ohm, Michael G. Edwards, Jennifer
Symonds.
15.
3305
glucocorticoid differentially regulates gene
expression in luminal and basal subtypes of breast
cancer. Jun Ling, Zenaida Lopez-Dee, Shagufta H. Khan,
Raj Kumar.
30.
3320
Functional RANK expression is observed in
disaggregated primary human lung tumors. John M.
Rossi, Yang Pan, William C. Dougall, Daniel Branstetter,
Allison Jacob, Jude Canon, Robert D. Loberg.
POSTER SESSION
EGFR/HER2 Regulation and PI3K/AKT Signaling
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
3321
Using NLPs to study EGFR structure, activation,
and inhibition. Tiffany M. Scharadin, Matthew Saldana,
Michael Schlein, Steven Hoang-Phou, Denise Trans, Dennis
Chang, Wei He, Kit Lam, Kermit L. Carraway, Matthew A.
Coleman, Paul T. Henderson.
3322
Spatio-temporal regulation of epithelial
transformation by mistrafficking of EGFR ligand,
epiregulin. Bhuminder Singh, Galina Bogatcheva, Mary K.
Washington, Robert J. Coffey.
3323
PRAF2 regulates Rab5-dependent endocytic
trafficking of EGFR in neuroblastoma. Lisette P. Yco,
Andre S. Bachmann.
3324
The endocannabinoid system inhibits non-small
cell lung cancer tumorigenesis by modulating the EGF/
EGFR pathway. Janani Ravi, Amita Sneh, Konstantin Shilo,
Mohd Nasser, Ramesh Ganju.
3325
Role of AP2A1 in EGFR nuclear translocation
and transcriptional activation activity. Huai-Gu Chen,
Sheng-Chieh Hsu.
3326
Parallel EMT pathways mediated by epidermal
growth factor, EpCAM and mesenchymal cadherins in
benign endometriotic lesions and endometrial cancer.
Ya-Ting Hsu, Joseph Liu, Peter A. Binkley, Robert S.
Schenken, Rajshwar R. Tekmal, Tim H. Huang, Nameer B.
Kirma.
3327
Epidermal growth factor receptors and penile
carcinoma: the role of EGFR and HER2 expression as
prognostic and predictive markers. Alice M. SilvaAmancio, Isabela W. Cunha, Gustavo C. Guimaraes,
Fernando A. Soares.
3328
Novel regulation of HER2 degradation and
breast cancer cell proliferation by junctional adhesion
molecule-a (JAM-A). Kieran Brennan, Elaine A. McSherry,
Lance Hudson, Elaine W. Kay, Leonie S. Young, Arnold D.
Hill, Ann M. Hopkins.
3329
Investigations into the tumor specific regulation
of HER2 by Grp94 in breast cancer. Pengrong Yan, Hardik
Patel, Chenghua Yang, Tony Taldone, Gabriela Chiosis.
3330
HER2 overexpression induces membrane
deformation that increases cell motility. Inhee Chung,
Mike Reichelt, Donald Dowbenko, Ira Mellman, Mark
Sliwkowski.
3331
CD24 promotes HER2 signaling pathways and
CD24 inhibition sensitizes anti-HER2 therapy in breast
cancer. Yoshimi Arima, Mari Hosonaga, Hideyuki Saya.
3332
HER2-dependent RNA polymerase II binding in
human breast tumors defines a regulon including a
stem cell network. Farah Rahmatpanah, Xin Chen, Zhenyu
Jia, Bozhao Men, Michael McClelland, Dan Mercola.
3333
In vitro-based biochemical studies of erbb2
gene variation to address racial disparities in breast
cancer mortality. Wei He, Matthew Saldana, Tiffany
Scharadin, Steven Hoang-Phou, Denise Trans, Dennis
Chang, Kermit Carraway, Paul Henderson, Matthew A.
Coleman.
3334
The role of nuclear HER3 in breast cancer
resistance. Patrick Ming Kuen Tang, Ui Soon Khoo, Adrian
L. Harris, Anthony Kong.
3335
Increased ErbB3 and EGFR activity mediate
lapatinib resistance in prostate cancer. Maitreyee K.
Jathal, Thomas M. Steele, Benjamin A. Mooso, Leandro S.
D’Abronzo, Salma Siddiqui, Christiana Drake, Paramita M.
Ghosh.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3336
The heterotypic interaction between CXCR7 and
EGFR is an alternative proliferation mechanism in breast
cancer. Nicole Salazar, Daniel Muñoz, Rajendra K. Singh,
Bal L. Lokeshwar.
3337
LRIG1 decreases cell proliferation and motility
through downregulation of ErbB2 611-CTF. Maria E.
Cedano-Prieto.
3338
IGFBP2 promotes EGFR/STAT3 nuclear crosstalk
in glioma. YingXuan Chua, Yuexin Liu, Limei Hu, Kirsi
Granberg, Maartje Verploegen, Wei Zhang.
3339
The regulatory subunit of PI3K, p85␤, induces
cellular transformation, enhanced cell proliferation and
increased PI3K signaling. Yoshihiro Ito, Jonathan R. Hart,
Lynn Ueno, Peter K. Vogt.
3340
Exploiting the non-overlapping dysregulation of
Notch and PI3K/AKT signaling pathways as a guide for
personalizing uterine cancer therapy. Rebecca A. Previs,
Cristina Ivan, Heather J. Dalton, Ashley N. Davis, Justin N.
Bottsford-Miller, Behrouz Zand, Michael H. McGuire,
Guillermo N. Armaiz-Pena, Robert L. Coleman, Keith A.
Baggerly, Anil K. Sood.
3341
Cross-talk between PI3K/AKT and ER␣
signaling leads to STAT3/6-modulated epigenetic
transcription in aggressive breast cancer. Hang-Kai Hsu,
Pei-Yin Hsu, Yao Wang, Zelton D. Sharp, Tim H.-M. Huang,
Victor X. Jin.
3342
The p110␤ isoform of PI3K modulates response
to growth factor receptor signaling in breast cancer
cells irrespective of PTEN status. Stephanie J. Bouley,
Lloye M. Dillon, Todd W. Miller.
3343
Anomalous expression of claudin 16 in ovarian
cancer: Role of PKC, PI3K and estrogen. Nayara G.
Tessarollo, Marcela Paes, Murilo Cerri, Alice Herlinger,
Klesia Madeira, Renata Daltoé, Ian Silva, Leticia Rangel.
3344
Akt1 and Akt3 exert opposing roles in the
regulation of vascular tumor growth. Thuy L. Phung, Qi
Xue, Sokha Nhek, Damien Gerald, Carole Perruzzi, Sriram
Ayyaswamy, Wa Du, Sandaruwan Geeganage, Laura
Benjamin.
3345
Measurement of Akt activity in single primary
human pancreatic cancer cells using chemical
cytometry. Angela Proctor, S. Gabriela Herrera-Loeza, Jen
Jen Yeh, Nancy L. Allbritton.
3346
Development of a multiplex screening panel for
Akt signaling pathway biomarkers in cell and tissue
lysate models. Thomas W. Miller, Karen Tressler, Jill
Dunty, Paula Eason, Leonid Dzantiev, Sripriya Ranganathan,
Laura Schaefer, David Stewart, Pankaj Oberoi, Jacob
Wohlstadter.
3347
Post-translational modifications of Akt isoform
in chemoresistance of endometrial cancer. Jérôme
Grenier-Naud, Sophie Parent, Eric Asselin.
3348
Netrin-4/Integrin beta-4 interaction promotes
glioblastoma cell proliferation and protects from
temozolomide induced cellular senescence via
activating PI3K/AKT pathway. Yizhou Hu, Irene Ylivinkka,
Li Li, Ping Chen, Sampsa Hautaniemi, Tuula A. Nyman,
Jorma Keski-Oja Keski-Oja, Marko Hyytiäinen.
3349
Crosstalk between Runx2 regulatory network
and insulin-like growth factor receptor/Akt signaling
pathway in bone metastasis of breast cancer. Manish
Tandon, Zujian Chen, Jitesh Pratap.
3350
CIP2A regulates cell proliferation via akt
signaling pathway in human lung cancer. Ningjing Lei,
Bo Peng, Jiangying Zhang.
Poster
Section
15
15
449
POSTER SESSION
Poster
Section
16
16
Energetics and the Warburg Effect
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
450
3351
Survival of colorectal cancer cells following
chemotherapy relies on a SIRT1-dependent increase in
oxidative phosphorylation. Thomas T. Vellinga, Vincent C.
de Boer, Tijana Borovski, Kari Trumpi, Szabolcs Fatrai, Onno
Kranenburg, Inne H. Borel Rinkes, Jeroen Hagendoorn.
3352
miR-122 targets pyruvate kinase M2 and
affects metabolism of hepatocellular carcinoma. Zhi Xu,
Angela Liu, Nikki Lee, Jinfei Chen, John M. Luk.
3353
Docosahexaenoic acid enhances 2deoxyglucose treatment in breast and lung cancer cells
in vitro. Michael Mouradian, Irvin V. Ma, Erika D. Vicente,
Amy M. Chattin, Ronald S. Pardini.
3354
The level of aerobic glycolysis as an effective
predictor of tumorigenicity. Doo Young Lee, Young Jin
Park, Jung Yoon Bae, Jin Kim.
3355
Inhibiting glyoxylase 1 as a strategy to target
highly glycolytic cancer cells. Sylvia Gruenewald, Michael
Steckel, Andreas Timmermann, Hartmut Rehwinkel, Patrick
Steigemann, Sylvia Zacharias, Alexander Walter, Marcus
Bauser, Andrea Haegebarth.
3356
Temozolomide resistance in human
glioblastoma is associated with marked increase in
PDK1 and MGMT expression. William Lee, Kiran Kumar
Velpula, Andrew J. Tsung.
3357
Glucose transporter 1 positivity on primary
lesions of esophageal squamous cell carcinoma is
associated with hematogenous recurrence. Hiroshi
Sawayama, Takatsugu Ishimoto, Masayuki Watanabe, Naoya
Yoshida, Yoshifumi Baba, Hidetaka Sugihara, Daisuke Izumi,
Hideo Baba.
3358
Significant increase in survival of triple
negative breast cancer animal model in response to
BPM31510 alone or in combination with standard of
care: BPM31510 mediated dynamic metabolic (Warburg)
shift in breast cancer as potential mechanism. Niven R.
Narain, Anne R. Diers, Tony E. Walshe, Arleide Lee, Rakib
Ouro-Djobo, Vivek K. Vishnudas, Ely Benaim, Rangaprasad
Sarangarajan.
3359
JMJD5 regulates PKM2 nuclear translocation
and reprograms HIF-1␣-mediated glucose metabolism.
Hung-Jung Wang.
3360
Loss of sulf-1 reprograms energy metabolism in
ovarian cancer. Susmita Mondal, Debarshi Roy, Juliana C.
Pereira, Eduardo N. Chini, Vijayalakshmi Shridhar.
3361
EGFR signaling regulates aerobic glycolysis in
EGFR-mutated lung adenocarcinoma. Hideki
Makinoshima, Masahiro Takita, Shingo Matsumoto, Atsushi
Yagishita, Satoshi Owada, Hiroyasu Esumi, Katsuya
Tsuchihara.
3362
Tyr-phosphorylation of PDP1 toggles
recruitment between ACAT1 and SIRT3 to regulate
pyruvate dehydrogenase complex and promote the
Warburg effect. Jun Fan, Ting-Lei Gu, Titus Boggon, Sumin
Kang, Jing Chen.
3363
Inhibition of glycolysis and proliferation of
colon cancer cells by 3-(3-pyridinyl)-1-(4-pyridinyl)-2propen-1-one (3PO) an inhibitor of 6-phosphofructo-2kinase (PFKFB3). Michael A. Lea, Raymond Geherty,
Rachelle David, Charles desBordes.
3364
Extracellular ATP-induced intracellular ATP
concentration elevation mediated by macropinocytosis
promotes growth, survival, and drug resistance of
cancer cells. Yanrong Qian, Xuan Wang, Yi Liu, Yunsheng
Li, Robert A. Colvin, Lingying Tong, Shiyong Wu, Xiaozhuo
Chen.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3365
Aldolase A induces invasion/metastasis of lung
cancer through modulating HIF1-␣ and is a marker for
poor clinical outcome. Yu-Chan Chang.
3366
The role of glucose metabolism and SIRT6 in
skin carcinogenesis. Jee-Eun Choi, Carlos Sebastian, Raul
Mostoslavsky.
3367
Understanding the role of metabolic
reprogramming in breast cancer progression and
metastasis. Fanny Dupuy, Julianna Blagih, Sébastien
Tabariès, Julie St-Pierre, Russell G. Jones, Peter M. Siegel.
3368
Down-regulation of LDH-A reduced lactate
production and changed the expression of glycolysisassociated transporters. Henrike Schroer, Christian G.
Fabian, Marina Kreutz, Kristina Goetze, Wolfgang MuellerKlieser.
3369
Differential biotherapeutic advantages of honey
in targeting the Warburg effect and survival of MRC-5
and A549 cell lines. Ibrahim O. Farah, Veshell L. Lewis,
Wellington K. Ayensu, Joseph A. Cameron.
3370
Natural compound targeting metabolism: A new
insight for the treatment of triple negative breast
cancer. Ritu Arora, David Schmitt, Steve McClellan, Ming
Tan, Windy Dean-Colomb.
3371
Iodoacetate and 3-bromopyruvate exert
differential effects on human neuronal tumor SK-N-SH
and U-87 cells. Alok Bhushan, Tanushree Chatterji, Wendy
Wong, Nisha Rizvi, Anurag K. Balaraju, Aishwarya Neti,
James C. Lai.
3372
Constraints-based metabolic flux analysis
approach links tumor stage to metabolic adaptations
and survival in cancer cells. Abhinav Achreja, Lifeng
Yang, Hongyun Zhao, Juan Marini, Deepak Nagrath.
3373
Contribution of microRNA-122 to the
homeostasis of liver energy metabolism. Ann-Ping Tsou,
Shuo-Ting Wang, Tse-Wen Tao.
3374
Fasting chemosensitizes tumor cells by
affecting their metabolism. Giovanna Bianchi, Roberto
Martella, Silvia Ravera, Andrea Petretto, Danilo Marimpietri,
Laura Emionite, Selene Capitanio, Gianluca Bottone,
Annamaria Orengo, Cecilia Marini, Gianmario Sambuceti,
Vito Pistoia, Valter D. Longo, Lizzia Raffaghello.
3375
Targeting glucose metabolism by 2deoxyglucose in gastrointestinal stromal tumors. Thomas
Mühlenberg, Susanne Grunewald, Martin Schuler, Sebastian
Bauer.
3376
Targeting metabolic flux of tumor cells to
prevent pancreatic cancer associated cachexia. Surendra
K. Shukla, Pankaj K. Singh.
3377
Glutamine mediated aggressiveness and drug
sensitivity in ovarian cancer cells. Lifeng Yang, Tyler J.
Moss, Juan C. Marini, Selanere Mangala, Stephen Wahlig,
Julia Win, Dan Su, Anil K. Sood, Prahlad T. Ram, Deepak
Nagrath.
3378
Glutaminase activity determines cytotoxicity of
L-asparaginases on leukemia cell lines. Jean-Hugues
Parmentier, Maristella Maggi, Erika Tarasco, Claudia Scotti,
Vassilios Avramis, Steven D. Mittelman.
3379
Metabolic influences of pancreatic tumor
microenvironment on pancreatic cancer cell’s
metabolism. Joelle Baddour, Lifeng Yang, Juan C. Marini,
Janusz Franco-Barraza, Edna Cukierman, Chaoxin Hu,
Anirban Maitra, Deepak Nagrath.
3380
Cancer usurps skeletal muscle as an energy
repository. Yi Luo, Junya Yoneda, Hitoshi Ohmori,
Takamitsu Sasaki, Hiroki Kuniyasu.
POSTER SESSION
Gene Expression and Transcriptional Control 4
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
3381
Investigation of C/EBPG transcription factor role
in regulation of ERCC4 and ERCC5 in human lung
cancer cells. Xiaolu Zhang, Jiyoun Yeo, Erin L. Crawford,
James C. Willey.
3382
Nifurtimox enhances the therapeutic efficacy of
radiation by inducing reactive oxygen species and
related pathways: Pre-clinical study in
medulloblastoma. Don Eslin, Umesh T. Sankpal, Chris M.
Lee, Giselle Saulnier Sholler, Robert M. Sutphin, Paul
Bowman, Jeffrey C. Murray, Riyaz M. Basha.
3383
JunB/AP-1 controls MM cell proliferation,
survival and drug resistance in the bone marrow
microenvironment. Fengjuan Fan, Sonia Vallet, Martin
Sattler, Giovanni Tonon, Muhammad H. Bashari, Latifa
Bakiri, Hartmut Goldschmidt, Erwin F. Wagner, Dirk Jaeger,
Klaus Podar.
3384
An internal ribosomal entry site in the 5’untranslated region of p16INK4a mRNA provides a novel
mechanism for the regulation of its translation.
Alessandra Bisio, Elisa Latorre, Virginia Andreotti, Alessandro
Provenzani, Giovanna Bianchi- Scarrà, Paola Ghiorzo, Alberto
Inga.
3385
Sox2 is necessary for glioblastoma cell
plasticity. Artem D. Berezovsky, Laila M. Poisson, Xin Hong,
Tom Mikkelsen, Ana C. deCarvalho.
3386
Post-translational mechanisms related to PAR-4
regulation in endometrial cancer. Kevin Brasseur, Sophie
Parent, François Fabi, Éric Asselin.
3387
Upregulation of gene expression in
oligodendrogliomas is linked to an increase in GA
binding protein alpha transcription. Barbara Klink, Karol
Szafranski, Jaime Campos-Valenzuela, Sophie Eisenreich,
Dietmar Krex, Eva-Maria Gerlach, Karl Hackmann, Andreas
Rump, Gabriele Schackert, Matthias Platzer, Lars Kaderali,
Evelin Schröck, Khalil Abou-El-Ardat.
3388
The CD44s splice isoform is essential for breast
tumor initiating cell properties. Rhonda Brown, Sali Liu,
Lauren Reinke, Chonghui Cheng.
3389
Targeting SALL4 in lung cancer through a novel
Cbl-b/IGF1R&EGFR axis. Ailing Li, Wenbin Ou, Jonathan
Fletcher, Kol Jia Yong, Henry Yang, Ross Soo, Daniel Tenen,
Li Chai.
3390
Epigenetic corruption of the Vitamin D signaling
in prostate cancer. Sebastiano Battaglia, Steven
Seedhouse, Ellen Karasik, Dominic Smiraglia, Barbara
Foster.
3391
Alteration of mammary tumor cell behavior by
FLIZ1. Torri Anderson, Christopher Cali, Katherine Bell, Keith
G. Danielson, Ashley Klein, Christina Martin, Sara Radecki,
Adam Santoro, John A. Schmidt, Janice E. Knepper.
3392
Thromboxane-A2 receptor ␤-isoform regulates
the activity of the tumor suppressor FOXO3 via
phosphorylation by ERK in urothelial cancer. Philip M.
Sobolesky, Perry V. Halushka, Elizabeth Garrett-Mayer, Omar
Moussa.
3393
Nuclear receptor Nurr1 mediates cell
proliferation and is involved in a p53-microRNA-34
regulatory network. Jordan A. Beard, Justin L. Hills, Alexa
Tenga, Apana A. Takwi, Taosheng Chen.
3394
In-depth gene expression profiling of
seminomatous testicular germ cell tumors. Sunali Patel,
Shirley Chu, Lovorka Degoricija, Kathy Y. Lee, Ad J. Gillis,
Martin Rijlaarsdam, Lambert C. Dorssers, Leendert H.
Looijenga.
3395
Role of the activating protein 2 transcription
factor in regulating cell invasion and migration in
malignant glioma. Saket Jain, Ho Yin Poon, Roseline
Godbout.
3396
Dual lineage inhibition of ETV1 and KIT disrupts
the ETV1-KIT feed forward circuit and potentiates
imatinib antitumor effect in GIST oncogenesis. Leili Ran,
Inna Sirota, Zhen Cao, Devan Murphy, Shipra Shukla,
Ferdinando Rossi, John Wongvipat, William D. Tap, Peter
Besmer, Cristina R. Antonescu, Yu Chen, Ping Chi.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3397
Rational targeting of protein translation for
cancer treatments. Elizabeth Chang, Duc Nguyen,
Qingyuan Yang, France Carrier.
3398
Reciprocal regulation of MYB and CXCR4 in
pancreatic cancer cells: Potential pathobiological
implications. Sanjeev K. Srivastava, Arun Bhardwaj, Sumit
Arora, Seema Singh, William E. Grizzle, Ajay P. Singh.
3399
Detection and validation of novel RNA cancer
biomarkers by single molecule RNA fluorescence in situ
hybridization (smRNA FISH). Hans E. Johansson, Arturo V.
Orjalo, Sally R. Coassin, Raymund Yin.
3400
Integrated functional RNAi screening and
structural genomics identifies inverse co-modulators of
TP53 family and NF-kB transitional activation as
potential therapeutic targets in head and neck
squamous cell carcinoma. Anthony D. Saleh, Shaleeka
Cornelius, Hui Cheng, Scott Martin, Pinar Ormanoglu,
Xinping Yang, Zhong Chen, Carter VanWaes.
3401
Inter-individual variation in MUC5B allele
specific expression in normal bronchial epithelial cells
and relationship to lung cancer. Xiaolu Zhang, Jiyoun Yeo,
Erin L. Crawford, Thomas M. Blomquist, James C. Willey.
3402
⌬N-p63␣ and TA-p63␣ exhibit intrinsic
differences in transactivation specificities that depend
on distinct features of DNA target sites. Yari Ciribilli,
Alessandra Bisio, Paola Monti, Giorgia Foggetti, Ivan
Raimondi, Paola Campomenosi, Paola Menichini, Gilberto
Fronza, Alberto Inga.
3403
Circadian fluctuations in “housekeeping” gene
expression measured by RNA-seq. Tracy L. Peters,
Elizabeth J. Ferree, Yaou Sheng, Aaron E. Hoffman.
3404
Identifying genes involved in retinoic-acidmediated breast tumor progression by total-genomeknockdown screen. Krysta M. Coyle, Cheryl Dean, Lu-Zhe
Pan, Dae-Gyun Ahn, Mohammad Sultan, Jayme Salsman,
Graham Dellaire, Carman Giacomantonio, Patrick W. Lee,
Paola Marcato.
3405
E12 and E47 are essential for TWIST1
dependent suppression of oncogene-induced
senescence in NSCLC. Lucia Mazzacurati, Sarah N.
Chatley, Zachary Yochum, Charles M. Rudin, Phuoc T. Tran,
Timothy F. Burns.
3406
Activity of catechol-O-methyltransferase gene
promoter polymorphisms in renal cancer cells. Inik
Chang, Shinichiro Fukuhara, Darryn K. Wong, Ankurpreet
Gill, Varahram Shahryari, Soichiro Yamamura, Shahana
Majid, Sharanjot Saini, Hiroshi Hirata, Koji Ueno, Guoren
Deng, Rajvir Dahiya, Yuichiro Tanaka.
3407
Regulation of c-Myc and p53 by splicing factor
SRp20. Xiaolong He, Jilai Yang, Shijie Wang.
3408
FOXM1 regulates doxorubicin resistance
through the non homologous end joining pathway and is
associated with recurrence of bladder cancer. Yun-Gil
Roh, Se-Ra Lee, Won-Tae Kim, Seon-Kyu Kim, In-Sun Chu,
Sun-Hee Leem.
3409
Transcription factor signature of head and neck
squamous cell carcinoma. Daria A. Gaykalova, Judi
Manola, Hiroyuki Ozawa, Kathryn Morton, Justin Bishop,
Michael Considine, Rajni Sharma, Chi Zhang, Elana Fertig,
Marietta Tan, Patrick Hennessey, Julie Ahn, Wayne Koch,
Zubair Khan, Christine H. Chung, Michael F. Ochs, Joseph
A. Califano.
3410
A novel regulatory region of the MYC oncogene
decreases Myc transcriptional activity. Manpreet Kalkat,
Amanda Wasylishen, Pak-Kei Michael Chan, Aleksandra
Pandyra, Sam Sulgi Kim, Christina Bros, Brian Raught, Linda
Z. Penn.
Poster
Section
17
17
451
POSTER SESSION
Poster
Section
18
18
Genomic and Molecular Characterization of Cancer 1
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
452
3411 A genome-wide RNA interference screen identifies
synthetic lethal interactions with the BRAF oncogene. Chengyin
Min, David Konieczkowski, Christine Kwon, Marika Linja, Krishna
Vasudevan, Bokang Rabasha, Barbara Weir, Eva Goetz, Levi
Garraway.
3412 Distinct copy number alterations in genomes of oral
cavity squamous cell carcinomas. Huei-Tzu Chien, Shiang-Fu
Huang, I-How Chen, Chun-Ta Liao, Hung-Ming Wang, Sou-De Cheng,
Ling-Ling Hsieh.
3413 A genetic analysis of splicing in neuroblastoma
identifies opposing functions for FUBP1 splice variants in MYC
regulation. Justin Chen, Christopher S. Hackett, Shile Zhang, Young
K. Song, Annette Molinaro, David A. Quigley, Allan Balmain, William
C. Gustafson, Terry A. Van Dyke, Pui-Yan Kwok, Javed Khan, William
A. Weiss.
3414 Genomic signatures of melanoma maintenance.
Faranak Ghazi Sherbaf, Koichiro Inaki, Denis Bertrand, Xing Yi Woo,
Dave Hoon, Axel Hillmer, Edison Liu.
3415 Genetic analysis of multifocal glioblastoma multiforme
foci points to their monoclonal evolution and highlights early
and late events in their development. Khalil Abou-El-Ardat,
Dietmar Krex, Michael Seifert, Kerstin Becker, Morten Hillmer, Sophie
Eisenreich, Arleta Käßner-Frensel, Petra Freitag, Eva-Maria Gerlach,
Karl Hackmann, Andreas Rump, Gabriele Schackert, Evelin Schröck,
Barbara Klink.
3416 Transcriptome analysis of papillary thyroid cancer
using next-generation sequencing technologies in Korean
patients. Seungbok Lee, Hyeon-Gun Jee, Kyu Eun Lee, Jeong-Sun
Seo.
3417 The genomic landscape of canine melanoma reveals
broad mutational heterogeneity and recurrent patterns of
structural variation. William P. Hendricks, Victoria Zismann, Berry
Button, Christophe Legendre, Waibhav Tembe, Holly Yin, Michael
Bittner, Donald Berry, Matthew Huentelman, Chand Khanna, Patricia
LoRusso, Matthew Breen, Aleksandar Sekulic, Jeffrey Trent.
3418 Rare germline copy number variations in hereditary
cutaneous melanoma. Felipe Fidalgo, Tatiane Rodrigues, Amanda
G. Silva, Luciana Facure, Amanda Nóbrega, Bianca Sá, João P.
Duprat, Maria I. Achatz, Carla Rosenberg, Dirce M. Carraro, Ana C.
Krepischi.
3419 Frequency and function of ERBB3 mutations in bladder
cancer. Aphrothiti J. Hanrahan, John P. Sfakianos, Ricardo Ramirez,
Phillip H. Kim, Gopa Iyer, Hikmat A. Al-Ahmadie, Sasinya N. Scott,
Dean F. Bajorin, Bernard H. Bochner, Jonathan A. Coleman,
Jonathan E. Rosenberg, Michael F. Berger, Sarat Chandarlapaty,
David B. Solit.
3420 TERT promoter mutations are rare in uveal melanoma.
Adriana A. AMARO, Marina Gualco, Maria Dono, Ulrich Pfeffer, Irena
Maric, Carlo Mosci.
3421 Serial whole exome sequencing showed the genetic
aggravation of refractory osteosarcoma. Su Jin Heo, Ji Woong
Kim, Woo Sun Kwon, Hyo Ki Kim, Min Hee Hong, Woo Ick Yang, SeKyu Kim, Hyo Song Kim, Hyun Cheol Chung, Tae Hyun Hwang, Sun
Young Rha.
3422 RNAi screening identifies FGFR4 as a modulator of
growth and survival in Ewing sarcoma. David O. Azorsa, Irma M.
Gonzales, Shilpi Arora, R. Tanner Hagelstrom, Tanya H. Little, Robert
J. Arceci, Spyro Mousses.
3423 The genomic evolution of prostate cancer under the
selective pressure of anti-androgen therapy. Joël R. Gsponer,
Tanja Dietsche, Alexander Rufle, Thomas Lorber, Darius Juskevicius,
Valeria Perrina, Elisabeth Lenkiewicz, Tobias Zellweger, Alexander
Bachmann, Michael T. Barrett, Cyrill A. Rentsch, Christian Ruiz,
Lukas Bubendorf.
3424 Deciphering the genomic heterogeneity and evolution
in malignant melanoma by genomic profiling of clonal tumor
populations. Thomas Lorber, Tanja Dietsche, Valeria Perrina,
Michael Barret, Kathrin Glatz, Christian Ruiz, Lukas Bubendorf.
3425 Whole-transcriptome analyses of EBV-associated
nasopharyngeal carcinoma using next-generation transcriptome
sequencing. Cathy Ka-Yan Mak, Grace Tin-Yan Chung, Kevin YukLap Yip, Ken Kai-Yuen Tso, Sau-Dan Lee, Siu-Tim Cheung, Sai-Wah
Tsao, Pierre Busson, Ka-Fai To, Kwok-Wai Lo.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3426 A novel approach to copy number assessment by
whole genome sequencing reveals extensive spatial
heterogeneity in diffuse low-grade glioma. Ilari Scheinin, Hinke F.
van Thuijl, Daoud Sie, Hendrik F. van Essen, Paul P. Eijk, Francois
Rustenburg, Ahmed Idbaih, Agusti Alentorn, Gerrit A. Meijer, Mark A.
van der Wiel, Henrik Bengtsson, Adam Olshen, Eleonora Aronica, Jan
J. Heimans, Jaap C. Reijneveld, Pieter Wesseling, Donna G.
Albertson, Dan Pinkel, Bauke Ylstra.
3427 Uncovering vulvar cancer: Integrated analysis of
genomic and transcriptomic data. André M. Lavorato-Rocha,
Beatriz de Melo Maia, Iara S. Rodrigues, Fabio A. Marchi, Gabriel R.
Fernandes, Glauco Baiocchi, Fernando A. Soares, Silvia R. Rogatto,
Yukie Sato-Kuwabara, Rafael M. Rocha.
3428 Validation and utilization of next generation
sequencing in the clinical assessment of gliomas. MacLean P.
Nasrallah, Maria Martinez-Lage, Alan Fox, Shrey Sukhadia, Arati
Desai, Donald M. O’Rourke, Steven Brem, David Roth, Jennifer J.
Morrissette, Robert D. Daber.
3429 Synthetic lethal RNAi screens to nominate potential
therapeutic combinations for uveal melanoma. Chelsea S. Place,
Glenn S. Cowley, David E. Root, Levi A. Garraway.
3430 Recurrent somatic mutations of nitric oxide synthase
NOS3, netrin receptor UNC5C and DNA repair genes in muscleinvasive bladder carcinoma. Kai Lee Yap, Kazuma Kiyotani, Kenji
Tamura, Miran Jang, Magdeline Montoya, Cory Ganshert, Tomoaki
Fujioka, Gary Steinberg, Peter O’Donnell, Yusuke Nakamura.
3431 Functional characterization of ARID2 in melanoma and
melanocytes. Flora Luo, Levi Garraway.
3432 A genome-wide shRNA screen for suppressors of
prostate cancer cell invasion. Sean J. Leith, Susan E. Kuruvilla,
Jason Moffat, Ann F. Chambers, Eva A. Turley, Joseph L. Chin, Hon
S. Leong.
3433 ARHGAP30 and DEDD as potential genomic drivers of
invasive urothelial carcinomas. Andrew L. Hong, Markus Riester,
Anna C. Schinzel, Amy Schlauch, Rosalyn M. Adam, David J.
Kwiatkowski, Jonathan E. Rosenberg, William C. Hahn.
3434 Genomic exome DNA sequencing identifies top driver
genetic alterations in head and neck cancer cell lines of
different HPV status. Hui Cheng, Xinping Yang, Han Si, Anthony
Saleh, Jamie Coupar, Robert L. Ferris, Wendell G. Yarbrough, Mark
E. Prince, Thomas E. Carey, Carter Van Waes, Zhong Chen.
3435 Genome-wide RNA and DNA high throughput
sequencing reveals proinflammatory and death gene signatures
in head and neck squamous cell carcinoma lines with different
HPV status. Xinping Yang, Hui Cheng, Han Si, Anthony Saleh, Emine
G. Maiorov, Jamie Coupar, Ozlem Keskin, Attila Gursoy, Ruth
Nussinov, Robert L. Ferris, Wendell G. Yarbrough, Mark E. Prince,
Thomas E. Carey, Carter Van Waes, Zhong Chen.
3436 Ameloblastoma driver mutations revealed by nextgeneration sequencing of formalin-fixed paraffin-embedded
specimens. Andrew C. McClary, Robert T. Sweeney, Jewison
Biscocho, Benjamin R. Myers, Lila Neahring, Kevin A. Kwei, Kunbin
Qu, Xue Gong, Tony Ng, Carol D. Jones, Sushama Varma, Justin I.
Odegaard, Brian Rubin, Megan L. Troxell, Robert J. Pelham, James
L. Zehnder, Philip A. Beachy, Jonathan R. Pollack, Robert B. West.
3437 Differential transcript expression in nasopharyngeal
carcinoma by cDNA microarray analysis. Timothy T.C. Yip, Dora
L.W. Kwong, Roger K.C. Ngan, Cadmon K.P. Lim, Wai Wai Cheng,
Victor W.S. Ma, Stephen C.K. Law, Loretta Tse.
3438 Integrated analysis of germline and somatic variants
in renal clear cell carcinoma. Jiayin Wang, Charles Lu, Mingchao
Xie, Piyush Tripathi, Michael McLellan, Feng Chen, Kimberly J.
Johnson, Li Ding.
3439 Recurrent CDC25C mutations drive malignant
transformation in FPD/AML. Akihide Yoshimi, Takashi Toya,
Masahito Kawazu, Toshihide Ueno, Ayato Tsukamoto, Hiromitsu
Iizuka, Masahiro Nakagawa, Yasuhito Nannya, Shunya Arai, Motoshi
Ichikawa, Hironori Harada, Kensuke Usuki, Yasuhide Hayashi, Etsuro
Ito, Keita Kirito, Hideaki Nakajima, Hiroyuki Mano, Mineo Kurokawa.
3440 Cell-based screening identify gene expression
signature correlated with sensitivity to an MEK1/2 inhibitor. Jing
Zhang.
POSTER SESSION
Growth Factors and Receptors
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
3441
Suppression of colorectal cancer cell
proliferation is associated with modulation of Wnt
pathway signaling components by Resveratrol. Irshad Ali,
Adriana Rosales, Donald P. Braun.
3442
Non-canonical Wnt pathway stimulation in
response to LiCl is related to suppression of cell
proliferation in histologically distinct human tumors.
Donald P. Braun, Adriana Rosales, Irshad Ali.
3443
Wnt-beta-catenin-Rac1 signaling axis regulates
metastasis-associated phenotypes in TNBC. Nandini Dey,
Jennifer Carlson, Pradip De, Brian Leyland-Jones.
3444
The effect of IGFs on ER␤ isoforms: Potential
targets in TNBC. Chane’ O’Bannon-Joseph, Daisy D.
DeLeon.
3445
The role of the truncated product of the
neuregulin 4 gene in cancer and normal tissues.
Markella J. Alatsatianos, Edith Blackburn, William Gullick.
3446
Fibroblast growth factor 23 promotes prostate
cancer cell proliferation and invasiveness in vitro. Shu
Feng, Michael Ittmann.
3447
Role of fibroblast growth factor receptors in
esophageal squamous cell carcinoma. Yutaka Shimada,
Tomoyuki Okumura, Takuya Nagata, Yoshinori Takei,
Kazuhiro Tsukada, Kazuharu Shimizu.
3448
Fibroblast growth factor receptor is expressed
as a constitutively active receptor tyrosine kinase in
chronic lymphocytic leukemia B cells and exists in an
active complex with Axl: Dual targeting in CLL. Sutapa
Sinha, Justin Boyson, Charla Secreto, Steven L. Warner, Neil
E. Kay, Asish K. Ghosh.
3449
Overexpression of activin A and B as well as
altered activation of canonical and non-canonical
signaling pathways in malignant mesothelioma. Jenni A.
Tamminen, Mikko Rönty, Eva Sutinen, Arja Pasternack, Olli
Ritvos, Marjukka Myllärniemi, Katri Koli.
3450
Internalization and recycling of RET receptor
tyrosine kinase isoforms. Mathieu J. Crupi, Douglas S.
Richardson, Lois M. Mulligan.
3451
Blockade of BDNF-induced Trk B signaling
inhibits peritoneal carcinomatosis arising arising from
colorectal cancer. Hiroki Imaoka, Koji Tanaka, Yoshinaga
Okugawa, Tadanobu Shimura, Takahito Kitajima, Satoru
Kondo, Shozo Ide, Susumu Saigusa, Yuji Toiyama, Yasuhiro
Inoue, Toshimitsu Araki, Keiichi Uchida, Yasuhiko Mohri,
Kenichiro Ishii, Masato Kusunoki.
3452
N-glycosylation on lung cancer cell-secreted
IL-6 prolongs its activation on JAK/STAT pathway. ChunHua Hung, Hsuan-Heng Yeh, Hao-Chen Wang, Chien-Chung
Lin, Tsung-Lin Tsai, Wei-Lun Huang, Chuan-Fa Chang, WuChou Su.
3453
Autophagic regulation of the Met receptor
tyrosine kinase in breast cancer. Emily S. Bell, Dongmei
Zuo, Morag Park.
3454
Integrin-linked kinase and proximal signaling
contributes to the cisplatin resistance of ovarian cancer
cells. Daniel Soto, Fatima Valiyeva, Ileabett Echevarria,
Jeyshka Reyes, Pablo E. Vivas-Mejia.
3455
TRP channel regulation of insulin-like growth
factor singling and prostate cancer cell migration.
Talearia Young, Cynthia M. Van Golen.
3456
ANE upregulates COX-2 to modulate HB-EGF
expression and result in consequent chemoresistance in
HNSCC. Cheng-Chieh Yang, Hsi-Feng Tu.
3457
A possible role for the Hedgehog pathway
ligands Desert and Indian in rhabdomyosarcoma. Josep
Roma, Anna Almazán-Moga, Pablo Velasco, Carla Molist,
Vidal Isaac, Miguel F. Segura, Aroa Soriano, Jubierre Luz,
Paris Laia, Reventós Jaume, José Sánchez de Toledo,
Soledad Gallego.
Poster Abstract
Board Number
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3458
Role of the EphB1 gene in mediating migration,
proliferation, and radiosensitization of medulloblastoma
cells. Nimrah A. Baig*, Olga Timofeeva*, Anatoly Dritschilo,
Elena Pasquale, Marcel Kool, Brian Rood, Olga Rodriguez,
Christopher Albanese, Sana Karam.
3459
SRC family kinase FYN promotes MET tyrosine
kinase activation, epithelial to mesenchymal transition
and metastasis in human prostate cancer. Murali
Gururajan, Margarit Sievert, Sheldon Mink, Chia-Yi (Gina)
Chu, Matteo Morello, Jake Lichterman, Michael R. Freeman,
Edwin M. Posadas.
3460
Regulatory roles of conserved phosphorylation
sites in the activation loop of the MAP kinase. Shenshen
Lai, Steven Pelech.
3461
Profiling the effects of MEK inhibition on kinase
phosphorylation and protease secretion using antibody
arrays. Greta Wegner, Erin Eleria, Wen-Chieh Liao, Dave
Finkel, Amy James.
3462
Comparative RNA-Seq analysis of MIS signaling:
Potential relevance as therapeutic strategy in ovarian
cancer treatment. Qing Zhang, Eati Basal, Jaime I. Davila,
Xueqian Yin, Edward B. Leof, William A. Cliby.
3463
Identification and characterization of novel
cancer cell derived factors that dictate vascular
endothelial cell biology. Tony Walshe, Justin J. Bourdelais,
Arleide Lee, Rakib Ouro-Djobo, Vivek Vishnudas, Michael
Kiebish, Rangaprasad Sarangarajan, Niven R. Narain.
3464
The effect of EPO-receptor in estrogen receptor
positive breast cancer. Marica C. Vaapil, Susann
Reinbothe, Anna-Maria Larsson, Caroline Wigerup, Jianmin
Sun, Annika Jögi, Drorit Neumann, Lars Rönnstrand, Sven
Påhlman.
3465
Impact of intratumoral protein signaling
network activation heterogeneity: Implication for
precision medicine. Erika M. Parasido, Alessandra Silvestri,
Claudio Belluco, Vincenzo Canzonieri, Maria Grazia Diodoro,
Massimo Milione, Lance A. Liotta, Emanuel F. Petricoin,
Mariaelena Pierobon.
3466
Mediated by cancer cell and stroma cell TGF-␤
signaling, the periostin / ␤-Ig-H3 expression ratio is
altered during breast cancer progression. Michelle M.
Coleman, Anindita Das Burman, Amanda L. Lance, Didier
Dreau.
3467
Progesterone inhibits endometrial cancer
growth and invasiveness by modulating the TGF-ß
pathway. Amber A. Bokhari, Laura R. Lee, Dewayne
Raboteau, Chad A. Hamilton, George L. Maxwell, Jane M.
Turbov, Larry G. Thaete, Gustavo C. Rodriguez, Viqar Syed.
3468
Integrin-␤6 is required for transforming growth
factor (TGF)-␤-mediated epithelial-mesenchymal
transition (EMT) and promotes the disease progression
of intrahepatic cholangiocellular carcinoma. Takaaki
Higashi, Hiromitu Hayashi, Hideyuki Kuroki, Shigeki
Nakagawa, Keita Sakamoto, Hidetoshi Nitta, Akira
Chikamoto, Toru Toru, Hideo Baba.
3469
The effect of TGF-beta on matrix
metalloproteinase-2, 9, and 13 expression and
secrection in human prostate cancer cells. Yang Cao,
Clement J. Bolton, Shafiq A. Khan.
3470
Transforming growth factor-beta (TGF␤)mediated growth inhibition of human myeloid leukemia
cells is CAK-independent but links to cdc25c-CDK1
pathway. Alejandra Toro, Daria Vasilyeva, Talia Guardia,
Tamara Guardia, Jazmine Duran, Xiaotang Hu.
19
19
453
POSTER SESSION
Poster
Section
20
20
In Vitro Diagnostics and Other Innovative Technologies
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
454
3471
Gene expression profiling of a single laser
capture microdissected (LCM) cell. Shirley Chu.
3472
Mesodissection of slide mounted tissue:
Applications including tumor tissue enrichment,
expression analysis, and FISH on tissue fragments. Nils
Adey, Dale Emery, Derek Bosh, Robert Parry.
3473
Identification of progesterone-dependent genes
regulated by ablation of mitogen-inducible gene-6 (Mig6) in the murine uterus. Tae Hoon Kim, Jung-Yoon Yoo,
Jae-Wook Jeong.
3474
Comparison of CTC capture efficiency of the
CellCollector™ technology versus CellSearch® in
prostate cancer patients at multiple time points. Gerit
Theil, Kathrin Haubold, Paolo Fornara, Antje Stresemann,
Arndt Schmitz, Thomas Krahn, Klaus Lücke.
3475
Negative impact of evaporation on cervical
cancer cells during long term incubation is alleviated by
Thermo Scientific Edge plate. Cindy Neeley, Sarah Verna.
3476
Profiling CD antigens signature in human
hepatocellular carcinoma (HCC) by cell-based highthroughput screening flow cytometry (HTS-FC). Kui Chen,
Laurie Ailles, John E. Dick, Anand Ghanekar.
3477
Continuous isolation, labeling and collection of
viable CTCs using an integrated microfluidic device.
Rhonda M. Jack, Meggie M. Grafton, Robert A. Cieslak,
Denise C. Jue, Cathy Griffith, Danika Rodrigues, Sunitha
Nagrath, Diane Simeone.
3478
Differential level of L-homocysteic acid and
lysophosphatidylcholine (16:0) in sera of patients with
ovarian cancer. Yun Hwan Kim, Woong Ju, Seung Cheol
Kim, Byong Chul Yoo.
3479
The cellular thermal shift assay as a tool for
setting indivual treatment schemes. Daniel M. Molina, Pär
Nordlund.
3480
High-throughput size and deformability-based
cancer cell separation. Gordon Yip, Daniel Ionescu, Edwin
Johnson, Mikael Dick, Zecong Fang, Wael A. Harb, Bin
Hong, Jie Xu.
3481
Genetically-engineered mice as a cell line
isolating tool . Hirohiko Kamiyama, Sherri Rauenzahn,
Anirban Maitra, James R. Eshleman.
3482
A robust TALENs system for highly efficient
mammalian genome editing. Siliang Zhang, Yuanxi Feng,
Xin Huang.
3483
A centrifugal ultrafiltration-based method for
rapid purification of exosomes from biological samples.
Amedeo Cappione, Sara Gutierrez, Masaharu Mabuchi, Janet
Smith, Ivona Strug, Timothy Nadler.
3484
Ex-vivo cultures of freshly explanted tumor
specimens (TIPCAN®), a potent translational approach
for screening novel targeted agents. Annemilai TijerasRaballand, Maria Serova, Miguel Albuquerque, Nathalie
Colnot, pierre Bourgoin, Nelly Müller, Safi Dokmak,
Mohamed Bouattour, Jacques Belghiti, Eric Raymond,
Sandrine Faivre, Valérie Paradis, Armand de Gramont.
3485
Efficient transfection of cancer cell lines using
the 4D-NucleofectorTM System. Jenny Schroeder, Ludger
Altrogge, Elke Lorbach, Srinivasan Kokatam, Sabine
Schaepermeier, Meike Weigel, Gina Andretta-Beu, Stefanie
Buesch, Tamara Grabeck, Alexandra Krumnow, Sonja
Spicker, Sampada Kallol, Preeti Kapoor, Andrea Toell.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3486
Efficacy of neoadjuvant chemotherapy in
combination with fluorescence-guided surgery on a
pancreatic cancer patient-derived orthotopic xenograft
(PDOX). Yukihiko Hiroshima, Ali Maawy, Yong Zhang, Sho
Sato, Takashi Murakami, Mako Yamamoto, Fuminari Uehara,
Shinji Miwa, Shuya Yano, Masashi Momiyama, Takashi
Chishima, Kuniya Tanaka, Michael Bouvet, Itaru Endo,
Robert M. Hoffman.
3487
CA9 expression highly correlates with cancer
stem cell markers during passaging of PDX lines. Julia
Friedman, Wenyan Zhong, Christine Loreth, Veronica Diesl,
Xin Han, Justin Lucas, Andrea Hooper, Vlad Buklan, Edward
Rosfjord, Danielle Leahy, Judy Lucas, Maximillian Follettie,
Kim Arndt.
3488
HPV detection by PCR in real time in peruvian
women. Javier Manrique, Gustavo Sarria, Abelardo Arias,
Pamela Mora, Abel Limache, Maria del Carmen Nuñez,
Yasser Sullcahuaman, Tatiana Vidaurre.
3489
A novel investigation into chemotherapyinduced peripheral neuropathy using iPSC-derived
human neurons. Masaaki Komatsu, Heather E. Wheeler,
Claudia Wing, Shannon Delaney, M E. Dolan.
3490
Measurement of Gifinitib (ZD1839) effect on
electrophysiological properties of head and Neck cancer
cells using Dielectrophoresis (DEP). Sina Mahabadi,
Michael P. Hughes, Fatima H. Labeed.
3491
Rapid and ultra-sensitive single-cell transcript
profiling with droplet digital PCR (ddPCR): Application to
cell cycle analysis. George Karlin-Neumann, Shenglong
Wang, Camille Troup, Yann Jouvenot, Eli Hefner.
3492
A next generation sequencing biopsy protocol.
Myriam Kossai, Marc Schiffman, Olivier Elemento, Andrea
Sboner, Jacqueline Fontugne, Rob Kim, Juan Miguel
Mosquera, Himisha Beltran, Mark A. Rubin.
3493
An in-situ proximity assay using biotin ligase.
Zeyu (David) Jiang, Rui Hong, Mike Farrell.
3494
Microfluidic platform for a protein-based
thyroid cancer diagnostics. Shichu Huang, Siddhartha
Sharma, Lena Liu, Andy Fan, Catherine Klapperich, Jennifer
Rosen.
3495
A nucleolus-predominant piggyBac transposase
increases transposition efficiency in human cancer
cells. Jin-Bon Hong, Fu-Ju Chou, Amy T. Ku, Hsiang-Hsuan
Fan, Tung-Lung Lee, Yung-Hsin Huang, I-Chang Su, YouTzung Chen.
3496
Breast cancer and obesity impact the lipid
composition of breast adipose tissue: a preliminary
study using shotgun lipidomics. Osvaldo Perez, Michael
Margolis, Ana M. Santander, Mitchell Martinez, Sanjoy
Bhattacharya, Marta Torroella-Kouri.
3497
A novel method of active paraffin removal and
efficient extraction of NGS-quality DNA from FFPE
tissues. Hamid Khoja, Edwin Rudd, Austin Purdy, James
Han, Srikanth Kakumanu, Adrian Palmer, Guillaume Durin,
Jim Laugharn.
3498
A systematic approach to evaluate and select
preclinical study workflow software applications for
oncology. Eric M. Ibsen, Jeffrey Kumer.
3499
Funding innovative technologies for cancer
research at the National Cancer Institute. Anthony
Dickherber.
3500
NCI’s Provocative Questions Initiative. Michelle
A. Berny-Lang, Emily J. Greenspan.
POSTER SESSION
Nuclear Oncoproteins, Tumor Suppressors, and Other Topics
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
3501
Aspirin modulates oncogene expression in hct
116 colon cancer cells. Rakesh Dachineni, Goqiang Ai,
Jayarama B. Gunaje.
3502
Simultaneous characterization of mrtl and
MycHex1 along with c-Myc p64 and p67 from c-myc
locus. Hyun Jin Jun, Mi Hong Ji, Scott W. Blume, Hyoung
Soo Choi.
3503
Somatic mutations and aberrant expression of
RNF43 are recurrently found in intraductal papillary
mucinous neoplasms of the pancreas. Hitomi Sakamoto,
Yuko Kuboki, Takashi Hatori, Masakazu Yamamoto,
Masanori Sugiyama, Noriyuki Shibata, Kyoko Shimizu, Keiko
Shiratori, Toru Furukawa.
3504
Regulation of cell cycle progression by Ikaros
in leukemia. Elanora Dovat, Jonathon Payne, Carlos M.
Casiano, Justin Sloane, Chandrika Gowda, Kimberly J.
Payne, Sinisa Dovat, Chunhua Song.
3505
Regulation of Cyclin A1 promoter by the Wilms
tumor gene, WT1. Sony Pandey, Mustafa Moazam, Steven
J. Kuerbitz, Gail C. Fraizer.
3506
Heregulin induces transformation of mammary
epithelial cells via HER3 activation. Ruth Lupu, Ashwani
Khurana, Ghiara Lugo, Anatilde Gonzalez Guerrico.
3507
STAT3beta suppresses tumorigenesis via
modulating the phosphorylation dynamics and
transcription activity of STAT3alpha in esophageal
squamous cell carcinoma. Haifeng Zhang, Raymond Lai,
Enmin Li, Liyan Xu.
3508
The role of BRCA1 in the regulation of
telomeres: Implications for genomic stability and
malignant transformation. Orit Uziel, Lital Zuriano, Rinat
Yerushalmi, Einat Beery, Yardena Nordenberg, Dan Frumkin,
Meir Lahav.
3509
Overexpression of 14 –3-3␥ contributes to
chromosomal instability in human lung cancer. Cecil J.
Gomes, Sara Centuori, Jesse D. Martinez.
3510
N-Myc positively influences mitochondrial
biogenesis in neuroblastoma. Manika Sharma, James A.
Graves.
3511
Sustained adrenergic signaling promotes
cervical cancer progression. Nouara C. Sadaoui, Guillermo
N. Armaiz-Pena, Archana S. Nagaraja, Rajesha Rupaimoole,
Rebecca A. Previs, Heather J. Dalton, Mangala S.
Lingegowda, Lois M. Ramondetta, Anil K. Sood, Susan K.
Lutgendorf, Steve W. Cole.
3512
MYCN and survivin cooperatively contribute to
malignant transformation of fibroblasts. Nora Hipp, Lisa
Christner, Thomas Wirth, Wolfgang Mueller-Klieser, Stefan
Walenta, Evelin Schröck, Klaus-Michael Debatin, Christian
Beltinger.
3513
Ketoconazole-induced O-GlcNAcylated c-Myc
expression and inhibition of cell proliferation in cancers.
So Hee Kim, Eun-Sin Du, Aby Joiakim, Sung-Su Park, David
Kaplan, David Putt, Hyesook Kim.
3514
MED12 and FH mutations in HLRCC associated
uterine leiomyomas. Kati Kämpjärvi, Netta Mäkinen, Miika
Mehine, Jaana Tolvanen, Tuomas Heikkinen, Ralf Bützow,
Lauri A. Aaltonen, Pia Vahteristo.
3515
Increased TSH signaling by overexpressed
thyrotrophin receptor is essential for B-RafV600E
induced thyroid carcinogenesis. Young Hwa Kim, Yong
Won Choi, Jang-Hee Kim, Tae Jun Park.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3516
The mitochondrial sirtuin SIRT3 promotes
survival of human melanoma cells in vitro. Jasmine
George, Minakshi Nihal, Chandra K. Singh, Weixiong Zhong,
Nihal Ahmad.
3517
Role of primary cilia in breast and prostate
cancer. Nadia B. Hassounah, Martha Nunez, Raymond
Nagle, Kimberly M. McDermott.
3518
TP53 mutations and MDM2 single nucleotide
polymorphism 309T>G predicts outcome and treatment
resistance in acute myeloid leukemia. Ingrid Jakobsen
Falk, Kerstin Willander, Roza Chaireti, Johan Lund, Monica
Hermanson, Henrik Greén, Peter Söderkvist, Kourosh Lotfi.
3519
The c-Myc oncogene over-activates dormant
replication origins and sensitizes cancer cells to
chemotherapy drugs. Victoria Bryant, Mark G. Alexandrow.
3520
TAZ (WWTR1), a key transcription co-activator
of hippo-pathway, promotes hepatocellular carcinoma
progression via PI3K/Akt/mTOR pathway. Hiromitsu
Hayashi, Hideyuki Kuroki, Shigeki Nakagawa, Takaaki
Higashi, Keita Sakamoto, Naomi Yokoyama, Takatoshi
Ishiko, Toru Beppu, Hideo Baba.
3522
A novel BAP1 mutation is associated with
melanocytic neoplasms and thyroid and pancreatic
cancers. Gregory T. Gallanis, Kathleen A. Heller, EleniMarina Melas, Stephen B. Gruber.
3523
Targeting FOXM1 in pancreatic cancer. Marianna
Halasi, Andrei L. Gartel.
3524
Unraveling the dichotomy of Runx1 in breast
cancer. Gillian Browne, Nicole M. Bishop, Jason R. Dobson,
Sharath C. Madasu, Farina H. Nicholas, Maria L. La Porta,
Dana Frederick, Jennifer L. Colby, Leslie M. Shaw, Justine
Landis, Janet L. Stein, Jane B. Lian, Gary S. Stein.
3525
SOX2 promotes tumor growth via activation of
the PI3K/Akt/mTORC1 signaling pathway in esophageal
squamous cell carcinoma. Yasuyuki Gen, Kohichiroh Yasui,
Tomoko Kitaichi, Akira Tomie, Yoshito Ito.
3526
The mTORC2 component RICTOR plays a key
role in lung cancer cell growth. Haiying Cheng, Yiyu Zou,
Alain Borczuk, Wanglong Qiu, Bilal Piperdi, Mimi Kim, Balazs
Halmos, Roman Perez-Soler.
3527
YYEI motif is critical to oncogenicity of 14 –3-3
proteins. Wen-Hsin Chang, Ching-Hsien Chen, Qi-Sheng
Hong, Jian-Wei Chen, Sung-Liang Yu, Chiung-Tong Chen.
3528
Genotype discordance between circulating
tumor cells in blood and disseminated tumor cells in
bone marrow at single cell level in breast cancer
patients. Glenn Deng, Sujatha Krishnakumar, Marc A.
Coram, Ashley A. Powell, Haiyu Zhang, Michael N.
Mindrinos, Melinda L. Telli, Katharina E. Effenberger,
Michael Herrler, Klaus Pantel, Ronald W. Davis, Stefanie S.
Jeffrey.
3529
KIM-1 is a novel therapeutic target in renal cell
carcinoma. Venkata S. Sabbisetti.
3530
The parathyroid hormone-related peptide region
likely features seven discrete breast cancer
susceptibility loci. Adam N. Freeman, Terence ’Jack’
Martin, Michael Henderson, Enes Makalic, Daniel F.
Schmidt, Miroslaw K. Kapinski, Melissa C. Southey, Graham
G. Giles, John L. Hopper.
Poster
Section
21
21
455
POSTER SESSION
Poster
Section
22
22
Regulation of MicroRNA Expression
Poster Abstract
Board Number
1.
3531
MicroRNA delivery by bionanoparticles:
regulation of the liver cancer susceptibility gene MICA
expression in hepatocytes. Motoko Ohno, Motoyuki
Otsuka, Takahiro Kishikawa, Takeshi Yoshikawa, Akemi
Takata, Kazuhiko Koike.
2.
3532
Hypoxia is a master regulator of Drosha- and
Dicer-dependent miRNA biogenesis in cancer. Rajesha
Rupaimoole, Cristina Ivan, Chad Pecot, Sherry Wu, Sunila
Pradeep, Behrouz Zand, Archana Nagaraja, Kshipra
Gharpure, Heather Dalton, Nouara Sadaoui, Wei Zhang,
Gabriel Lopez-Berestein, Anil Sood.
3.
4.
3534
Epigenetic control of the tumor suppressive
microRNA miR-34a in bladder cancer. Wen-Yu Huang,
Pi-Che Chen, Chia-Ming Yeh, Frank H. Cheng, Hsiao-Yen
Hsieh, Cheng-Huang Shen, Cheng-Da Hsu, Michael W.
Chan.
17.
3547
FoxD3-regulated microRNA-137 suppresses
tumour growth and metastasis in human hepatocellular
carcinoma by targeting AKT2. Li-Li Liu, Shi-Xun Lu, Min
Li, Jia Fu, Chris Zhiyi Zhang, Jing-Ping Yun.
18.
3548
Study of the tumor suppressive machinery of
arsenic trioxide-induced glioblastoma multiforme
inhibition via microRNA-182-Sestrin2 regulatory circuit.
Liang-Ting Lin, Shih-Hwa Chiou, Yi-Jang Lee.
19.
3549
miRNAs and androgen receptor interplay in
prostate cancer. Lorenza Pasqualini, Huajie Bu, Narisu
Narisu, Johannes Rainer, Michal R. Schweiger, Peter S.
Chines, Christian Fuchsberger, Helmut Klocker.
20.
3550
Inhibition of either LIN28A or ZCCHC11 (TUT4)
provides distinct effects on the expression of the let-7
miRNA family and tumor cell proliferation. Laurent
VIDARD, Claire MARIET, Eric BOITIER, Véronique SIERRA,
Elisabeth CAVROIS, Carlos GARCIA-ECHEVERRIA, Hélène
GOULAOUIC.
21.
3551
Non-coding RNA HOTAIR connects DNA damage
signaling to NF-␬B activation in cisplatin resistant
ovarian cancer. Ali R. Ozes, Dave F. Miller, Yunlong Liu,
Kenneth P. Nephew.
5.
3535
Epigenetic regulation of miR-31 and miR-205 of
apoptosis in prostate cancer. Qunshu Zhang.
6.
3536
Roles of miR-215 and regulatory mechanisms
for its biogenesis in response to hypoxia in
glioblastoma stem cells. Jing Hu, Tao Sun, Hui Wang,
Pingping Wang, Xiang-Dong Fu, Qi-Jing Li, Xiao-Fan Wang.
22.
3552
Differential expression of microRNAs in
gastrointestinal neuroendocrine tumors. Amarpreet
Bhalla, Shadan Ali, Fazlul Sarkar, Anthony Shields, Amy
Jencks, Romil Nathan, Vinod B. Shidham.
7.
3537
Suppression of miR-145 by long noncoding RNA
RoR in colon cancer. Jianguo Huang, Yin-Yuan Mo.
23.
8.
3538
Obligate haploinsufficiency of the microRNAprocessing molecule dicer1 in a murine colitisassociated tumorigenesis model. Takeshi Yoshikawa,
Motoyuki Otsuka, Kazuhiko Koike.
3553
The expression of metastasis-associated long
non-coding RNA, HOTAIR, is involved in cancer
development and peritoneal metastasis in gastric
cancer. Yoshinaga Okugawa, Yuji Toiyama, Keun Hur,
Shusuke Toden, Susumu Saigusa, Koji Tanaka, Yasuhiro
Inoue, Yasuhiko Mohri, Masato Kusunoki, C. R. Boland, Ajay
Goel.
9.
3539
The noncoding PTEN pseudogene influences
PI3K signaling and inhibits breast cancer progression.
Synnøve Yndestad, Eilin Austreid, Hans Petter Eikesdal.
24.
3554
Gene and miRNA expression networks specific
to never smoker lung adenocarcinoma. Rebecca Kusko,
Carly Garrison, Teresa Wang, Josh Campbell, Joseph PerezRogers, Lingqi Luo, Jennifer Beane, Gang Liu, Humam
Kadara, Steven Belinsky, Marc E. Lenburg, Avrum Spira.
25.
3555
LncRNA-21a is a potential tumor suppressor in
breast cancer. Ramesh Singh, Yin-yuan Mo.
26.
3556
Alcohol-dysregulated non-codingRNAs in the
pathogenesis of oropharyngeal cancer. Maarouf A. Saad,
Elizabeth Kim, Vicky Yu, Jonjei Ku, Selena Z. Kuo, Hao
Zheng, Elham Rahimy, Jessica Wang-Rodriguez, Weg M.
Ongkeko.
27.
3557
Epigenetic modulation of microRNA-363 in
human papillomavirus-positive head and neck
squamous cell carcinoma. Bhavana S. Vangara, Parvez
Akhtar, Jennifer R. Grandis, Saleem A. Khan.
28.
3558
The role of miRNA in PAX3-FKHR positive
rhabdomyosarcoma. Shannon Muir, Jason Nathanson,
Melissa Wilbert, Gene Yeo, Frank Furnari, Karen Arden,
Webster Cavenee.
29.
3559
Long non-coding RNA subtype classification of
clear-cell renal cell carcinoma. Gabriel G. Malouf,
Jianping Zhang, Nizar Tannir, Erika J. Thompson, David
Khayat, Jean-Philippe Spano, Xiaoping Su.
30.
3559A
Molecular subtype-specific methylation of the
miR-29c promoter in breast cancer correlates with
basal-like pattern of gene expression. Elizabeth C. Poli,
Rachel Tolbert, Jing Zhang, Yoo-Jeong Han, Olufunmilayo I.
Olopade.
10.
3540
Overexpression of incrna h19 enhances
development and metastasis of gastric cancer. Jiangfang
Li, Hao Li, Liping su, Zheng-gang Zhu, Bingya Liu.
11.
3541
HOTAIR modulates ␤-catenin signaling pathway
through NLK and NFAT5 in human glioblastoma. Xuan
Zhou, Yu Ren, Lei Han, Chunsheng Kang.
12.
3542
Upregulation of microRNA-372 & 373 associates
with cervical lymph node metastasis and poor
prognosis of oral carcinomas. Chung Ji Liu, Hsi-Feng Tu,
Hui-Wen Cheng, Kuo-Wei Chang.
13.
3543
A long noncoding RNA plays a critical role in
Bcr-Abl-mediated cellular transformation. Guijie Guo,
Qingzheng Kang, Qinghuang Chen, Ouyang Jing, Jilong
Chen.
14.
3544
Tumor suppressor function of loc285194 in
breast cancer. YAYUN CHI, Sheng Huang, Jiong Wu.
15.
3545
A high-throughput screen identifies microRNAs
regulating lung cancer cell survival and response to
paclitaxel. Xiaojie Yu, Zhenze Zhao, Xiuye Ma, Liqin Du,
Alexander Pertsemlidis.
16.
456
3533
ADAM9 regulates microRNAs expression for
lung cancer metastasis. Yuh-Pyng Sher, Li-Ju Wang,
Mong-Hsun Tsai, Ting-Ting Kuo, Eric Y. Chuang, LiangChuan Lai.
Poster Abstract
Board Number
3546
Transcriptional activation of Thioredoxin
interacting protein by small activating RNA exerts cell
growth inhibition in A549 human lung cancer cells. Ki
Hwan Park, Moo-Rim Kang, Sang-Bae Han, Jieun Yun,
Chang Woo Lee, Soo Jin Oh, Youngsoo Kim, Jong Soon
Kang.
POSTER SESSION
Sequencing
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
3560
Genome and RNA sequencing identifies fusion
transcripts in bladder cancer. Iver K. Nordentoft, Karin
Birkenkamp-Demtroder, Philippe Lamy, Thomas Reinert,
Søren Vang, Jakob Hedegaard, Kasper Thorsen, Lars
Dyrskjøt, Jakob S. Pedersen, Torben F. Ørntoft.
3561
Whole transcriptome analysis of testicular germ
cell tumors. Lovorka Degoricija, Kathy Y. Lee, Sunali Patel,
Shirley Chu, Ad J. Gillis, Martin Rijlaarsdam, Lambert C.
Dorssers, Leendert Looijenga.
3562
Building workflows for gene fusion detection by
RNA-seq. Stephen Gross, Lisa Watson, Smita Pathak, Irina
Khrebtukova, Gary Schroth.
3563
New tools for RNA-sequencing of FFPE tumor
samples. Lisa Watson, Smita Pathak, Stephen Gross, Irina
Khrebtukova, Gary Schroth.
3564
A new method for preparation of low-input,
PCR-free next generation sequencing libraries. Laurie
Kurihara, L. Banks, S. Chupreta, C. Couture, V. Kelchner,
J.Laliberte, S. Sandhu, R. Spurbeck, V. Makarov.
3565
Ultra-sensitive multiplex analysis of somatic
mutations in plasma DNA by InsightTM Onco mutant
enrichment parallel sequencing for cancer personalized
medicine. Deokhwe Hur, Minsik Song, Jinwook Jung,
Heekyung Park.
3566
A robust and rapid targeted sequencing
technology for iterative multiple genomic features in
cancer. Billy Lau, Anna Cushing, Hanlee Ji.
3567
Testing of KRAS, NRAS, BRAF and PIK3CA
somatic mutations on FFPE tumors samples using
bidirectionnal ultra-deep pyrosequencing. Alexandre
Harlé, Marie Husson, Marie Rouyer, Agnès Leroux, JeanLouis Merlin.
3568
Quantitative t cell receptor (tcr) repertoire
analysis by next-generation sequencing (ngs) in nonsmall cell lung cancer patients treated with therapeutic
cancer peptide vaccines. Hua Fang, Rui Yamaguchi, Xiao
Liu, Yataro Daigo, Satoru Miyano, Yusuke Nakamura.
3569
Transcriptional signatures in human melanoma
epitope MART-127–35 specific TCR-engineered T cells.
Prashant Singh, Nitya G. Chakraborty, Umar Farooq,
Upendra P. Hegde, Richard Everson, David I. Dorsky, Bijay
Mukherji.
3570
Development and validation of a clinical next
generation sequencing-based assay for hematologic
malignancies. Doron Lipson, Michelle K. Nahas, Geoff A.
Otto, Jie He, Kai Wang, Kristina M. Knapp, Kristina W.
Brennan, Amy L. Donahue, Lauren E. Young, Geneva Young,
Alex Fichtenholtz, Jeffrey S. Ross, Roman Yelensky, Philip J.
Stephens, Vincent A. Miller, Ross Levine.
3571
mRNA spike-in control materials for cancer
fusion gene detection assays. Winnie Liang, Stephanie J.
Pond, Waibhav D. Tembe, Han-Yu Chuang, Christophe
Legendre, Nancy Kim, Valerie Montel, Shukmei Wong,
Timothy K. McDaniel, David Craig, John Carpten.
3572
Copy number detection using genomics
technologies: A comparison between aCGH and NGS.
George Vasmatzis, Andrew L. Feldman, Sarah H. Johnson,
Erik C. Thorland, Rafael Fonseca, Esteban Braggio, Troy J.
Gliem.
3573
Comprehensive non-invasive tumor sequencing:
High fidelity sequencing of tumor-derived circulating
cell-free DNA across 300 cancer patients. Stefanie A.
Mortimer, Dragan Sebisanovic, Gangwu Mei, Benjamin
Schiller, Lai Mun Siew, Aubrey Zapanta, Helmy Eltoukhy,
AmirAli Talasaz.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
3574
Analysis of whole genome and transcriptome
sequencing in single cell. Nak-Jung Kwon, Woo Chung
Lee, Jiwoong Kim, Hyeri Kim, Ahreum Seong, Bong Cho
Kim, Doo Hyun Park, Kap-Seok Yang.
3575
The OncoNetwork Consortium: A global
collaborative research study on the development and
verification of an Ion AmpliSeq RNA gene lung fusion
panel. Susan M. Magdaleno, Angie Cheng, Rosella Petraroli,
Orla Sheils, Bastiaan Tops, Delphine Le Corre, Henriette
Kurth, Helene Blons, Eliana Amato, Andrea Mafficini, Anna
Maria Rachiglio, Anne Reimann, Christoph Noppen,
Chrysanthi Ainali, Jin Katayama, Renato Franco, Harriet
Feilotter, Jeoffrey Schageman, Ian Cree, Andrew Felton,
Jose L. Costa, Alain Rico, Aldo Scarpa, Jose C. Machado,
Kazuto Nishio, Nicola Normanno, Marjolijn Ligtenberg, Cecily
P. Vaughn, Ludovic Lacroix, Pierre Laurent-Puig.
3576
Creating and accurately interpreting clinical
grade cancer exomes: Challenges and solutions. Michael
J. Clark, Deanna Church, Mark Pratt, Elena Helman, Gabor
Bartha, Stephen Chervitz, Sarah Garcia, Shujun Luo, Jason
Harris, Anil Patwardhan, Richard Chen, John West.
3577
Reproducible copy number variation patterns
among single circulating tumor cells of lung cancer
patients. Xiaohui Ni, Minglei Zhuo, Zhe Su, Jiachun Duan,
Yan Gao, Zhijie Wang, Chenghang Zong, Fan Bai, Jie Wang,
X. Sunney Xie.
3578
Alternative RNA splicing and protein products in
leukemia outcome. Hideaki Suzuki.
3579
Routinely applicable, highly multiplexed triplenegative breast cancer (TNBC) genotyping. Vassiliki
Kotoula, Kyriaki Papadopoulou, Elpida Charalambous, Flora
Zagouri, Sotiris Lakis, Angeliki Lymperopoulou, Eleftheria
Tsolaki, George Pentheroudakis, Kostas Lilakos, Dimitrios
Pectasides, George Fountzilas.
3580
Hotspot mutation and fusion transcript
detection from the same non-small lung
adenocarcinoma sample. Angie Cheng, Varun Bagai, Joey
Cienfuegos, Natalie Hernandez, Mu Li, Jeff Schageman,
Richard Fekete, Rosella Petraroli, Alexander Vlassov, Susan
Magdaleno.
3581
Characterization of T cell repertoire in
transplanted patients with graft versus host disease
using next generation DNA sequencer. Poh Yin Yew, Rui
Yamaguchi, Michael Bishop, Amittha Wickrema, Andrew
Artz, Satoru Miyano, Yusuke Nakamura.
3582
A simple multiplex PCR approach for target
enrichment in next-gen sequencing. Xiaochuan Zhou, Qi
Zhu, Chris Hebel.
3583
Reducing GC-bias and improving coverage
distribution in Illumina sequencing using the Kapa
Biosystems library construction method. Aaron R.
Thorner, Ashwini Sunkavalli, Ling Lin, Robert T. Jones,
Laura Schubert, Matthew D. Ducar, Ravali Adusumilli, Deniz
N. Dolcen, Liuda Ziaugra, Jack Lepine, Laura E. MacConaill,
William C. Hahn, Matthew Meyerson, Paul Van Hummelen.
3584
Analysis of colorectal intratumoral genetic
heterogeneity by high efficiency and rapid deep
targeted sequencing. Erik S. Hopmans, Hojoon Lee, Laura
Miotke, Rowza Tur Rumma, Sue Grimes, John M. Bell,
Hanlee P. Ji.
23
23
457
POSTER SESSION
Poster
Section
24
24
Tumor-Stroma Interactions
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
458
3585
Metastasis of 4T1 murine breast cancer cells to
the lung is dependent on the chemokine CCL2/MCP-1
produced by stromal cells in the primary tumor. Teizo
Yoshimura, O.M. Zack Howard, Toshihiro Ito, Masaki
Kuwabara, Akihiro Matsukawa, Keqiang Chen, Ying Liu,
Mingyong Liu, Ji Ming Wang.
3586
HIF-1␣ from tumor-surround fibroblasts
contributes to breast cancer malignant progression. Yi
Lu, Jun Zhang.
3587
Carcinoma-associated fibroblast-mediated
regulation of anoikis in breast cancer cells. Zachary T.
Schafer.
3588
Reactivation of dormant estrogen-dependent
breast cancer micrometastases by bone marrow stromal
injury in an in vitro model of dormancy. Samir Tivari,
Haiyan Lu, Tanya Dasgupta, Robert Wieder.
3589
Adipose stem cell-derived interferon gamma
alters breast epithelial stem cell hierarchy. Manjushree
Anjanappa, Riesa M. Burnett, Stephanie Merfeld-Clauss,
William A. Wooden, Keith L. March, Sunil Tholpady,
Harikrishna Nakshatri.
3590
Investigation of exosome-encapsulated
microRNA secretion in breast cancer. Claire Glynn, Sonja
Khan, Cathy Brougham, Cillian Clancy, Doireann Joyce,
Peter Dockery, Michael J. Kerin, Roisin M. Dwyer.
3591
15-Deoxy-⌬12,14-prostaglandin J2-induced
epithelial-to-mesenchymal transition in human breast
cancer cells promotes fibroblast activation. Do-Hee Kim,
Jeehye Choi, Jin-Young Suh, Hye-Kyung Na, Young-Joon
Surh.
3592
Macrophages confer resistance to cisplatin in
MTLn3 and MDA-MB 231 breast cancer cells. Joshua K.
Sabari, Ramon Cabrera, Jeffrey Segall.
3593
Examining the role of tumor cell secreted
factors in intravasation and enhancing paracrine loop
invasion. Ramon M. Cabrera, Zhen N. Zhou, Minna RohJohnson, John Condeelis, Dianne Cox, Jeffrey E. Segall.
3594
Tumor microenvironment derived exosomes
regulate prostate cancer metabolism. Hongyun Zhao,
Lifeng Yang, Abhinav Achreja, Juan Marini, Donna Peehl,
Deepak Nagrath.
3595
Mesenchymal stem cells play crucial roles in
the generation of osteogenic prostate to bone
metastases. Jeremy J. Mcguire, Gemma Shay, Leah Cook,
Jeremy Frieling, Conor Lynch.
3596
The role of PIM1 kinase in the prostate tumor
microenvironment. Marina Zemskova, Andrew S. Kraft.
3597
Malignancy of bladder cancer cells is enhanced
by tumor associated fibroblasts through a cytokinechemokine loop. Susanne Grimm, Susanne Jennek, Jens
Bratsch, Andreas Wohlmann, Vrinda Mohta, Kerstin Junker,
Karlheinz Friedrich.
3598
Macrophage-derived reactive oxygen species
suppress miR-328 targeting CD44 in gastrointestinal
cancer cells and promote redox adaptation. Takatsugu
Ishimoto, Naoya Yoshida, Hidetaka Sugihara, Daisuke Izumi,
Keisuke Miyake, Hiroshi Sawayama, Yu Imamura, Shiro
Iwagami, Yoshifumi Baba, Hideo Baba.
3599
Long-distance intercellular transport of
microRNAs via tunneling nanotubes: Role in tumorstroma interactions and malignant potential. Venugopal
Thayanithy, Elizabeth L. Dickson, Subbaya Subramanian,
Clifford J. Steer, Emil Lou.
3600
NanoChannel-mediated communication between
tumor cells and endothelium mediates metastatic
parasitism. Yamicia D. Connor, Sarah Tekleab, Amjad
Husain, Cherelle Walls, Bruce Zetter, Harold Dvorak,
Shiladitya Sengupta.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
3601
Stromal fibroblasts mediate extracellular matrix
remodeling and invasion of scirrhous gastric carcinoma
cells. Hideki Yamaguchi, Kazuyoshi Yanagihara, Masakazu
Yashiro, Ryuichi Sakai.
3602
PTEN dependent angiogenesis is mainly
regulated by (tumor secreted-) uPAR. Matthias Unseld,
Anastasia Chilla, Clemens Pausz, Johannes Breuss, Gernot
Schabbauer, Gerald Prager.
3603
A novel approach to enhance delivery and
sensitivity of gemcitabine in pancreatic cancer by
suppression of desmoplasia. Sheema Khan, Mara Ebeling,
Ansarullah ., Neeraj Chauhan, Rishi K. Gara, Meena Jaggi,
Haotian Zhao, Subhash C. Chauhan.
3604
Investigation of the role of CSF-1 and its
receptor in the bone marrow stroma microenvironment
in acute myeloid leukemia. Ayesha Rashid, Mohammed
Fateen, Rhe Juan, Rob C. Laister, Mark Minden.
3605
The inhibitor of NF-KB kinase, IKK␤, regulates
the stability of GLI1 transcription factor. Nitin K. Agarwal,
Kranthi Kunkalla, Francisco Vega.
3606
The effect of PGE2 receptor inhibitor on the
microenviroment of scirrhous gastric cancer. Tatsunari
Fukuoka, Masakazu Yashiro, Hiroshi Takeda, Takayuki
Maruyama, Hiroaki Kasashima, Go Masuda, Haruhito
Kinoshita, Tamami Morisaki, Katsunobu Sakurai, Masatsune
Shibutani, Sadaaki Yamazoe, Kenjiro Kimura, Hisashi
Nagahara, Takahiro Toyokawa, Ryosuke Amano, Naoshi
Kubo, Hiroaki Tanaka, Kazuya Muguruma, Hiroshi Otani,
Kiyoshi Maeda, Masaichi Ohira, Kosei Hirakawa.
3607
Modulation of neuroblastoma metabolism by an
extracellular chaperone SPARC. Alexandre Chlenski,
Marija Dobratic, Helen R. Salwen, Mark Applebaum, Susan
L. Cohn.
3608
HIF-1␣ inhibition blocks the cross talk between
multiple myeloma plasmacells and tumour
microenvironment. Enrica Borsi, Giulia Perrone, Carolina
Terragna, Marina Martello, Angela Flores Dico, Lucia
Pantani, Annamaria Brioli, Giovanni Martinelli, Michele Cavo.
3609
Fibroblast influence on keratinocyte tumorigenic
and metastatic potential in cutaneous squamous cell
carcinoma. J C. Gwilliam, Alexander CVitan, Nicholas
Watson, Lauren Falkenberg, Nyousha Yousefi, Hepzibha
Alexander, Adam Morin, Jonathan S. Wiest, Katie L.
DeCicco-Skinner.
3610
High stromal S100A9 expression serves an early
oral cancer recurrence marker possibly through
enhancing cancer cell invasivenes, angiogenesis, and
differentially recruiting infiltrating immune cells. Li-Wha
Wu.
3611
Stromal transforming growth factor-beta 1 is
crucial for reinforcing the invasive potential of low
invasive cancer. Young Sun Hwang, Kwang-Kyun Park,
Won-Yoon Chung.
3612
Effect of cancer associated fibroblast on gastric
cancer cells under hypoxia. Haruhito Kinoshita, Masakazu
Yashiro, Go Masuda, Hiroaki Kasashima, Tamami Morisaki,
Tatsunari Fukuoka, Masatune Shibutani, Sadaaki Yamazoe,
Katsunobu Sakurai, Hisashi Nagahara, Kenjiro Kimura,
Takahiro Toyokawa, Ryosuke Amano, Naoshi Kubo, Hiroaki
Tanaka, Kazuya Muguruma, Hiroshi Otani, Kiyoshi Maeda,
Masaichi Ohira, Kosei Hirakawa.
3613
Opposite effects of adipocytes and adenosine
on hematological cancer cell survival and proliferation
in vitro. Cécile Bossard, Charles Dumontet, Lars P.
Jordheim.
POSTER SESSION
Immunology 7
Antigen Presentation and Immune Regulation
Poster
Section
Poster Abstract
Board Number
1.
3614
Coordinated action of phagocytosis and
autophagy by TIM4-AMPK␣1 pathways in tumorassociated macrophages suppresses chemotherapyinduced antitumor immunity. Masahisa Jinushi.
2.
3615
IL-6/STAT3-dependent immunosuppressive
function of tumor-infiltrating dendritic cells in colorectal
cancer. Yosuke Ono, Jyunya Ohtake, Shun Kaneumi,
Kazutaka Masuko, Kentaro Sumida, Takuto Kishikawa,
Satoshi Terada, Toshiyuki Kita, Norihiko Takahashi, Akinobu
Taketomi, Hidemitsu Kitamura.
3.
3616
Hypoxia determines the fate of myeloid cell
differentiation by controlling STAT3 activation in tumor
site. Vinit Kumar.
Poster Abstract
Board Number
8.
3621
Regulation of antigen-presentaion by dendritic
cells by TLR ligands and its application to cancer
vaccine immunotherapy. Junya Ohtake, Takuto Kishikawa,
Shun Kaneumi, Kazutaka Masuko, Yosuke Ono, Kentaro
Sumida, Satoshi Terada, Toshiyuki Kita, Hidemitsu Kitamura.
9.
3622
Total loss of HLA class I expression by two
sarcomatoid hepatocellular carcinoma cell lines sHCC29
and sHCC63 was caused by a ⬃49-kbp deletion at
chromosome 15q15 across the ␤2m gene locus. Wei-Yi
Lei, Chin-Hsuan Hsieh, Chien-Chung Chang, Shao-Hsuan
Wen, Chi-Tan Hu, Shuen-Kuei Liao.
10.
3623
Fluctuating antibody response and CD4-positive
T-cells in a small-cell lung cancer mouse model. Mario
A. Pulido, Vincent Lombardi, Diane Lee, Yiwei Wang, Eric
Chung, Lina Wang, W. M. Kast, Omid Akbari, Ite A. LairdOffringa.
4.
3617
Clustered regularly interspaced short
palindromic repeats (CRISPR)/CRISPR-associated (CAS)
system mediated endogenous CD19 gene knockout
model in burkitt lymphoma. Sanghoon Lee, Changhong
Yin, Janet Ayello, Carmella van de Ven, Mitchell S. Cairo.
11.
5.
3618
Ikk␣ modulates primary sclerosing cholangitis
and intrahepatic cholangiocarcinoma. Qun Jiang,
Zuoxiang Xiao, Timothy Back, Anthony Scarzello, Scott
Roan, Jami Willette-Brown, Feng Zhu, Yinling Hu, Robert H.
Wiltrout.
3624
Activation of tumor specific antibody response
following systemic delivery of receptor targeted
nanoparticles into Balb/c mice bearing mouse mammary
tumors. Christina Ward, Weiping Qian, Emmy Yang, Erica
Bozeman, Y. A. Wang, Lily Yang.
12.
3625
Tumor-specific human monoclonal antibodies
isolated from cancer patients. Huiwu Zhao, Jiping Zhang,
Ramdev Puligedda, Cezary Swider, Paul Simon, Baron
Heimbach, Sharad Adekar, Maureen Murphy, Hossein
Borghaei, Scott Dessain.
14.
3627
Phosphopeptides as novel T cell epitopes in
colorectal cancer. Sarah A. Penny, Jennifer G. Abelin, Abu
Z. Saeed, Stacy A. Malaker, Paisley D. Trantham, Jeffrey
Shabanowitz, Stephen T. Ward, Donald F. Hunt, Mark
Cobbold.
6.
3619
Specificity of the human autoantibody response
against the stress oncoprotein LEDGF/p75. Anamika
Basu, Greisha L. Ortiz-Hernández, Carlos A. Casiano.
7.
3620
Neuropeptide signaling activates Type-1
immunity through the NK1 and NK2 receptors on human
dendritic cells. Hidemitsu Kitamura, Junya Ohtake, Shun
Kaneumi, Kazutaka Masuko, Kentaro Sumida, Satoshi
Terada, Takuto Kishikawa, Yosuke Ono, Toshiyuki Kita,
Hiroya Kobayashi.
25
25
459
POSTER SESSION
Immunology 8
Poster
Section
26
26
Immune Modulation in the Tumor Microenvironment
Poster Abstract
Board Number
1.
3628
Modulation of macrophages in breast tumors
towards an antitumor phenotype. Jennifer L. Guerriero,
Anthony Letai.
2.
3629
Overcoming macrophage immunosuppression in
small cell lung cancer with high-affinity SIRPa variants.
Kipp Weiskopf, Peter J. Schnorr, Nadine Jahchan, Aaron M.
Ring, Roy L. Maute, Anne K. Volkmer, Jens-Peter Volkmer,
Kenan C. Garcia, Julien Sage, Irving L. Weissman.
3.
3630
Immunoengineering of tumor associated
macrophages using targeted, siRNA delivering
nanoparticles. Ryan Ortega, Whitney Barham, Oleg
Tikhomirov, Kavya Sharman, Fiona Yull, Todd Giorgio.
4.
3631
Modulation of monocyte- and macrophagemediated antibody-dependent cell phagocytosis and
cytotoxicity (ADCP/ADCC) by Fc engineering of
therapeutic antibodies. Herter Sylvia, Christian Klein,
Martina Birk, Thomas Weber, Pablo Umana, Marina Bacac.
5.
6.
3633
Combination of innate immune activators
stimulates leukocyte populations in the tumor
microenvironment. Ehud Shahar, Raphael Gorodetsky, Elina
Aizenshtein, Jacob Pitcovski.
7.
3634
Postoperative neutrophil-lymphocyte ratio as a
surrogate marker for recurrence of gastric cancer.
Hiroaki Tanaka, Kazuya Muguruma, Katsunobu Sakurai,
Takahiro Toyokawa, Naoshi Kubo, Masaichi Ohira, Kosei
Hirakawa.
8.
9.
460
3632
Targeting of tumor myeloid suppressor cells by
Salmonella bacteria causes a shift to M1 phenotype and
leads to inhibition of tumor growth. Basel K. al-Ramadi,
Suneesh Kaimala, Yassir A. Mohamed, Jincy M. Issac, Eyad
Elkord, Salem Chouaib, Maria J. Fernandez-Cabezudo.
3635
Enhanced intra-tumoral immune cell infiltration
following tumor targeted delivery of chemotherapy
using theranostic nanoparticles in an orthotopic mouse
pancreatic model. Erica N. Bozeman, Ning Gao, Weiping
Qian, Andrew Wang, Lily Yang.
3636
Anti-CD20 therapy prevents protumor regulatory
T-cell expansion and triggers a memory Th1 response
in tumor-bearing mice. Claire Deligne, Sophie Siberil,
Jean-Luc Teillaud.
10.
3637
Targeted inhibition of MER tyrosine kinase in
the tumor microenvironment decreases tumor growth in
a mouse model of breast cancer. Kristen M. Jacobsen,
Deborah DeRyckere, Weihe Zhang, Xiaodong Wang, Stephen
V. Frye, H. Shelton Earp, Douglas K. Graham.
11.
3638
Vaccine-draining lymph nodes of cancer
patients for generating anticancer antibodies. Girja S.
Shukla, Stephanie C. Pero, Yu-jing Sun, Chelsea L. Carman,
Walter C. Olson, Craig L. Slingluff, David N. Krag.
Poster Abstract
Board Number
12.
3639
Combinatorial therapy for triple negative breast
cancer. Yangyang Wang, Shalin S. Patel, Juan Cong, Nan
Zhang, Yuan Qi, Francesco Sabbatino, Steven Isakoff, Albert
B. DeLeo, Soldano Ferrone, Xinhui Wang.
13.
3640
IL-9 is involved in the establishment of a
tolerogenic milieu that prevents anti-tumor immunity.
Dominique B. Hoelzinger, Ana Lucia Dominguez, Peter A.
Cohen, Sandra J. Gendker.
14.
3641
Antibody targeting the IgM B-cell receptor
(mBCR) induces growth inhibition and apoptosis. Rachel
S. Welt, Yamuna D. Gangadharan, Jonathan A. Welt, Virginia
Raymond, David Kostyal, Sydney Welt.
15.
3642
Cancer therapy by resuscitating Notch immune
surveillance. Duafalia F. Dudimah, Samuel T. Pellom Jr.,
Roman V. Uzhachenko, David P. Carbone, Mikhail M. Dikov,
Anil Shanker.
16.
3643
Tumor-specific oncolytic adenovirus coding for
trastuzumab results in local production of functional
monoclonal antibody from tumor cells. Ilkka Liikanen,
Paula Savola, Akseli Hemminki.
17.
3644
C-Jun N-terminal kinases and autophagy
promote adenoviral and ectopic tumor-associated
antigen presentation. Sarah R. Klein.
18.
3645
CD24 polymorphisms and susceptibility to
inflammatory bowel disease and colorectal cancer risk.
Victoria Lisiansky, Sarah R. Kraus, Inna Naumov, Dina
Kazanov, Ilana Nabiochtchikov, Ohad Toledano, Moshe
Leshno, Doran Avivi, Menachem Moshkowitz, Iris Dotan,
Nadir Arber.
19.
3646
Pegylated recombinant human hyaluronidase
PH20 (PEGPH20) enhances cetuximab efficacy in BxPC3/HAS3 human pancreatic cancer xenografts. Ryan J.
Osgood, James F. Skipper, Susan Zimmerman, Rebecca C.
Symons, Harold M. Shepard, Daniel C. Maneval, Curtis B.
Thompson, David W. Kang.
20.
3647
Treatment of glioblastoma through the
controlled localized production of IL-12 by the
RheoSwitch Therapeutic System® Platform. John A.
Barrett, Hongliang Cai, Francois Lebel, Kay R. Meshaw,
Tami Zmetra, Jonathan Lewis.
21.
3648
Expression of tolerogenic enzymes IDO-1, IDO-2
and TDO in commonly used mouse tumor models and
impact on model selection for evaluation of
immunosuppression reversal by novel therapeutics.
Rajkumar Noubade, Holbrook Kohrt, Lisa Marshall, Idit
Sagiv-Barfi, Jonathan Hebb, Cariad Chester, Amanda
Rajapaksa, Erin Waller, Steve Young, Jay Powers, Juan
Jaen.
22.
3649
Significance of HIV viral load and CD4 count on
Kaposi sarcoma in the era of highly active antiretroviral
therapy. Gentry T. King, Shivani Garg.
POSTER SESSION
Immunology 9
Inflammation and Innate Immunity
Poster
Section
Poster Abstract
Board Number
1.
3650
PI3-kinase gamma controls the macrophage
M1-M2 switch, thereby promoting tumor
immunosuppression and progression. Megan Kaneda,
Sara Gorjestani, Judith A. Varner.
2.
3651
Natural killer cells eradicate galectin-1 deficient
glioma in the absence of adaptive immunity. Gregory J.
Baker, Viveka N. Yadav, Peter Chockley, Robert Doherty,
Michael Ritt, Sivaraj Sivaramakrishnan, Maria G. Castro,
Pedro R. Lowenstein.
3.
3652
Surface expression and shedding of NKG2D
ligands by (metastasizing) tumor cells is altered by
platelets leading to impaired NK cell
immunosurveillance. Stefanie Raab, Korbinian N. Kropp,
Alexander Steinle, Gerd Klein, Hans-Georg Kopp, Helmut R.
Salih.
4.
3653
Nanoparticle-delivered T7-synthesized siRNA
enhances cell killing in HER-2 (ⴙ) breast cancer. Felix
Alonso-Valenteen, Medina-Kauwe.
5.
3654
The role of structure-specific endonuclease
MUS81 in the induction of cytosolic DNA in tumor cells.
Samantha Ho, Stephan Gasser.
7.
3656
MDSC-generated nitric oxide leads to an
impairment of NK cell functions in metastatic melanoma
patients. Prashant Trikha, Bethany Mundy-Bosse, Ian Landi,
Elizabeth McMichael, Amanda Harper, Megan Duggan,
Nancy Stasik, Kari Kendra, Thomas Olencki, William Carson.
8.
3657
Cross-regulation between the two subsets of
NKT cells is dependent on interferon-gamma. Liat Izhak,
Shingo Kato, Stanley T. Parish, Masaki Terabe, Jay A.
Berzofsky.
9.
3658
90K attenuates the development of colitisassociated colorectal tumors through negative
regulation of intestinal epithelial Toll-like receptor 4.
Ik-Joo Chung, Jun-Eul Hwang, Ji-Hee Lee.
10.
3659
Engagement of myelomonocytic siglecs by
tumor-associated ligands modulates innate immune
responses to cancer. Heinz Läubli, Oliver M. Pearce, Flavio
Schwarz, Lingquan Deng, Michal Stanczak, Liwen Deng,
Andrea Verhagen, Patrick Secrest, Chrissy Lusk, Ann G.
Schwartz, Nissi Varki, Jack Bui, Ajit Varki.
Poster Abstract
Board Number
14.
3663
Immune suppressive myeloid cells expansion in
vitro requires a simulated tumor microenvironment.
Joseph Markowitz, Taylor R. Brooks, William E. Carson.
15.
3664
High frequency of a circulating monocytic
subpopulation of myeloid-derived suppressor cells
predicts worst clinical outcome in untreated non-small
lung cancer patients. Eleni K. Vetsika, Filippos Koinis,
Marianthi Gioulmpasani, Despoina Aggouraki, Anna
Koutoulaki, Eirini Skalidaki, Dimitris Mavroudis, Vassilis
Georgoulias, Athanasios Kotsakis.
16.
3665
IDO1 is an integrative determinant of tumorpromoting, pathogenic inflammation. Alexander J. Muller,
Courtney Smith, Mee Young Chang, James DuHadaway,
Arpita Mondal, Hollie Flick, Katherine Parker, Daniel Beury,
Suzanne Ostrand-Rosenberg, George C. Prendergast.
17.
3666
Tumor microenvironment modulation enhances
macrophage polarization and T-cell activation resulting
in synergized anti-cancer effect. Yuhui Huang, Wen Jiang,
Betty Y. Kim.
18.
3667
Attenuation of NF-␬B signaling in myeloid cells
enhances urethane-induced lung tumorigenesis via
neutrophil-derived IL-1␤. Allyson McLoed, Rinat
Zaynagetdinov, Taylor Sherrill, Fiona Yull, Timothy Blackwell.
19.
3668
Tumor-associated macrophages (TAMs)
promote murine neuroblastoma tumor growth through
upregulation of MYC and independent of IL6 expression.
Michael D. Hadjidaniel, Soheila Shirinbak, Sakunthala
Muthugounder, Long Hung, Michael Sheard, Janahan
Gnanachandran, Jin Kim, Richard Sposto, Hiroyuki Shimada,
Shahab Asgharzadeh.
20.
3669
IDH mutant glial cell resistance to natural killer
cell cytotoxicity. Xiaoran Zhang, Yigang Chang, Aofei Li,
Joseph C. Glorioso, Paola Grandi, Mike Lotze, Nduka
Amankulor.
21.
3670
Toll-like receptor (TLR) 7 expression in the
human tumor microenvironment. Nicola Haughton, Foster
Emily, Christopher Womack, Simon Barry, Setsuko
Yamamoto, Masashi Murata, Marie Cumberbatch.
11.
3660
Chronic alcohol consumption inhibits iNKT cell
activation-induced antitumor response in B16BL6
melanoma-bearing mice. Hui Zhang, Faya Zhang, ZhaoHui
Zhu, Gary G. Meadows.
22.
3671
Myeloid-derived suppressive cells require
education from tumor-evoked Bregs to mediate
metastasis. Monica Bodogai, Catalina Lee Chang, Arya
Biragyn.
12.
3661
Crucial roles of cytokine-signaling for alteration
in functions of myeloid-derived suppressor cells. Kentaro
Sumida, Yosuke Ono, Junya Ohtake, Kazutaka Masuko,
Satoshi Terada, Shun Kaneumi, Takuto Kishikawa, Toshiyuki
Kita, Hidemitsu Kitamura.
23.
13.
3662
Tumor-derived interleukin-1 promotes
lymphangiogenesis and lymph node metastasis through
activation of M2-type macrophages by lung cancer
cells. Kosuke Watari, Tomohiro Shibata, Akihiko Kawahara,
Yuichi Murakami, Hiroshi Nabeshima, Ai Shinoda, Koichi
Azuma, Hiroto Izumi, Masayoshi Kage, Michihiko Kuwano,
Mayumi Ono.
3672
Role and presence of cancer associated
fibroblasts and M2 macrophages in high grade cervical
intraepithelial neoplasia and invasive cervical
carcinomas. Leonel Maldonado, Teresa Diaz-Montes,
Abdulrahman Sinno, Edward J. Tanner, Christopher
VandenBussche, Richard Roden, Iveta Yotova, Benjamin
Tycko, Cornelia L. Trimble.
24.
3673
Role of IL-6 in inflammatory breast cancer and
its modulation by Ganoderma lucid (Reishi). Yaliz
Loperena-Alvarez, Luis A. Cubano, Michelle M. MartínezMontemayor.
27
27
461
POSTER SESSION
Experimental and Molecular Therapeutics 25
Poster
Section
30
30
Cellular and Molecular Pharmacology
Poster Abstract
Board Number
1.
3674
Targeted oncology therapeutics show unique
cardiotoxic profiles: Ponatinib as a case study.
Dominique Talbert, Kimberly Doherty, Patricia Trusk,
Diarmuid Moran, Scott Shell, Sarah Bacus.
2.
3675
PAN-811 blocks anticancer drug-induced
neurotoxicity. Zhi-Gang Jiang, Steven Fuller, Hossein A.
Ghanbari.
3.
3676
Influence of early toxicology assessment on the
selection of azd9291. Mark J. Anderton, Richard A. Ward,
Paula Daunt, Anne Galer, Darren A. Cross, Louise Marks, M.
Raymond V. Finlay.
4.
5.
6.
7.
8.
9.
10.
11.
12.
462
3677
Model-based optimization of combined
antiangiogenic ⴙ cytotoxics modalities: application to
the bevacizumab-paclitaxel association in breast cancer
models. Severine Mollard, Sebastien Benzekry, Sarah
Giacometti, Christian Faivre, Florence Hubert, Joseph
Ciccolini, Dominique Barbolosi.
3678
An immunoassay for measurement of
methotrexate on ARCHITECT i system. Robert J. Smalley,
Raymond E. Picard, Beth A. Burkhart, Robert L. Frescatore,
Curtis L. Glover, Lisa C. Zhu, Elizabeth A. Roessner, Karin
MajnesjÖ, Anders Öhrvik, Kuanglin He, Zhong Q. Li, Timothy
R. Kettlety.
3679
Inhibition of LSD1 disrupts global EWS/ETS
transcriptional function in Ewing sarcoma. Emily R.
Theisen, Savita Sankar, Jared Bearss, Timothy Mulvihill,
Venkataswamy Sorna, Sunil Sharma, Stephen L. Lessnick.
3680
(R,R’)-4’-methoxy-1-naphtylfenoterol inhibits
pro-survival signaling, proliferation and motility of
select human melanoma cell lines. Artur Wnorowski,
Rajib K. Paul, Lucita Jimenez, Lawrence Toll, Abdelmohsen
Kotb, Michel Bernier, Irving W. Wainer.
3681
Synergism analysis of dose matrices for
combinations of BKM120 (a PI3K inhibitor), MEK162 (a
MEK1/2 inhibitor) and chemotherapy in colorectal
cancer (CRC) cell lines. Diego Tosi, Salima Atis, Caroline
Mollevi, Pierre Martineau, Céline Gongora.
3682
Contribution of hepatic uptake transporters
OATP1B1/OATP1B3 to the disposition of docetaxel. Hye
Jeong Lee, Brenda F. Leake, Wendy Teft, Richard B. Kim,
Richard H. Ho.
3683
Targeting PIK3CA mutant breast cancer with
the combination of PIK3CA-specific inhibitor, BYL719,
and IGF1-R antibody, ganitumab. Z. Alexander Cao, Maria
Pinzon-Ortiz, Yan Chen, Xiaoyan Li, Pedro J. Beltran,
Jennifer Gansert, Malte Peters, Robert Schlegel, Karl M.
Schumacher, Alan Huang.
3684
The combination of JAK inhibitor, ruxolitinib,
pan-PIM inhibitor, LGH447, and CDK4/6 inhibitor,
LEE011, in a preclinical mouse model of
myeloproliferative neoplasia. Maria Pinzon-Ortiz, Xianhui
Rong, Abdel Saci, Robert Schlegel, Gary Vanasse, Giordano
Caponigro, Z. Alexander Cao.
3685
BAY 1125976, is a selective allosteric AKT1/2
inhibitor with high efficacy in AKT1-mutated cancers.
Oliver Politz, Arne Scholz, Andrea Haegebarth, Ningshu Liu,
Lars Baerfacker, Stuart Ince, Roland Neuhaus, Ulf Boemer,
Martin Michels, Dominik Mumberg.
Poster Abstract
Board Number
13.
3686
HEXIM1 induction exerts a mechanistic role and
is a biomarker of lethal activity of BRD4 antagonist
against human AML cells. Santhana G. Devaraj, Warren
Fiskus, Sunil Sharma, Jun Qi, Bhavin Shah, Leasha J.
Schaub, Melissa Rodriguez, Ka Liu, Swaminathan P. Iyer,
James E. Bradner, Kapil N. Bhalla.
14.
3687
Analgesic effects of capsazepine on a mouse
model of bone cancer pain. Matthew D. Balenko, Eric
Seidlitz, Gurmit Singh.
15.
3688
Arctigenin induced immunogenic cell death
through a reactive oxygen species/endoplasmic
reticulum stress pathway in lung cancer. Chih-Hsin Kuo,
Ya-Ling Hsu, Ming-Shyan Huang.
16.
3689
Minocycline regulates hypoxia-inducible factor1␣ expression through the induction of its degradation
in ovarian cancer: in vitro and in vivo studies. Parvin
Ataie-Kachoie, David L. Morris, Mohammad H. Pourgholami.
17.
3690
MMP-1 and pro-MMP-10 as potential urinary
pharmacodynamic biomarkers of FGFR3-targeted
therapy in patients with bladder cancer. Benjamin C. Lin,
Xiangnan Du, Qian-Rena Wang, Hao Li, Ellen Ingalla, Janet
Tien, Isabelle Rooney, Avi Ashkenazi, Elicia Penuel, Jing
Qing.
18.
3691
Met target inhibition-guided efficacy in
preclinical models. Apurva K. Srivastava, Melinda G.
Hollingshead, Jeevan P. Govindharajulu, Joseph M. Covey,
Dane Liston, James Peggins, Donald P. Bottaro, John J.
Wright, Robert J. Kinders, Joseph E. Tomaszewski, James
H. Doroshow, Ralph E. Parchment.
19.
3692
Preclinical studies of a mutant p53 reactivating
drug in pancreatic cancer. Xin Yu, Zhe Li, Oliver S. Eng,
Ashley T. Tsang, Hongxia Lin, Murugesan Gounder, Darren
R. Carpizo.
20.
3693
Preclinical antitumor activity of SST0116CL1, a
novel heat shock protein 90 (HSP90) inhibitor. Loredana
Vesci, Ferdinando Milazzo, Valeria Carollo, Silvia Pace,
Giuseppe Giannini.
21.
3694
Relationship between in vivo antitumor activity
of ADC and payload release in preclinical models. Fu Li,
Xinqun Zhang, Kim Emmerton, Mechthild Jonas, Jocelyn
Setter, Bill Arthur, Nicole Okeley, Robert Lyon, Dennis
Benjamin, Che-Leung Law.
22.
3695
The utility of plasma vascular endothelial
growth factor and heparanase as pharmacodynamic
markers following treatment with PG545, a heparan
sulfate mimetic: preliminary evidence from preclinical
and clinical settings. Keith Dredge, Edward Hammond,
Boris Winterhoff, Shailendra Giri, Attila Teoman, Darryn
Bampton, Michael Millward, Viji Shridhar.
23.
3696
Inhibition of OATP1B1 by tyrosine kinase
inhibitors: in vitro-in vivo correlations. Shuiying Hu, Peter
D. Bruijn, Ron H. Mathijssen, Sharyn D. Baker, Alex
Sparreboom.
POSTER SESSION
Drug Resistance 3: BRAF, MEK, ALK, and MET Inhibitors
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
3697 SIRT2 is a modulator of response to targeted therapies
through regulation of MEK kinase activity. Prashanth K. Bajpe,
Anirudh Prahallad, Hugo Horlings, Iris Nagtegaal, Roderick
Beijersbergen, Rene Bernards.
3698 Hyperactive AKT pathway and reactivation of the
MAPK/ERK pathway in melanoma cells resistant to dual BRAF
and MEK inhibition. Victoria E. Wang, Frank McCormick, Jeffrey
Settleman.
3699 Molecular profiling of BRAFi-resistance in melanoma
cancer models using high-throughput sequencing in patientderived xenografts. Bruno Zeitouni, Gerhard Kelter, Armin Maier,
Florian Kiefer, Frederic Foucault, Anne-Lise Peille, Tim Kees, Torsten
Giesemann, Vincent Vuaroqueaux, Thomas Metcalfe, Heinz-Herbert
Fiebig.
3700 eIF4F is a key and targetable convergence nexus of
multiple resistance mechanisms to anti-RAF and anti-MEK
cancer therapies. Lise Boussemart, Helene Malka-Mahieu, Isabelle
Girault, Oskar Hemmingsson, Gorana Tomasic, Marina Thomas,
Delphine Allard, Nigel Ribeiro, Frederic Thuaud, Christine Mateus,
Emilie Routier, Nyam Kamsu-Kom, Sandrine Agoussi, Alexander
Eggermont, Laurent Desaubry, Caroline Robert, Stephan Vagner.
3701 BRAF inhibitor (vemurafenib) resistance confers
sensitivity to arginine deprivation in melanoma. Ying-Ying Li,
Chunjing Wu, Shu-Mei Chen, Medhi Wangpaichitr, Min You, Seth
Spector, Lynn G. Feun, Macus T. Kuo, Niramol Savaraj.
3702 Integrated genomic and proteomic analysis identifies
PTEN loss and AKT/MTOR as drivers of resistance to MEK
inhibitors in NSCLC cells. Dianren Xia, Lauren A. Byers, Lixia Diao,
Jing Wang, Steven H. Lin, Don L. Gibbons, Kathryn A. Gold, Juliane
Paul, Ningshu Liu, John V. Heymach.
3703 PDGFR␣ up-regulation mediated by Sonic Hedgehog
Pathway activation leads to BRAF inhibitor resistance in
melanoma cells with BRAF mutation. Francesco Sabbatino,
Yangyang Wang, Xinhui Wang, Keith T. Flaherty, David Pepin, Giosuè
Scognamiglio, Ling Yu, Zachary A. Cooper, Stefano Pepe, John M.
Kirkwood, Dennie T. Frederick, Jennifer A. Wargo, Soldano Ferrone,
Cristina R. Ferrone.
3704 Novel panRAF inhibitors active in melanomas that are
resistant to BRAF-selective, or BRAF-selective/MEK inhibitor
combinations. Maria R. Girotti, Filipa Lopes, Natasha Preece, Dan
Niculescu-Duvaz, Alfonso Zambon, Lawrence Davies, Steven
Whittaker, Grazia Saturno, Amaya Viros, Malin Pedersen, Bart M.
Suijkerbuijk, Delphine Menard, Robert Mcleary, Louise Johnson,
Laura Fish, Sarah Ejiama, Berta Sanchez-Laorden, Neil Carragher,
Kenneth Macleod, Garry Ashton, Anna Marusiak, Alberto Fusi, John
Brognard, Margaret Frame, Paul Lorigan, Caroline J. Springer,
Richard Marais.
3705 Overcoming drug resistance in BRaf mutated
melanoma cells. Ramin Samadani, Jun Zhang, Alexander Mackerell,
Steven Fletcher, Paul Shapiro.
3706 Oncogenic RAF mutants that signal as functional
dimers are resistant to current RAF inhibitors but sensitive to a
novel inhibitor of RAF dimer kinase activity. Zhan Yao, Merna
Torres, Min Wei, Aphrothiti Hanrahan, Omar Abdel-Wahab, David
Solit, Lusong Luo, Poulikos Poulikakos, Neal Rosen.
3707 The multitargeted kinase inhibitor dasatinib induces
DNA damage, Hippo pathway engagement and senescence in
lung cancer cell lines that possess kinase-inactivating BRAF
mutations. Banibrata Sen, Shaohua Peng, Tuhina Mazumdar, Lauren
A. Byers, Humam Kadara, Faye M. Johnson.
3708 microRNAs involved in BRAF inhibitor resistance. Lisa
Koetz, Elena Sokolova, Brian D. Brown, Eva Hernando.
3709 Resistance mechanisms to targeted molecular therapy
in thyroid cancer. Elyse K. Hanly, Neha Y. Tuli, Robert Suriano,
Robert Bednarczyk, Zbigniew Darzynkiewicz, Augustine L.
Moscatello, Edward J. Shin, Jan Geliebter, Raj K. Tiwari.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
29.
30.
3710 The role of eIF4E in promoting melanoma cell
proliferation and maintaining acquired resistance to
Vemurafenib in melanoma. Yao Zhan, Michael S. Dahabieh, Filippa
Pettersson, Monica C. Dobocan, Marie Noel M Boutchou, Leon Van
Kempen, Sonia V. del Rincon, Wilson H. Miller, Jr.
3711 Erk inhibition as a therapeutic option for the treatment
of Raf- and Mek- inhibitor resistant tumors. Irene Seipelt, Peter
Schmidt, Helene Maerzhaeuser, Matthias Gerlach, Kai Jung, Tilmann
Schuster, Michael Teifel.
3712 HGF mediated resistance to BRAF inhibition in BRAF
V600E mutant melanoma xenograft models. Keegan Cooke, Guo
Huang, Sean Caenepeel, Hong Ma, Cherylene Plewa, Ki Jeong Lee,
Angela Coxon, Paul E. Hughes, Pedro Beltran.
3713 Identifying a mechanism of acquired resistance to the
combined inhibition of PI3K/mTOR and MEK in colorectal
carcinoma. Scott J. Garza, Paul Lira, Stephen D. Huang, Hengmiao
Cheng, Stephen G. Dann, Todd L. VanArsdale, Valeria Fantin, James
Christensen, Julie L. Kan.
3714 Trametinib (Mekinist TM) has limited brain distribution
in the mouse model. Shruthi Vaidhyanathan, Rajendar K. Mittapalli,
Daniel J. Ma, Mark A. Schroeder, Jann N. Sarkaria, William F.
Elmquist.
3715 Discovery of novel targets for effective combination
drug therapy in ALKⴙ NSCLC patient derived models of
acquired resistance. Adam S. Crystal, Jeffrey A. Engelman, Cyril H.
Benes, Maria G. Gomez-Caraballo, Rosa Frias, Elizabeth Lockerman,
Alice T. Shaw.
3716 Overexpression of the adaptor protein CRKL as a
mechanism of acquired resistance to Crizotinib in ALK-positive
NSCLC. Magda Bahcall, Takaaki Sasaki, Atsuko Ogino, Marzia
Capelletti, Mohit Butaney, Pasi A. Jänne.
3717 Therapeutic strategies to overcome the crizotinib
resistance in ROS1-rearranged lung cancers. Ryohei Katayama,
Yuka Kobayashi, Sumie Koike, Naoya Fujita.
3718 Adaptive drug escape of EML4-ALK lung cancer
against targeted ALK inhibitor involving TGF␤2-mitochondrial
priming. Lihong Yin, Wei Zhang, Ivy Shi, Yan Feng, Rakesh Bagai,
Daniel Lindner, Patrick C. Ma.
3719 Mechanisms of resistance to the second-generation
alk inhibitor ap26113 in human npm-alk-positive anaplastic
large cell lymphoma cells. Monica Ceccon, Luca Mologni, Giovanni
Giudici, Rocco Piazza, Alessandra Pirola, Diletta Fontana, Carlo
Gambacorti-Passerini.
3720 Intrinsic and acquired resistance mechanisms of
alectinib in ALK rearranged cells. Yukiko Hibino, Sasaki Takaaki,
Yoshinori Minami, Pasi A. Janne, Yoshinobu Ohsaki.
3721 ALK inactivation induced acquired resistance to
alectinib in lung cancer harboring EML4-ALK fusion gene. Hideko
Isozaki, Eiki Ichihara, Masayuki Yasugi, Ochi Nobuaki, Katsuyuki
Hotta, Nagio Takigawa, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki
Kiura.
3722 The HSP90 inhibitor ganetespib synergizes with the
MET kinase inhibitor crizotinib in both crizotinib-sensitive and
crizotinib-resistant MET-driven renal tumor models. Naoto
Miyajima, Tomoshige Akino, Kunihiko Tsuchiya, Satoru Maruyama,
Takashige Abe, Nobuo Shinohara, Katsuya Nonomura, Len Neckers.
3723 TAS-115, a novel MET ⴙ VEGFRs dual inhibitor,
decreases the cytotoxic anticancer drug resistance in lung
cancer. Eiji Kunii, Hiroaki Ozasa, Tetsuya Oguri, Ken Maeno, Osamu
Takakuwa, Takehiro Uemura, Niimi Akio.
3725 HGF/c-Met axis drives cancer aggressiveness in the
neo-adjuvant setting of ovarian cancer. Marisa Mariani, Mark
McHugh, Marco Petrillo, Steven Sieber, Shiquan He, Mirko Andreoli,
Paul Fiedler, Giovanni Scambia, Shohreh Shahabi, Cristiano Ferlini.
3726 Inhibition of MET overcomes invasive resistance to
Bevacizumab and prolongs survival in orthotopic mouse models
of glioblastoma multiforme. Manuela Cazzanti, Paolo Michieli.
Poster
Section
31
31
463
POSTER SESSION
Poster
Section
32
32
Novel Preclinical Models and Assay Technology
Poster Abstract
Board Number
1.
3727
Drug screen on six co-cultured GBM cell lines
using a multiplex luciferase assay. Sjoerd van Rijn, Lotte
Hiddingh, Thomas Wurdinger, Ravi Narayan.
2.
3728
A discovery platform for allosteric modulators
of c-Abl kinase function. Prerna Grover, Thomas E.
Smithgall.
3.
4.
3730
A quick and cost effective 12-cell line panel
assay to predict drug activity in human tumor xenograft
models. Michael J. Roberts, Tommie A. Gamble, Richard D.
May, Murray Stackhouse, Kristy L. Berry, Andrew D.
Penman, Robert J. Rooney, Yulia Maxuitenko, Michael S.
Koratich.
13.
3739
An in vitro fluorescence-based co-culture model
identifies tumour microenvironment-mediated
chemoresistance in pancreatic cancer. Ruiling Xu,
Frances M. Richards, Yao Lin, Duncan I. Jodrell.
14.
3740
Paired ADCC reporter bioassays enable
quantification and differentiation of antibody Fc-effector
activities via V158 and F158 variant Fc␥RIIIa receptors.
Zhi-Jie J. Cheng, Denise Garvin, Aileen Paguio, Rich
Moravec, Frank Fan, Teresa Surowy.
15.
3741
Development and characterization of a cell
based assay for the validation of mutant IDH1 inhibitors.
Nicole D. Fer, Erik Harris, Stephen Fox, Ming Zhou,
Catherine Simpson, Jing ,Liu, Ilia Korboukh, Emily A. HullRyde, William P. Janzen, Stephen V. Frye, Anne Monks,
Beverly Teicher, Annamaria Rapisarda.
16.
3742
Detection of EGFR, HER2, HER3 and HER4
homodimerization and heterodimerization using EFCbased cellular assays. Jane Lamerdin, Abhishek Saharia,
Jennifer Lin-Jones, Mimi Nguyen, Hyna Fabionar, Sangeetha
Gunturi, Abha Srivastava, Tom Wehrman.
5.
3731
Luminescent cell health assays for tumor
spheroid evaluation. Michael P. Valley, Kevin R. Kupcho,
Chad A. Zimprich, Andrew L. Niles, James J. Cali, Jens M.
Kelm, Wolfgang Moritz, Dan F. Lazar.
6.
3732
Utilizing Bimolecular Fluorescent
Complementation to Identify Inhibitors of RAL and
KRAS. Marytheresa Ifediba, David Burnett, Nicholas Hovda,
William Burnett, Matthew VanBrocklin.
17.
3743
Bioluminescent, non-lytic, real-time cell viability
assay. Sarah J. Duellman, Jolanta Vidugiriene, Wenhui
Zhou, Jean Osterman, Ruslan Arbit, Laurent Bernad, Poncho
Meisenheimer, James J. Cali.
7.
3733
SilenciX®, novel stable knock-down cellular
models to screen new molecular targets through the
synthetic lethality approach. Eric Mennesson, Anne-Marie
Renault, Isabelle Fixe, Catherine GRILLON, Claudine Kiéda,
Nadia Normand.
18.
3744
High-throughput in vitro screening of glioma
stem cell lines: Evaluation of over 350 tyrosine kinase
inhibitors. Craig Thomas, Ji Liang, Yuji Piao, Nghi Nguyen,
Erik Sulman, Clifford Stephan, Alfred Yung, John F. de
Groot.
8.
3734
Development of a nanostring copy number
assay for a customized 55 gene panel using challenging
formalin-fixed paraffin-embedded (ffpe) tumor samples.
Tingdong Tang, Wenge Shi, Loretta Hipolito, Julie Mayer,
Jelveh Lameh, Shabnam Tangri, Reinhold Pollner.
19.
9.
3735
Monitoring the level of the universal nucleotide
AMP in diverse enzymatic reactions using
bioluminescent homogenous assay platform. Said A.
Goueli, Kevin Hsiao, Hicham Zegzouti, Subhanjan Mondal.
3745
Optimization of an assay for the detection of
phosphorylated FAK by immunohistochemistry in
formalin-fixed, paraffin-embedded human tissue and
cell lines. Lisa M. Dauffenbach, Gela C. Sia, Patricia A.
Cash, Sherif K. Girees, Ryan S. Lim, Jianping Zheng, Eric P.
Olsen, Rana Richeh, Christopher A. Kerfoot.
20.
3746
Anticipating the maximum tolerated dose for
combinations based on early toxicity signals. Ekta
Kadakia, Christopher J. Zopf, Mayankbhai Patel, Dean
Bottino, Greg Hather, Wen Chyi Shyu, Arijit Chakravarty.
21.
3747
Predicting Maximum Tolerated Dose during
Phase I using anticipatory toxicity models. Ekta Kadakia,
Snehal Samant, Christopher J. Zopf, Dean Bottino, Greg
Hather, Santhosh Palani, Wen Chyi Shyu, Arijit Chakravarty.
22.
3748
Clinicopathological characterization of nonalcoholic Steatohepatitis (NASH)-derived hepatocellular
carcinoma (HCC) as a patient stratification model in
mice. Kazuki Takakura, Masato Fujii, Taishi Hashiguchi,
Yuichiro Shibazaki, Hiroyuki Yoneyama, Shigeo Koido,
Sadamu Homma, Toshifumi Ohkusa, Hisao Tajiri.
10.
464
3729
An individualized approach to bladder cancer
treatment using patient-derived cell lines to predict
response to chemotherapeutic agents. LaMont Barlow,
Chee Wai Chua, Ming Lei, G. Joel DeCastro, Ketan Badani,
Mitchell Benson, James McKiernan, Michael Shen.
Poster Abstract
Board Number
3736
Application of patient tumors-derived tumor
ecosystem platform for the development of novel HDAC
inhibitor in solid cancers. Mallikarjun Sundaram,
Baraneedharan Ulaganathan, Muthu Dhandapani, Allen
Thayakumar, Pragnashree Mukhopadhyay, Saravanan
Thiyagarajan, Biswanath Majumder, Prasad Shivarudriah,
Jagadheshan H, Ganesh Sambasivam, Steve Birnbuam,
Padhma Radhakrishnan, Pradip K. Majumder.
11.
3737
Use of intestinal organoids as a preclinical
screen for agents modulating epithelial regeneration
and gastrointestinal toxicity. Sarah Hoyle, Shaun
Ainsworth, Aude-Marine Bonavita, Jo Read, Alan Murdoch,
Lorna Woolford, Elliott Harrison, Gino Miele, Cath Booth.
12.
3738
Crizotinib induces tumor suppressor miR-146a,
autophagy and p21 waf1/cip1 by alternative targeting
non-TK target Akt-mTOR-Foxo axis: A CPI-based
systemic study on discovery of phenotypic off-target.
Jiazhi Sun, Lun Yang, Minghua Li, Ian E. Heller, Issac
Raplee, Steven Guzman, John P. Pasciak, Feng Cheng,
Kevin B. Sneed, Lin He, Shu-Feng Zhou.
POSTER SESSION
Resistance to Platins, Alkylating Agents, and Temozolamide
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
3749
Novel aldehyde dehydrogenase inhibitors as
potential anti-chemoresistance drugs for head and neck
cancers. Jeewon Kim, JuneHo Shin, Che-Hong Chen, Leslie
Cruz, Lovisa Farnebo, Jieying Yang, John B. Sunwoo, Daria
Mochly-Rosen.
3750
Targeting PD-L1 sensitizes head and neck
squamous cell carcinoma to cisplatin. Peter Qiao,
Shayanne A. Lajud, Danish A. Nagda, Nobuaki Tanaka,
Alyssa Civantos, Bert W. O’Malley, Daqing Li.
3751
The potential role of CXCR4 in cisplatin
associated resistance in esophageal carcinoma. Yue
Zhao, Yan Wang, Christiane Bruns.
3752
PKM2 subcellular localization is involved in
oxaliplatin resistance acquisition in human colorectal
cancer cell lines. Alba Ginés, Anna Martínez-Cardús,
Vicenç Ruiz de Porras, Eva Musulén, José Luis Manzano,
Laura Layos, Cristina Bugés, Albert Abad, Eva MartinezBalibrea.
3753
Copper-chelator exerts synergistic interaction
with platinum drugs through modulating copper
transporters in oxaliplatin-resistant human gastric
cancer cell. Szu-Jung Chen, Jang-Yang Chang, ChingChuan Kuo, Hsin-Yi Pan.
3754
Hippo pathway effector Yes-associated protein
and cisplatin resistance in transitional cell carcinoma of
the bladder. Eric S. Ciamporcero, He Shen, Sreenivasulu
Chintala, Swathi Ramakrishnan, Sheng Yu Ku, Kiersten M.
Miles, Stefania Pizzimenti, Candace Johnson, Jianmin
Zhang, Giuseppina Barrera, Roberto Pili.
3755
Restoring sensitivity to cisplatin or TRAIL by
targeting drug resistance master regulators in
endometrial cancer. Xiangbing Meng, Shujie Yang, Xinjun
Wang, Yichen Jia, Yuping Zhang, Kimberly K. Leslie.
3756
The DNA hypomethylating agent SGI-110,
reverses the platinum resistance of ovarian cancer
models. Joanne M. Munck, John Lyons, Neil T. Thompson,
Nicola G. Wallis, Pietro Taverna.
3757
Vacuolar ATPase ‘a’ subunit mediates platinum
resistance in ovarian cancer. Arpita Kulshrestha, Gajendra
K. Katara, Sahithi Pamarthy, Alice Gilman-Sachs, Kenneth D.
Beaman.
3758
Inhibition of ATR, but not ATM, sensitizes
gynecologic cancer cells to cisplatin. Pang-Ning Teng,
Nicholas W. Bateman, Chad A. Hamilton, G. L. Maxwell,
Christopher J. Bakkenist, Thomas P. Conrads.
3759
Identification of novel carboplatin resistance
gene in ovarian cancer. Han Wei, Yun She, Tao Lu.
3760
Role of epithelial to mesenchymal transition in
response to cisplatin in patient-derived ovarian
carcinomas. Francesca Ricci, Federica Guffanti, Fratelli
Maddalena, Patrizia Perego, Robert Fruscio, Romina Baldo,
Sonia Magni, Massimo Broggini, Giovanna Damia.
3761
Nanoliposomal c-MYC-siRNA inhibits in vivo
tumor growth of cisplatin-resistant ovarian cancer.
Jeyshka M. Reyes-González, Guillermo N. Armaiz,
Lingegowda S. Mangala, Fatma Valiyeva, Sunila Pradeep,
Anil K. Sood, Pablo E. Vivas-Mejía.
3762
Downregulation of TRPC3 enhances sensitivity
to cisplatin and inhibits motility in epithelial ovarian
cancer. Xiang Tao, Hongyan Jin, Zhenbo Zhang, Robert C.
Bast, Youji Feng, Yinhua Yu.
3763
Ribonucleotide reductase subunit M2 plays
important role in cisplatin resistance of cancer cells.
Mohammad A. Rahman, A.R.M. R. Amin, Xianghong Peng,
Jun Zhang, Zhuo G. Chen, Dong M. Shin.
3764
Antibody therapy against granulin-epithelin
precursor sensitizes liver cancer to chemotherapy.
Nicholas Wong, Phyllis Cheung, Chi Wai Yip, Kui Fat Chan,
Irene Ng, Sheung Tat Fan, Siu Tim Cheung.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3765
Indoleamine 2,3-dioxygenase mediates immuneindependent human tumor cell resistance to olaparib, ␥
radiation, and cisplatin. Saman Maleki Vareki, Mateusz
Rytelewski, Rene Figueredo, Di Chen, Peter J. Ferguson,
Mark Vincent, Weiping Min, Xiufen Zheng, James
Koropatnick.
3766
The response of cervical cancer cells to
chemotherapeutic agents depends on endogenous ROS
levels as well as the drug-induced ROS profile. Maria
Filippova.
3767
Transcriptional and proteomic profiling of drugtolerant cancer cell subpopulations using colonies that
emerge in the presence of anticancer agents. Kohei
Kume, Satoshi Nishizuka, Miyuki Ikeda, Sawako Miura,
Fumitaka Endo, Katagiri Hirokatsu, Kaoru Ishida, Kei Sato,
Chihaya Maesawa, Go Wakabayashi.
3768
C3: A small molecule that reverses
chemoresistance by inhibition of cell cycle arrest.
Kathryn E. Wolak, Kenan Onel.
3769
K-ras Silencing has diverse effect on the
response of cells to chemotherapeutic drugs. Ladan
Teimoori-Toolabi, Kayhan Azadmanesh, Mohammadreza
Khorramizadeh, Saba Hashemi.
3770
MLN4924, a neddylation inhibitor, abolishes
chemoresistance of bladder cancer stem-like cells
through suppression of stemness. Kuan-Lin Kuo, I-Lin Ho,
Yeong-Shiau Pu, Yu-Chieh Tsai, Tsung-Hsien Shih, Kuo-How
Huang.
3771
Splenic macrophages induce chemotherapy
resistance via DNA damage repair. Julia M. Houthuijzen,
Laura G. Daenen, Jeanine M. Roodhart, Klaas M. Govaert,
Michelle E. Smith, Juergen Thomale, Sahar J. Sadatmand,
Hilde Rosing, Fabian Kruse, Nico van Rooijen, Jos H.
Beijnen, Piet Borst, Sven Rottenberg, Bodduluri Haribabu,
Emile E. Voest.
3772
Developing a molecular understanding of nonsmall cell lung cancer resistance to standard taxaneplatin chemotherapy. Maithili P. Dalvi, Carmen Behrens,
Milind Suraokar, Rui Zhong, Brenda Timmons, Luc Girard,
Yang Xie, Ignacio Wistuba, John D. Minna.
3773
Identification of ALDH1A3 as a driver of
resistance to both low-dose metronomic and
conventional cyclophosphamide chemotherapy in
prostate cancer. Van C. Hoang, Annabelle Chow, Amy
Wong, Lavarnan Sivanathan, Urban Emmenegger.
3774
Hyperthermia treatment overcomes
temozolomide resistance in glioma cells by
downregulating MGMT expression and increasing
temozolomide uptake. Chen-Ting Lee, Aaron Blackley,
Chelsea Landon, Ivan Spasojevic, John P. Kirkpatrick, Mark
W. Dewhirst.
3775
Identification of PHF6 as a temozolomide
resistance factor in glioblastoma using mirConnX. Lotte
Hiddingh, Rajiv S. Raktoe, Gertjan J. Kaspers, W. P.
Vandertop, David P. Noske, Pieter Wesseling, Thomas
Wurdinger.
3776
Identification of gene regulatory networks
mediating melanoma cell resistance to temozolomide.
Tongwu Zhang, Mai Xu, Donald Chow, Chris Sereduk,
Jeffrey M. Trent, Hongwei Yin, Kevin M. Brown.
3777
Combining VELIPARIB (ABT-888) with
temozolomide shows strong synergy when treating
temozolomide-resistant and recurrent GBM cell lines.
Kerrie McDonald, Kyoko Nozue-Okada, Mustafa Khasraw.
3778
Glioblastoma multiforme utilizes system Xc- in
survival under oxidative stress and chemoresistance.
Rosyli F. Reveron, Monika D. Polewski, Karen S. Aboody.
Poster
Section
33
33
465
POSTER SESSION
Poster
Section
34
34
Role of Microenvironment in Therapeutic Responses to Anticancer Drugs
Poster Abstract
Board Number
1.
3779
Treatment of experimental brain metastasis of
human breast cancer by macitentan, a dual antagonist
of endothelin receptors combined with paclitaxel. Ho
Jeong Lee, Sun Jin Kim, Seung Wook Kim, Junqin He,
Qiuyu Wu, Erica J. Lawson, Francois Lehembre, Urs
Regenass, Isaiah J. Fidler.
2.
3780
On the role of experimental microenvironmental
conditions in targeted inhibition of the pH-regulating
carbonic anhydrase IX in colorectal carcinoma cells.
Helga H. Hektoen, Kjersti Flatmark, Kirsti S. Landsverk,
Marie G. Saelen, Kathrine Roe, Anne H. Ree.
3.
4.
3782
Cl-amidine, a PAD inhibitor, prevents UC and
CRC in mice: Exploring novel mechanisms of miRNA and
oxidative stress regulation. Erin E. Witalison, Xiangli Cui,
Paul R. Thompson, Lorne J. Hofseth.
5.
3783
Adipocytes inhibit trastuzumab-mediated ADCC
via induction of GDF15. Minh Ngoc Duong, Aurore Cleret,
Eva-Laure Matera, Kamel Chettab, Doriane Poloni, Sandrine
Valsesia-Wittmann, Béatrice Clémenceau, Charles Dumontet.
6.
3784
Induction of BRCAness phenotype by curcumin
and hydroxyurea in WT BRCA ovarian cancer cells.
Yuehua Mao, Richard D Dinnen, Robert L. Fine.
7.
3785
Olaparib increases the effectiveness of
radiation in hypoxic tumor cells in xenograft models of
human non-small-cell lung cancer. Yanyan Jiang, Tom
Verbiest, Aoife M. Devery, Sivan M. Bokobza, Anika M.
Weber, Anderson J. Ryan.
8.
3786
Gambogic acid inhibits chemokine receptor
CXCR4 signaling pathways and osteoclastogenesis in
multiple myeloma. Manoj K. Pandey, Vijay P. Kale,
Chunhua Song, Shen-shu Sung, Arun K. Sharma, Sinisa
Dovat, Shantu G. Amin.
9.
3787
Effects of hyperthermia on DNA repair capacity
and long term survival in ovarian and colon carcinoma
cells. Lea Schaaf, Heiko Van Der Kuip, Thomas E. Mürdter,
Christoph Ulmer, Walter E. Aulitzky.
10.
3788
Drug mechanisms of action: Triangulating with
cultured cancer cells. John N. Weinstein, Bo Peng, William
C. Reinhold, Yves Pommier, Philip L. Lorenzi.
12.
3789
Harnessing the electrophilic character of
michael acceptor- and isothiocyanato-centric
compounds as thioredoxin reductase inhibitors. Eng-Hui
Chew, Kamila K. Kaminska, Fei-Fei Gan, Wanling Zeng, RuiYi Neo, Shridhivya A. Reddy, Navanita D. Thirumoorthi,
Christina Chai, Helene Bertrand, Geoff Wells.
13.
466
3781
A spheroid-based screen identifies
mitochondrial targeting as a promising strategy for
cancer treatment and drug repositioning. Wojciech
Senkowski, Xiaonan Zhang, Maria Hägg Olofsson, Stig
Linder, Rolf Larsson, Mårten Fryknäs.
Poster Abstract
Board Number
14.
3791
The inhibition of protein kinase CK2 activity by
the CIGB-300 synthetic peptide impairs the threedimensional cell growth, Wnt and nuclear factor к B
signaling pathways in lung cancer cells. Stéfano M.
Cirigliano, María Inés Díaz Bessone, Carolina Flumian,
Damián E. Berardi, Silvio E. Perea, Elisa Bal De Kier Joffé,
Hernán Farina, Laura Todaro, Alejandro Urtreger.
15.
3792
Upregulation of TNF-␣ by ethanol extract of
Moringa oleifera leaves in benzene-induced leukemic
Wister rat: a possible mechanism of anticancer
property. Olufemi E. Akanni, Adebayo L. Adedeji, Kola J.
Oloke.
16.
3793
Effects of DCA and metformin on murine colon
cancer growth. Robert P. Sticca, Tonya C. Murphy.
17.
3794
Sorafenib suppresses desmoid tumor growth
and invasion via inhibition of ERK signaling. Laura M.
Rosenberg, Monica M. Bertagnolli, Nancy L. Cho.
18.
3795
Cabozantinib affects multiple signaling
pathways in glioblastoma and is effective in a subset of
xenograft tumors. Ana C. deCarvalho, Kimberly Arnold,
Claudius Mueller, Emanuel F. Petricoin, Laila M. Poisson,
Tom Mikkelsen.
19.
3796
Biochemical and biophysical characterization of
AD-O51.4 a novel anticancer biological therapeutic
agent with dual mechanism of action. Sebastian D.
Pawlak, Jerzy S. Pieczykolan, Bartlomiej Zerek, Katarzyna
Poleszak, Malgorzata Teska-Kaminska, Marlena Galaska,
Michal Szymanik, Albert Jaworski, Anna Pieczykolan,
Katarzyna Bukato, Wojciech Strozek, Piotr K. Rozga.
20.
3797
Efficacy and pharmacokinetics of gold nanorods
coupled with laser-induced photoplasmonic therapy in
solid tumor bearing mice. Ahmed M. Al-Abd, Ali A.
Shabaka, Osama A. El-Shabrawy, Nemat A. Yassin, Sawsan
S. Mahmoud, Siham M. El-Shenawy, Emad Al-Ashqar, Wael
H. Eisa, Niveen M. Farag, Marwa A. El-Shaer, Nabila Salah,
Mostafa A. El-Sayed.
21.
3798
Shift of Cx43 isoform expression by PQ1 in
SW480 human colorectal cancer cells. Kristina M.
Bigelow, Thu Annelise Nguyen.
22.
3799
Urokinase kringle-derived peptide UP-7 potently
inhibits angiogenesis and tumor growth. Hyun-Kyung
Kim, Purevjargal Naidansuren, Seung Woo Lee, Young Ae
Joe.
23.
3800
Antiproliferative effect of fingolimod (FTY720) in
human prostate cancer cells: Insights to estrogen
metabolism in situ. Rasha M. Allam, Hisham A. Mosli,
Amany E. Khalifa, Salwa M. Nofal, Ola A. Sharaf, Ashraf B.
Abdel-Naim, Ahmed M. Al-Abd.
3790
Artesunate inhibits multiple proinflammatory
transcription factors leading to the suppression of
growth and induction of apoptosis in prostate cancer
cells. Alamelu Nachiyappan, Muthu K Shanmugam, Feng Li,
Alan Prem Kumar, Gautam Sethi.
POSTER SESSION
Transcription Factors and Nuclear Targets
Poster
Section
Poster Abstract
Board Number
1.
3801
Small molecule inhibitor of Stat3 induces
antitumor cell effects in vitro and antitumor effects in
vivo against human glioma or breast cancer model.
Peibin Yue, Francisco Lopez-Tapia, Marcus Tius, James
Turkson.
2.
3802
Withacnistin blocks binding of STAT3 and
STAT5 to growth factor and cytokine receptors and
induces regression of breast tumors in vivo. Xiaolei
Zhang, Michelle A. Blaskovich, Kara D. Forinash, Said M.
Sebti.
3.
3803
Obatoclax analogue SC-2001 inhibits STAT3
phosphorylation by enhancing protein tyrosine
phosphatase SHP-1 expression and induces apoptosis in
human breast cancer cells. Chun-Yu Liu, Jung-Chen Su,
Ling-Ming Tseng, Pei-Yi Chu, Wei-Tien Tai, Chung-Wai
Shiau, Kuen-Feng Chen.
4.
3804
CPA-7, an inhibitor of STAT3, is a potent
tumoricidal agent in peripheral tumor models and is
impermeable to the CNS. Hikmat Assi, Chris Paran, Jon
Savakus, James Hoeschle, Leda Raptis, Pedro R.
Lowenstein, Maria G. Castro.
5.
3805
Anticancer agent HJC0416 inhibits the growth
of breast cancer xenografts via downregulating STAT3
signaling. Ailian Xiong, Haijun Chen, Zhengduo Yang,
Guoshuai Cai, Lili Wang, Chunyong Ding, Grace G. Xu,
Christopher Wild, Na Ye, Ivan P. Uray, Jia Zhou, Qiang
Shen.
Poster Abstract
Board Number
9.
3809
Evaluation of the novel, orally bioavailable
selective inhibitor of nuclear export (SINE) KPT-335
(verdinexor) in spontaneous canine cancer: Results of
phase I and phase II clinical trials. Cheryl A. London, Luis
Feo Bernabe, Sandra Barnard, William Kisseberth, Antonella
Borgatti, Michael Henson, Heather Wilson-Robles, Kiersten
Jensen, Daisuke Ito, Jaime Modiano, Misty Bear, Michael
Pennell, Jean-Richard Saint-Martin, Dilara McCauley,
Michael Kauffman, Sharon Shacham.
10.
3810
Selinexor (KPT-330), a novel selective inhibitor
of nuclear export (SINE), shows single agent efficacy
against alveolar soft part sarcoma (ASPS) in vivo.
Marsha L. Crochiere, Trinayan Kashyap, Boris Klebanov,
William Senapedis, Diego del Alamo, Sharon Tamir, Erkan
Baloglu, Dilara McCauley, Robert Carlson, Michael Kauffman,
Sharon Shacham, George Demetri, Andrew Wagner, Ewa
Sicinska, Prafulla Gokhale, Nancy Kohl, Amy Saur, Yosef
Landesman.
11.
3811
G-quadruplex-forming genomic sequences
homologous to Pu27 interact with c-Myc promoter and
regulate c-Myc transcription. Francine Rezzoug, Shelia D.
Thomas, Eric C. Rouchka, Donald M. Miller.
12.
3812
Targeting BRCA1-deficient breast cancer by
inhibition of the DEAD box RNA helicase DDX3X. Marise
R. Heerma van Voss, Farhad Vesuna, Guus M. Bol, Paul J.
van Diest, Venu Raman.
6.
3806
STAT3/STAT5 blockade by WP1066 inhibits
ovarian cancer cell proliferation and induces cell death.
Rafal Zielinski, Aleksandra Rusin, Anna Priebe, Jayakumar
Arumugam, Radjendirane Venugopal, Stanislaw Skora,
Izabela Fokt, Waldemar A. Priebe.
13.
3813
Role of the ERG transcription factor in the
resistance of prostate cancer cells to the topoisomerase
I inhibitor camptothecin. Emmanuel Roche, Danièle
Montaudon, Samer Kayali, Nadine Houédé, Philippe
Pourquier.
7.
3807
A novel imidazole derivate inhibits STAT3
activation via induction of SHP-1 hepatocellular
carcinoma. Jung-Chen Su, Szu-Hsien Wu, Kuen-Feng Chen,
Wei-Tien Tai, Jui-Wen Huang, Chung-Wai Shiau.
14.
8.
3808
Preclinical efficacy of the novel, oral Selective
Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)
on castration resistant prostate cancer. Sankar N. Maity,
Guanglin Wu, Jing-Fang Lu, Anh Hoang, Yosef Landesman,
Dilara McCauley, Sharon Shacham, Michael G. Kauffman,
Ana M. Aparicio, Eleni Efstathiou, John C. Araujo,
Christopher J. Logothetis.
3814
FAK inhibition targets nucleostemin, a nucleolar
protein, impacting breast cancer spheroid growth and
tumor progression. Isabelle Tancioni, Sean Uryu, Nichol
L.G. Miller, Christine Lawson, Christine Jean, Xiao L. Chen,
David D. Schlaepfer.
35
35
467
POSTER SESSION
Clinical Research 11
Poster
Section
36
36
Prognostic Biomarkers 2
Poster Abstract
Board Number
1.
3815
CHEK2 mutation is an adverse prognostic
survival factor for patients diagnosed with high-grade
serous ovarian carcinoma. Ghim Siong Ow, Anna V.
Ivshina, Gloria Fuentes, Vladimir A. Kuznetsov.
2.
3816
Correlation between worse prognosis and
higher expression of the JAK2 gene in corresponding
non-neoplastic tissue in patients with hepatocellular
carcinoma, extracted by multiarray analysis. Shuji
Nomoto, Mitsuhiro Hishida, Yoshikuni Inokawa, Nao Takano,
Mitsuro Kanda, Yasuhiro Kodera.
3.
4.
5.
3818
Tumor budding and E-cadherin expression are
useful predictors of nodal involvement in T1 esophageal
squamous cell carcinoma. Naoshi Kubo, Masaichi Ohira,
Katsunobu Sakurai, Takahiro Toyokawa, Hiroaki Tanaka,
Kazuya Muguruma, Masakazu Yashiro, Kiyoshi Maeda,
Naoyoshi Onoda, Kosei Hirakawa.
3819
Clinical potential of the Eph/ephrin profile in
breast cancer. Gizeh Perez-Tenorio, Anna-Maria Husa, Olle
Stål.
6.
3820
Expression of ST6Gal-1 in colorectal cancer and
patient prognosis. Trafina Jadhav, Saksham Narang,
Jeehyun Bae, Matthew Schultz, Isam-Eldin Eltoum, Susan
Bellis, Sejong Bae, Upender Manne.
7.
3821
A prognostic model of head and neck cancer
ties TP53 mutation to 3p loss. Andrew M. Gross, Ryan K.
Orosco, John P. Shen, Ann M. Egloff, Hannah Carter, Matan
Hoffree, Michel Choueiri, Charles S. Coffey, Scott M.
Lippman, David N. Hayes, Ezra E. Cohen, Jennifer R.
Grandis, Quyen T. Nguyen, Trey Ideker.
8.
3822
Correlation between worse prognosis and lower
expression of the TPPP gene in patients with
hepatocellular carcinoma, detected by multiarray
analysis. Yoshikuni Inokawa, Shuji Nomoto, Mitsuhiro
Hishida, Nao Takano, Mitsuro Kanda, Michitaka Fujiwara,
Masahiko Koike, Hiroyuki Sugimoto, Tsutomu Fujii, Goro
Nakayama, Suguru Yamada, Chie Tanaka, Daisuke
Kobayashi, Naoki Iwata, Yasuhiro Kodera.
9.
3823
Prognostic value of gene expression analysis in
Iranian breast cancer patients treated with tamoxifen.
Sanaz Tabarestani, Sayyed Mohammad Hossein Ghaderian,
Hamid Rezvani, Reza Mirfakhraee, Abdolali Ebrahimi.
10.
3824
c-MET as a prognostic biomarker and
therapeutic target in patients with poor prognostic
pancreatic adenocarcinoma following surgical resection.
Cindy NEUZILLET, Jérôme CROS, Annemilaï TIJERASRABALLAND, Julien MOROCH, Louis DE MESTIER, Pierre
BEDOSSA, Valérie PARADIS, Alain SAUVANET, Jean-Baptiste
BACHET, Armand DE GRAMONT, Esteban CVITKOVIC, Eric
RAYMOND, Pascal HAMMEL, Anne COUVELARD.
11.
468
3817
Nestin is an independent molecular prognostic
factor in patients with anaplastic thyroid carcinoma.
Kento Kurata, Naoyoshi Onoda, Noda Satoru, Shinichiro
Kashiwagi, Yuka Asano, Kotarou Miura, Yukie Go, Hiroaki
Kasashima, Hidemi Kawajiri, Tsutomu Takashima, Kosei
Hirakawa.
3825
High DAPK expression is correlated with worse
prognosis in colorectal cancer patients. Jelena Ivanovska,
Inti Zlobec, Eva Diamantis-Karamitopoulou, Heather Dawson,
Viktor H. Koelzer, Abbas Agaimy, Fabian Garreis, William
Laqua, Alessandro Lugli, Arndt Hartmann, Regine SchneiderStock.
Poster Abstract
Board Number
12.
3826
Breast cancer metastasis suppressor-1
promoter methylation in cell free DNA provides
prognostic information in non-small cell lung cancer.
Ioanna Balkouranidou, Maria Chimonidou, Georgia Milaki,
Emily Tsaroucha, Stelios Kakolyris, Danny Welch, Vasilis
Georgoulias, Evi Lianidou.
13.
3827
Predictions for recurrence of non-muscle
invasive bladder cancers by circulating miRNAs. ShuHong Lin, Jie Lian, Yuanqing Ye, Colin P. Dinney, Xifeng Wu.
14.
3828
An 18-gene signature for vascular invasion is
associated with aggressive features and reduced
survival in breast cancer . Monica Mannelqvist, Elisabeth
Wik, Ingunn M. Stefansson, Lars A. Akslen.
15.
3829
Genomic index is a strong predictor of
metastatic outcome in intermediate gastrointestinal
stromal tumors and an inclusion criteria for imatinib
adjuvant therapy. Lydia Lartigue, Pauline Lagarde, Céline
Brulard, Agnès Neuville, Piotr Rutkowski, Paolo Dei Tos, Eva
Waldermann, Maria Debiec-Rychter, Antoine Italiano, JeanMichel Coindre, Frédéric Chibon.
16.
3830
E2F1-FOXM1 activation predicts progression of
non-muscle invasive bladder cancer. Seon-Kyu Kim, SeRa Lee, Yun-Gil Roh, Bicna Song, Kiejung Park, Sun-Hee
Leem, In-Sun Chu.
17.
3831
Clinical significance of SMAD4 expression in
resectable pancreatic cancer: correlation with tumor
progression and recurrence pattern. Suguru Yamada,
Tsutomu Fujii, Mitsuro Kanda, Hiroyuki Sugimoto, Shuji
Nomoto, Yasuhiro Kodera.
18.
3832
Characterizing breast cancer CTCs for brain
metastasis competence. Dario Marchetti.
19.
3833
Molecular subtypes of breast cancer in Algeria:
a population-based study of 3014 women. Farid Cherbal,
Hadjer Gaceb, Chiraz Mehemmai, Rabah Bakour, Kada
Boualga, Wassila Benbrahim, Hassen Mahfouf.
20.
3834
The National Biomarkers Development Alliance
(NBDA): A comprehensive solution. Carolyn C. Compton,
The NBDA Team.
21.
3835
The PATH biobank - procedures and results of
a breast cancer biospecimen research resource. Tobias
Anzeneder, Cathrin Mayer, Ulla Ohlms, Doris C. Schmitt,
Carmen Waldner, Reinhard Büttner, Heinz Bodenmueller.
22.
3836
TNFAIP8 protein expression in normal,
inflammatory and neoplastic pancreatic tissues:
Correlation with endocrine phenotype and advanced
stage in ductal adenocarcinomas. Jeffrey S. Ross,
Bhaskar V. Kallakury, Hwa Jeong Lee, David M. Jones,
Sanaz Ainechi, Gregory M. Sheehan, Christine E. Sheehan,
Usha N. Kasid.
23.
3837
Innovative rapid gene methylation analysis of
surgical margin tissues in head and neck cancer.
Masamichi Hayashi, Rafael Guerrero-Preston, Zubair Kahn,
Xiufeng Li, Julie Ahn, Marla Goldsmith, Christina Michailidi,
Wayne Koch.
24.
3838
Differential expression of Notch1 in lung,
ovarian and breast cancers. Dat Nguyen, Larry Rubinstein,
Mark E. Sherman, Joseph E. Tomaszewski, Naoko Takebe,
Percy Ivy, James H. Doroshow, Sherry X. Yang.
25.
3839
Oxidative damage in predicting early adverse
skin reactions from adjuvant radiotherapy in a tri-racial/
ethnic breast cancer population. Omar L. Nelson,
Cristiane Takita, Jean Wright, Eunkyung Lee, Jennifer J. Hu.
POSTER SESSION
Symptom Burden, Side Effects, and Quality of Life / Clinical Research in
Minority Populations
Poster Abstract
Board Number
1.
3840
Cetuximab-induced testicular toxicity. Mattan
Levi, Aaron Popovtzer, Moran Tzabari, Salomon M.
Stemmer, Ruth Shalgi, Irit Ben-Aharon.
2.
3841
Bevacizumab (BEV) and risk of arterial (ATE)
and venous thromboembolism (VTE) in metastatic
castration-resistant prostate cancer (mCRPC) patients
treated on CALGB 90401(ALLIANCE). Jai N. Patel, Chen
Jiang, Daniel L. Hertz, Flora A. Mulkey, Paula N. Friedman,
Susan Halabi, Mark J. Ratain, Michael J. Morris, Eric J.
Small, Kouros Owzar, William K. Kelly, Howard L. McLeod.
3.
3842
Relationship between weight change and
response to trastuzumab-based neoadjuvant
chemotherapy among women with operable HER2
overexpressing breast cancer. Nawale Hajjaji, Dorothee
Chocteau, Sylvie Gerard, Marie Brigitte Orgerie.
4.
3843
Pulmonary toxicities of molecular targeted
antineoplastic agents. Seug Yun Yoon, Namsu Lee, SookJa Kim, Hee-Jeong Cheong, Kyoung Ha Kim, Jong-Ho Won.
5.
3844
Venous thromboembolism in patients with
pancreatic cancer. Seug Yun Yoon, Namsu Lee, Sook-Ja
Kim, Hee-Jeong Cheong, Kyoung Ha Kim, Jong-Ho Won,
Hee Sook Park.
6.
3845
Symptoms burden in subjects with cervical
cancer and supportive care:A view from a developing
country. Andrew T. Olagunju, Olatunji F. Aina, Foluke O.
Sarimiye, Tinuke O. Olagunju.
7.
3846
On the way to specialized cancer rehabilitation
in Switzerland: Preliminary results of a naturalistic
controlled comparative cohort study. Maria Ture, Josef
Jenewein, Felix Angst, André Aeschlimann, Chantal MartinSoelch, Ulrich Schnyder, Christoph Renner, Heinrich Walt.
8.
3847
The anti-hepcidin Spiegelmer® Lexaptepid
Pegol (NOX-H94) as treatment of anemia of chronic
disease in patients with multiple myeloma, low grade
lymphoma, and CLL: A phase II pilot study. Pencho
Georgiev, Mihaela Lazaroiu, Luminita Ocroteala, Janet
Grudeva-Popova, Emanuil Gheorghita, Mariana Vasilica,
Sanda M Popescu, Andrei Cucuianu, Luciana Summo, Frank
Schwoebel, Kai Riecke, Heinz Ludwig.
9.
Poster Abstract
Board Number
10.
3849
Do cancer patients with better quality of life
report higher satisfaction with the quality of care they
receive. Digant Gupta, James F. Grutsch, Mark Rodeghier,
Christopher G. Lis.
11.
3850
Genetic and intermediate phenotypic
susceptibility markers of gastric cancer in HispanicAmericans: A case control study. Yuhui Sun, John
Stroehlein, Jaffer Ajani, David Chang, Xifeng Wu, Jian Gu.
12.
3851
Molecular profiling of aggressive breast cancer
in a unique patient population from Kenya. Rispah
Torrorey, Maggie Kerper, Emilia Hartland, Zonggao Shi,
Jenifer Prosperi, Sunil Badve, Sharon Stack, Simeon Mining,
Laurie Littlepage.
13.
3852
Obesity is associated with clinical
characteristics in African American multiple myeloma
patients. Amie E. Hwang, Sikander Ailwadhi, Carol Ann
Huff, Leon Bernal-Mizrachi, Christopher A. Haiman, Edward
Peters, Seema Singhal, Karen Pawlish, Cathryn Bock, Todd
Zimmerman, David J. Van Den Berg, David V. Conti, Brenda
B. Birmann, Jayesh Mehta, John J. Graff, Daniel O. Stram,
Niquelle Brown, Yang Yu, Moosa Azadian, Laurence Kolonel,
Brian E. Henderson, Ann Mohrbacher, Graham Colditz,
Brian-C Chiu, Michael Tomasson, Jeffrey Zonder, Robert Z.
Orlowski, Sagar Lonial, Wendy Cozen.
14.
3853
Predictive and prognostic analysis of KRAS and
MSI markers in treatment of urban African American
colorectal cancer patients. Priya Gopie, Maryam Yazdy,
Bashira Giwa, Sanjeev Solomon, Gladys Onojobi, SeyedMehdi Nouraie, Bonnie Davis, Kamyar Sartip, Shokrani
Babak, Lee Edward, Hassan Brim, Hassan Ashktorab.
15.
3854
B-catenin expression and obesity in African
Americans with colorectal neoplasia: Is there a
relationship. Babak Shokrani, Tahmineh Hydari, SeyedMehdi Nouraie, Sally Hassan, Vandana Kansal, Edward Lee,
Hassan Brim, Hassan Ashktorab.
16.
3855
Adjuvant chemotherapy in the elderly with nonsmall cell lung cancer. Mijung Lee, Dongliang Wang, Ian
G. Pinto, Stephen Graziano, Ajeet Gajra.
Poster
Section
37
37
3848
Association between functional variants of 5hydroxytryptamine receptor 3C (HTR3C) and
chemotherapy-induced symptoms in women receiving
adjuvant treatment for breast cancer. Ido Wolf, Dorit Pud,
Yael Laitman, Gil Har-Zahav, Tami Rubinek.
469
POSTER SESSION
Poster
Section
38
38
This session wil linclude clinical trials submitted at the Late-Breaking Abstract deadline. The full text of all abstracts
in this session will be available online through www.aacr.org and in the print Proceedings, Part 2 distributed to
registrants.
Clinical Trials
Phase II/III Clinical Trials
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
470
CT301
Late disease recurrence in estrogen receptor
positive (ERⴙ) premenopausal breast cancer (BC).
Francesco Recchia, Giampiero Candeloro, Stefano
Necozione, Silvio Rea, William Soo Hoo, Tom Cantor.
CT302
A phase II clinical trial of weekly paclitaxel
and carboplatin in combination with panitumumab in
metastatic or recurrent breast cancer patients with
triple negative disease. Stacy Cowherd, Susan Melin,
Steven Akman, John Cole, Julia Lawrence.
CT303
A multicenter phase ii study of adjuvant
chemotherapy with oral fluoropyrimidine s-1 for nonsmall-cell lung cancer . Tomoshi Tsuchiya, Naoya
Yamasaki, Keitaro Matsumoto, Takuro Miyazaki, Takeshi
Nagayasu.
CT304
Anti-prostate-specific membrane antigen
(PSMA) monoclonal antibody J591 plus low-dose
interleukin-2 (IL-2) in patients with recurrent prostate
cancer (PC). Yulian Khagi, Gurveen Kaur, Paul Christos,
Naveed H. Akhtar, David M. Nanus, Neil H. Bander, Scott T.
Tagawa.
CT305
Pre-surgical evaluation of the AKT inhibitor
MK-2206 in patients with operable invasive breast
cancer. Kevin Kalinsky, Joseph Sparano, Eleni
Andreopoulou, Bret Taback, Lisa Wiechmann, Sheldon
Feldman, Preya Ananthakrishnan, Hanina Hibshoosh, John
Mavalan, Katherine Crew, Matthew Maurer, Dawn
Hershman.
CT306
Breast cancer chemoprevention by IGF-I
inhibition in women with atypical hyperplasia of the
breast: A phase 1/2 proof of principle trial. David L.
Kleinberg, Deborah Axelrod, Julia Smith, Baljit Singh, Martin
Lesser, Pietro Ameri, Ann Danoff, Irineu Illa Bochaca,
Cristina de Angelis.
CT307
Phase I/II study of vosaroxin and decitabine in
older patients (pts) with acute myeloid leukemia (AML)
and high risk myelodysplastic syndrome (MDS). Naval
Daver, Hagop M. Kantarjian, Guillermo Garcia - Manero,
Naveen Pemmaraju, Tapan Kadia, Courtney DiNardo, Nitin
Jain, Gautum Borthakur, Jorge Cortes, Craig Adam, Farhad
Ravandi.
CT308
Pre-surgical statin-treatment in a window-ofopportunity breast cancer trial: Changes in gene
expression profiles. Olof Bjarnadottir, Ida Johansson,
Srinivas Veerla, Karin Jirstrom, Dorthe Grabau, Ingrid
Hedenfalk, Signe Borgquist.
CT309
Influencing the tumor microenvironment: A
phase II study of copper-depletion using
tetrathiomolybdate (TM) in patients (pts) with breast
cancer (BC) at high risk for recurrence. Nancy Chan,
Naomi Kornhauser, Maureen Ward, Amy Willis, Tessa Cigler,
Ellen Chuang, Anne Moore, Diana Donovan, Sarah E.
Schneider, Christina Lam, David J. Warren, Anna Rubinchik,
Sandra Hurtado Rua, Sharrell Lee, Maureen Lane, Vivek
Mittal, Linda Vahdat.
CT310
Molecular correlates of activity and survival in
a phase I/II trial of sorafenib plus gemcitabine and
capecitabine for advanced renal cell carcinoma. Bishoy
Faltas, Gurveen Kaur, Naveed Akhtar, Paul Christos, Brian
Robinson, Beerinder Singh, Himisha Beltran, David Nanus,
Scott T. Tagawa.
CT311
A randomized, open-label phase 2 study of
efatutazone and erlotinib as second- or third-line
therapy for non-small cell lung cancer (NSCLC). Ana B.
Oton, Byoung Chul Cho, Myung-Ju Ahn, Sang-We Kim,
Kirushnakumar Subramanian, Chirag Desai, Dale Shuster,
Terri Goldberg, Hamim Zahir, Dipen Dutta, Shuquan Chen,
Richard Von Roemeling, Joachim von Pawel.
Poster Abstract
Board Number
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
CT312
Ponatinib is well tolerated and active in
patients with relapsed/refractory philadelphia positive
leukemias: The Bologna experience. Cristina
Papayannidis, Caterina De Benedittis, Simona Soverini, Ilaria
Iacobucci, Maria Chiara Abbenante, Chiara Sartor, Maria
Teresa Bochicchio, Anna Ferrari, Claudia Venturi, Valentina
Robustelli, Andrea Ghelli Luserna di Rorà, Viviana
Guadagnuolo, Emanuela Ottaviani, Nicoletta Testoni, Carmen
Baldazzi, Simona Luatti, Sarah Parisi, Stefania Paolini,
Alberto Conficoni, Federica Frabetti, Elisa Lani, Silvia Piccari,
Paolo Di Bartolomeo, Roberto Di Lorenzo, Renato Fanin,
Giuseppe Cimino, Fabio Ciceri, Giovanni Martinelli.
CT313
An exploratory analysis of efficacy and safety
of abiraterone acetate (AA) in black patients (pts) with
metastatic castration-resistant prostate cancer (mCRPC)
without prior chemotherapy (ctx). Eleni Efstathiou, Hari
Deshpande, Daniel George, Anthony M. Joshua, Mary-Ellen
Taplin, Thomas W. Griffin, Anil Londhe, Mary Todd, Arturo
Molina.
CT314
“Multi-metronomic” algorithms for targeted
therapy to improve value of response and “failed drugs”
for “resistant” women’s cancers. Howard W. Bruckner,
Azriel Hirschfeld, Jeanetta Stega, Peter Dottino.
CT315
IG-002 Phase 3 data: Absence of correlation
between unbound paclitaxel and response in MBC.
Monica Choi, Jeff Hsu, Vuong Trieu.
CT316
IG-001 phase 4 data in Korea: Safety and
efficacy. Larn Hwang, Caleigh Douglass, David Nam, Vuong
Trieu.
CT317
CirCe T-DM1 phase II trial: Assessing the
relevance of HER2-amplified circulating tumor cells as a
tool to select HER2-negative metastatic breast cancer
for treatment with TDM1. François-Clément Bidard, Yann
de Rycke, Bernard Asselain, Paul Cottu, Manuel Rodrigues,
Ronald Lebofsky, Jean-Yves Pierga.
CT318
FOLFOXIRIⴙB-mab showed powerful effect as
preoperative chemotherapy for multiple liver metastases
of colorectal cancer. Yasushi Ichikawa, Ayumu Goto,
Noritoshi Kobayashi, Motohiko Tokuhisa, Takashi Ishikawa,
Atsushi Ishibe, Kazuteru Watanabe, Kazunori Nojiri,
Yoshibumi Kumamoto, kazuhisa Takeda, Mitsuyoshi Ota,
Hirotoshi Akiyama, Kuniya Tanaka, Itaru Endo.
CT319
A randomized, controlled trial of high dose vs.
standard dose vitamin D for aromatase inhibitorinduced arthralgia in breast cancer survivors. Polly A.
Niravath, Sue Hilsenbeck, Tao Wang, Mothaffar Rimawi.
CT320
Longitudinal observational study to
simultaneously evaluate multiple blood-based
biomarkers to track the emergence of metastasis and
drug resistance in colorectal cancer. Clarinda Chua,
Rachel Ten, Thinzar Aung, Maricel Ang, Thein Htut Oo, Su
Pin Choo, Matthew Ng, Iain Beehuat Tan.
CT321
Prevention of cardiac dysfunction during
adjuvant breast cancer therapy: the PRADA study. Geeta
Gulati, Siri Lagethon Heck, Anne H. Ree, Åse Bratland, Kjetil
Steine, Jeanette Schulz-Menger, Berit Gravdehaug, Pavel
Hoffmann, Helge Røsjø, Jürgen Geisler, Torbjørn Omland.
CT322
Efficacy of first-line capecitabine (CAP) ⴞ
bevacizumab (BEV) according to risk factors in the
RIBBON-1 randomized phase III trial in locally recurrent/
metastatic breast cancer (LR/mBC). Nicholas J. Robert,
Veronique Dieras, Christian Jackisch, Stefanie Srock, Ulrich
Freudensprung, Leonardo Faoro, Joyce O’Shaughnessy.
POSTER SESSION
Hall A-E • Tuesday, 8:00 a.m.-12:00 p.m.
Advocates Poster Session 2
Poster
Section
Poster Abstract
Board Number
Poster Abstract
Board Number
1
ADV201 Michigan Breast Cancer Coalition: Educate,
advocate, eradicate. Maria Lyzen, Michigan Breast Cancer
Coalition, Northville, MI.
8.
ADV208 Understanding cancer through the eyes of the
community. Linda Horton, Vanderbilt Ingram Cancer Center,
Nashville, TN.
2.
ADV202 How to be a proactive zealous cancer fighter
advocate for yourself and for others. Jack David Marcus,
Us TOO! International, Inc., New York, NY.
9.
ADV209 Young Survival Coalition research think tank:
A model for giving advocates a voice in setting research
priorities. Tracy Leduc, Independent Advocate, Tampa, FL.
3.
ADV203 Pancreatic Cancer Action Network: Building a
community for progress of researchers and supporters.
Anna Martin, Pancreatic Cancer Action Network, Phoenix, AZ.
10.
ADV210 Breast cancer: Advocates in action. Lori MarxRubiner, Metavivor, Encino, CA.
11.
4.
ADV204 Breast cancer research advocacy. Theresa
(Terri) Martyka, Susan G Komen- Advocates in Science,
Chicago Ridge, IL.
ADV211 Breast cancer: Advocates in action. Jody
Schoger, Alamo Breast Cancer Foundation, The Woodland, TX.
12.
ADV212 Advocate Poster. Jeri Francoeur, Susan G.
Komen, Ormond Beach, FL.
13.
ADV213 Advocate Poster. Eduard Battiste-Alentorn,
FECEC, Barcelona, Spain.
14.
ADV214 Advocate Poster. Vinna D. Royer, Dominica
Cancer Society, St. Joseph, Dominica.
5.
ADV205 Woman to woman. Lori A. Whaley, African
American Women in Touch, South Bend, IN.
6.
ADV206 Clinical trials: The safer treatment option with
personalized medicine. Jack Whelan, Jack-Whelan.com,
Andover, MA.
7.
ADV207 Dana Farber/Harvard Cancer Center (DF/HCC)
Breast Cancer Advocacy Group: An established patient
advocacy organization within a major research
institution. Penny Blaidell, Dana-Farber Cancer Institute,
Marblehead, MA.
1
1
471
LATE-BREAKING POSTER SESSIONS
Tuesday, 8:00 a.m.-12:00 p.m.
Hall A-E, San Diego Convention Center
Abstracts will be available online and in the Proceedings Part 2 beginning Friday, April 4.
Poster Section 39
Late-Breaking Research: Clinical Research/Clinical Endocrinology
Poster Section 40
Late-Breaking Research: Tumor Biology 4
Poster Section 42
Late-Breaking Research: Experimental and
Molecular Therapeutics 2
472
PLENARY SESSION
Tuesday, 8:15 a.m.-10:15 a.m.
Hall F-G, San Diego Convention Center
Novel Therapeutic Combinations in Cancer: Principles and Practice
Chairperson: Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA
The development and successful deployment of rational therapeutic combinations is required to
achieve lasting clinical responses in patients with advanced cancer. The rapidly expanding
repertoire of targeted agents and immunotherapies with increasingly diverse mechanisms of action
has created an unprecedented opportunity for clinical evaluation of many types of anticancer drug
combinations. Several exemplary treatment combinations have already shown remarkable benefits
in clinical trials; however, toxicity has limited the impact of some combinatorial regimens. This
session will highlight several guiding principles and noteworthy scientific advances in the
development of anticancer drug combinations, and describe how the growing clinical and
translational experience in this area is informing the path forward in this exciting arena.
8:15 a.m.
8:45 a.m.
Combination therapies for lung cancer:
Opportunities and challenges
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
9:15 a.m.
9:45 a.m.
Evolutionary dynamics of cancer in response
to targeted therapy
Martin Nowak, Harvard University, Cambridge, MA
Combining immunotherapy and targeted
therapy for melanoma
Antoni Ribas, UCLA Medical Center, Los Angeles, CA
Combinatorial approaches to prevent compensatory
pathways activation
José Baselga, Memorial Sloan-Kettering Cancer Center,
New York, NY
473
PROFESSIONAL ADVANCEMENT SESSION
Tuesday, 8:30 a.m.-2:00 p.m.
Marina Ballroom D-E, South Tower, San Diego Marriott Marquis & Marina
Special Program for High School Students: The Conquest of Cancer
and the Next Generation of Cancer Researchers
Organized by the Science Education Committee
Chairperson: Kathleen W. Scotto, UMDNJ-The Cancer Institute of New Jersey, Newark, NJ
This free day of learning includes distinguished scientists discussing topics such as understanding
cancer, cancer control and prevention, and cancer career opportunities. In addition, students listen
to an inspiring presentation from a young cancer survivor, visit state-of-the-art exhibit booths to
learn about the latest equipment for laboratory and clinical research, and get an introduction to
scientific posters describing the most current research on the causes, diagnosis, treatment, and
prevention of cancer.
During a complimentary networking lunch, students meet one on one with leading scientists,
present posters of their school or lab research projects, and learn about summer internship
opportunities. AACR Members volunteer as mentors for this program, and we thank them for
supporting the next generation of cancer researchers.
8:30 a.m.
Registration and Refreshments
9:00 a.m.
Welcome
Kathleen W. Scotto, UMDNJ-The Cancer Institute of New Jersey, Newark, NJ
9:10 a.m.
Understanding Cancer
Donald S. Coffey, Johns Hopkins University School of Medicine, Baltimore, MD
9:35 a.m.
Keys to Cancer Prevention
William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center,
Baltimore, MD
10:05 a.m.
Message from a Cancer Survivor
Sonia Baez-Hernandez, Florida Breast Cancer Foundation, Fort Lauderdale, FL
10:20 a.m.
Why Cancer Research Needs You
Sanya A. Springfield, NCI-CRCHD, Bethesda, MD
10:40 a.m.
Tour of Exhibits and Posters
12:30 p.m.
Networking Luncheon
1:30 p.m.
Student Poster Presentations
1:50 p.m.
Evaluation and Departure
474
NCI/NIH-SPONSORED SESSION
Tuesday, 10:30 a.m.-12:00 p.m.
Room 28D-E, San Diego Convention Center
NCI SBIR Programs Support Technology Innovation for Cancer
Detection and Treatment - with Insight Genetics
Moderator: Christie Canaria, National Cancer Institute-SBIR, Bethesda, MD
With diverse programs that bring together academic innovators, industrial entrepreneurs, and
federal resources, the National Cancer Institute (NCI) tackles the challenges of fighting cancer and
works to improve patient outcomes every day. This session highlights valuable resources provided
through the NCI Small Business Innovation Research (SBIR) Development Center and also
provides a case study of a company – Insight Genetics – that has successfully utilized the SBIR
program to develop and advance their companion diagnostic technology to meet the needs of
cancer patients. Insight will provide their experience in collaborating with academic investigators
in obtaining Phase I, Phase II, and Fast Track contract awards; discuss the benefits of academics
and businesses collaborating on SBIR-funded research; and highlight publication opportunities
that stem from collaborations between commercial enterprises and academic investigators.
The NCI SBIR Development Center provides a unique funding vehicle to translate innovative
technologies from the lab to the small business community to patients. Via the SBIR and Small
Business Technology Transfer (STTR) programs, startups and small companies receive seed
funding to support the development and commercialization of new technologies to prevent,
diagnose, and treat cancer. The SBIR/STTR awards aim to:
• Harvest innovation from academia and translate it into commercially useful therapies and
products
• Support early-stage R&D to commercialization
• Foster innovation in high-priority areas such as therapeutics, diagnostics, devices, research
tools, and more.
In this session, experts and leaders from the NCI SBIR Development Center and SBIR awardee
Insight Genetics will discuss:
• Funding opportunities for small businesses and academic partners
• Program eligibility and tips on how to develop a strong application for SBIR and STTR
• Programs that NCI SBIR offers to facilitate access to federal resources and processes pivotal to
the commercialization and clinical adoption of cancer technologies
• Special NCI initiatives to support R&D and preclinical work
Speakers:
Michael Weingarten, National Cancer Institute-SBIR, Bethesda, MD
Andrew J. Kurtz, National Cancer Institute-SBIR, Bethesda, MD
Eric B. Dahlhauser, Insight Genetics, Inc., Nashville, TN
David Hout, Insight Genetics, Inc., Nashville, TN
475
CLINICAL TRIALS SYMPOSIUM
Tuesday, 10:30 a.m.-12:30 p.m.
Novel Therapeutics
Chairperson: Jordi Rodon, Vall d’Hebron University Hospital, Barcelona, Spain
10:30 a.m.
CT325 First-in-human study of JNJ-42756493, a potent pan-fibroblast
growth factor receptor (FGFR) inhibitor in patients with advanced
solid tumors
Rodrigo Dienstmann, Sage Bionetworks, Seattle, WA
10:50 a.m.
CT326 Phase I study of BGJ398, a selective pan-FGFR inhibitor in
genetically preselected advanced solid tumors
Lecia V. Sequist, Massachusetts General Hospital, Boston, MA
11:10 a.m.
Discussant to be announced
11:30 a.m.
CT327 Multicenter phase I study of MRX34, a first-in-class microRNA
miR-34 mimic liposomal formulation
Muhammad Shaalan Beg, UT Southwestern Medical Center, Dallas, TX
11:50 a.m.
Discussant: Carlo M. Croce, The Ohio State University Comprehensive Cancer
Center, Columbus, OH
12:00 p.m.
CT328 Clinical results of a phase Ib dose-escalation study of the Mek
inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib
(GDC-0068) in patients (pts) with solid tumors
Johanna C. Bendell, Sarah Cannon Research Institute, Nashville, TN
12:20 p.m.
Discussant: Anthony W. Tolcher, South Texas Accelerated Research
Therapeutics, San Antonio, TX
476
CURRENT CONCEPTS IN DIAGNOSTICS
AND THERAPEUTICS RESEARCH
Tuesday, 10:30 a.m.-12:30 p.m.
Single Cell Analysis of the Tumor
Chairperson: James B. Hicks, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Recently devised methods for the analysis and classification of single cells provide an
unprecedented opportunity to observe the cellular complexity of tumors and to characterize rare
cancer cells trafficking in the blood and other fluids. Talks in the this session will present the use of
proteomic, transcriptomic, and genomic methods as applied to solid tumors and circulating tumor
cells and their potential for identifying potentially useful biomarkers for precision medicine.
10:30 a.m.
Single-cell genomic and clonal analysis of breast and prostate
tumor biopsies
James B. Hicks, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
10:50 a.m.
Discussion
10:55 a.m.
A single cell systems-structured for cancer and immunity
Garry P. Nolan, Stanford University School of Medicine, Stanford, CA
11:15 a.m.
Discussion
11:20 a.m.
Molecular characterization of single circulating tumor cells
Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA
11:40 a.m.
Discussion
11:45 a.m.
Diversity of circulating tumor cells in a mouse pancreatic cancer model
identified by single-cell RNA sequencing
*David T. Ting, Massachusetts General Hospital Cancer Center/Harvard Medical
School, Charlestown, MA
12:00 a.m.
Discussion
12:05 a.m.
High-content single-cell analysis as a temporal signature of
tumor evolution
Peter Kuhn, The Scripps Research Institute, La Jolla, CA
12:25 p.m.
Discussion
*NextGen Star, selected to give a talk by the AACR President and Annual Meeting Program Chairperson
through a competitive application process designed to bring more visibility to early-career scientists. Abstract
can be found in the Invited Abstracts: NextGen Stars section of the Proceedings.
477
CURRENT CONCEPTS IN EPIDEMIOLOGY
AND PREVENTION RESEARCH
Tuesday, 10:30 a.m.-12:30 p.m.
Updates on Transdisciplinary Research on Energetics and Cancer
Chairperson: Kathryn H. Schmitz, Center for Clinical Epidemiology and Biostatistics,
Philadelphia, PA
The NCI-funded Centers Initiative Transdisciplinary Research on Energetics and Cancer (TREC)
fosters research in nutrition, physical activity, energy balance, and cancer. TREC’s mission is to
integrate diverse disciplines to find effective interventions across the lifespan to reduce the burden
of obesity and cancer and to improve population health. TREC does this by building teams of
collaborators from within and across multiple TREC Centers and across diverse disciplines such
as preclinical (animal models), molecular biology, physiology and metabolism, kinesiology,
nutrition, health behavior and behavior change, sociology, communications, geospatial analysis,
and biostatistics. Other TREC disciplines include cancer survivorship, childhood obesity,
genomics, and environmental determinants of obesity. This session, led by TREC Principal
Investigators of the University of Pennsylvania, Harvard University, University of California San
Diego, and Washington University in St. Louis, will showcase the current trends and most exciting
scientific advances in the area of transdisciplinary research in energetics and cancer.
10:30 a.m.
Introduction
Kathryn H. Schmitz, Center for Clinical Epidemiology and Biostatistics,
Philadelphia, PA
10:35 a.m.
Intermittent fasting and cancer risk
Ruth E. Patterson, UCSD Moores Cancer Center, La Jolla, CA
10:55 a.m.
Discussion
11:00 a.m.
A transdisciplinary research project: Transformation of monoclonal
gammopathy of undetermined significance into multiple myeloma – Does
obesity or metformin use play a role?
Graham A. Colditz, Washington University, St. Louis, MO
11:20 a.m.
Discussion
11:25 a.m.
Developmental origins of cancer: TREC experience in cross-center and
cross-species studies
Jorge E. Chavarro, Harvard School of Public Health, Boston, MA
11:45 a.m.
Discussion
11:50 a.m.
Cancer, exercise, and obesity: Current evidence and future directions
Kathryn H. Schmitz, University of Pennsylvania, Philadelphia, PA
12:10 p.m.
Discussion
12:15 p.m.
Panel Discussion
478
CURRENT CONCEPTS IN
ORGAN SITE RESEARCH
Tuesday, 10:30 a.m.-12:30 p.m.
Hepatocellular Carcinoma
Invasive Bladder Cancer: Genomic
Insights and Therapeutic Promise
Chairperson: Michiie Sakamoto, Keio University School
of Medicine, Tokyo, Japan
Hepatocellular carcinoma (HCC) is the fifth most
common cancer and the third most common cause of
cancer deaths worldwide. Detailed analysis of high-risk
patients has revealed the major developmental pathway
of HCC from chronic viral infection to dysplastic nodules,
early HCC, and progressed HCC. Typical pathologic
findings of HCC are cohesive tumor nests associated
with rich vascular stroma, which is different from
adenocarcinoma in other organ malignancies. HCC is
also a fairly heterogeneous disease with unique and
variable clinical features. Information on driver gene
mutations is rather limited, and work to discover
therapeutic targets for HCC is ongoing. Various
approaches have been tried to dissect the molecular
pathogenesis of HCC and to identify molecular
biomarkers useful for predicting patient outcome and
response to therapy. This session summarizes the
present situation and challenges of HCC research and
discusses future directions that may help us to
successfully overcome this highly malignant disease.
10:30 a.m.
Molecular pathogenesis of
hepatocellular carcinoma
Lars Zender, University Hospital
Tuebingen, Tuebingen, Germany
10:50 a.m.
Discussion
10:55 a.m.
Molecular pathology of human
Michiie Sakamoto, Keio University
School of Medicine, Tokyo, Japan
Chairperson: David J. Kwiatkowski, Brigham and
Women’s Hospital, Boston, MA
Multiple genome-wide analyses of genetic events in
invasive bladder cancer have recently been reported,
highlighting both kinase-activating mutations and other
mechanisms of activation in FGFR3, ERBB2, and ERBB3;
and activating and inactivating mutations in the PI3KmTOR pathway (PIK3CA, PTEN, TSC1). Furthermore,
multiple cell cycle and chromatin regulatory gene
mutations are seen in the majority of invasive bladder
cancer. In addition, metabolic changes in metastatic
bladder cancer have been identified which are similar to
those seen in glycogen storage disease. These findings
introduce a new era in bladder cancer research in which
therapies targeting these alterations should be tested in
genotype-restricted patient populations. In this session,
these recent findings will be reviewed in detail with an eye
toward therapeutic strategies.
10:30 a.m.
Genomic insights from the TCGA
analysis and therapeutic targets in
invasive bladder cancer
David J. Kwiatkowski, Brigham and
Women’s Hospital, Boston, MA
10:50 a.m.
Discussion
10:55 a.m.
Therapeutic implications of FGF
receptor activation in bladder cancer
Margaret Knowles, Cancer Research
UK, Leeds, United Kingdom
11:15 a.m.
Discussion
11:20 a.m.
Disrupted glycogen metabolism
regulators: An unexpected common
denominator between human
glycogen storage diseases and
advanced bladder cancer
Dan Theodorescu, University of
Colorado Cancer Center, Aurora, CO
11:15 a.m.
Discussion
11:20 a.m.
Molecular classification and
prediction of prognosis of
Yujin Hoshida, Icahn School of
Medicine at Mt. Sinai, New York, NY
11:40 a.m.
Discussion
11:40 a.m.
Discussion
11:45 a.m.
Biomarkers and therapeutic targets
in hepatocellular carcinoma
Richard S. Finn, University of
California, Los Angeles, CA
11:45 a.m.
12:05 p.m.
Discussion
Next-generation clinical trials for
translating the genomic landscape
in bladder cancer
Seth P. Lerner, Baylor College of
Medicine, Houston, TX
12:10 p.m.
Panel Discussion
12:05 p.m.
Discussion
12:10 p.m.
Panel Discussion
479
CURRENT CONCEPTS IN
ORGAN SITE RESEARCH
Tuesday, 10:30 a.m.-12:30 p.m.
A Systems Approach to Ovarian Cancer
Chairperson: Benjamin G. Neel, University of Toronto
Ontario Cancer Institute, Toronto, ON, Canada
Serous ovarian cancer is the most common and deadly
subtype of ovarian cancer. Although debulking surgery
and platinum/taxane-based chemotherapy can often
produce complete responses, the vast majority of
patients recur and die of their disease, and patient
survival has remained static for almost 30 years. This
session will review the multiple recent developments that
promise to improve these outcomes, including progress
on genomics and detection, mouse models, metabolism,
and functional genomics.
10:30 a.m.
Insights into the pathogenesis of
ovarian cancer
Ronny I. Drapkin, Dana-Farber Cancer
Institute, Boston, MA
10:50 a.m.
Discussion
10:55 a.m.
At the juncture of carbon
metabolism, histone
reprogramming, and cell shape
Sandra Orsulic, Cedars-Sinai Medical
Center, Los Angeles, CA
11:15 a.m.
Discussion
11:20 a.m.
Circulating tumor DNA as a genomic
biomarker of response in high-grade
serous ovarian carcinoma
James D. Brenton, Cancer Research
UK, Cambridge, United Kingdom
11:40 a.m.
Discussion
11:45 a.m.
Functional genomics of ovarian
cancer
Gordon B. Mills, The University of
Texas MD Anderson Cancer Center,
Houston, TX
12:05 a.m.
Discussion
12:10 a.m.
Panel Discussion
480
MAJOR SYMPOSIUM
Tuesday, 10:30 a.m.-12:30 p.m.
11:30 p.m.
Lifting the metabolic break on
caspase 2 to enhance
chemotherapy
Sally Kornbluth, Duke University
School of Medicine, Durham, NC
11:50 p.m.
Discussion
11:55 p.m.
Bcl-2 family proteins as a paradigm
for protein:protein interactions as
chemotherapy targets
David W. Andrews, Sunnybrook
Research Institute, Toronto, ON,
Canada
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
The 2014 Stanley J. Korsmeyer
Memorial Symposium: Targeting
the Death Pathway in Cancer
Chairperson: Loren D. Walensky, Dana-Farber Cancer
Stan Korsmeyer embodied laser-focused commitment to
making a difference for cancer patients by transforming
mechanistic discoveries of the apoptotic pathway into
blueprints for cancer drug development. As important as
the science he discovered was the manner in which he
discovered it. Stan’s sincerity, integrity, creative insight,
serious work ethic, and meticulous attention to detail were
among the drivers of his scientific success. Above all,
Stan was a cherished leader, mentor, colleague, friend,
husband, and father. The 2014 Stanley J. Korsmeyer
Memorial Symposium will honor Stan’s accomplishments
and legacy by examining the present and future of the cell
death field. A seemingly limitless sea of apoptosis
discovery continues to provide new hope for nextgeneration therapeutics that will effectively reactivate cell
death to realize cancer cures. The 2014 symposium
speakers will emphasize novel aspects of the proteins and
protein interactions that comprise the apoptotic pathway.
Stan’s emphasis on new technologies, multidisciplinary
studies, and scientific open-mindedness serve as the
inspiration for this year’s presentations.
10:30 p.m.
Introduction
10:40 p.m.
Dissecting the canonical and
noncanonical interactions of the
BCL-2 family for therapeutic benefit
Loren D. Walensky, Dana-Farber
Cancer Institute, Boston, MA
11:00 p.m.
Discussion
11:05 p.m.
Revealing the contributions of
antiapoptotic MCL-1 to normal and
malignant biology
Joseph T. Opferman, St. Jude
Children’s Research Hospital,
Memphis, TN
11:25 p.m.
Discussion
481
MAJOR SYMPOSIA
Ballroom 20A-C, San Diego Convention Center
Advances in Cancer Genome Discovery:
Biology to Clinic
Application of Nanotechnology to the
Treatment of Cancer Patients
Chairperson: Levi A. Garraway, Dana-Farber Cancer
Chairperson: Mark E. Davis, California Institute of
Technology, Pasadena, CA
Recent years have witnessed an explosion of cancer
genome characterization that has propelled the
discovery of new cancer genes and revealed multiple
insights into tumor biology. Increasingly, this knowledge
is providing a framework for novel therapeutic
development. This symposium will provide an overview
of recent discoveries that have emerged from cancer
genomics studies in representative hematologic
malignancies and solid tumors. In a growing number of
cases, the tumorigenic mechanisms enacted by these
cancer gene mutations are beginning to be elucidated.
Furthermore, examples will be presented for how this
information is expanding avenues for dissecting
therapeutic resistance and implementing personalized or
“precision” cancer medicine.
Nanotechnology is being exploited to create new
methodologies for the diagnoses and treatments of
cancer. In this session, we will explore the theme of how
nanotechnology is being used to provide new methods
for the diagnoses (and monitoring of cancer patients),
and new approaches to therapy based on nanoparticle
therapeutics. Emphasis will be placed on results from
clinical studies and whether they have been predictive
from cell/animal data. Additionally, issues of importance
for translating nanotechnology into approved products
for patient use will be discussed.
10:30 a.m.
Introduction
10:40 a.m.
Systematic genomic studies of
tumor biology and therapeutic
resistance
Levi A. Garraway, Dana-Farber Cancer
11:00 a.m.
Discussion
11:05 a.m.
Whole-genome pictures of live
cancers and personalized medicine
Hidewaki Nakagawa, RIKEN,
Yokohama, Japan
11:25 a.m.
Discussion
11:30 a.m.
Somatic genome alterations in
human lung cancers
Matthew L. Meyerson, Dana-Farber
Cancer Institute, Boston, MA
11:50 a.m.
Discussion
11:55 a.m.
The acute lymphoblastic leukemia
genome: Implications for
pathogenesis and therapy
Charles G. Mullighan, St. Jude
Children’s Research Hospital,
Memphis, TN
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
482
10:30 a.m.
Introduction
10:40 a.m.
Nanoparticle therapeutics for
cancer
Mark E. Davis, California Institute of
11:00 a.m.
Discussion
11:05 a.m.
Nanotechnology and single-cell
proteomics as a diagnostic tool
James R. Heath, California Institute of
11:25 a.m.
Discussion
11:30 a.m.
Nanotechnology from a clinician’s
point of view
Anil K. Sood, The University of Texas
MD Anderson Cancer Center, Houston,
TX
11:50 a.m.
Discussion
11:55 a.m.
A perspective on nanotechnology
from a commercialization/pharma
point of view
Paul A. Burke, Burke Bioventures LLC,
Cambridge, MA
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
Tuesday, 10:30 a.m.-12:30 p.m.
Chromatin Alterations in Development
and Disease
Complexity in the Tumor
Microenvironment
Chairperson: Sharon Y. R. Dent, The University of Texas
MD Anderson Cancer Center, Smithville, TX
Chairperson: Mary Helen Barcellos-Hoff, New York
University, New York, NY
Alterations in DNA methylation and chromatin
organization are often associated with oncogenesis, and
much effort is currently directed at developing therapies
to reset aberrant epigenetic states. This session will
present the latest advances in our understanding of the
normal functions of histone-modifying enzymes,
regulators of DNA methylation, and ATP-dependent
chromatin remodelers, as well as disruptions of these
functions that contribute to cancer development and
progression.
The concept of the tumor microenvironment (TME)
recognizes that the interplay between cancer cells and
stromal cells is a crucial determinant of cancer growth.
Understanding the carcinogenic process as a
partnership of aberrant host cells and cancer cells is
critical for cancer prevention. Recent initiatives focused
on the biology of stromal cells that contribute to tumor
growth and survival have produced new strategies to
control established cancer. The last decade has
generated a detailed roster of host cells that participate
in the establishment and progression of malignancy. This
symposium will discuss new data on the contribution of
specific signals and host cells from inception of cancer
to development of metastasis and the potential for
therapeutically targeting the distinctive behaviors of
stromal cells under the influence of cancer cells.
10:30 a.m.
Introduction
10:40 a.m.
A SAGA of GCN5 and USP22 in stem
cells and cancer
Sharon Y. R. Dent, The University of
Texas MD Anderson Cancer Center,
Smithville, TX
11:00 a.m.
Discussion
11:05 a.m.
TET proteins and methylcytosine
oxidation
Anjana Rao, La Jolla Institute for
Allergy and Immunology, La Jolla, CA
11:25 a.m.
10:30 a.m.
Introduction
10:40 a.m.
The contribution of
microenvironment to mammary
carcinogenesis
Mary Helen Barcellos-Hoff, New York
Discussion
11:00 a.m.
Discussion
11:30 a.m.
Chromatin regulation in cancer
Gerald Crabtree, Stanford University,
Stanford, CA
11:05 a.m.
Neural regulation of prostate cancer
Paul Frenette, Albert Einstein College
of Medicine, Bronx, NY
11:50 a.m.
Discussion
11:25 a.m.
Discussion
11:55 a.m.
Epigenetic readers and human
cancer
Xiaobing Shi, The University of Texas
MD Anderson Cancer Center,
Houston, TX
11:30 a.m.
Immune cell phenotypes in NSCLC
A. McGarry Houghton, Fred
Hutchinson Cancer Research Center,
Seattle, WA
11:50 a.m.
Discussion
12:15 p.m.
Discussion
11:55 a.m.
12:20 p.m.
General Discussion
TGF-beta signaling in colorectal
cancer metastasis
Eduard Batlle, Institute for Research in
Biomedicine, Barcelona, Spain
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
483
MAJOR SYMPOSIA
Tuesday, 10:30 a.m.-12:30 p.m.
Immunoprevention in Cancer
MICR Scientific Symposium: Will
Prognostic and Predictive Biomarkers
Be Useful Tools in Cancer Disparities?
Chairperson: Elizabeth M. Jaffee, Johns Hopkins
University, Baltimore, MD
We are in a new era of approvals of immune-based
therapies that include vaccines for cancer prevention
and agents that block signals that inhibit effective
anticancer immunity. These groundbreaking examples
have opened the floodgates for immunotherapies that
target both traditionally “immunogenic” and “nonimmunogeneic” cancers. This revolution in
immunotherapy is the result of recent advances in the
identification of new targets for developing cancer
vaccines, and new signaling pathways for developing
agents that convert the suppressive tumor
microenvironment into one that supports anticancer
immunity. This symposium will highlight these recent
advances and the future expectations for
immunotherapies that prevent cancer.
10:30 a.m.
Introduction
10:40 a.m.
Vaccine-induced immunity against
cancer genes to prevent and treat
pancreatic cancer
Elizabeth M. Jaffee, Johns Hopkins
University, Baltimore, MD
11:00 a.m.
Discussion
11:05 a.m.
Immunoprevention of colorectal
cancer
Robert Schoen, University of
Pittsburgh, Pittsburgh, PA
11:25 a.m.
Discussion
11:30 a.m.
Vaccination to prevent and treat
HPV-associated cancer
Ian Frazer, University of Queensland,
Brisbane, Australia
11:50 a.m.
Discussion
11:55 a.m.
Her2-derived peptide vaccine
for the prevention of breast
cancer recurrence
Elizabeth A. Mittendorf, The University
of Texas MD Anderson Cancer Center,
Houston, TX
12:15 p.m.
Discussion
12:20 p.m.
General Discussion
484
Organized by the Minorities in Cancer Research
(MICR) Council
Co-Chairpersons: Rick A. Kittles, University of Illinois at
Chicago, Chicago, IL, and Edith A. Perez, Mayo Clinic,
Jacksonville, FL
Our current focus on the molecular characterization of
cancer genomic signatures continues to provide
important insight for personalized treatments. These
emerging biomarkers provide prognostic and predictive
information on overall outcome and/or best targeted
therapy based on tumor signatures. Will understanding
genomic variation of a tumor improve outcomes and
provide insight on high-risk individuals within specific
ethnic groups? The purpose of this session is to address
recent advances in the identification of prognostic and
predictive biomarkers, their utility in personalized
oncology, and potential impact on cancer disparities.
10:30 a.m.
Introduction of program
Rick A. Kittles, University of Illinois at
Chicago, Chicago, IL
10:40 a.m.
Novel markers for childhood ALL in
ethnically diverse populations
Jun J. Yang, St. Jude Children’s
Research Hospital, Memphis, TN
11:05 a.m.
Racial aspects of DNA mismatch
repair effects in colon cancer
John M. Carethers, University of
Michigan, Ann Arbor, MI
11:30 a.m.
Genomic markers for predictive
testing of breast cancer
Lyndsay N. Harris, University Hospitals
Seidman Cancer Center, Cleveland, OH
11:55 a.m.
Panel Discussion
Edith A. Perez, Mayo Clinic,
Jacksonville, FL
Tuesday, 10:30 a.m.-12:30 p.m.
Large-Scale Genomics Data for the Research Community through
the NCI Center for Cancer Genomics
Co-Chairpersons: Jaime M. Guidry Auvil, National Cancer Institute, Bethesda, MD, and Jean C.
Zenklusen, National Cancer Institute, Bethesda, MD
The NCI’s Center for Cancer Genomics (CCG), which includes the Office of Cancer Genomics and
The Cancer Genome Atlas Program Office, provides the research community access to large-scale
molecular characterization data, which is largely sequence-based. CCG programs aim to improve
patient outcome through identification of valid molecular targets and associated molecular
markers (prognostic or diagnostic), in and across diseases investigated, which should ultimately
lead to the rapid development of novel, more effective therapies. Current CCG initiatives include
the Cancer Genome Characterization Initiative (CGCI; http://ocg.cancer.gov/programs/cgci),
Therapeutically Applicable Research to Generate Effective Treatments (TARGET;
http://ocg.cancer.gov/programs/target), and the Cancer Genome Atlas (TCGA;
http://cancergenome.nih.gov). The project web pages include details of the studies, as well as
information on how to access the data generated.
TARGET and TCGA are comprehensive genome-wide molecular characterization initiatives to
discover the molecular changes that drive the development and progression of certain childhood
and adult cancers. The session will report briefly on program missions and goals of the CCG
initiatives, discuss published results, as well as outline various ways for the broad research
community to access genomics data including next-generation sequencing. TARGET investigators
will highlight discoveries and lessons learned from the projects in acute lymphoblastic leukemia
(ALL) and neuroblastoma. TCGA researchers will additionally provide overviews of recent
publications: Comprehensive Molecular Characterization of Gastric Adenocarcinoma, which
described four subtypes emerging from a “cluster of clusters” analysis, Comprehensive Molecular
Characterization of Clear Cell Renal Cell Carcinoma, which found that metabolic shift correlated
with tumor stage and severity, Diversity of Lung Adenocarcinoma Revealed by Integrative
Molecular Profiling, which uncovered changes that may expand the number of potential molecular
targets, and The Somatic Genomic Landscape of Glioblastoma, which analyzed of the genomic
data generated from 590 GBM cases.
TARGET initiative overview and highlights
Jaime M. Guidry Auvil, National Cancer Institute, Bethesda, MD
Neuroblastoma
John Maris, Children’s Hospital of Philadelphia, Philadelphia, PA
Acute lymphoblastic leukemia
Charles G. Mullighan, St. Jude Children’s Research Hospital, Memphis, TN
Accessing TARGET genomics data
Tanja M. Davidsen, National Cancer Institute, Bethesda, MD
TCGA initiative data overview
Jean C. Zenklusen, National Cancer Institute, Bethesda, MD
Gastric adenocarcinoma
Peter W. Laird, University of Southern California, Los Angeles, CA
Renal cell carcinoma
Chad J. Creighton, Baylor College of Medicine, Houston, TX
Lung adenocarcinoma
Ramaswamy Govindan, Washington Unviersity School of Medicine. St. Louis, MO
Glioblastoma
Lynda Chin, The University of Texas MD Anderson Cancer Center, Houston, TX
485
Tuesday, 10:30 a.m.-12:30 p.m.
Grand Ballroom A-C, Level 4, Omni San Diego Hotel
Career Development Plans: Designing a Blueprint for
Your Dream Job
Organized by the Associate Member Council
This session will feature a keynote lecture that discusses using IDPs and the myIDP software to
critically analyze your skills, interests, and values, and help you figure out how these match up to
various scientific careers. Learn how to find out which career opportunities could be the best fit for
you. Attendees will also learn about various careers from a prestigious panel of speakers who will
discuss how they selected their respective professions as well as provide tips on what you must
include in your blueprint to attain your dream job. For AACR members, Professional Advancement
Sessions are free with your Annual Meeting registration and are an added benefit of your
membership. For nonmembers, there is an additional fee of $50 for attendance at each session
to be paid onsite. #AACR14 #AACRCDP
Keynote: Introduction to IDPs
Jennifer A. Hobin, American Association for Cancer Research, Washington, DC
Panelists:
Jeff D. Allen, Friends of Cancer Research, Washington, DC
Trevor K. Archer, NIH-National Institute of Environmental Health Sciences, Research Triangle Park, NC
Diane M. Simeone, University of Michigan, Ann Arbor, MI
Django Sussman, Seattle Genetics, Inc., Bothell, WA
Manzoor A. Zarger, NIH-Center for Scientific Review, Bethesda, MD
486
SPECIAL SESSION
Tuesday, 10:30 a.m.-12:30 p.m.
Gallery 1-2, Omni San Diego Hotel
Pancreatic Cancer Action Network-AACR Research Grants Poster
Presentation and Discussion
Facilitator: Lynn M. Matrisian, Pancreatic Cancer Action Network, Manhattan Beach, CA
This session aims to stimulate opportunities for collaboration between Pancreatic Cancer Action
Network-AACR grantees and others in the pancreatic cancer research field. The Pancreatic
Cancer Action Network has adopted a goal of doubling survival from pancreatic cancer by the
year 2020 and is building a robust Community for Progress comprised of researchers working
together to accelerate scientific and medical advances. The grants portfolio targets early career
and established investigators. Funding mechanisms support new and cutting-edge ideas and
approaches, accelerate projects poised for important next steps, encourage team science, and
provide strategic management support to fast track research with a clinical component. Beyond
the financial support of their research, Pancreatic Cancer Action Network-AACR grantees are
provided with opportunities for information exchange and collaborations, professional
development, and mentorship. Come meet the 2013 Pancreatic Cancer Action Network-AACR
grantees, learn about their funded projects, and participate in the discussion. The session
moderators serve on the Pancreatic Cancer Action Network’s Scientific and Medical
Advisory Boards.
Moderator: Steven D. Leach, Johns Hopkins University School of Medicine, Baltimore, MD
Pancreatic Cancer Action Network-AACR Career Development Award,
in memory of Skip Viragh:
Molecular dissection of Hmga2 function during pancreatic cancer progression
Monte M. Winslow, Stanford University School of Medicine, Stanford, CA
Pancreatic Cancer Action Network-AACR Career Development Award:
Role of HMGB1 in pancreatic cancer initiation and progression
Daolin Tang, University of Pittsburgh Cancer Institute, Pittsburgh, PA
Pancreatic Cancer Action Network-AACR Fellowship, in memory of Samuel Stroum:
Validation of novel KRAS synthetic lethal targets in pancreatic cancer
Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, MA
Moderator: Michael A. Hollingsworth, UNMC Eppley Cancer Center, Omaha, NE
Targeting a novel metabolic chemoresistance mechanism in pancreatic cancer
Pankaj Kumar Singh, UNMC Eppley Institute for Cancer Research, Omaha, NE
Pancreatic Cancer Action Network-AACR Innovative Grant:
Role of Hif1a in inflammation, tissue repair, and cancer of the pancreas
M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, PA
Pancreatic Cancer Action Network-AACR Innovative Grant,
supported by the Blum-Kovler Foundation:
Interplay between tension and inflammation in pancreatic tumor progression
Valerie M. Weaver, University of California, San Francisco Medical Center,
San Francisco, CA
Pancreatic Cancer Action Network-AACR Innovative Grant,
in memory of Abby Sobrato:
Targeting desmoplasia in pancreatic cancer to improve drug efficacy
Yves Boucher, Massachusetts General Hospital, Boston, MA
487
SPECIAL SESSION
Tuesday, 10:30 a.m.-12:30 p.m.
Moderator: Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, TX
Using human circulating pancreas cells as a biomarker for early PDAC
Andrew D. Rhim, University of Michigan, Ann Arbor, MI
Pancreatic Cancer Action Network-AACR Inaugural Research Acceleration Network
Grant, in memory of Skip Viragh:
CAPS multicenter trial: Imaging and markers for pancreatic cancer screening
Michael G. Goggins, Johns Hopkins Medical Institutions, Baltimore, MD
Moderator: George A. Fisher, Stanford Cancer Center, Stanford, CA
Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant:
Immunomodulatory mechanisms in KRAS-driven pancreatic cancer and metastasis
Yuliya Pylayeva-Gupta, New York University School of Medicine, New York, NY
Exploiting the cancer mutome for personalized tumor immunotherapy
Eric R. Lutz, Johns Hopkins University School of Medicine, Baltimore, MD
Pancreatic Cancer Action Network-AACR Inaugural Research Acceleration Network
Grant, supported by Tempur-Pedic in memory of Tim Miller:
Accelerating development of CD40 therapy for pancreatic cancer
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania,
Philadelphia, PA
488
REGULATORY SCIENCE
AND POLICY SESSION
Tuesday, 10:30 a.m.-12:30 p.m.
Novel Clinical Trial Designs in the Whole-Exome Era
Co-Chairpersons: David D. Chang, Amgen, Inc., Thousand Oaks, CA, and Eric H. Rubin, Merck
Research Laboratories, North Wales, PA
Advances in high-fidelity, low-cost genome sequencing technology have accelerated the
molecular characterization of tumors, creating both an opportunity and imperative to incorporate
tumor genomic or gene expression information in drug development. The desired outcome is the
ability to match the drug to the patient population, thus avoiding unnecessary treatment and at the
same time maximizing the likelihood of deriving a clinically meaningful benefit. Strategies to detect
treatment effects by simultaneously testing multiple targeted investigational drugs in parallel
have been employed in recent years. Examples of these studies include the I-SPY 2 TRIAL
(Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and
Molecular Analysis 2), the NCI’s MATCH (Molecular Analysis for Therapy Choice) study, and
the Lung Master Protocol.
Although these studies range from early exploratory studies to mature registration protocols, they
share some common innovative features. These innovations include improvements in trial design
that result in efficiencies related to screen failures and the need for multiple biopsies from an
individual patient. The ultimate goal of these novel trial designs is to mitigate the complicated,
expensive, and often inefficient processes employed in traditional registration studies in our
current era of constrained resources. This session will discuss the design and implementation of
nontraditional multi-armed studies in early and late stages of drug development and how these
can be more widely adopted. A panel discussion moderated by David Chang, Amgen, and
audience Q and A will follow the presentations.
Overview of novel multi-arm studies
Eric H. Rubin, Merck Research Laboratories, North Wales, PA
Clinical perspective on innovative trial designs to accelerate availability of highly
effective anticancer therapies
Patricia M. LoRusso, Barbara Ann Karmanos Cancer Institute, Detroit, MI
The I-SPY 2/3 study as an example of an approach that encompasses exploratory
as well as registration studies
Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San
Francisco, CA
The Lung Master Protocol as an example of a biomarker-driven, multidrug,
multi-arm phase 2/3 registration trial
Roy S. Herbst, Yale Cancer Center, New Haven, CT
Regulatory considerations for biomarker and diagnostic test requirements in
exploratory and registration studies
Elizabeth Mansfield, U.S. Food and Drug Administration, Rockville, MD
FDA perspective on innovative trial designs to accelerate availability of highly
effective anticancer therapies
Gideon Blumenthal, U.S. Food and Drug Administration, Silver Spring, MD
489
SPECIAL SESSION
Tuesday, 10:30 a.m.-12:30 p.m.
Pediatric Cancer Working Group Special Session: Application of
Genomics, Epigenomics, and Immunology Towards Improving
Outcomes in Pediatric Cancer
Chairperson: Lee J. Helman, National Cancer Institute, Bethesda, MD
All meeting attendees are invited to attend this special Pediatric Cancer Working Groupsponsored event showcasing cutting-edge pediatric cancer-based research.
Translating genomics into theranostics for patients with pediatric cancers
Javed Khan, National Cancer Institute-CCR, Bethesda, MD
Hippo pathway inactivation in aveolar rhabdomyosarcoma
Corinne Linardic, Duke University School of Medicine, Durham, NC
Epigenetic suppression of the Kv1.5 ion channel – A novel mechanism of
cancer cell survival under conditions of stress
Elizabeth R. Lawlor, University of Michigan, Ann Arbor, MI
Title to be announced
Stephan A. Grupp, Children’s Hospital of Philadelphia, Philadelphia, PA
490
Tuesday, 12:00 p.m.-1:30 p.m.
Approaches to Post-GWAS Research: Meta-Analyses and
Integration of Diverse Data Types
Co-Chairpersons: Daniela Seminara, National Cancer Institute, Bethesda, MD, Carolyn M. Hutter,
National Cancer Institute-NHGRI, Rockville, MD, and Stefanie A. Nelson, National Cancer
Institute-DCCPS, Bethesda, MD
Genome-wide association studies (GWAS) have identified hundreds of common genetic variants
associated with cancer risk, and new variants are being discovered as the field moves to
incorporate data from next-generation sequencing studies. Understanding cancer risk and
carcinogenesis, particularly for variants in noncoding and unannotated regions of the genome, will
require integration of a broad range of data types, including data from the germline and somatic
(tumor) genomes, gene expression, and epigenetic data. The session will describe NCI resources
for post-GWAS research, with a focus on activities occurring in the Genetic Associations and
Mechanisms in Oncology (GAME-ON) project and will also explore strategies for and tools needed
to integrate multiple data types, challenges for identifying causal variants, how to begin to
understand variant function and impact on the phenotype, and the potential clinical translation of
research results.
A key step in post-GWAS research is pooled analysis to identify additional novel loci and fine-map
identified genetic regions of interest. To this end the international OncoArray Consortium has
developed a customized genotyping array of >560,000 single nucleotide polymorphisms (SNPs)
which will be applied to 425,000 samples comprising patients affected with breast, ovarian,
prostate, lung, and head and neck cancer and controls. GAME-ON investigators have a leading
role in this consortium, with NCI is providing approximately half of the funding. When completed,
the OncoArray Consortium analysis will allow for comprehensive assessment of the genetic
architecture of common cancers and facilitate comparative studies among cancer types.
Understanding the biological impact of common variants on cancer risk is another leading goal of
post-GWAS research. Tumor molecular data from The Cancer Genome Atlas (TCGA), information
on regulatory features and gene expression data from ENCODE and GTEx, and epigenetic data
from NIH’s Epigenetic RoadMap project, are being mined to understand risk variant function.
Integrative analysis of multiple data types can facilitate interpretation, prioritization of loci for
follow up, and development of biological hypothesis. To evaluate the function of risk loci, a range
of experimental assays area also needed. GAME-ON investigators have established multicenter
collaborations to develop effective strategies to systematically address questions about variant
function.
A final step in the post-GWAS continuum is investigating epidemiologic and clinical applications of
GWAS findings. This involves novel approaches for large-scale, harmonized, studies of gene-gene
and gene-environment interactions. It also involves developing and evaluating genetic risk
prediction models, and exploring the role of common variation in survival and other clinical
outcomes. Such work provides a solid basis for expediting clinical translation and public health
dissemination of GWAS and post-GWAS findings.
This session will provide an overview of NCI efforts in post-GWAS research. Talks will describe
recent advances and lessons learned, and will include information on resources of use to the
scientific community. The session will also highlight future directions for research in the postGWAS era.
491
Tuesday, 12:00 p.m.-1:30 p.m.
Progress in post-GWAS cancer research: The GAME-ON Initiative as a model
Stephen B. Gruber, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Genome-wide association studies “post-GWAS”: Further discoveries via crosscancer analyses and economies of scale (the OncoArray)
Peter Kraft, Harvard School of Public Health, Boston, MA
Functional characterization of common variant cancer susceptibility loci
Simon A. Gayther, University of Southern California, Los Angeles, CA
Integrating different data types for rare cancer susceptibility variant discovery
Li Ding, Washington University School of Medicine, St. Louis, MO
Clinical translational application of germline genetic variation
Rosalind A. Eeles, Institute of Cancer Research, Sutton, United Kingdom
Future directions for the discovery and characterization of the spectrum of
cancer susceptibility variants
Stephen J. Chanock, National Cancer Institute, Bethesda, MD
492
CAREER CONVERSATIONS
Tuesday, 1:00 p.m.-2:00 p.m.
AACRcentral, Exhibit Hall A-E, San Diego Convention Center
Managing Life’s Challenges
Career Conversations, organized by the Associate Member Council, are informal networking and
discussion sessions designed to allow early-career scientists the opportunity to interact with junior
faculty and scientists. This session will address best practices for managing the time between
your professional responsibilities and the different aspects of your personal life. Open to all
graduate students, medical students, residents, and clinical and postdoctoral fellows, this session
will take place in the Associate Member Resource and Career Center located in AACRcentral;
limited seating is available on a first-come, first-served basis. #AACR14 #AACRCC
Speakers:
Aime T. Franco, University of Arkansas for Medical Sciences, Little Rock, AR
Rajeev S. Samant, University of Alabama at Birmingham, Birmingham, AL
493
Tuesday, 1:00 p.m.-2:30 p.m.
Marina Ballroom G, South Tower, San Diego Marriott Marquis & Marina
Successfully Negotiating the Next Step of Your Career
Organized by the Associate Member Council
Negotiation skills are essential in all aspects of life, but they become especially relevant in
navigating career opportunities. This session aims to address the gap between formal research
training and understanding how to negotiate your next career step. Through three presentations,
examples of real-life negotiations, and Q&A via a live Twitter feed, you will learn how to effectively
negotiate and turn professional challenges into win-win situations. For AACR members,
Professional Advancement Sessions are free with your Annual Meeting registration and are an
added benefit of your membership. For nonmembers, there is an additional fee of $50 for
attendance at each session to be paid onsite. #AACR14 #AACRnegotiate
The negotiation table and how to evaluate your future employer
Candace S. Johnson, Roswell Park Cancer Institute, Buffalo, NY
Negotiation concepts and common pitfalls
Michael A. Caligiuri, James Cancer Hospital and Solove Research Institute,
Columbus, OH
Show me the goods!
Victoria M. Richon, Sanofi Oncology, Cambridge, MA
After the three lectures, the speakers will present a mock negotiation folllowed by a Q&A featuring
audience questions delivered via a live Twitter feed.
494
CLINICAL TRIALS MINISYMPOSIUM
Tuesday, 1:00 p.m.-3:00 p.m.
San Diego Convention Center
Immunotherapeutic Trials, Immune Response to Targeted Agents,
and Prevention
Chairpersons to be announced
1:00 p.m.
Introduction
1:05 p.m.
CT329 A phase I study of IMCgp100: Durable responses with a novel first-inclass immunotherapy for advanced melanoma
Mark Middleton, Jeff Evans, Neil Steven, Pippa Corrie, Clive Mulatero, Mario
Sznol, William H. Shingler, Dominic Smethurst, Namir Hassan, Yvonne
McGrath, Bent Jakobsen
1:20 p.m.
CT330 Adjusting for confounding effects of treatment crossover in a
randomized phase II study of dabrafenib plus trametinib in BRAF V600+
metastatic melanoma
Nicholas Latimer, Mayur Amonkar, Ceilidh Stapelkamp, Peng Sun
1:35 p.m.
CT331 Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64,
in the treatment of melanoma
Lindy G. Durrant, Christian H. Ottensmeier, Paul Lorigan, Clive Mulatero,
Ruth Plummer, Michelle Cunell, Rachael Metheringham, Victoria Brentville,
Lee Machado, Poulam Patel
1:50 p.m.
CT332 Biomarker analysis predicts antitumor activity of ipilimumab therapy in
patients with refractory metastatic melanoma
Nitin Chakravarti, Isabella C. Glitza, Van A. Trinh, Roland L. Bassett, Jr.,
Wen-Jen Hwu, Victor G. Prieto
2:05 p.m.
CT333 Elypse-7: A randomized, placebo-controlled, phase 2a evaluating the
impact of IL-7 immunotherapy on CD4 count, risks of severe
hematological toxicity and tumor progression in metastatic breast
cancer patients
Ray-Coquard Isabelle, Olivier Tredan, Gwenaele Garin, Christine MénétrierCaux, Sylvie Chabaud, Thomas Bachelot, Claire Cropet, Pierre-Etienne
Heudel, Paul Rebattu, Patricia Dupont, Estelle Verronese, Anne-claire
Cadore, Valérie Fouillat, Olfa Derbel, Nathalie Bonnin, Thérèse Croughs,
Michel Morre, Nicolas Pasqual, Manuari Manuel, Gilles Clapisson,
Christophe Caux, David Pérol, Jean-Yves Blay
2:20 p.m.
CT334 Pazopanib as third-line therapy for metastatic renal cell carcinoma:
Clinical efficacy and temporal analysis of cytokine profile
Sumanta K. Pal, Dewan Md Sakib Hossain, Qifang Zhang, Chan Gao,
Jeremy O. Jones, Paul H. Frankel, Robert A. Figlin, Marcin Kortylewski
2:35 p.m.
CT335 A clinical trial of supplementation with vitamin D and/or calcium for the
prevention of colorectal adenomas
John A. Baron, Elizabeth L. Barry, Dennis J. Ahnen, Carol A. Burke, Roberd
M. Bostick, Robert S. Bresalier, Timothy R. Church, Marcia Cruz-Correa,
Michael Goodman, Robert Haile, Anastasia Ivanova, Richard I. Rothstein,
Robert S. Sandler, Dale Snover, Robert W. Summers
2:50 p.m.
Discussion
495
CURRENT CONCEPTS IN DIAGNOSTICS
AND THERAPEUTICS RESEARCH
Tuesday, 1:00 p.m.-3:00 p.m.
Exosomes and Microvesicles in Cancer
Chairperson: David C. Lyden, Weill Cornell Medical College of Cornell University, New York, NY
Exosomes and microvesicles are small spherical membrane fragments shed by various cell types
during physiological processes. Increasing attention has been focused on the role of exosomes
and microparticles in malignant progression and metastasis. Recent studies have revealed
selective packaging of proteins, lipids, and genetic material, such as mRNAs, miRNAs, and DNA,
into exosomes and microvesicles. Thus, exosomes can mediate the horizontal transfer of these
functional molecules into recipient cells promoting their “education” in migration, angiogenesis
and pro-metastatic properties. Many types of tumor cells can secrete large amounts of exosomes
and microparticles in circulation. In this session, we will address the use of tumor exosomes and
their particular signatures (i.e., proteins, lipids, and genes) as potential biomarkers for prognostic
and diagnostic means, as well as the possibility as targets for specific therapeutic development.
We will address the complexities of identifying tumor exosomes and microparticles and their
functional properties as compared to other stromal-derived particles in circulation. We will also
compare the strengths of exosome and microparticle as unique biomarkers in contrast to other
circulating biomarkers, such as circulating tumor cells and cell-free DNA.
1:00 p.m.
Tumor-derived exosomes promote premetastatic niche formation and
organotropism
David C. Lyden, Weill Cornell Medical College of Cornell University,
New York, NY
1:20 p.m.
Discussion
1:25 p.m.
Functional analysis of lipidome profile alterations in malignant and metastatic
colon adenocarcinoma cell-derived exosomes
Gavin E. Reid, Michigan University, East Lansing, MI
1:45 p.m.
Discussion
1:50 p.m.
Exosome mobilization of planar cell polarity signaling in cell
motility and metastasis
Jeffrey L. Wrana, Samuel Lunenfeld Research Institute, Toronto, ON, Canada
2:10 p.m.
Discussion
2:15 p.m.
Effect of mutant KRAS on composition and behavior of exosomes in colorectal
cancer
Robert J. Coffey, Vanderbilt University Medical Center, Nashville, TN
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
496
CURRENT CONCEPTS IN
ORGAN SITE RESEARCH
Tuesday, 1:00 p.m.-3:00 p.m.
2:15 p.m.
Have we really gone from rags to riches?
The evolving disease and therapeutic
landscape
Johann S. de Bono, Institute of Cancer
Research, Sutton, United Kingdom
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
From Rags to Riches? Prostate Cancer
in 2014
Chairperson: Johann S. de Bono, Institute of Cancer
Research, Sutton, United Kingdom
Prostate cancer has been described as “the Cinderella
Cancer.” The commonest male cancer and the second
commonest killer from cancer after lung cancer in the
Western world, this is a complex heterogeneous disease.
Frequently driven, and maybe partly caused by,
androgen receptor signaling, treatment for this disease
has largely focused on endocrine therapeutic strategies.
The last decade has resulted in major progress in our
understanding of the pathogenesis, molecular pathology,
and treatment of prostate cancer. This session will focus
on describing these advances and what the future holds
for prostate cancer science and medicine.
1:00 p.m.
What have we learned about the
molecular pathology of prostate cancer?
Discovery and translation
Scott A. Tomlins, University of Michigan
Medical School, Ann Arbor, MI
1:20 p.m.
Discussion
1:25 p.m.
What have we learned from mouse
models? Signaling targets and
signatures
Cory Abate-Shen, Columbia University
Irving Comprehensive Cancer Center, New
York, NY
1:45 p.m.
Discussion
1:50 p.m.
What have we learned from targeting the
AR? Understanding refractory and
resistant disease
Peter S. Nelson, Fred Hutchinson Cancer
Research Center, Seattle, WA
2:10 p.m.
Discussion
Neuroendocrine Cancer: Current
Molecular and Genomic Strategies in
Diagnosis and Management
Chairperson: Edward M. Wolin, Cedars-Sinai Medical
Gastroenteropancreatic neuroendocrine tumors (GEPNETs), arising from the diffuse neuroendocrine system,
are a heterogeneous group of malignancies, markedly
increasing in incidence and prevalence. Neuroendocrine
cancers have become the second most prevalent
gastrointestinal malignancy in the United States, second
only to colon cancer. Nevertheless, we are just starting
to understand the molecular pathogenesis of these
tumors, and to develop potentially effective therapies.
Most neuroendocrine tumors express G-protein-coupled
somatostatin receptors, which have become important
targets for diagnostic and therapeutic interventions.
Therapies directed at the PI3K/AKT/mTOR signaling
pathway, antiangiogenics, and tyrosine kinase receptor
inhibitors are also being widely studied. This session will
focus on advances in molecular biology and genomics
that are revolutionizing the treatment and diagnosis of
neuroendocrine tumors, and stimulating new directions
in research.
1:00 p.m.
The somatostatin receptor as a target
for diagnosis and therapy of
neuroendocrine tumors
Edward M. Wolin, Cedars-Sinai Medical
1:20 p.m.
Discussion
497
CURRENT CONCEPTS IN
ORGAN SITE RESEARCH
1:25 p.m.
Attacking PI3K/AKT/mTOR,
angiogenesis, and other novel targets in
neuroendocrine tumors
Alexandria Phan, Houston Methodist
Hospital, Houston, TX
1:45 p.m.
Discussion
1:50 p.m.
The molecular pathology of
neuroendocrine tumors: From
phenotype to genotype
Laura H. Tang, Memorial Sloan-Kettering
Cancer Center, New York, NY
2:10 p.m.
Discussion
1:00 p.m.
Deploying effective immune therapy
strategies in pancreatic cancer
Gregory L. Beatty, University of
Pennsylvania, Philadelphia, PA
1:20 p.m.
Discussion
1:25 p.m.
Deciphering the epigenome in
pancreatic cancer
Nabeel M. Bardeesy, Massachusetts
General Hospital Cancer Center,
Boston, MA
1:45 p.m.
Discussion
1:50 p.m.
Developing new diagnostics for
pancreatic cancer
Kenneth W. Kinzler, Johns Hopkins
Kimmel Comprehensive Cancer Center,
Baltimore, MD
2:15 p.m.
The genomics of neuroendocrine
neoplasia: From gnosis to sunesis
Irvin Modlin, Yale University,
New Haven, CT
2:35 p.m.
Discussion
2:10 p.m.
Discussion
2:40 p.m.
Panel Discussion
2:15 p.m.
Devising new model systems for
pancreatic cancer
David A. Tuveson, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
Pancreatic Cancer
Chairperson: David A. Tuveson, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY
Pancreatic cancer is a lethal disease that strikes without
warning and responds poorly to therapies. Improved
approaches of modeling pancreatic cancer offer the
opportunity to delve more deeply into the basic biology
and medical applications for this disease, and will be
discussed here. For example, recent studies have shown
that the epigenetic alterations in pancreatic cancer cells
play important roles in tumorigenesis and will be
highlighted as potential therapeutic targets. In addition,
new diagnostic methods that can detect the disease in its
earliest stages will be described, for potential
applications as early detection methods in high-risk
patients. Finally, new means to trigger a specific immune
response to pancreatic cancer cells will be demonstrated,
with promising clinical applications. An improved future
for our patients will be dependent upon scientific
breakthroughs such as those covered in this session.
498
Tuesday, 1:00 p.m.-3:00 p.m.
2:10 a.m.
Discussion
Pediatric Brain Tumors:
Novel Molecular Insights and
Preclinical Studies
2:15 a.m.
Pediatric medulloblastoma: Mouse
models and preclinical studies
Martine F. Roussel, St. Jude Children’s
2:35 p.m.
Discussion
2:40 p.m.
Panel Discussion
Chairperson: Martine F. Roussel, St. Jude Children’s
Recent large-scale genomic and transcriptomic analysis
of pediatric brain tumors revealed a relatively small
number of genetic aberrations in known genes and
cancer pathways and unexpectedly uncovered
mutations in genes that control the epigenome. New
genetic discoveries have enabled development of
improved mouse models, now being used in preclinical
studies to identify novel therapeutically relevant drugs
and small molecules. The four speakers in this session
will address the development of mouse models and their
use in preclinical studies, as well as the identification of
key genetic and epigenetic regulators driving
tumorigenesis.
1:00 a.m.
MYC and medulloblastoma
William A. Weiss, University of California,
San Francisco, CA
1:20 a.m.
Discussion
1:25 a.m.
Pediatric high-grade astrocytomas: An
epigenetic disease of the developing
brain
Nada Jabado, McGill University
Department of Pediatrics, Montreal, QC,
Canada
1:45 a.m.
Discussion
1:50 a.m.
Adult and pediatric gliomas in mice and
humans
Eric C. Holland, Fred Hutchinson Cancer
Research Center, Seattle, WA
499
MAJOR SYMPOSIA
Adaptive Tumor Immune Resistance
DNA Damage Responses
Chairperson: Drew M. Pardoll, Johns Hopkins Kimmel
Comprehensive Cancer Center, Baltimore, MD
Chairperson: John Petrini, Memorial Sloan-Kettering
Recent dramatic clinical responses via blockade of
immune checkpoints have opened the door to a broad
vision for cancer immunotherapy. Basic immunology has
identified roughly twenty ligand receptor interactions
with potential relevance to cancer immune resistance. As
with the PD-1 pathway, other immunomodulating
pathways are likely operative within the immune
microenvironment. Following Sutton’s Law, we find that
direct profiling of the immune microenvironment of
cancer reveals histology selective and individual tumor
specific patterns on co-expression of co-stimulatory and
co-inhibitory pathways. These analyses drive the
development of combinatorial immunotherapies linked to
biomarker assessment and thereby individualized to
each patient’s tumor.
The DNA damage response is an inducible barrier to
tumorigenesis. It comprises the integrated activities of
DNA repair, DNA damage signaling, apoptosis, and cell
cycle checkpoints. The four speakers in this session will
touch upon each of these functional categories, with an
emphasis on the relationship between the DNA damage
response network and DNA replication stress, such as
that induced by oncogene activation or replication
blocking DNA lesions. This crucial relationship underlies
the ability of the DNA damage response network to
suppress tumorigenesis, and is often compromised in
diseases associated with increased cancer risk.
1:00 p.m.
Introduction
1:10 p.m.
Therapeutic targets and biomarkers
revealed through profiling of the tumor
immune microenvironment
Drew M. Pardoll, Johns Hopkins Kimmel
Comprehensive Cancer Center, Baltimore,
MD
1:30 p.m.
Discussion
1:35 p.m.
Building highly effective antitumor
T cells
Nicholas P. Restifo, National Cancer
Institute, Bethesda, MD
1:55 p.m.
Discussion
2:00 p.m.
Defects in T cell migration within
tumors: A role for extracellular matrix
architecture
Emmanuel Donnadieu, Institut Cochin,
Inserm, U1016, Université Paris Descartes,
Paris, France
2:20 p.m.
Discussion
2:25 p.m.
Targeting immune escape pathways
Glenn Dranoff, Dana-Farber Cancer
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
500
1:00 p.m.
Introduction
1:10 p.m.
Mechanism of tumor suppression by the
Fanconi anemia proteins
Agata Smogorzewska, Rockefeller
1:30 p.m.
Discussion
1:35 p.m.
DNA double-strand break repair in the
context of chromatin
Michael B. Kastan, Duke Cancer Institute,
Durham, NC
1:55 p.m.
Discussion
2:00 p.m.
Mechanisms for the maintenance of
genome stability
Karlene A. Cimprich, Stanford University,
Stanford, CA
2:20 p.m.
Discussion
2:25 p.m.
Tumor suppression by the DNA damage
response
John Petrini, Memorial Sloan-Kettering
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
Tuesday, 1:00 p.m.-3:00 p.m.
New Insights into Nonapoptotic
Cell Death
New Opportunities in Epigenetic
Therapies
Chairperson: Douglas R. Green, St. Jude Children’s
Chairperson: Scott A. Armstrong, Memorial SloanKettering Cancer Center, New York, NY
While avoidance of cell death is widely understood as a
“hallmark” of cancer, little is known about nonapoptotic
cell death and its control in the oncogenic process. In
this session, we will overview forms of active cell death
that are not apoptosis, but are under molecular control.
These include necroptosis, which is driven by the
functions of RIP kinases; autosis, which is promoted by
molecular events linked to autophagy; and entosis, in
which living cells are engulfed and destroyed. Cuttingedge research into these cell death processes and their
implications for cancer will be discussed.
Protein complexes that regulate chromatin structure and
gene expression (epigenetic regulators) play a critical
role in cancer development and maintenance. Recent
studies have demonstrated that small molecules
targeting these complexes have significant efficacy
against a number of cancers in preclinical studies. This
has stimulated interest in a potential new class of cancer
therapeutics. Indeed, clinical trials are underway to
assess novel small molecules that target these
mechanisms. The presentations in this session will cover
a number of approaches that are being taken to
understand the mechanisms of action of complexes that
control gene expression, and to characterize the latest
small molecules that inhibit these mechanisms.
1:00 p.m.
Introduction
1:10 p.m.
RIP kinases and caspases in
development
Douglas R. Green, St. Jude Children’s
1:30 p.m.
Discussion
1:35 p.m.
Autosis: An Na+,K+-ATPase-regulated
form of autophagic cell death
Beth C. Levine, UT Southwestern Medical
Center, Dallas, TX
1:55 p.m.
Discussion
2:00 p.m.
Competition between tumor cells
by entosis
Michael Overholtzer, Memorial SloanKettering Cancer Center, New York, NY
2:20 p.m.
Discussion
2:25 p.m.
Beyond necroptosis: Regulated necrosis
in the kidney
Andreas Linkermann, Universitätsklinikum
Schleswig-Holst, Kiel, Germany
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
1:00 p.m.
Introduction
1:10 p.m.
Unexpected results of prolonged EZH2
inhibition in an in vivo model for
glioblastoma
Maarten van Lohuizen, Netherlands Cancer
Institute, Amsterdam, The Netherlands
1:30 p.m.
Discussion
1:35 p.m.
Mechanisms and clinical translation of
DOT1L inhibition in leukemia
Scott A. Armstrong, Memorial SloanKettering Cancer Center, New York, NY
1:55 p.m.
Discussion
2:00 p.m.
Novel antitumor activity of targeted
LSD1 inhibition
Ryan G. Kruger, GlaxoSmithKline,
Collegeville, PA
2:20 p.m.
Discussion
2:25 p.m.
Chemical modulation of chromatin
structure and function
James E. Bradner, Dana-Farber Cancer
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
501
MAJOR SYMPOSIA
Targeting Non-Oncogene Addiction in
Cancer
Therapeutic Implications of Rb Status
Chairperson: William C. Hahn, Dana-Farber Cancer
Although direct targeting of oncogenic drivers is a key
strategy in developing targeted therapies, the acquisition
of genetic alterations during oncogenesis induces
fundamental alterations in cell physiology. In some
cases, these changes lead to new dependencies that
may be exploited therapeutically. This symposium will
focus on recent work to use directed and open-ended
approaches to identify codependencies, which may form
the basis of novel combination therapies.
Chairperson: Jacqueline Lees, MIT Koch Institute for
Integrative Cancer Research, Cambridge, MA
This session focuses on the GI restriction point and
particularly the retinoblastoma protein-cell cycle kinase
pathway, which controls cellular proliferation and is a
target of mutation within the majority of human tumors.
The talks will describe retinoblastoma protein functions
that are cell cycle kinase sensitive versus resistant,
discuss the role of this pathway in normal development
and cancer, and address the efficacy of cell cycle kinase
inhibition as a cancer treatment.
1:00 p.m.
Introduction
1:10 p.m.
GI restriction point mechanism and
therapy
Jacqueline Lees, MIT Koch Institute for
Integrative Cancer Research, Cambridge,
MA
1:00 p.m.
Introduction
1:10 p.m.
Functional genomics and cancer
dependencies
William C. Hahn, Dana-Farber Cancer
1:30 p.m.
Discussion
1:30 p.m.
Discussion
1:35 p.m.
Seeking unique dependencies of RAS
mutant cancers
Julian Downward, Cancer Research UK,
London, United Kingdom
1:35 p.m.
1:55 p.m.
Discussion
Targeting mitogenic signaling in
K-Ras oncogene-driven tumors
Mariano Barbacid, Spanish National
Cancer Research Center (CNIO), Madrid,
Spain
2:00 p.m.
How aneuploidy drives tumorigenesis
Stephen J. Elledge, Harvard Medical
School, Boston, MA
1:55 p.m.
Discussion
2:00 p.m.
Braking the cycle: Inhibition of the cyclin
D-Cdk4/6 pathway in breast cancer (not
eligible for CME credit)
Robert T. Abraham, Pfizer Oncology
Research Unit, Pfizer Worldwide Research
and Development,
San Diego, CA
2:20 p.m.
Discussion
2:25 p.m.
Cell cycle machinery in development
and in cancer
Piotr Sicinski, Harvard Medical
School/Dana-Farber Cancer Institute,
Boston, MA
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
2:20 p.m.
Discussion
2:25 p.m.
Controlling cell fate through the
unfolded protein response using kinase
inhibitors
Feroz Papa, UCSF School of Medicine, San
Francisco, CA
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
502
Tuesday, 1:00 p.m.-3:00 p.m.
2:25 p.m.
Evolution of clinical trial design in the
‘omics era
Susan Geyer, Ohio State University
Comprehensive Cancer Center,
Columbus, OH
2:45 p.m.
Discussion
2:50 p.m.
General Discussion
Transformative Clinical Trials Design
Chairperson: Rafael G. Amado, GlaxoSmithKline,
Collegeville, PA
The advent of highly active anticancer therapy in
molecularly segmented malignancies is fueling the
evolution of clinical trials design. Phase 1 studies are
evolving from sequential dose escalation in patients with
advanced malignancies using toxicity and clinical
pharmacology endpoints to the evaluation of maximum
biological activity in patients with molecularly selected
tumor types. Evidence of target engagement and clinical
efficacy in a molecularly defined disease segment are
key aims of modern Phase I studies. Activity in specific
disease segments can be quickly followed by definitive
trials. Definitive trials involve the use of molecular
testing, and generally require relatively small sample
sizes to observe larger than historical treatment effects.
This session will deal with innovative trial designs in
oncology with an emphasis in molecular selection and
use of multiplex assay testing to access rare disease
segments, selection of endpoints in randomized trials,
and designs to ascertain the role of novel combinations.
1:00 p.m.
Introduction
1:10 p.m.
New trends in drug development in
oncology
Rafael G. Amado, GlaxoSmithKline,
Collegeville, PA
1:30 p.m.
Discussion
1:35 p.m.
Clinical trials in the brave new world of
cancer research
Donald A. Berry, The University of Texas
MD Anderson Cancer Center, Houston, TX
1:55 p.m.
Discussion
2:00 p.m.
Evaluation of targeted therapies in
advanced breast cancer
Martine J. Piccart, Institut Jules Bordet,
Brussels, Belgium
2:20 p.m.
Discussion
503
REGULATORY SCIENCE
AND POLICY SESSION
Tuesday, 1:00 p.m.-3:00 p.m.
Room 6E, San Diego Convention Center
Regulatory Perspectives in the Codevelopment of Molecular
Diagnostic Tests with Targeted Therapies and Their Use in
Clinical Settings
Chairperson: Laura J. van ‘t Veer, UCSF Helen Diller Family Comprehensive Cancer Center,
San Francisco, CA
As oncologists increasingly treat cancer patients with therapies that target the individual’s unique
molecular signature, it is becoming vitally important that the diagnostic tests used to match
patients to therapies are sensitive and accurate. Multiple assays and tests are currently in use to
optimize treatment by matching patients to appropriate targeted therapies. These results may also
be used to screen patients for clinical trials of targeted agents, thus potentially creating a sample
bias in the patient population accrued into a study. This is particularly challenging in studies that
seek to determine the safety and efficacy of not only the therapeutic but also establish the analytic
and clinical validity of the diagnostic. The recent FDA clearance of a high-throughput DNA
sequencer presents new opportunities as well as regulatory challenges. Further, as more of these
platforms are expected to get cleared for marketing in the near future and the cost of sequencing
falls, individual patients will be able to gain access to their tumor sequence more easily, and
overall guidance is of significance. This session will discuss the importance of best practices to
establish analytic and clinical validation of diagnostic tests, while acknowledging the rapidly
advancing technical progress in sequencing technology. The session will discuss: 1) how to
establish practices that balance clinical trial accrual such that prescreened, biomarker-positive
patients are not overrepresented, 2) how to establish standards and operating procedures to
validate actionable mutations for NGS panels, 3) how individual loci within a screening panel can
be validated to gain approval as a companion diagnostic, 4) how new loci/variants can be
integrated into a testing or screening panel, 5) how levels of evidence can be established for rare
variants such that analytic and clinical validation of these can be established in a reasonable time
frame, and 6) how use of screening versus testing panels can be established in the clinical setting
such that patients receive the best targeted treatments. A panel discussion moderated by
Laura van ‘t Veer, UCSF Helen Diller Family Comprehensive Cancer Center and audience Q and A
will follow the presentations.
Regulatory perspective in pre-screening patients before accrual into trials
Laura J. van ‘t Veer, UCSF Helen Diller Family Comprehensive Cancer Center,
San Francisco, CA
The era of fast, cost-effective, high-throughput sequencing and its impact on
oncology care
Richard D. Klausner, Illumina Inc., San Francisco, CA
Establishing standards such that cross-platform comparisons and validations
can be undertaken to validate variants
Mickey Williams, National Cancer Institute-DCTD, Frederick, MD
Clinical implications of screening tests for patient accrual into trials and
directing patient care
Geoffrey S. Kim, U.S. Food and Drug Administration, Silver Spring, MD
Patient perspectives and concerns
Andrea Ferris, LUNGevity Foundation, Potomac, MD
Establishing optimal regulatory pathways for efficient approval of analytical and
clinically validated tests
Elizabeth Mansfield, U.S. Food and Drug Administration, Rockville, MD
504
POSTER SESSION
Hall A-E, Poster Section 1 • Tuesday, 1:00 p.m.-5:00 p.m.
Tumor Biology 34
Cancer Stem Cell Genomics, Epigenomics, and Biomarkers
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
3856
Progesterone generates breast cancer stem
cells through nuclear receptor-independent mechanisms
in irradiated human mammary cell lines. Guillaume
Vares, Xing Cui, Bing Wang, Tetsuo Nakajima, Mitsuru
Nenoi.
3857
Induction of ALDH1A2 expression is critical for
cancer stem cell properties in neuroblastoma. Noriyuki
Nishimura, Tri Budi Hartomo, Thi Van Huyen Pham,
Nobuyuki Yamamoto, Satoshi Hrase, Akira Hayakawa,
Daiichiro Hasegawa, Keiichiro Kawasaki, Yoshiyuki Kosaka,
Masafumi Matsuo, Yasuhiro Takeshima, Kazumoto Iijima,
Hisahide Nishio.
3858
Implications of the downregulation of
stemness/reprogramming factor expression by ibuprofen
and biguanides. Laura Grenlin, Tuan-Anh Tran, Sarah
Lomahan, Naohiko Ikegaki, Xao X. Tang.
3859
MicoRNAs in regulation of colon cancer stem
cells. Yingjie Yu, Nangia-Makker Pratima, Sindhu Rajendra,
Edi Levi, Adhip P. Majumdar.
3860
Cisplatin-induced CD24 upregulation in CD44ⴙ
stem-like head and neck squamous carcinoma cells: a
potential marker for unfavorable cisplatin response.
Vishnu Modur.
3861
Hyaluronan-CD44v3 interaction with oct4/sox2/
nanog promotes miR-302 expression leading to selfrenewal, clonal formation and cisplatin resistance in
cancer stem cells from head and neck squamous cell
carcinoma. Lilly Y. Bourguignon, Gabriel Wong, Christine
Earle.
3862
Isolation and nanoscale visualization of
glioblastoma stem-like cells utilizing the Notch1
receptor. Elliot Pohlmann, Susan Murphy, Debbie Kelly, Zhi
Sheng.
3863
The stemness of gastric cancer stem cells is
sustained by TGF␤ produced from cancer-associated
fibroblasts. Masakazu Yashiro, Tsuyoshi Hasegawa,
Tatsunari Fukuoka, Haruhito Kinoshita, Tamami Morisaki,
Hiroaki Kasashima, Go Masuda, Naoshi Kubo, Kosei
Hirakawa.
3864
A transition zone showing highly discontinuous
or rapidly oscillating levels of stem cell and
proliferation markers characterizes the development of
colorectal cancer. Kevin J. Arvai, Ya-Hsuan Hsu, Lobin A.
Lee, Dan Jones.
3865
ATOH8 depletion can reprogram noncancer
stem cells into cancer stem cells. Yangyang Song, XinYuan Guan.
3866
Inactivation of p53/PTEN confers a specific
epigenetic profile regulated by IL6-SOCS3 signaling.
Maria Ouzounova, Gwangil Kim, April Davis, Ahmed A.
Quraishi, Nader Tawakkol, Shalini Kota, Max S. Wicha,
Hasan Korkaya.
3867
ROCK1 inhibition promotes the self-renewal of a
novel mouse mammary cancer stem cell. Jochen Maurer,
David J. Castro, Mihee Kim, Robert G. Oshima.
3868
Six1 overexpression promotes malignant
progression in models of cervical and colon cancer.
Hanwen Xu, Yu Zhang, Lucia Pirisi, Maria Marjorette Pena,
Kim E. Creek.
3869
SOCS3-mediated regulation of inflammatory
cytokines in triple-negative breast cancer. Hasan
Korkaya, Maria Ouzounova, Gwangil Kim, Ali Quraishi, April
Davis, Nader Tawakkol, Sumeyye Korkaya, Max S. Wicha.
3870
Effects of carbon ion beam, alone or in
combination with cisplatin, on triple-negative breast
cancer stem-like cells. Sei Sai, Kumiko Karasawa,
Guillaume G. Vares, Toshiyuki Shirai.
3871
Tie-2 regulates stemness and metastasis of
prostate cancer cells. Kai Dun Tang, Ming-Tat Ling.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
3872
Identification and characterization of ITGA7 as
cancer stem cell marker in esophageal squamous cell
carcinoma (ESCC). Xiaoyan Ming, Li Fu, Liyi Zhang,
Xinyuan Guan.
3873
Hedgehog signaling maintains gastric cancer
stem cells and promotes chemotherapy resistance:
results from laboratory and clinical studies. Changhwan
Yoon, Do Joong Park, Benjamin Schmidt, Nicholas
J. Thomas, Hae-June Lee, Teresa S. Kim, Yelena Y.
Janjigian, Deirdre J. Cohen, Sam S. Yoon.
3874
Loss of DDB2 enhances the tumorigenicity of
ovarian cancer cells through expanding cancer stemlike cell population. Chunhua Han, Ran Zhao, Xingluo Liu,
Amit K. Srivastava, Li Gong, Hsiaoyin Mao, Meihua Qu,
Weiqiang Zhao, Jianhua Yu, Qi-En Wang.
3875
Functional and molecular characterization of
colon cancer stem cells in tumor heterogeneity and
disease relapse using a 3D-model of patient-derived
tumors. Joseph L. Regan, Dirk Schumacher, Karsten
Boehnke, Cathrin Davies, Ulrich Keilholz, Johannes
Haybaeck, Christoph Reinhard, Hans Lehrach, David
Henderson, Reinhold Schaefer, Christian Regenbrecht,
Martin Lange.
3876
Can Nanog activity identify aggressive breast
cancer stem cell populations. Thomas J. Sayers, Rachel
de Kluyver, Marcella Kaddoura, Jim Stauffer, Poonam
Tewary, Alan D. Brooks.
3877
Evolution of cancer stem cells in glioma to
promote their therapy-resistant phenotype. Ichiro
Nakano.
3878
Differential expression of cancer stem cell
markers and their clinicopathological features in
hepatocellular carcinoma patients with different
etiologies. Tomomi Kogiso, Etsuko Hashimoto, Kazuhisa
Kodama, Maki Tobari, Noriko Matsushita, Nobuyuki Torii,
Makiko Taniai, Katsutoshi Tokushige, Keiko Shiratori.
3879
Crosstalk initiated by endothelial cells endows
head and neck cancer stem cells with an invasive
phenotype. Hong S. Kim, Zhaocheng Zhang, Kristy A.
Warner, Kelsey A. Finkel, April Adams, Jacques E. Nor.
3880
Targeting the root of cancer: a data-driven
approach for identification of lung cancer stem cell
biomarkers. Hua Fan-Minogue, Atul Butte.
3881
A distinct DNA methylation signature defines
breast cancer stem cells and predict cancer outcome.
Rita El Helou, Julien Wicinski, Arnaud Guille, Jose Adelaide,
Pascal Finetti, Francois Bertucci, Max Chaffanet, Daniel
Birnbaum, Emmanuelle Charafe-Jauffret, Christophe
Ginestier.
3882
Downregulation of PRRX1 confers cancer stem
cell-like properties and poor prognosis in hepatocellular
carcinoma. Hidenari Hirata, Keishi Sugimachi, Ryutaro Uchi,
Junji Kurashige, Tae Matsumura, Yuki Takano, Hiroki Ueo,
Masami Ueda, Shotaro Sakimura, Yoshiaki Shinden,
Hidetoshi Eguchi, Tomoya Sudo, Masakazu Hirakawa,
Hiroshi Honda, Koshi Mimori.
3883
Thyroid cancer cells with low proteasome
activity have therapeutic resistance. Takahito Fukusumi,
Hideshi Ishii, Masamitsu Konno, Shimpei Nishikawa,
Yoshihiro Kano, Shinichiro Hasegawa, Hisataka Ogawa,
Atsushi Hamabe, Kozo Noguchi, Masaaki Miyo, Taroh Satoh,
Yuichiro Doki, Masaki Mori, Hidenori Inohara.
3884
Gene expression profiling and copy number
alterations of circulating clonotypic B cells of multiple
myeloma newly diagnosed patients reveals pathways
potentially involved in the development and in the
disease persistence. Marina Martello, Carolina Terragna,
Giovanni Martinelli, Flores Dico, Enrica Borsi, Elena
Zamagni, Lucia Pantani, Paola Tacchetti, Beatrice Zannetti,
Katia Mancuso, Serena Rocchi, Annamaria Brioli, Viviana
Guadagnuolo, Michele Cavo.
Poster
Section
1
1
505
POSTER SESSION
Tumor Biology 35
Poster
Section
2
2
Cancer Stem Cell Phenotype, Function, and Targeting
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
506
3885
ITGA6 (CD49F) is directly regulated by hypoxiainducible factors. Danielle L. Peacock, Luciana P. Schwab,
Tiffany N. Seagroves.
3886
Clec12a: A new AML stem cell-associated
antigen. Viviana Guadagnuolo, Enrica Imbrogno, Andrea
Ghelli Luserna di Rorà, Antonella Padella, Giorgia Simonetti,
Emanuela Ottaviani, Cristina Papayannidis, Ilaria Iacobucci,
Anna Ferrari, Simona Soverini, Giovanni Martinelli.
3887
The association between expression of ALDH1,
KI67 and grading system in breast adenocarcinoma.
Yahya I. Elshimali, Pierre Tamer, Sami Dwabe, Yanyuan Wu,
Marianna Sarkissyan, Jaydutt V. Vadgama.
3888
Expression of ABCG2, ALDH1A1, CD44, and
CD44 variant 9 in human oral squamous cell carcinoma
and its relationship with clinical factors. Tetsuya
Tamatani, Natsumi Takamaru, Makoto Kinouchi, Nobuyuki
Kuribayashi, Daisuke Uchida, Hirokazu Nagai, Youji
Miyamoto.
3889
Modulation of breast cancer stem cell marker
CD44 by all-trans-retinoic acid (ATRA). Rui Kitadai,
Robert Bednarczyk, Neha Tuli, Elyse Hanly, Ghada
Benrahoma, Robert Suriano, Abraham Mittelman, Raj K.
Tiwari.
3890
MicroRNA-551b is highly expressed in
hematopoietic stem cells and expression in acute
myeloid leukemia is associated with relapse and poor
survival. David C. de leeuw, Fedor Denkers, Peter Valk, Iris
de Rink, Ron Kerkhoven, Gerrit Jan Schuurhuis, Gert J.
Ossenkoppele, Linda Smit.
3891
CD133 is associated with resistance of
melanoma to multikinase inhibition. Hengbo Zhou,
Maryam Abdussamad, Amani Alomari, Anirudh Gaur, Cynthia
S. Rosenthal, John L. Zapas, Dean S. Rosenthal.
3892
Inhibitory effects and regulatory mechanism of
nestin in pancreatic cancer. Yoko Matsuda, Toshiyuki
Ishiwata, Hisashi Yoshimura, Satoshi Yamashita, Toshikazu
Ushijima, Kaiyo Takubo, Tomio Arai.
3893
Interleukin 6 and interleukin 8 inhibitors, when
used in combination with docetaxel, inhibit tumor
progression in mouse model of triple-negative breast
cancer. Yajing Liu, Leonel Hernandez-Aya, April Davis, Max
Wicha, Monika Burness.
3894
Targeting colorectal and pancreatic cancer
stem cells with the LGR5 monoclonal antibody BNC101.
Peter Chu, Kristen Smith, John Norton, Colin Walsh, Farbod
Shojaei, Jose Iglesias, Christopher Reyes.
3895
Tumor suppressor activity of the ERK/MAPK
signaling: inhibition of cell reprogramming by
degradation of specific proteins. Xavier DeschênesSimard, Filippos Kottakis, Frédéric Lessard, Emmanuelle
Saint-Germain, Véronique Bourdeau, Nabeel Bardeesy,
Gerardo Ferbeyre.
3896
The Hippo coactivator YAP1 upregulates SOX9
and endows cancer stem cell properties in nontransformed cells and esophageal cancer cells. Shumei
Song, Jaffer A. Ajani, Soichiro Honjo, Dipen M. Maru,
Qiongrong Chen, Jiankang Jin, Ailing W. Scott, Todd R.
Heallen, Lianchun Xiao, Wayne L. Hofstetter, Brian Weston,
Jeffrey H. Lee, Roopma Wadhwa, Kazuki Sudo, James F.
Martin, John R. Stroehlein, Mien-Chie Hung, Randy L.
Johnson.
3897
Sam68 sustains self-renewal and invasiveness
of breast cancer initiating cells. Alice Turdo, Miriam
Gaggianesi, Antonina Benfante, Mauro Piantelli, Matilde
Todaro, Giorgio Stassi.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
3898
Disseminated cells from primary lung cancers
contain a distinct cancer initiating subpopulation with
mesenchymal-like features. Giulia Bertolini, Massimo
Moro, Monica Tortoreto, Roberto Caserini, Ugo Pastorino,
Luca Roz, Gabriella Sozzi.
3899
ROCK inhibitor as a differentiation-inducing
agent to target glioma stem cells. Brenda Auffinger, Alex
L. Tobias, Yu Han, Maciej S. Lesniak, Atique U. Ahmed.
3900
Pten deletion in SOX9ⴙ cells leads to tumor
initiating cell expansion and tumor development in
mouse liver. Ni Zeng, Janel Kopp, Lina He, Maike Sander,
Bangyan Stiles.
3901
Evi1 defines leukemia-initiating capacity and
tyrosine kinase inhibitor resistance in chronic myeloid
leukemia. Tomohiko Sato, Susumu Goyama, Keisuke
Kataoka, Ryo Nasu, Takako Tsuruta-Kishino, Yuki Kagoya,
Arika Nukina, Katsuyoshi Kumagai, Naoto Kubota, Masahiro
Nakagawa, Shunya Arai, Akihide Yoshimi, Hiroaki Honda,
Takashi Kadowaki, Mineo Kurokawa.
3902
Liver cancer stem cells initiate extracellular
matrix remodeling. Zhiqian Zhang, Wei Zhao, Xueying
Yang, Haibo Han.
3903
A sub-set of DCLK1ⴙve colon cancer stem cells
(CSCs) survive curcumin induced autophagy, while cotreatment with curcumin ⴙDCLK1-siRNA eliminates
CSCs: Role of long and short isofoms of DCLK1.
Shubhashish Sarkar, Malaney O’Connell, Carla, Kantara,
Pomila Singh.
3904
Targeting NOTCH1 effectively inhibits the
growth of breast cancer stem cells and breast cancer
cells. Suman Suman, Trinath P. Das, Chendil Damodaran.
3905
Stem like cells in human breast cancer: EP4 as
a therapeutic target. Mousumi Majumder, Xiping Xin, Ling
Liu, Gillian Bell, Erin Landman, Mauricio Rodriguez- Torres,
Lynne-Marie Postovit, David Hess, Peeyush K. Lala.
3906
Combined inhibition of PI3K isoforms and mTOR
kinase is critical for cancer stem cell inhibition by VS5584. Vihren N. Kolev, Quentin G. Wright, David T. Weaver,
Jennifer E. Ring, Christian M. Vidal, Mahesh V. Pavdal,
Jonathan A. Pachter, Qunli Xu.
3907
Human pancreatic cancer stem cells utilized to
generate an in-vivo mouse/rat model system for
screening potential drug candidates for treatment of
pancreatic cancer patients. Cristian Sharma, Patrick
Cleary, Esteban Gomez, Shruthi Satish, Michael Sharma,
Michael Perez, Natalee Amecuza, Jitesh Jani, Rubio
Punzalan, Jay P. Sharma.
3908
Focal adhesion kinase (FAK) inhibitor VS-6063
(defactinib) preferentially targets cancer stem cells in
triple negative breast cancer. Qunli Xu, Vihren N. Kolev,
Quentin G. Wright, Jennifer E. Ring, Christian M. Vidal, Irina
M. Shapiro, David T. Weaver, Mahesh V. Padval, Jonathan
A. Pachter.
3909
Cisplatin resistant head and neck cancer cells
are susceptible to growth inhibition by CDF curcumin.
Saroj K. Basak, Alborz Zinabadi, Natarajan Venkatesan,
Victor M. Duarte, Clifton L. Dalgard, Meera Srivastava,
Marilene B. Wang, Fazlul H. Sarkar, Eri S. Srivatsan.
3910
Identification of lead organic compounds active
against stem cell-like neuroblastoma cells by high
throughput screening. Naohiko Ikegaki, Kiira Ratia, Ruth
Hsiao, Mariko M. Limpar, Sarah Lomahan, Xao X. Tang.
POSTER SESSION
Tumor Biology 36
Model Organisms in Tumorigenesis
Poster
Section
Poster Abstract
Board Number
1.
3912
The role of autophagy in prostate tumorigenesis
and its therapeutic implications. Marco A. De Velasco,
Yurie Kura, Naomi Ando, Emiko Fukushima, Yuji Hatanaka,
Yutaka Yamamoto, Nobutaka Shimizu, Kazuhiro Yoshimura,
Masahiro Nozawa, Kazuhiro Yoshikawa, Kazuto Nishio,
Hirotsugu Uemura.
2.
3913
ATP1A1 overexpression correlates with clinical
diagnosis and staging of esophageal cancer: from in
vivo to human. Ming-Tsang Wu.
3.
3914
Tcfap2c regulates growth and oncogenesis in
neu-activated breast cancer. Jung M. Park, Tong Wu,
George Woodfield, Anthony Cyr, James De Andrade,
Weizhou Zhang, Frederick Domann, Ronald J. Weigel.
4.
3915
Establishment of novel cell lines recapitulating
the genetic landscape of uveal melanoma and
preclinical validation of mTOR as a therapeutic target.
Nabil Amirouchene-Angelozzi, Fariba Nemati, David Gentien,
May-Linda Lepage, André Nicolas, Jordan Madic, Amaury
Dumont, Guillaume Carita, Jaques Camonis, Laurence
Desjardins, Nathalie Cassoux, Sophie Piperno-Neumann,
Pascale Mariani, Xavier Sastre, Didier Decaudin, Sergio
Roman-Roman.
5.
6.
7.
8.
3916
HSP90 mediates tumor-associated matrix
metalloproteinase 2 and Cathepsin L protease activities
in ovarian carcinoma. Shane W. O’Brien, Fang Xiao,
Marsia A. Maglaty, Joshua S. Trinadad, Lainie P. Martin,
David A. Proia, Denise C. Connolly.
3917
Understanding the mechanisms driving
pancreatic neuroendocrine tumorigenesis. Amanda R.
Wasylishen, Guillermina Lozano.
3918
Characterizing growth features, allograft
generation and transcriptomes of cultured conditionally
reprogrammed cells (CRC) prepared from primary triple
negative cancer from Brca1-mutant mice. Ahmad M.
Alamri, Svenja Groeneveld, Keunsoo Kang, Sarah Dabydeen,
Weisheng Wang, Lothar Hennighausen, Bhaskar Kallakury,
Xuefeng Liu, Priscilla A. Furth.
3919
Transformation of mouse embryonic neuronal
stem cells by EphB2 requires receptor mediated
activation of the MAPK pathway. Samuel Priddy, Phylip
Chen, Nathan Rossi, Robert A. Johnson.
Poster Abstract
Board Number
13.
3924
Establishment and characterization of two cell
lines of anaplastic pancreatic cancer. Kotaro Miura,
Kenjiro Kimura, Ryosuke Amano, Sadaaki Yamazoe, Keiichiro
Hirata, Masatsune Shibutani, Katsunobu Sakurai, Hisashi
Nagahara, Takahiro Toyokawa, Naoshi Kubo, Hiroaki
Tanaka, Kazuya Muguruma, Hiroshi Otani, Masakazu
Yashiro, Kiyoshi Maeda, Masaichi Ohira, Kosei Hirakawa.
14.
3925
The PIK3CA H1047R mutation can initiate
tumorigenesis in the colon. Cheri Pasch, Molly Maher,
Dustin Deming.
15.
3926
Influence of tumor microenvironment on
engraftment capacity of hematological cell lines in
immunocompromized mice. Eva Oswald, Kerstin Klingner,
Ralph Waesch, Katja Zirlik, Monika Engelhardt, Julia B.
Schüler.
16.
3927
Obesity induces changes in adipokines profile
and activates Akt/mTOR signaling accelerating breast
carcinogenesis and tumor growth. Enrique FuentesMattei, Guermarie Velazquez-Torres, Liem Phan, Fanmao
Zhang, Ping-Chieh Chou, Ji-Hyun Shin, Hyun-Ho Choi, JiunSheng Chen, Ruiying Zhao, Jian Chen, Chris Gully, Colin
Carlock, Yuan Qi, Ya Zhang, Yun Wu, Francisco Esteva,
Yongde Luo, Wallace L. McKeehan, Joe E. Ensor, Gabriel N.
Hortobagyi, Lajos Pusztai Pusztai, W. Fraser Symmans,
Mong-Hong Lee, Sai-Ching J. Yeung.
17.
3928
Genetic deletion or pharmacologic blockade of
the amino acid transporter Slc6a14 in mice suppresses
breast cancer induced by Polyoma middle T oncogene.
Babu Ellappan, Yangzom D. Bhutia, Muthusamy Thangaraju,
Puttur D. Prasad, Vadivel Ganapathy.
18.
3929
Orthotopic human choroidal melanoma model
characterization with bioluminescence and magnetic
resonance imaging for therapeutic efficacy evaluation.
John L. Chunta, Meridith Baugher, Deanne Lister, Erin
Trachet, Kevin P. Guley, Chris Bull, Scott Wise, Wilbur R.
Leopold, Patrick McConville.
19.
3930
Recapitulating the microenvironment in vitro for
comparative study of factors affecting tumor growth
and vascularization. Luis F. Alonzo, Claire J. Robertson,
Monica L. Moya, Marian L. Waterman, Christopher C.
Hughes, Steven C. George.
20.
3931
A novel canine histiocytic sarcoma cell line
provides a potential path to effective treatments with
relevance for translational and comparative studies in
humans. Marilia Takada, Maciej Parys, Emmalena GregoryBryson, Vilma Yuzbasiyan-Gurkan.
21.
3932
p53 mutation cooperates with Rb loss to
promote aggressive metastatic small cell lung cancer in
the absence of gain-of-function effects. Nagako Akeno,
Rebecca Greaves, Ashley L. Miller, Kathryn A. WikenheiserBrokamp.
9.
3920
Understanding the molecular nature of cancer
cell lines. Lysa A. Volpe, Anupreet Bal, John Foulke,
Michael Jackson, Luping Chen, Fang Tian.
10.
3921
Generation of a T-cell lymphoma mouse model
based on chronic LPS challenge and TGF-␤ signaling
disruption. Nina M. Muñoz, Lior H. Katz, Mihai I. Gagea,
Asif Rashid, Lopa Mishra.
11.
3922
Deregulated thymidylate synthase promotes
tumorigenecity in pancreatic neuroendocrine tumors.
Kyungah Maeng, Hye Seung Lee, Min Chen, Maria ZajacKaye.
22.
3933
Characterization of single nucleotide
polymorphisms of Aurora Kinase A in tumorigenesis.
Rajamani Rathinam, Mutsuko Ouchi, Sara Cuesta Sancho,
Toru Ouchi.
12.
3923
Molecular characterization of an animal model
for neuroendocrine thyroid cancer. Karine Pozo, Antje
Hillmann, Alexander Augustyn, Tanvir Singh, Florian Plattner,
John Minna, Herbert Chen, Gilbert J. Cote, James A. Bibb,
Fiemu E. Nwariaku.
23.
3934
Angiogenin and PlexinB2 promote glioblastoma
progression by stimulating tumor angiogenesis, cancer
cell survival and invasion. Hailing Yang, Guo-fu Hu.
24.
3935
A perfused 3D co-culture model of
vemurafenib-resistant melanoma. Chaitra Cheluvaraju,
Stephen Shuford, Christina Mattingly, Teresa DesRochers,
Matthew Gevaert, David E. Orr, Hal E. Crosswell.
3
3
507
POSTER SESSION
Tumor Biology 37
Poster
Section
4
4
Modifiers and Predictors of Tumor Response to Radiation and Other DNADamaging Agents 1
Poster Abstract
Board Number
1.
3936
Potential relationship of deiodinases to
radiation sensitivity. Aleck A. Hercbergs, Paul Davis, John
Leith.
14.
3949
Microrna142 3p promotes tumorinitiating and
radioresistant properties in malignant pediatric brain
tumors. Shih-Hwa Chiou.
2.
3937
Inhibition of Notch and HIF enhances the
antitumor effect of radiation in Notch expressing lung
cancer. Yasuyuki Ikezawa, Jun Sakakibara-Konishi, Hidenori
Mizugaki, Satoshi Oizumi, Masaharu Nishimura.
15.
3.
3938
Localized synchrotron radiation affects serum
cytokine levels and modulates gene expression in
irradiated mouse skin and in skin distant from the
irradiated site. Helen B. Forrester, Alesia Ivashkevich,
Andrew W. Stevenson, Christopher J. Hall, Pavel
Lobachevsky, Carl N. Sprung, Olga A. Martin.
3950
Integrative analysis of acute and late
radiotherapy effects using genome-wide transcriptomics
and quantitative proteomics. Tilmann Rackwitz, Philipp
Seidel, Martin Winter, Cheng Zhou, Ramona Mayer, Uwe
Warnken, Peter Hofner, Jürgen Debus, Martina Schnölzer,
Amir Abdollahi.
16.
3951
Dual phosphoinositide 3-kinase/Mammalian
target of rapamycin inhibitors, GSK2126458 and PKI587, suppress tumor progression and increase
radiosensitivity in nasopharyngeal carcinoma. Wei Wang,
Qi Li, Tongxin Liu, Longhua Chen.
17.
3952
Recurrent prostate cancer genomic alterations
predict response to brachytherapy treatment. Jacqueline
Fontugne, Daniel Lee, Chiara Cantaloni, Christopher E.
Barbieri, Caffo Orazio, Esther Hanspeter, Guido Mazzoleni,
Paolo Dalla Palma, Mark A. Rubin, Giovanni Fellin, Juan
Miguel Mosquera, Mattia Barbareschi, Francesca
Demichelis.
18.
3953
Enhanced radiation reponse in MCF-7
radioresistant cells by targeting Peroxiredoxin II. Tieli
Wang, Anthony J. Diaz, Jian-Jian Li, Yun Yen, Daniel
Tamae.
19.
3954
SAT1 (Spermidine/spermine-N1-acetyltrasferase
1) promotes radiation resistance in glioblastoma
multiforme. Adina Brett-Morris, Scott M. Welford, Eli Bar,
Raffaella Spina, Bradley Wright, Junran Zhang, Jun Lu, Yuji
Seo.
20.
3955
53BP1 facilitates the ATM-dependent
phosphorylation of APLF in the DNA damage response.
Amanda L. Fenton, Diana Tran, Christine A. Koch.
21.
3956
Combination of SPARC and radiation
suppresses HSP27 and induces p21(CIP1/WAF1) in
neuroblastoma tumor cells. Christopher S. Gondi, Smita
Tanpure, Reuben Antony, Karen S. Fernández, Meena
Gujrati, Julian Lin.
22.
3957
Analyzing the effects of radiotherapy on the
metastatic phenotype: a role for combined therapeutic
approaches incorporating Src and PI3K targeting. Emily
J. Rowling, Brian Telfer, Paul Elvin, Kaye J. Williams.
23.
3958
Investigation of HMGB1 as a potential marker
for radiation response in muscle invasive bladder
cancer. Jose J. Mansure, Sanhita Shrivastava, Roland
Nassim, Gerardo Ferbeyre, Wassim Kassouf.
24.
3959
Depleting macrophage or blocking cell fusion
machinery ameliorates intestine fibrosis after radiation.
Ya-Hui Chang, Hui-Ju Ch’ang, Li-Mei Lin.
25.
3960
Identification of osteosarcoma cancer stem
cells using an imaging system for proteasome activity.
Keisuke Tamari, Kazuhiko Hayashi, Yoshihiro Kano,
Masamitsu Konno, Takahito Fukusumi, Shimpei Nishikawa,
Shinichiro Hasegawa, Hisataka Ogawa, Atsushi Hamabe,
Masaaki Miyo, Kozo Noguchi, Yuji Seo, Hideshi Ishii,
Yuichiro Doki, Masaki Mori, Kazuhiko Ogawa.
26.
3961
Effectiveness of the combined treatment with
hsp90 inhibitor and heavy ion irradiation. Ryuichi
Okayasu, Aya Masaoka, Hirokazu Hirakawa, Hiroshi
Fujisawa, Shigeaki Sunada, Ryoichi Hirayama, Miho
Noguchi, Huizi Li, Akira Fujimori.
4.
3939
Delineation of the ATM-Snail pathway in the
DNA damage response. Rebecca J. Boohaker, Joshua
Fried, Xiaoli Cui, Bo Xu.
5.
3940
Activation of HER2 changes the cetuximab
sensitivity in radioresisitant head and neck cancer cells.
Jung Je Park, Sang Yoon Kim, Ji Hyun Seo, Hyo Won
Chang, Roza Khalmuratova, Thomas E. Carey, Jin Pyeong
Kim, Seung Hoon Woo.
6.
3941
The Egr1 transcription factor contributes to
radiation-induced apoptosis in the mouse hippocampus
and intestinal crypts. Diana Y. Zhao, Keith M. Jacobs,
Rowan M. Karvas, Jarrett L. Joubert, Dennis E. Hallahan,
Dinesh Thotala.
7.
8.
9.
508
Poster Abstract
Board Number
3942
Cell death resistance promoted by radiotherapy
in a colorectal cell line. Antuani R. Baptistella, Bruna
Rodrigues, Marcos Dias, Fernanda Giudice, Tonielli Lacerda,
Tiago Santos, Felipe Silva, Petrus Paulo Silva, Samuel
Aguiar, Vilma Martins.
3943
siRNA-mediated HuR silencing sensitizes triplenegative breast cancer cells to radiation therapy.
Kanthesh M. Basalingappa, Meghna Mehta, James N.
Griffith, Ranganayaki Muralidharan, Myriam Gorospe,
Rajagopal Ramesh, Anupama Munshi.
3944
Caveolin-mediated Tie2 nuclear translocation
results in enhanced NHEJ repair and glioma
radioresistance. Mohammad B. Hossain, Nahir CortesSantiago, Xuejun Fan, Konrad Gabrusiewicz, Joy Gumin, Erik
P. Sulman, Frederick Lang, Raymond Sawaya, W.K.Alfred
Yung, Juan Fueyo, Candelaria Gomez-Manzano.
10.
3945
Inhibition of MMP2 expression enhances the
efficacy of radiation therapy for a murine astrocytoma.
Ching-Fang Yu, Ying-Chieh Yang, Ji-Hong Hong, Chi-Shiun
Chiang.
11.
3946
Wnt/ß-catenin signaling mediates resistance of
colorectal cancer cells to chemoradiotherapy. Georg
Emons, Melanie Spitzner, Sebastian Reineke, Janneke
Möller, Emil Kendziorra, Tim Beissbarth, Margret RaveFraenk, Jochen Gaedcke, Thomas Ried, Michael Ghadimi,
Marian Grade.
12.
3947
Radiation treatment solubilizes membrane
receptors in meningioma cells. Venkateswara Rao
Gogineni, Dilip R. Maddirela, Chandramu Chetty, Jasti S.
Rao.
13.
3948
The role of ␣7 nicotinic acetylcholine receptor
activation and pharmacologic tobacco cessation agents
on response to radiotherapy. Samantha L. Sobus, Michelle
A. Romano, Graham W. Warren.
POSTER SESSION
Tumor Biology 38
Pediatric Cancers 3
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
3962
PM01183 shows an improved therapeutic index
relative to trabectedin and suppresses EWS/FLI1 activity
at clinically achievable concentrations. Matt Harlow,
Nichole Maloney, Maria Jose Guillen Navarro, Maurizio
D’Incalci, Carlos Galmarini, Pablo Manuel Aviles Marin,
Patrick Grohar.
3963
MYCN-dependent expression of sulfatase2
regulates neuroblastoma cell survival. Valeria Solari,
Lucia Borriello, G. E. Fernandez, Hiroyuki Shimada, Richard
Sposto, Shahab Asgharzadeh, Edwin A. Yates, Jeremy E.
Turnbull, Yves A. Declerck.
3964
NVP-BEZ235 enhances dexamethasone-induced
BIM expression and apoptosis in models of T-ALL with
PTEN dysfunction and increased PI3K/AKT activity.
Connor Hall, Min Kang.
3965
Modulating glutathione s-transferase M4
activity for the treatment of Ewing sarcoma. Rupeng
Zhuo, Kenneth M. Kosak, Savita Sankar, Elizabeth T. Wiles,
Yin Sun, Jianxing Zhang, Glenn D. Prestwich, Paul J. Shami,
Stephen L. Lessnick, Mitchell S. Cairo, Wen Luo.
3966
PLK1 regulates PAX3-FOXO1 stability and its
inhibition mediates regression of alveolar
rhabdomyosarcoma xenograft tumors. Verena
Thalhammer, David Herrero-Martin, Regina Hecker, Dominik
Laubscher, Laura Lopez-Garcia, Marco Wachtel, Peter Bode,
Beat Schäfer.
3967
BET protein inhibitor OTX015 has selective antitumoral activity in preclinical models of MYCNamplified neuroblastoma. Johannes H. Schulte, Kristina
Althoff, Emma Bell, Andrea Odersky, Anneleen Beckers,
Frank Speleman, Simon Schäfers, Alexander Schramm,
Angelika Eggert, Frank Westermann, Eugenia Riveiro,
Esteban Cvitkovic, Anton Henssen.
3968
Polycomb-mediated suppression of the voltagegated potassium channel KCNA5 promotes Ewing
sarcoma cell survival. Katherine Ryland, Laurie Svoboda,
Jeffrey R. Martens, Elizabeth R. Lawlor.
3969
Pediatric preclinical testing program (PPTP)
evaluation of BMN 673, an inhibitor of poly-adp ribose
polymerase (PARP), with temozolomide (TMZ). Malcolm
Smith, Min Kang, Patrick Reynolds, Richard Gorlick, Anders
Kolb, John Maris, Richard Lock, Hernan Carol, Stephen Keir,
Catherine Billups, Raushan Kurmasheva, Peter Houghton.
3970
EGF has stimulatory and survival effects in
osteosarcoma in vitro and pan-ERBB kinase inhibition
causes cell growth inhibition in vitro and reduces lung
metastases in vivo. Laura D. Nelson, Tiffany N. Lynch,
Yanwen Yang, Wei-Lien Wang, Diane Liu, Dafydd G.
Thomas, Dennis P. Hughes.
3971
PPM1D/WIP1, a potential target in
neuroblastoma. Jelena Milosevic, Malin Wickström, Diana
Treis, Hjalmar Ståhlberg Nordegren, Lotta Elfman, Ninib
Baryawno, Susanne Fransson, Baldur Sveinbjörnsson,
Tommy Martinsson, John Inge Johnsen, Per Kogner.
3972
Activity of MM-398, nanoliposomal irinotecan
(nal-IRI), in Ewings family tumor xenografts is
associated with high exposure of tumor to drug and
high SLFN11 expression. Min H. Kang, Michael M. Song,
Monish Makena, Joo-Sang Lee, Connor P. Hall, Ashly
Hindle, Winford Ko, Nancy Paz, Jonathan Fitzgerald, Daryl C.
Drummond, Timothy J. Triche, C. Patrick Reynolds.
3973
BRICHOS genes CHM1 and ITM2A maintain an
undifferentiated, invasive phenotype in Ewing sarcoma.
Kristina von Heyking, Annette Fasan, Stefan Burdach,
Günther H. Richter.
3974
Insulin-like growth factor-1 receptor (IGF-1R)
inhibition promotes expansion of human NK cells with
potent antitumor activity against Ewing sarcoma cells.
Silke Landmeier, Andrea-Caroline Krueger, Stephanie
Piepke, Saskia Janneschuetz, Bianca Altvater, Sareetha
Kailayangiri, Christian Spurny, Heribert Juergens, Claudia
Rossig.
Poster Abstract
Board Number
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
3975
PID1, a new growth-inhibitory gene, sensitizes
brain tumor cell lines to chemotherapy. Jingying Xu,
Xiuhai Ren, Anthony Tran, Gregory M. Shackleford, Anat
Erdreich-Epstein.
3976
Expression of formyl peptide receptor 1 (FPR1)
in neuroblastoma: Implications in tumorigenesis. Igor
Snapkov, Per Kogner, John-Inge Johnsen, Baldur
Sveinbjørnsson.
3977
Molecular reprogramming in high-risk
progressive neuroblastoma. Vijayabaskar Pandian, Faizan
H. Khan, Satish K. Ramraj, Sheeja Aravindan, Mohan
Natarajan, Terence S. Herman, Natarajan Aravindan.
3978
Reactive oxygen species in Sonic hedgehogdriven proliferation of cerebellar granule neuron
precursors. Chad R. Potts, Rachel D. Rotenberry, Anna M.
Kenney.
3979
NSC305787 inhibits specific protein–protein
interactions involving ezrin in osteosarcoma cells.
Haydar Celik, Jenny Han, Sung-Hyeok Hong, Gulay Bulut,
Jeffrey Toretsky, Aykut Uren.
3980
Pre-clinical evaluation of a novel DNA
crosslinking agent, Ureidomustin (BO-1055) in pediatric
sarcomas. Srikanth R. Ambati, Elissa W. Wong, Benet Pera,
Elizabeth Peguero, Eloisi Caldas Lopes, Jin-Jer Chen, JaeHung Shieh, Tsann-Long Su, Malcolm A. Moore.
3981
Targeted delivery of temozolomide to pediatric
brain tumors using micelle-based theranostic
nanocarriers. Kayla Miller, Suraj K. Dixit, Amy-Lee Bredlau,
Ann-Marie Broome.
3982
Repurposing disulfiram for treatment of
relapsed/refractory acute myeloid leukemia. Eiman A.
Aleem, David O. Azorsa, Ranjan Bista, Oliver B. Pepper,
David W. Lee, Daniel H. Wai, Robert J. Arceci.
3983
The role of UBE4B in neuroblastoma
pathogenesis. Sandra M. Indiviglio, Sarah E. Woodfield,
Linna Zhang, Rongjun Guo, Dolores Lopez-Terrada, Andrew
J. Bean, Peter E. Zage.
3984
Elucidating expression patterns of GPNMB and
potential anti-tumor effects of the antibody-drug
conjugate, glembatumumab vedotin (CDX-011) in human
osteosarcoma primary samples and cell lines. Sajida
Piperdi, Vicky Kuo, Amy Park, Michael Roth, Richard Gorlick.
3985
Differential activation of unfolded protein
response in metastatic vs. non-metastatic osteosarcoma
cells following hypoxia and chemotherapeutic stress.
Janine Faraj, Pooja Hingorani, Aparna R. Sertil.
3986
Characterization of prostaglandin signaling in
primary neuroblastoma. Anna Kock, Karin Larsson, Linda
Ljungblad, Helena Idborg, Marina Korotkova, Lotta Elfman,
John-Inge Johnsen, Per-Johan Jakobsson, Per Kogner.
3987
Evaluation of anti–malarial compounds as
inhibitors of ezrin in osteosarcoma cells. Haydar Celik,
Abraham Kallarakal, Daisy Colon-Lopez, Jeffrey Toretsky,
Jurgen Bosch, Aykut Uren.
3988
The omega-3 fatty acids DHA and EPA inhibit
medulloblastoma growth. Linda M. Ljungblad, Malin
Wickström, John-Inge Johnsen, Per Kogner, Helena
Gleissman.
3989
High throughput screening highlights NFkB
signaling in Ewing sarcoma. Didier Surdez, Gautier Stoll,
Franck Tirode, Karine Laud, Emmanuel Barillot, Olivier
Delattre.
3990
Chemerin and chemerin receptors in
neuroblastoma tumor microenvironment. Conny
Tuemmler, Igor Snapkov, Ugo L. Moens, Baldur
Sveinbjørnsson.
3991
Increased expression of cancer stem cells
markers (CD44, CD90 and CD133) contributes to disease
progression and reduced survival in hepatoblastoma
patients from Egypt: four years survival data. AbdelRahman N. Zekri, Abeer A. Bahnassy, Mohamed Fawzy,
Mohamed El-Wakil, Ahmed Abdel-Sayed, Marwa E. Sheta.
5
5
509
POSTER SESSION
Tumor Biology 39
Poster
Section
6
6
Profiling and Characterization of Metastatic Cells
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
510
3992
Modes of metastasis evolution in human and
murine cancer revealed by whole exome sequencing.
Scott L. Carter, Priscilla K. Brastianos, David G. McFadden,
Thales Papagiannakopoulos, Amaro Taylor-Weiner, Kristian
Cibulskis, Tyler Jacks, William Hahn, Gad Getz.
3993
A microarray-based gene expression analysis
identified diagnostic biomarkers for unknown primary
cancer. Yoshihiko Fujita, Issei Kurahashi, Takayasu Kurata,
Yasuhiro Koh, Kazuko Sakai, Kazuhiko Nakagawa, Kazuto
Nishio.
3994
Identifying molecular networks linked to
colorectal liver metastasis progression during liver
regeneration by RNA-seq. Eve Simoneau, Jarred Chicoine,
Ayat Salman, Robert Sladek, Anthoula Lazaris, Ramila Amre,
Peter Metrakos.
3995
Quantitative protein profiling of tumor
angiogenesis and metastasis biomarkers in mouse and
human models. Wen-Rong Lie, Jonathan Lipsey, Tim
Warmke, Lin Yan, Jehangir Mistry.
3996
Liquid to solid: Leukemic breast tumors assume
the morphologic and genetic characteristics of breast
cancer. Isabel Cunningham, Diane Hamele-Bena, Takayuki
Shiomi, Stephen Emerson, Jose M. Silva, Jeanine M.
D’Armiento, Ashani T. Weeraratna.
3997
Circulating tumor cell expression analysis using
highly multiplexed qPCR to quantify a panel of 624
common cancer genes. Brian Hu, Yucheng Xu, Tong Xu,
Amir Goldkorn.
3998
Network-based identification of gene signatures
of epithelial-mesenchymal transition in breast cancer.
YANG CONG, Ming Zhan, Stephen T. Wong.
3999
Characterization of the limiting steps in the
melanoma metastatic cascade. Elena Piskounova, Sean
Morrison.
4000
Biological basis of aggressive phenotype in
African-American prostate cancer cell line. Bita
Nickkholgh, Xiaolan Fang, Kenneth Gyabaah, K.C. Balaji.
4001
Interaction of CD200 overexpression on tumor
cells with CD200R1 overexpression on stromal cells: An
escape from the host immune response in rectal cancer
patients. Atil Bisgin, Wen J. Meng, Gunnar Adell, Xiao F.
Sun.
4002
Exploring the miRNA and proteomic contents of
exosomes isolated from rhabdomyosarcoma tumor cells
to understand their paracrine signaling. Sandra E.
Ghayad, Farah Ghamloush, Raya Saab.
4003
Clinical and biological significance of CXCR6 in
lung cancer. Hina Mir, Pranav Gupta, Rajesh Singh,
Praveen K. Sharma, Gurpreet Kaur, Ashley B. Ward, William
E. Grizzle, James W. Lillard, Shailesh Singh.
4004
Molecular characterization of circulating
glioblastoma cells identifies a mesenchymal-like tumor
cell subpopulation. James P. Sullivan, Brian V. Nahed,
Andrew S. Chi, Marissa N. Madden, Samantha M. Oliveira,
Simeon Springer, Hiroaki Wakimoto, Deepak Bhere, Khalid
Shah, Phil Spuhler, Ajay M. Shah, David N. Louis, Mehmet
Toner, Shyamala Maheswaran, Daniel A. Haber.
4005
CD44 isoform variant 6 is associated with
prostate cancer progression, metastasis and chemo-/
radio-resistance via PI3K/Akt/mTOR and Wnt/␤-catenin
signaling pathways in vitro. Jie Ni, Paul Cozzi, Jingli Hao,
Julia Beretov, Lei Chang, Wei Duan, Warick Delprado, Peter
Graham, Joseph Bucci, John Kearsley, Yong Li.
4006
MicroRNA footprints of circulating tumor cells
in patients with non-small cell lung cancer. Viswam S.
Nair, Maria Giraldez, Madelyn Luttgen, Khun Visith Keu,
Minal Vasanawala, George Horng, Mehran Jamali, Anand
Kolatkar, Ware Kuschner, Peter Kuhn, Sanjiv S. Gambhir,
Muneesh Tewari.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
24.
25.
26.
27.
28.
29.
30.
4007
The identification of a microRNA signature
associated with risk of distant metastasis in
nasopharyngeal carcinoma. Jeffrey P. Bruce.
4008
cDNA and miRNA microarray analysis
comparing gastric and metastatic liver gastrointestinal
stromal tumors. Hirotoshi Kikuchi, Ichirota Iino, Shinichiro
Miyazaki, Yusuke Ozaki, Yoshihiro Hiramatsu, Manabu Ohta,
Kinji Kamiya, Takanori Sakaguchi, Satoshi Baba, Haruhiko
Sugimura, Mitsutoshi Setou, Hiroyuki Konno.
4009
N-ras codon 61 mutation is associated with
distant metastasis in patients with follicular thyroid
carcinoma. MinJi Jeon, Eun Kyung Jang, Dong Eun Song,
So Young Sim, Eui Young Kim, Yun Mi Choi, Ji Min Han,
Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae
Kim.
4010
MicroRNA regulator of NMI: implications for
breast cancer. Hawley C. Pruitt, Jack W. Rostas III,
Brandon J. Metge, Daniel J. Devine, Sarah K. Bailey, Lalita
A. Shevde, Rajeev Samant.
4011
Single cell transcriptomic analysis identified a
potential dormant signature in prostate cancer
disseminated tumor cells. Hung-Ming Lam, Lisly Chéry,
Ilsa Coleman, Bryce Lakely, Sandy Larson, Roger Coleman,
Julio Aguirre-Ghiso, Jing Xia, Roman Gulati, Peter S. Nelson,
Bruce Montgomery, Paul H. Lange, Linda A. Snyder, Robert
L. Vessella, Colm Morrissey.
4012
Large-scale characterization of DNA methylation
changes in human gastric carcinomas with and without
metastasis. Zhaojun Liu, Jun Zhang, Yanhong Gao, Lirong
Pei, Naoko Hattori, Budong Zhu, Jiafu Ji, Yasuhito Yuasa,
Wooho Kim, Toshikazu Ushijima, Huidong Shi, Dajun Deng.
4013
A novel quantitative histomorphological tool to
assess multiple biomarkers to predict prostate cancer
aggression. Zhi Liu, Christhunesa Christudass, Hui Zhang,
Joon-Yong Chung, Stephen Hewitt, Jonathan Epstein, Robert
W. Veltri.
4015
Nuclear receptor mutations in breast cancer.
Guowei Gu, Yassine Rechoum, Amanda Beyer, Nancy
Weigel, Sue Hilsenbeck, Qianxing Mo, Bert O’Malley, John
Minna, David Mangelsdorf, Suzanne A.W. Fuqua.
4016
Serum proteomics uncover possible biomarkers
associated with progression of metastatic breast
cancer. Adhari A. AlZaabi, Marc Hansen, Steven Graves.
4017
Dynamic biochemical tissue analysis detects
functional selectin ligands expressed on breast,
colorectal, liver, lung, ovarian, pancreatic, prostate, and
stomach cancer tissues. Eric Martin, Ramiro Malgor,
Douglas Goetz, Monica Burdick.
4018
Development and analytical validation of a
novel real-time multiplex RT-qPCR assay for the
simultaneous quantification of ER, PR, HER-2 and EGFR
mRNA expression in circulating tumor cells of breast
cancer patients. Areti D. Strati, Evi S. Lianidou.
4019
MicroRNA-150 inhibits tumor invasion and
metastasis by targeting IL-22-CC20-CCR6 autocrine
signaling in advanced T-cell lymphoma. Hiroyuki Tagawa,
Mitsugu Ito, Sho Ikeda, Akihiko Kitadate, Kenichi Sawada.
4020
Exploring target gene(s) within chromosome
19-amplification detected in a subclone from metastatic
tumors in mouse transplantable OSCC. Tomoki
Muramatsu, Ken-ichi Kozaki, Seiya Imoto, Rui Yamaguchi,
Hitoshi Tsuda, Tatsuyuki Kawano, Satoru Miyano, Johji
Inazawa.
4021
A kinome screen identifies SRPK1 to mediate
breast cancer metastasis. Bob van de Water, Wies van
Roosmalen, Sylvia Le Devedec, John Meerman, John
Foekens, John Martens, Benny Geiger.
POSTER SESSION
Tumor Biology 40
Therapeutic Approaches for Metastatic Tumors
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
11.
12.
4022
Combination of PI3K inhibitor BAY 1082439 with
radium-223 is a promising treatment of cancer with
bone metastases. Mari I. Suominen, Katja Fagerlund,
Enrico Stasik, Andrea Haegebarth, Arne Scholz, Jukka P.
Rissanen, Martin Kornacker, Dominik Mumberg, Jussi M.
Halleen, Karl Ziegelbauer, Ningshu Liu.
4023
Identification of novel compounds to target
dormant micrometastatic cells. Robert E. Hurst, Michael
A. Ihnat, Paul J. Hauser, Lora C. Bailey-Downs, Lilly Y.
Bourgignon.
4024
iNOS inhibition increases survival in triple
negative breast cancer by targeting metastasis and
epithelial-mesenchymal transition. Sergio M. Granados, Yi
Liu, Bhuvanesh Dave, Melissa D. Landis, Steven S. Gross,
Jenny C. Chang.
4025
Combination strategy of endoscopic resection
and telomerase-targeting oncolytic virus for eradicating
lymph node metastasis of submucosal invasive
colorectal cancer. Naoto Hori, Satoru Kikuchi, Hiroyuki
Kishimoto, Hiroshi Tazawa, Yuuri Hashimoto, Shinji Kuroda,
Shunsuke Kagawa, Yasuo Urata, Robert M. Hoffman,
Toshiyoshi Fujiwara.
4026
Attenuation of pancreatic cancer cell migration
and invasion through a targeted inhibition of the Rac
GEF Vav1. Gina L. Razidlo, Christopher Magnine, Arthur C.
Sletten, Rachel M. Hurley, Mark A. McNiven.
4027
Traditional Chinese Medicine herbal mixture LQ
prevents cyclophosphamide-induced metastasis and
toxicity. Lei Zhang, Chengyu Wu, Lingna Li, Yong Zhang,
Robert M. Hoffman.
4028
Identification of a novel combination therapy
that prevents the metastatic outgrowth and reduces the
viability of dormant breast cancer cells. Lara H. El
Touny, Anthony Vieira, Arnulfo Mendoza, Chand Khanna,
Mark J. Hoenerhoff, Jeffrey E. Green.
4029
BL-011256 is a novel VEGFR3 selective
inhibitor, which suppresses tumor lymphatics and
lymph node metastasis in an animal model of
melanoma. Annabell Leske, Richard Foitzik, Donna
Beaumont, John Bentley, Ylva Bergman, Chloe Brown,
Michelle Camerino, Susan Charman, Neil Choi, Melanie De
Silva, Matthew Chung, Hendrik Falk, Danny Ganame, Alison
Gregg, Julian Grusovin, Andrew Harvey, Catherine Hemley,
Ian Holmes, Belinda Huff, Daniel Inglis, Wilhelmus Kersten,
Tina Lavranos, Romina Lessene, Gillian Lunniss, Brendon
Monahan, Benjamin Morrow, Marica Nikac, George
Nikolakopoulos, Dharam Paul, Tom Peat, Justin Ripper,
Michaela Scherer, Paul Stupple, Karen White, Ian Street,
Gabriel Kremmidiotis.
4030
In-vivo evaluation of the anti-metastatic
efficacy of small molecule Cathepsin L inhibitor KGP94
in a prostate cancer model. Dhivya R. Sudhan, Dietmar W.
Siemann.
4032
Targeting the isoprenoid biosynthetic pathway
in a murine model of metastatic prostate cancer.
Jacqueline E. Reilly, Jeffrey D. Neighbors, Nadine Bannick,
Michael D. Henry, Craig H. Kuder, Raymond J. Hohl.
4033
Epigenetic alterations in the multifaceted
inhibitory effects of metformin on castration resistant
prostate cancer. Xin Li, Juncheng Wei, Satoko Matsumura,
Yuqi Guo, Huawei Yuan.
Poster Abstract
Board Number
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
4034
The anti-peritoneal metastasis properties of
Yangzheng Xiaoji, the potential role of hyaluronan and
CD44. Wen G. Jiang, Yongning Jia, Lin Ye, Ke Ji, Yong Gao,
Cong Wei, Yiling Wu, Nick Topley, Anna Kift-Morgan, Jiafu
Ji.
4035
A mitochondrial switch promotes tumor
metastasis. Paolo E. Porporato, Valéry L. Payen, Jhudit
Pérez-Escuredo, Pierre Danhier, Olivier Feron, Bernard
Gallez, Pierre Sonveaux.
4036
Drug repurposing to treat melanoma brain
metastases. Terje Sundstrøm, Jobin K. Varughese,
Francisco Azuaje, Kjell Petersen, Clifford G. Tepper,
Elizabeth Ingham, Lisa Even, Sarah Tam, Kai Ove
Skaftnesmo, Morten Lund-Johansen, Rolf Bjerkvig, Katherine
W. Ferrara, Frits A. Thorsen.
4037
Combining tyrosine kinase inhibitors and
isoflavones to target metastatic activity in prostate
cancer cells. Lori P. Rice, Christine Pampo, Sharon Lepler,
Dietmar W. Siemann.
4038
Human prostate cancer invasion could be
suppressed by 5-Aza-2’-deoxycytidine which can inhibit
the TGF-␤ induced DNA methyltransferase (DNMT).
Qiang Zhang, Brian Helfand, Xiao Lin, Thomas Jang, Yinglu
Guo, Janardan Khandekar, Timothy M. Kuzel, Chung Lee.
4039
Exploration of a potent E-Selectin antagonist
(GMI-1271) as a potential novel therapeutic for treating
breast cancer metastasis to the bone and lung. Mark
Esposito, John L. Magnani, Yibin Kang.
4040
The MEK inhibitor trametinib delays tumor
outgrowth and prolongs survival in a patient-derived
mouse model of occult hepatic metastatic pancreatic
cancer. Timothy E. Newhook, James M. Lindberg, Sara J.
Adair, J. Thomas Parsons, Todd W. Bauer.
4041
Involvement of Notch1 signaling pathway in
medulloblastoma metastasis. Suzana A. Kahn, Sharareh
Gholamin, Michael Zhang, Ryan Nitta, Irving Weissman,
Siddhartha Mitra, Samuel Cheshier.
4042
MARCKS protein inhibitors attenuate cancer cell
migration/metastasis. Walker A. Long, Indu Parikh, Qi Yen,
Shijing Fang, Anne L. Crews, Kenneth B. Adler.
4043
Prevention of breast cancer lung metastasis via
the blockade of the adhesion cascade. Shin-Ae Kang,
Nafis Hasan, Stephen K. Suh, Hallgeir Rui, Takemi Tanaka.
4044
Effect of adjuvant chemotherapy on the
phenotype of circulating tumor cells in patients with
triple negative breast cancer. Galatea Kallergi, Melina
Dragolia, Dimitris Mavroudis, Vassilis Georgoulias, Sofia
Agelaki.
4045
Pediatric osteosarcoma lung metastasis:
variations in clinical management. Andrea T. Vo, Onita
Bhattasali, Michael Roth, Jonathan Gill, David Geller, Lor
Randall, Richard Gorlick.
4046
N-myc interactor impacts autophagy via
modulation of GSK3␤/mTOR signaling. Brandon J. Metge,
Aparna Mitra, Lalita A. Shevde, Rajeev S. Samant.
4047
Potential role of CXCR6-CXCL16 in prostate
cancer progression and chemotherapeutic efficacy.
Pranav Gupta, Ashley B. Ward, Hina Mir, Gurpreet Kaur,
William E. Grizzle, James W. Lillard, Shailesh Singh.
Poster
Section
7
7
511
POSTER SESSION
Tumor Biology 41
Poster
Section
8
8
Tumor Motility and Invasion 2
Poster Abstract
Board Number
1.
4048
GFR␣1 is required for GDNF-induced viability,
migration, and signaling through RET in breast cancer
cells. Catherine A. Ferrante, Nikki DeAngelis, Raluca
Verona.
11.
4058
Acid-sensing ion channel 1a (ASIC1a)
contributes to cell proliferation and migration caused by
acidic environment in human glioma cells. Mingli Liu,
Alyssa (Aihui) Guo, Christopher Ghiathi, Zhigang Xiong.
2.
4049
Stromal Wnt/␤-catenin antagonism with DKK1
promotes clonal expansion of multiple myeloma is
identified using hyaluronic acid based 3D hydrogel.
Bhagavathi A. Narayanan, Bin Duan, Jonathan T. Butcher,
Amitabha Mazumder, Narayanan K. Narayanan.
12.
4059
The bone morphogenic protein 7 (Bmp7) plays
a pro-tumorigenic role in pheochromocytoma. Ines
Leinhäuser, Ines Höfig, Natasa Anastasov, Felix Beuschlein,
Massimo Mannelli, Michael J. Atkinson, Natalia S. Pellegata.
13.
3.
4050
A central role for mTORC1 in CXCR4-mediated
directional migration and metastasis. Patricia DillenburgPilla, Vyomesh Patel, Constantinos M. Mikelis, Carlos R.
Zarate-Blades, Panomwat Amornphimoltham, Zhiyong Wang,
Daniel Martin, Kantima Leelahavanichkul, Colleen L. Doçi,
Robert T. Dorsam, Andrius Masedunskas, Nijiro Nohata,
Roberto Weigert, Alfredo A. Molinolo, J. Silvio Gutkind.
4060
Androgen receptor is involved in the migration
and invasion of triple-negative breast cancer cells. Qiaodan ZHENG, Wenyuan Wu, Cai Huang.
14.
4061
Evidence for hdac6 and er-␣ association in a
subset of clear cell renal cell carcinoma. Swathi
Ramakrishnan, Sheng-Yu Ku, Wendy Swetzig, Dylan Conroy,
Li Shen, Sreenivasulu Chintala, Paula Sotomayor, Kiersten
M. Miles, Remi Adelaiye, Eric Ciamporcero, Ashley Orillion,
Leigh Ellis, Gokul Das, Roberto Pili.
15.
4062
Nestin regulates proliferation, migration,
invasion and stemness of lung adenocarcinoma. Kosuke
Narita, Yoko Matsuda, Masahiro Seike, Zenya Naito, Akihiko
Gemma, Toshiyuki Ishiwata.
4052
Targeting PDK1 in breast cancer: kinasedependent regulation of tumor growth and kinaseindependent regulation of cell migration and invasion.
Paolo Armando Gagliardi, Laura di Blasio, Giorgio Seano,
Roberto Sessa, Alberto Puliafito, Federico Bussolino, Luca
Primo.
16.
4063
Potential targets of PTP4A3 involved in uveal
melanoma migration. Geraldine Liot, Oceane Anezo, Cecile
Laurent, Selma Maacha, Nathalie Planque, Simon Saule.
17.
4064
3D gel system to study tumor metastasis and
EMT. Josephine Y. Fang, ShiJye Tan, Zhi Yang, Marcel
Nimni, Bo Han.
6.
4053
Formin-binding protein-17 (FBP17) is a target of
p53 and promotes invadopodia formation in breast
cancer cells. Harish Chander, Kathleen Watts, Justin
Pogmore, Peter Truesdell, Colin Brien, Andrew W. Craig.
18.
7.
4054
Elongation factor-2 kinase (eEF-2K) promotes
cell invasion and epithelial mesenchymal transition
through regulation of TG2-mediated signaling in human
pancreatic cancer cells. Ahmed A. Ashour, Sultan N.
Alpay, Nilgun Gurbuz, Abdel-Aziz H. Abdel-Aziz, Ahmed M.
Mansour, Bulent Ozpolat.
4065
A novel imaging-based high-throughput assay
identifies Niclosamide as inhibitor of lysosome
anterograde trafficking and tumor invasion. Hazem E.
El-Osta, Samantha Dykes, Magdalena Circu, Jennifer Carroll,
Kinsey Kelly, Floyd Galiano, Glenn Mills, James Cardelli.
19.
4066
Glycodelin abolishes PMA-induced migration of
MCF-7 breast cancer cells. Laura C. Hautala, Riitta
Koistinen, Hannu Koistinen.
20.
4067
TRPM7 channels regulate glioma stem cell
through STAT3 and Notch signaling pathways. Mingli Liu,
Koichi Inoue, Tiandong Leng, Shanchun Guo, Zhigang Xiong.
21.
4068
Overexpression of anillin in colorectal cancer
promotes the cell proliferation, cell mobility and cell
invasion. Hui Yu Chuang, Yu Hsuan Ou.
22.
4069
Capn4 contributes to tumor growth and
metastasis of hepatocellular carcinoma by activation of
FAK-Src signaling pathways. Zhi Dai, Jian Zhou, Jia Fan.
23.
4070
Functional differences of actinin isoforms in the
formation of invadopodia by invasive cancer cells.
Yuumi Ito, Hideki Yamaguchi, Kiyoko Fukami, Kazufumi
Honda, Nami Miura, Tesshi Yamada, Ryuichi Sakai.
24.
4071
SAH-p53-mediated inhibition of cell migration
via alteration of actin dynamics. Bethanie L. Morrison,
Amanda L. Whiting, Federico Bernal.
4.
5.
8.
9.
10.
512
Poster Abstract
Board Number
4051
Prion protein and its ligand STI1/HOP modulate
migration and invasion of cell lines derived from
colorectal tumors. Tonielli S. Lacerda, Marcos Vinicios S.
Dias, Antuani Rafael Baptistella, Fernanda S. Giudice, Bruna
R. Roz, Iara S. Rodrigues, Vilma Regina Martins.
4055
The transcriptional regulator TBX3 promotes
progression of cells representing early premalignant
breast cancer. Connor D. MacMillan, Hon S. Leong, Allen
G. Clifford, Milica Krstic, Siddika Pardhan, David W. Dales,
Carl O. Postenka, Ann F. Chambers, Alan B. Tuck.
4056
Differential phosphorylation of focal adhesion
kinase and activation of Yes kinase are associated with
increased metastatic potential of prostate cancer.
Tanushree Chatterji, Jian H. Song, Nila U. Parikh, Chien-Jui
Cheng, Sue-Hwa Lin, Gary E. Gallick.
4057
Modulation of actin binding proteins by
docosahexaenoic acid reduces cancer cell migration.
Mehboob Ali, Alexander Long, Kathryn M. Heyob, Asha
Srinivasan, Lynette K. Rogers.
POSTER SESSION
Immunology 10
Adaptive Immunity and Immune Regulation
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
4073
STAT3 inhibitors elicit direct anti-tumor effects
against human biliary caner cell lines and limit release
of immune suppressive cytokines in vitro. Jennifer Yang,
Kaitlin Keenan, Thomas Mace, Tanios Bekaii-Saab, James
Fuchs, Eric Schwartz, Chenglong Li, Jiayuh Lin, Pui-Kai Li,
Gregory Lesinski.
4074
Direct interaction of CD40 on tumor cell with
CD40L on T cells increases the proliferation of tumor
cells via the enhancement of TGF-b production and
Th17 differentiation. Hyemin Kim, Yejin Kim, Jiwon Choi,
Mirim Jang, Jiyea Choi, Young-il Hwang, Jae Seung Kang,
Wang Jae Lee.
4075
LAG3 and PD1 co-inhibitory molecules directly
interact to limit CD8ⴙ T cell signaling. Ruea-Yea Huang,
Cheryl Eppolito, Ahmed Fadiel, Adel Hamza, Shashikant
Lele, Junko Mastuzaki, Kunle Odunsi.
4076
Characterizing tumor-specific memory stem like
T cells in blood and bone marrow of breast cancer
patients. Mudita Pincha, Paranchai Boonsawat, Christoph
Domschke, Philipp Beckhove.
4077
Impact of RET/PTC3 oncogene’s inflammatory
and transformative signaling on tumorigenicity of
thyroid and non-thyroid tumorigenic cell lines. Suresh C.
Kari, Laurence C. Eisenlohr.
4078
EZH2 marks polyfunctional memory T cells and
controls tumor immunity. Ende Zhao, Tomasz Maj, Ilona
Kryczek, Lili Zhao, Shuang Wei, Shanshan Wan, Joel
Crespo, Wojciech Szeliga, Linda Vatan, Ke Wu, Arul M.
Chinnaiyan, Theodore H. Welling, Victor E. Marquez, Jan
Kotarski, Yi Zhang, Rebecca Liu, Kaixiong Tao, Guobin
Wang, Weiping Zou.
4079
Reversal of immune evasion mediated by HER2
requires both humoral and cellular HER-2 targeted
immune interventions. Shuwen Xu, Jessica Cintolo,
Jashodeep Datta, Cinthia Rosemblit, Erik Berk, Julia
Terhune, Elizabeth Fitzpatrick, Brian Czerniecki.
4080
Smad and NFAT pathways cooperate to
regulate CD103 expression in human CD8 T lymphocytes
and TCR-mediated epithelial tumor cell killing. Fathia
Mami-Chouaib, M’barka Mokrani, Georges Bismuth.
4081
Id4 (inhibitor of dna binding 4) crosstalk with
pten-akt pathway. Shravan Kumar Komaragiri.
4082
CD47 blockade to enhance adaptive anti-tumor
immune responses. Katie L. Anderson, Daisuke Ito, Debra
C. Lins, Julie M. Curtsinger, Matthew F. Mescher, Jaime F.
Modiano.
4083
Opposing roles of B cells in Ras-driven
squamous tumor development dependent on tissue
compartment of oncogene expression and tumor
phenotype. Michael A. Podolsky, Andrew Gunderson, Kyle
Breech, Adam B. Glick.
4084
NKG2D receptor activation of mTOR and NF␬B
enhances antitumor immunity in effector CD8ⴙ T cells.
Emily Whitman, Amorette E. Barber.
4085
Crucial roles of helper and killer epitopes in
tumor antigens for developing dendritic cell-mediated
cancer immunotherapy. Kazutaka Masuko, Shun Kaneumi,
Junya Ohtake, Kentaro Sumida, Satoshi Terada, Takuto
Kishikawa, Yosuke Ohno, Toshiyuki Kita, Hidemitsu
Kitamura.
4086
Histone deacetylase 6 (HDAC6) as a new target
modulating the proliferation and immune-related
pathways in melanoma. Patricio Perez-Villarroel, Maritza
Lienlaf, Calvin Lee, Fengdong Cheng, David Woods, Kelly
Barrios, Karrune Woan, Jorge Canales, Tessa Knox, Danay
Marante, Hongwei Wang, Pedro Horna, Keiran Smalley,
Esteban Celis, Ed Seto, Jeffrey S. Weber, Eduardo M.
Sotomayor, Alejandro Villagra.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
4087
Identification of microRNAs involved in shaping
immune surveillance and growth properties of tumors.
Barbara Seliger, Simon Jasinski-Bergner, Juergen Bukur,
Kristin Schulz, Franziska Stehle.
4088
Methylselenic acid inhibits the soluble and cellsurface bound NKG2D-ligand ULBP2 in melanoma.
Franziska K. Uhlenbrock, Michael Hagemann Jensen,
Stephanie Kehlet, Lars Andresen, Søren Skov.
4089
Histone deacetylase 6 (HDAC6) as a regulator of
PD-L1 expression through STAT3 modulation in
melanoma. Maritza Lienlaf, Patricio Perez-Villarroel, Calvin
Lee, Fengdong Cheng, Jorge Canales, Tessa Knox, Danay
Marante, Amod Sarnaik, Pedro Horna, Ed. Seto, Keiran
Smalley, Jeffrey S. Weber, Eduardo M. Sotomayor, Alejandro
Villagra.
4090
Inhibition of class I histone deacetylases
promotes robust and durable enhancement of PDL1
expression in melanoma: Rationale for combination
therapy. David M. Woods, Andressa L. Sodre, Eva
Sahakian, John Powers, Maritza Lienlaf-Moreno, Patricio
Perez-Villarroel, Alejandro Villagra, Javier Pinilla-Ibarz,
Eduardo Sotomayor.
4091
Interfering with interferon: An axis of ATF2mediated chemoresistance. Eric Lau, Giuseppina Claps,
David S. Hoon, Ze’ev A. Ronai.
4092
Long-lived Dclk1ⴙ cells serve as colon cancer
initiating cells. Samuel Asfaha, Christoph B. Westphalen,
Yoku Hayakawa, Yoshihiro Takemoto, Dana J. Lukin, Wanda
Setlik, Helen Remotti, Ashlesha Muley, Xiaowei Chen,
Randal May, Courtney W. Houchen, James G. Fox, Michael
D. Gershon, Michael Quante, Timothy Wang.
4093
TGF-␤ insensitivity promotes the proliferation of
human CD8ⴙ T cells in metastatic castration resistant
prostate cancer (MCRPC) patients. Qiang Zhang, Brian
Helfand, Ann V. LeFever, Chung Lee, Timothy M. Kuzel.
4094
Identification of co-inhibitory receptor
expression on T cells from gastric cancer patients.
Yunhui Zong, Fuliang Chu, Songbing He, Yu Jing, Sally A
Hunsucker, Tina Yang, Ming Zhang, Sisi Ye, Yafen Li, Bin
Liu, Jinle Tang, Huimin Meng, Gangli An, Lin Yang.
4095
The potential of PD-1/PD-L1 signaling inhibition
outlined from clinical analysis of colorectal cancer.
Tanja Grimmig, Romana Mönch, Andreas Rosenwald,
Christoph T. Germer, Martin Gasser, Ana Maria WaagaGasser.
4096
A pilot study was initiated to determine if the
immunomodulatory protein, the progesterone-induced
blocking factor (PIBF), is present in higher quantity in
the sera of patients with gynecologic cancer as
compared to controls without cancer. Jerome H. Check,
Mojirayo Sarumi, Ann DiAntonio, Krystal Hunter, Gunda
Simpkins, Marie Duroseau.
4097
Vacuolar ATPase subunit a2 is associated with
immunosuppression in cancer. Gajendra K. Katara, Arpita
Kulshrestha, Mukesh Jaiswal, Alice Gilman-Sachs, Kenneth
D. Beaman.
4098
Inflammasome activation in obesity-associated
breast cancer progression. Ryan Kolb, Yinghong Liu, Qing
Xie, Nicholas Borcherding, Wei Li, Weizhou Zhang.
9
9
513
POSTER SESSION
Prevention Research 6
Poster
Section
10
10
Translational Studies in Cancer Prevention
Poster Abstract
Board Number
1.
2.
14.
4112
Inositol hexaphosphate (IP6) and inositol
against large granular lymphocytic leukemia (LGLL).
Ivana Vucenik, Jan H. Beumer, Julie L. Eiseman.
15.
4113
Restricted ketogenic diet reduces growth and
distant organ metastasis in the murine VM-M3
metastatic tumor model. Zeynep Akgoc, Laura M. Shelton,
David Ryan, Xijun Zhu, Thomas N. Seyfried.
16.
4114
Silibinin inhibits hypoxia-induced proliferation,
angiogenesis and lipogenesis in prostate cancer cells
both in vitro and in vivo. Gagan Deep, Anand M. Ramteke,
Dhanya K. Nambiar, Anil K. Jain, Natalie J. Serkova, Chapla
Agarwal, Rajesh Agarwal.
17.
4115
GS-19, a novel GSK inhibitor suppresses the
growth of pancreatic cancer cells by inhibiting EGFR/
AKT/STAT-3 signaling. Alok Ranjan, Ashlee Birkenfeld,
Jianyu Lu, Duy Hua, Sanjay K. Srivastava.
18.
4116
Grape seed extract impairs adipocyte-colorectal
cancer cell interaction and decreases adipocyte-driven
colon cancer stem colonosphere formation. Sushil
Kumar, Dileep Kumar, Komal Raina, Rajesh Agarwal, Chapla
Agarwal.
19.
4104
Obesity and colon cancer: Does time of
exposure matter. Jinyu Xu, Jennifer Thomas-Ahner,
Samantha DeMarsh, Steven K. Clinton, Susan E. OlivoMarston.
4117
Utilizing RNA aptamers for biomarker discovery
in a novel cell culture system for hepatocellular
carcinoma. Ibtehaj A. Naqvi, Rebekah R. White, Cynthia A.
Moylan, Anna Mae Diehl, Steve S. Choi.
20.
4105
Prevalence of breast stem cells in high-risk
benign breast lesions and association with
breastfeeding. Rachel L. Atkinson, Fraser Symmans,
Therese B. Bevers, Wendy A. Woodward, Abenaa M.
Brewster.
4118
To dine with red wine: Systems approach to
studying resveratrol’s protection against inflammatory
colorectal cancer. Shakir M. Saud, Amiran Dzutsev, Giorgio
Trinchieri, Nancy Colburn, Matthew R. Young, Young Kim.
21.
4119
Novel evidence for chemopreventive effects of
curcumin and boswellic acid through regulation of mir27a and mir-34a in human colorectal cancer. Shusuke
Toden, Yoshinaga Okugawa, Keun Hur, Thomas A. Jascur,
Constanze Burhrmann, Durgha Nattamai, Esperanza
Anguiano, Mehdi Shakibaei, C. R. Boland, Ajay Goel.
22.
4120
Periodic fasting mimicking diet started late in
life reduces and delays carcinogenesis. Sebastian
Brandhorst, Min Wei, Gerrardo Navarre, Louis Dubeau, Peter
Conti, Todd Morgan, Valter D. Longo.
23.
4121
Immunohistochemical characterization of
xenobiotic detoxification enzymes in normal mucosal
epithelium, benign tumors and carcinomas of the nasal
and nasopharyngeal regions. Victor W.S. Ma, Yuen Ping
Leung, Roger K.C. Ngan, Dora L.W. Kwong, Loretta Tse,
Stephen C.K. Law, Timothy T.C. Yip.
24.
4122
Anti-cancer activity of rosemary extract in
colon cancer cells: Involvement of Nrf2 and ERK
pathways. Miao Yan, Gongbo Li, Sakina M. Patiwala, Emily
Householter, Jeremy J. Johnson.
25.
4123
Exploiting sonic hedgehog pathway in
pancreatic carcinogenesis as a potential target for
chemoprevention. Rakesh Srivastava, Sharmila Shankar.
4100
Nutrition and breast cancer prevention: adipose
tissue proton magnetic resonance spectroscopy (1HNMR) as biomarker of past dietary intake of lipids.
Lobna Ouldamer, Lydie Nadal-Desbarats, Stephan Chevalier,
Caroline Goupille, Philippe Bougnoux.
3.
4101
Early detection of colonic neoplasia using
fluorescence microendoscopy. Wellington Pham, Hironori
Kumagai, Ken-Ichiro Hiwatari, Seiji Koike, Etsuo Tobita,
Tokio Kitamura, Kohta Mohri, Shinji Sakuma.
4.
4102
p27 as a biomarker and determinant of risk for
endometrial carcinoma arising in the setting of obesity.
Adrienne S. McCampbell, Megan L. Mittlestedt, Ruhee Dere,
Lijun Zhou, Bojana Djordjevic, Pamela T. Soliman, Qian
Zhang, Caimiao Wei, Stephen D. Hursting, Karen H. Lu,
Cheryl L. Walker, Russell R. Broaddus.
5.
6.
7.
8.
9.
4103
Biomarkers of thyroid function and
autoimmunity associated with thyroid cancer risk: A
nested case-control study. Jeongseon Kim, Young Ae Cho,
Aesun Shin, Jeonghee Lee, Sun-Young Kong, Eun Kyung
Lee, You Jin Lee.
4106
Curcumin inhibit PhIP induced cytotoxicity by
inhibiting ROS production, DNA strand breaks and DNA
adducts formation in MCF 10A cells. Ashok K. Jain,
Abhilash Samykutty, Carissa L. Jackson, Muthusamy
Thangaraju, Darren D. Browning.
4107
Efficient delivery of dietary compound
modulates mcp-1 in murine prostate cancer cells. Manoj
K. Mishra, James A. Stokes, Amanee Salaam, Elijah Nyairo,
Udai Singh, Derrick Dean.
10.
4108
Efficacy of ellagic acid and its major urolithin
metabolites in inhibiting growth of prostate cancer
cells. Anil Poudel, Manicka V. Vadhanam, Joseph Burlison.
11.
4109
Cucurbitacin B: A novel natural agent for the
management of non-small cell lung cancer. Naghma
Khan, Farah Jajeh, Sameh M. Shabana, Hasan Mukhtar.
12.
13.
514
4099
Doctor. Leah J. Cosgrove, Kim Fung, Ilka Priebe,
Leanne Purins, Bruce Tabor, Mike Buckley, Celine Pompeia,
Gemma Brierley, Edouard Nice, Tim Adams, Peter Gibbs,
Jeanne Tie, Andrew Ruszkiewicz, James Moore, Trevor
Lockett, Tony Burgess.
Poster Abstract
Board Number
4110
Gartanin from the mangosteen fruit modulates
androgen receptor and ER stress proteins in prostate
cancer cells leading to apoptosis. Gongbo Li, Sakina
Petiwala, Jeremy Johnson.
4111
Vitamin D for prevention of liver cancer in the
setting of disrupted TGF-␤ signaling pathway. Lior H.
Katz, Andrea Cortes, Vivek Shukla, Keigo Machida, Hidekazu
Tsukamoto, Kirty Shetty, Aiwu R. He, Lynt B. Johnson, Jian
Chen, Randa El-Zein, Ju-Seog Lee, Lopa Mshra.
POSTER SESSION
Epidemiology 10
Cancer Survival: Exposures, Biomarkers, and Genetics
Poster Abstract
Board Number
1.
4124
Ovarian cancer survival by tumor subtype.
Elizabeth M. Poole, Daniel W. Cramer, Allison F. Vitonis,
Kathryn L. Terry.
2.
4125
Robust feature selection and gene committee
predictor for breast cancer patient survival prediction.
Howard H. Yang, Maxwell P. Lee.
3.
4.
5.
6.
7.
4126
The association of serum 25-hydroxyvitamin D
with breast cancer characteristics and prognosis in the
Pathways Study. Song Yao, Chi-Chen Hong, Marilyn L.
Kwan, Ting-Yuan Cheng, Li Tang, Susan E. McCann, Isaac
J. Ergas, Janise M. Roh, Warren Davis, Christine B.
Ambrosone, Lawrence H. Kushi.
4127
A prospective study of breast cancer prognosis
in Kaiser Permanente Northern California: Cohort
description and initial findings from the Pathways
Study. Lawrence H. Kushi, Marilyn L. Kwan, Isaac J. Ergas,
Cecile A. Laurent, Julie R. Munneke, Janise M. Roh, Heather
Greenlee, Chi-Chen Hong, Theresa H. Keegan, Dawn L.
Hershman, Susan E. Kutner, Marion M. Lee, Jeanne
Mandelblatt, Alfred I. Neugut, Peggy Reynolds, Salma
Shariff-Marco, Li Tang, Song Yao, Janice Barlow, Scarlett L.
Gomez, John K. Wiencke, Christine B. Ambrosone.
4128
Disparities in breast cancer relative survival
according to payer status: Findings from national
cancer data bank. Runhua Shi, Srinivas S. Devarakonda,
Lihong Liu, Gary Burton, Glenn Mills.
4129
Outcome disparities in breast cancer of the
young: Is young age at diagnosis associated with
unique disease biology. Allyson L. Valente, Matthew T.
Hueman, Craig D. Shriver, Rachel E. Ellsworth.
4130
Frequency and prognostic value of PTEN loss in
patients with upper tract urothelial carcinoma treated
with radical nephroureterectomy. Daniel Lee, Malte
Rieken, Sharokh Shariat, Evanguelos Xylinas, Christopher
Wood, Jose Karam, Alon Weiner, Charles Guo, Yair Lotan,
angelo Marzo, Brian Robinson, Vitaly Margulis.
8.
4131
Individual and contextual factors associated
with overall prostate cancer survival in Florida. Hong
Xiao, Fei Tan, Georges Adunlin, Askal Ali, Pierre Goovaerts,
Youjie Huang, Clement K. Gwede.
9.
4132
Expression of pattern recognition receptor
genes and survival in colorectal adenocarcinoma. Liang
Chen, David Berger, Michael Ittmann, Hashem B. El-Serag,
Courtney J. Balentine, David Y. Graham, Peter A.
Richardson, Margaret R. Spitz, Susan G. Hilsenbeck,
Rolando Rumbaut, Zhigang Duan, Donna L. White, Li Jiao.
Poster Abstract
Board Number
10.
4133
Disparities in colon cancer survival according
to payer status: Findings from national cancer data
bank. Srinivas S. Devarakonda, Runhua Shi, Amarendra
Neppalli, Glenn Mills.
11.
4134
Prevalence of cervical cancer and associated
mortality in Grenada: A ten-year analysis (2000 - 2010).
Avi’ A. Bahadoor - Yetman, Laura Riley, Ashley Gibbons,
Paul J. Fields, Veronica Mapp-Alexander, Robert Hage, Amy
Baldwin.
12.
4135
Improving attendance to the cervical cancer
screening program: Does self-sampling at home
improve cervical cancer prevention. Kristina Schee,
Lönnberg Stefan, Helle Pedersen, Jesper Bonde, Mari
Nygård.
13.
4136
Comparison of overall survival of Chronic
Lymphocytic Leukemia (CLL) patients referred or not
referred to a specialized CLL clinic: A Canadian
population-based study. Sara Beiggi, Versha Banerji,
Angela Deneka, Jane Griffith, Spencer Gibson, James
Johnston.
14.
4137
Latent class model characterization of
neighborhood SES. Aimee Palumbo, Yvonne Michael, Terry
Hyslop.
15.
4138
Surgery improves survival in malignant pleural
mesothelioma: A Surveillance, Epidemiology, and End
Results (SEER) study. Marlene Camacho-Rivera, Andrea
Wolf, Raja Flores, Emanuela Taioli.
16.
4139
Healthcare resource utilization (HRU) in treated
mantle cell lymphoma (MCL) patients. Chris M. Kozma,
Terra Slaton, Lorie Ellis, R S. McKenzie.
17.
4140
Secular trends in incidence and mortality of
female cancers in Shanghai, China (1973–2009). Zhezhou
Huang, Alicia C. Beeghly-Fadiel, Ying Zheng, Wanqing Wen,
Yutang Gao, Chunxiao Wu, Pingping Bao, Weijian Zhong,
Fan Jin, Yongbing Xiang, Wei Zheng, Xiao Ou Shu, Wei Lu.
18.
4141
Access to medical or radiation oncology
consultation in patients who died from cancer in the
Sudbury-Manitoulin District of Northeastern Ontario,
Canada. Michael Conlon, Mark Hartman, Barbara
Ballantyne, Mary Bewick, Margaret Meigs, Natalie Aubin,
Andrew Knight.
19.
4142
Capacity building in cancer management in
Africa: Envisioning a future from past challenges.
Christopher K. Williams.
Poster
Section
11
11
515
POSTER SESSION
Epidemiology 11
Poster
Section
12
12
Molecular and Genetic Epidemiology of Lung and Head and Neck Cancers
Poster Abstract
Board Number
1.
4143
Oral microbiome and risk of head and neck
cancer, a nested case-control study. Jiyoung Ahn, Yingfei
Ma, Mark P. Purdue, Neal D. Freedman, Susan M. Gapstur,
Liying Yang, Richard B. Hayes, Zhiheng Pei.
12.
4154
Pathway-based approach to genome-wide
gene-environment interaction analysis for occupational
exposures in lung cancer susceptibility. Jyoti Malhotra,
Samantha Sartori, Paul Brennan, Paolo Boffetta.
2.
4144
Genetic and epidemiology characterization of
head and neck cancers by targeted sequencing. Sandra
Perdomo, Luciana Reis, Devasena Anantharaman, James
Mckay, Paul Brennan.
13.
4155
Genome-wide association study of survival in
early stage non-small cell lung cancer. Hongxia Ma,
Guangfu Jin, Zhibin Hu, Hongbing Shen.
3.
4145
Genetic polymorphisms of genes on the retinoic
acid pathway and risk of head and neck cancer. Jeffrey
S. Chang, Jenn-Ren Hsiao, Jang-Yang Chang, Tung-Yiu
Wong, Sen-Tien Tsai, Chun-Yen Ou, Hung-I Lo, Sheen-Yie
Fang, Cheng-Chih Huang, Wei-Ting Lee, Jiunn-Liang Wu,
Ken-Chung Chen, Jehn-Shyun Huang, Yi-Hui Wang, Ya-Ling
Weng, Han-Chien Yang.
14.
4156
Inter-individual variation in allele specific
expression of catalase (CAT) in normal bronchial
epithelial cells and association of putative cisregulatory CAT SNP rs12807961 with lung cancer risk.
Jiyoun Yeo, Xaiolu Zhang, Erin L. Crawford, James C.
Willey.
15.
4.
4146
Polymorphisms of GSTT1, APE1 and MUTYh
gene and the risk of oral squamous cell carcinoma.
Chih-Hsiung Lai, Li-Ling Chiu, Huei-Tzu Chien, Saou-Hsing
Liou, Shiang-Fu Huang, I-How Chen, Chun-Ta Liao, LingLing Hsieh.
4157
Autosome instability and loss of chromosome Y
in blood lymphocytes predict lung cancer risk. Bing Sun,
Ying Wang, Krishna Kota, Yaru Shi, Kepher H. Makambi,
Christopher A. Loffredo, Peter G. Shields, Curtis C. Harris,
Yun-Ling Zheng.
16.
5.
4147
Mate pair sequencing reveals that human
papillomavirus integration into the human genome in
oropharyngeal squamous cell carcinoma is rare and
different from cervical cancer. Ge Gao.
6.
4148
Adverse effects of TERT-CLPTM1L and doublestrand breaks repair contribute to risk for
nasopharyngeal carcinoma. Maria L. Lung, Josephine Ko,
Wei Dai, Elibe Wong, Dora Kwong, Wai Tong Ng, Anne Lee,
Roger Ngan, Chun Chung Yau, Stewart Tung.
4158
Identification of somatic mutations in EGFR/
KRAS/ALK-negative lung adenocarcinoma from never
smokers. Han Sang Kim, Jin Woo Ahn, Jung-Ki Yoon, Soo
Min Han, Hoon Jang, Sungho Eun, Hyo Sup Shim, Hyun
Jung Kim, Dae Joon Kim, Jin Gu Lee, Chang Young Lee, Mi
Kyung Bae, Kyung Young Chung, Eun Young Kim, Ji Ye
Jung, Se Kyu Kim, Joon Chang, Hye Ryun Kim, Joo Hang
Kim, Ji Hyun Lee, Duhee Bang, Byoung Chul Cho.
17.
4159
Characterization of three recurring STK11/LKB1
mutants in lung adenocarcinoma. Brienne E. Engel,
Matthew B. Schabath, Zachary J. Thompson, Steven A.
Eschrich, Stephen G. Brantley, Anastasia R. Belock, Anders
Berglund, Jhanelle E. Gray, Amer A. Beg, Eric B. Haura, W.
Douglas Cress.
18.
4160
Telomere length in white blood cell DNA and
lung cancer: a pooled analysis of three prospective
cohorts. Wei Jie Seow, Richard Cawthon, Mark Purdue, Wei
Hu, Yu-Tang Gao, Wen-Yi Huang, Stephanie J. Weinstein,
Bu-Tian Ji, Jarmo Virtamo, Dean Hosgood, Bryan Bassig,
Xiaoou Shu, Qiuyin Cai, Yongbin Xiang, Shen Min, Wong-Ho
Chow, Sonja Berndt, Christopher Kim, Unhee Lim, Demetrius
Albanes, Neil E. Caporaso, Stephen Chanock, Wei Zheng,
Nathaniel Rothman, Qing Lan.
19.
4161
Circulating Vitamin D in relation to cancers of
the upper aerodigestive tract within the EPIC cohort.
Anouar fanidi, David Muller, Per Magne Ueland, Paul
Brennan, Mattias Johansson.
20.
4162
Circulating C-reactive protein and lung cancer
risk: A nested case-control study in the Southern
Community Cohort Study. Jie Wu, Wei Zheng, Wanqing
Wen, Margaret K. Hargreaves, William J. Blot, Qiuyin Cai.
21.
4163
Chemokine and cytokine levels among lung
cancer cases responsive to HPV antigen stimulation.
Michael E. Scheurer, E S. Amirian, Paul Porter, David B.
Corry.
7.
4149
Genetic variation in CYP2A6, a
nicotine/nitrosamine metabolism enzyme, influences
lung cancer risk in two independent case-control
studies of African American smokers. Catherine A.
Wassenaar, Yuanqing Ye, Qiuyin Cai, Melinda Aldrich,
Joanne Knight, Margaret R. Spitz, Xifeng Wu, William J.
Blot, Rachel F. Tyndale.
8.
4150
Nicotine dependence impacts the relationship
between genetic variants and risk of lung
adenocarcinoma. Tung-Sung Tseng, Jong Y. Park, Jovanny
Zabaleta, Sarah Moody-Thomas, Melinda S. Sothern, Ted
Chen, Hui-Yi Lin.
9.
4151
ATM polymorphisms and risk of lung cancer in
a Chinese population. Ajay A. Myneni, Shen-Chih Chang,
Rungui Niu, Li Liu, Baoxing Zhao, Jianping Shi, Xiaoyou
Han, Jiawei Li, Jia Su, Shun-zhang Yu, Zuo-Feng Zhang,
Lina Mu.
10.
11.
516
Poster Abstract
Board Number
4152
Differences in nicotine metabolism among five
racial/ethnic groups with disparate risks for lung
cancer: The multiethnic cohort study. Sung-Shim L. Park,
Christian Caberto, Maarit Tiirikainen, Lynne Wilkens, Daniel
Stram, Christopher A. Haiman, Stephen S. Hecht, Sharon
Murphy, Loic Le Marchand.
4153
Global African ancestry is not associated with
lung cancer survival. Carissa C. Iverson, Sarah Fletcher,
Jeffery Blume, Holli Dilks, Heidi Chen, Stephen A. Deppen,
William S. Bush, Dana C. Crawford, William J. Blot, Eric L.
Grogan, Melinda C. Aldrich.
POSTER SESSION
Applications of Bioinformatics to Cancer Biology
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
4164
The druggable proteome: Identifying novel
target families for cancer. Parisa Razaz, Paul Workman,
Bissan Al-Lazikani.
4165
Differential pathway activation associated with
domain-specific PIK3CA mutations. Christina Yau,
Stephen Benz, Charles Vaske, Sam Ng, Josh Stuart,
Christopher C. Benz.
4166
Integrated molecular profiling of melanoma cell
lines reveals genotype-drug phenotype associations
giving insight on development of combination therapies.
Brian J. Capaldo, Devin G. Roller, Mark Axelrod, Alex
Koeppel, Michael J. Weber, Aaron Mackey, Dan Gioeli,
Stefan Bekiranov.
4167
Harvesting knowledge from unexploited
genomic data: Estimating relative telomere length from
targeted-resequencing. Ogan D. Abaan, Joshua Waterfall,
Sean Davis, Daniel Edelman, Allison Gomez, Sharon Savage,
Yves Pommier, Paul Meltzer.
4168
Dissect the clinical utility of TCGA genomic
data across tumor types. Han Liang, TCGA Pan-Cancer
Clinical/Predictor Group.
4169
ERK2 functional chromatin footprints in patientderived breast tumor cells predict molecular subtype,
clinical outcome, and drug response in breast cancers.
Zeynep Madak-Erdogan, Dorraya El-Ashry, Benita S.
Katzenellenbogen.
4170
Oncogenic activation of LMO2 by EGFR
signaling regulates STAT3 phosphorylation and
transcriptional activity in human glioma. Jun Fu, Dimpy
Koul, Shaofang Wu, Siyuan Zheng, Roel G. Verhaak, W.K
Yung.
4171
Integrating pan-molecular data sets by
bimodality to nominate synthetic lethal gene pairs and
biomarkers of drug response. Jonathan R. Dry, Mark
Wappett, Ron Yang.
4172
Noncoding mutation analysis reveals previously
unrecognized pathways in lymph node-invasive breast
cancer. Stephanie N. Dorman, Coby Viner, Ben C. Shirley,
Peter K. Rogan.
4173
Discovery at the interface: novel anticancer
agents targeting human estrogen receptor/S100
interactions. David H. Lee, Bethany K. Asare, Matthew L.
Hudson, Rajendram V. Rajnarayanan.
4174
An integrative genomic analysis for clinically
relevant cancer genetic aberration and targeted
therapeutic prediction. HoJoon Lee, Hanlee P. Ji.
4175
TGFBR1 and other immune-related genes
modify susceptibility to HPV-associated head and neck
cancer. Chaya Levovitz, Dan Chen, Emma Ivansson, Ulf
Gyllensten, James McKay, Paul Brennan, Paolo Boffetta,
Andrew Sikora.
4176
Identifying analytes associated with poor
prognosis in CRC. Christi L. French, Alissa Weaver.
4177
Identification of pathways relevant for
metastatic site prediction in prostate cancer. Adrian
Bivol, Kiley Graim, Evan Paull, Dan Carlin, Robert Baertsch,
Artem Sokolov, Josh Stuart.
4178
Global assessment of the protein tyrosine
phosphatome in cancer. Nicholas Tonks, Robert Lucito.
4179
Next generation sequencing predicts drug
response biomarkers in oral cancer cell lines.
Muhammad Z. H. Fadlullah, Kim N. I. Chiang, Kalen R.
Dionne, Gregory M. Kelly, Pei S. Yee, Chai P. Gan, Mannil T.
Abraham, Zainal A. Abdul Rahman, Aik C. Tan, Sok C.
Cheong.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
4180
Clonal evolution of tumor cell population in a
patient with repetitively recurrent dermatofibrosarcoma
protuberance (DFSP). Ensel Oh, Yoon-La Choi, Sang Yun
Ha, Eun Hee Lee, Jeeyun Lee, Sung Joo Kim, Yu Jin Kim,
Ji-Young Song, Young Kee Shin, Hae Min Jung, Mi Jeong
Kwon.
4181
Accurate and fast detection and comparison of
larger clinically relevant insertions and deletions. AnneMette K. Hein, Patrick Dekker, Anika Joecker, Cecilie
Boysen, Naomi Thomson, Bodil Oester, Anne Arens, Bjarne
Knudsen, Thomas Knudsen, Roald Forsberg.
4182
Bioinformatic analysis identifies polo-like
kinase as a therapeutic target in small-cell lung cancer.
Gary Wildey, Yanwen Chen, Ian Lent, Lindsay Stetson, John
Pink, Jill Barnholtz-Sloan, Afshin Dowlati.
4183
CL-Map: Connecting cell lines with therapeutics
for drug repurposing. Bernard K. Lee, Pei S. Yee, Ivy K.
Chiang, Zainal Ariff Abdul Rahman, Aik C. Tan, Sok C.
Cheong.
4184
Drug set enrichment analysis : A computational
approach to identify functional drug sets. John Patrick
Mpindi, Dimitry Bychkov, Yadav Bhagwan, Disha Malani,
Hirasawa Akira, Khalid Saeed, Susanne Hultsch, Sara
Kangaspeska, Astrid Murumägi, Caroline A Heckman,
Kimmo Porkka, Tero Aittokallio, Krister Wennerberg, Päivi
Östling, Olli Kallioniemi.
4185
Analysis of sequencing data to identify
potential drug targets for an individual newly diagnosed
with basal breast cancer who failed to respond to
current standard neoadjuvant chemotherapy. Krishna R.
Kalari, Xiaojia Tang, Kevin J. Thompson, Douglas W.
Mahoney, Poulami Barman, Jason P. Sinnwell, Hugues
Sicotte, Peter Vedell, Steven N. Hart, Travis J. Dockter, Katie
N. Jones, Amy L. Conners, Ann M. Moyer, Daniel W.
Visscher, Jia Yu, Bowen Gao, Sarah A. McLaughlin, John A.
Copland, Alvaro Moreno-Aspitia, Donald W. Northfelt,
Richard J. Gray, Vera J. Suman, Jeanette E. Eckel Passow,
Jean-Pierre A. Kocher, Eric D. Wieben, Gianrico Farrugia,
Cloann G. Schultz, James N. Ingle, Richard Weinshilboum,
Matthew P. Goetz, Liewei Wang, Judy C. Boughey.
4186
An integrative genomic pipeline to target the
NCOR1 cistrome with precision. Mark D. Long, Patrick van
den Berg, Moray J. Campbell, Prashant K. Singh, Sebastiano
Battaglia.
4187
Splicing factors ESRP1/ESRP2 as regulators of
endocrine resistance in breast cancer. Yesim GokmenPolar, Yaseswini Nellamraju, Xiaoping Gu, Sarath C. Janga,
Sunil S. Badve.
4188
Evolutionary dynamics in breast cancer via MRI
textural kinetic analysis. Jennifer S. Drukteinis, Baishali
Chaudhury, Lawrence O. Hall, Dmitry B. Goldgof, Robert
Gillies, Robert A. Gatenby.
4189
Discovery of a novel carcinoma-associated EF
hand containing protein by mining the dark matter of
the human proteome. Ana Paula Delgado, Pamela Brandao,
Sheilin Hamid, Wim Van de Ven, Ramaswamy Narayanan.
4190
A survey of the most common methods of
group randomization and distribution in preclinical in
vivo studies. Neil O’Brien, Jeffrey L. Kumer, Eric M. Ibsen.
4191
Whole exome sequencing of a case of olfactory
neuroblastoma. SooJin Cha, Se-Hoon Lee, Jong-Il Kim,
Jong-Yeon Shin.
Poster
Section
15
15
517
POSTER SESSION
Poster
Section
16
16
Cell Signaling 2: Glioma, Melanoma, and Other Cancers
Poster Abstract
Board Number
1.
4192
Exploiting discoidin domain receptor (DDR) and
collagen signaling as a new approach to treat human
malignant gliomas. Shumei Chen, Chunjing Wu, Min You,
Minh Tran, Medhi Wangpaichitr, Ying Ying Li, Ronald J.
Benveniste, Macus T. Kuo, Niramol Savaraj, Lynn G. Feun.
2.
4193
Prostaglandin E2 activates an okadaic acidsensitive Ser/Thr phosphatase that leads to transient
inhibition of the ERK 1/2 pathway in glioblastoma
multiforme cells. Maria Teresa Rizzo, Wilmer Mata-Castro,
Yoo Seung Ko, Aaron Cohen-Gadol.
3.
4.
5.
4195
Peroxisome proliferator-activated receptor ␣ is
regulated by E2F1-induced miR-19a in a feedback loop
in glioma progression. Junxia Zhang, Yan Shi, Yingyi
Wang, Wenkang Luan, Yongping You.
4196
An RNA aptamer-based approach for human
glioma treatment. Simona Camorani, Carla L. Esposito,
Silvia Catuogno, Paola Amero, Anna Rienzo, Gennaro De
Vita, Gerolama Condorelli, Vittorio de Franciscis, Laura
Cerchia.
16.
4207
JAK inhibition reverses IL10-mediated
resistance to B cell receptor (BCR) pathway inhibition in
DLBCL. Xuesong (Mike) Liu, Margaret Favata, Jun Li, Niu
Shin, Kathy He Wang, Qian Wang, Yun-Long Li, Andrew
Combs, Chu-Biao Xue, Robert Newton, Kris Vaddi, Peggy
Scherle.
17.
4208
Suppressor of Cytokine Signaling (SOCS)-3 and
the C-X-C chemokines CXCL1 and CXCL2 promote tumor
aggessiveness and radiation resistance in pancreatic
cancer. Sisi Jiang, Evangeline Mose, Giovanni Coppola,
Andrew Lowy, Christina Jamieson, Nicholas A. Cacalano.
18.
4209
AMPK suppression in bladder tumorigenesis.
Stavros Kopsiaftis, Kathryn N. Phoenix, Katie L. Sullivan,
John A. Taylor, Kevin P. Claffey.
19.
4210
CPAP contributes to HBx-mediated NF-␬B
activation in hepatocellular carcinoma. Liang-Yi Hung.
20.
4211
Protein kinase C alpha (PKC␣) signaling in
endometrial cancer. Alice H. Hsu, Kathryn J. Curry, KangSup Shim, Peter Frederick, Carl D. Morrison, Baojing Chen,
Subodh M. Lele, Gustavo Leone, Adrian R. Black, Jennifer
D. Black.
21.
4212
ADAM10/Kuzbanian is upregulated during
neuroendocrine prostate carcinogenesis. Brian D.
Shannon, Laurie E. Littlepage.
22.
4213
Evaluation of LMTK3 expression and tumor
phenotype in estrogen-dependent colorectal cancer.
Sybil Magturo, Georgios Giamas, Snay Mallick, Austin
Layton, Justin Stebbing, Heinz-Josef Lenz, Melissa J.
LaBonte.
23.
4214
Antitumoral effects of orexins and their
receptors OX1R in pancreatic ductal adenocarcinomas
(PDAC). Thierry Voisin, Daniela Speisky, Anne Couvelard,
Alain Couvineau.
6.
4197
Regulators of p21 transcription in melanoma.
Sigurd L. Bøe, Josef Thingnes, Sima Z. Golmakani, Eivind
Hovig.
7.
4198
cAMP signaling in BRAFV600E melanoma. Carlos
I. Rodriguez.
8.
4199
Riluzole modulates the production of exosomes
in melanoma cells. Allison L. Isola, Yvonne Wen, James
Goydos, Suzie Chen.
9.
4200
Interaction between mPGES-1 and iNOS
promotes human melanoma progression. Sun-Hee Kim,
Yuuri Hashimoto, Suhendan Ekmekcioglu, Elizabeth A.
Grimm.
24.
4201
Activation of p90 ribosomal S6 kinase (RSK)
and downstream targets are directly regulated by S100B
protein in malignant melanoma. Adam D. Pierce.
4215
SPAG5 upregulation predicts poor prognosis of
cervical cancer patients and alters the sensitivity of
Taxol treatment via mTOR signaling pathway. Lin-Jing
Yuan, Lan Zhang, Yun Zhou, Min Zheng.
25.
4216
Combination of anti-cancer small molecule
tolfenamic acid and curcumin or curcumin analog EF31
effectively inhibits pancreatic cancer cell growth. Riyaz
Basha, Sarah F. Connelly, Ganji P. Nagaraju, Umesh T.
Sankpal, Mamoru Shoji, Omar Kayaleh, Bassel El-Rayes.
10.
11.
4202
Deciphering the effects of GNA13 mutations in
B-cell lymphomas. Morgan L. O’Hayre, Irina Kufareva, Jose
P. Vaqué, Miguel A. Piris, J. Silvio Gutkind.
12.
4203
A transducer module consisting of Toll-like
receptor 9 and Bruton’s tyrosine kinase triggers acute
myeloid leukemia blast proliferation. Thomas Oellerich,
Sebastian Mohr, Hanibal Bohnenberger, Anjali Dubey, Silvia
Münch, Johannes Wicht, Mark F. Oellerich, Christina Perske,
Gesine Bug, Philipp Ströbel, Henning Urlaub, Hubert Serve.
26.
4217
Nuclear expression of BCL10 has a role in the
regulation of cell growth and progression of pancreatic
cancer through the activation of NF-␬B-related
signaling. Sung-Hsin Kuo, Shih-Hung Yang, Kun-Huei Yeh,
Pei-Yen Yeh, Yu-Wen Tien, Hsiao-Wei Lee, Li-Tzong Chen,
Ann-Lii Cheng.
13.
4204
Isatin analog as bruton tyrosine kinase
inhibitor: A promising novel agent for multiple myeloma
treatment. Krishne Gowda, Manoj K. Pandey, Arun K.
Sharma, Shantu Amin.
27.
14.
4205
Mass-spectroscopy phosphorylation profiling
identified differential activation of signaling molecules
via spleen tyrosine kinase in B-cell receptor signaling
and stromal cell stimulation in DLBCL and CLL cells that
are inhibited by GS-9973 . Julie A. Di Paolo, Astrid Clarke,
Hong Rong, Emma Rousseau.
4218
Combined effect of COX2 genotype, ER status,
body constitution, and treatment on risk of early events
in breast cancer patients. Andrea Markkula, Maria
Simonsson, Christian Ingvar, Carsten Rose, Helena
Jernström.
28.
4219
miR-34a, miR-93 and miR-200c - novel
molecular regulators of osteosarcoma dormancy. Galia
Tiram, Shiran Ferber, Paula Ofek, Noam Shomron, Taturo
Udagawa, Sarit Aviel-Ronen, Iris Barshack, Ronit SatchiFainaro.
30.
4220
A cell-penetrating nucleolytic lupus
autoantibody damages DNA and is toxic to BRCA2deficient cancer cells. Philip W. Noble, Melissa R. Young,
Richard H. Weisbart, James E. Hansen.
15.
518
4194
Gliomaspheres mimic the hypoxia-Notch
signaling axis of glioblastoma tumors. Khushboo Irshad,
Saroj K. Mohapatra, Harshit Garg, Seema Mishra, Chitra
Sarkar, Deepak Gupta, Parthaprasad Chattopadhyay, Subrata
Sinha, Kunzang Chosdol.
Poster Abstract
Board Number
4206
Increased responsiveness to ligand stimulation
of the STAT pathway at relapse in acute myelogenous
leukemia. Alexandra M. Stevens, Marcos Ruiz, Michele S.
Redell.
POSTER SESSION
Cell Signaling Inhibitors as Anticancer Agents
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
4221
HSP90 as a therapeutic target in colorectal
cancer. Ganji P. Nagaraju, Field F. Willingham, Kevin E.
Woods, Patrick Sullivan, Jerome C. Landry, Roberto Diaz,
Bassel F. El-Rayes.
4222
Targeting PI3K and mTOR with BEZ235, a dual
inhibitor, is efficacious in trastuzumab refractory and
HER2ⴙ/PIK3CA-mutated breast cancer models. Casey
Williams, Yuliang Sun, Jennifer Carlson, Brian LeylandJones, Nandini Dey, Pradip De.
4223
Combined PI3K-AKT and MEK-ERK pathway
inhibition provides broad antitumor efficacy in HER2ⴙ
breast tumor models. Pradip De, Yuliang Sun, Jennifer
Carlson, Lori Friedman, Nandini Dey, Brian Leyland-Jones.
4224
Histone deacetylase inhibitors induce ribosomal
protein acetylation and modulate breast cancer cell
viability. Kathleen A. Wilson-Edell, Amanuel Kehasse,
Christina Yau, Gary K. Scott, Jason M. Held, Bianca S.
Gabriel, Bradford W. Gibson, Christopher C. Benz.
4225
Estrogen regulated oncogene SHON mediates
the efficacy of anti-estrogen treatment in breast cancer.
Bing Xu, Yewon Jung, Jo Perry, Tao Zhu, Peter E. Lobie,
Baiqu Huang, Jun Lu, Dong-Xu Liu.
4226 〉-thujaplicin suppressed estrogen dependent
breast cancer via regulating estrogen receptor
signaling. Jiwon Ko, Cheng Bao, Jaehoo Lee, Hyun-Chang
Park, Hong Jin Lee.
4227
The ribonucleotide reductase inhibitor Didox
reverses tamoxifen resistance in breast cancer cells.
Khyati N. Shah, Howard L. Elford, Jesika S. Faridi.
4228
6,7,4-Trihydroxyisoflavone, a daidzein
metabolites, regulated glycogen synthase kinase 3␤/␤catenin signaling and inhibited cell proliferation in
MCF10DCIS.com human breast cancer cells. Hyun-Chang
Park, Cheng Bao, Jiwon Ko, Jaehoo Lee, Hong Jin Lee.
4229
The anti-estrogen effect of metformin in ER␣ⴙ
breast cancer and tamoxifen resistant cell lines.
Jinkyoung Kim, Jiyun Lee, Soonyoung Jang, Chungyeul Kim,
Aeree Kim.
4230
5␣-dihydrotestosterone down-regulates HER2
and sensitizes breast cancer cells to Herceptin-induced
apoptosis in vitro. Aisha Sultana, Zulfiqar A. Naqvi, Shaista
Khan, Anwar A. Siddiqui, El-Nasir Lalani.
4231
Enhanced antitumor efficacy of T-DM1 in
combination with pertuzumab in HER2-positive breast
cancer models. Yuliang Sun, Nandini Dey, Jennifer Carlson,
Melissa Brammer, Pradip De, Brian Leyland-Jones.
4232
Small molecule phenotypic targeting of
aggressive B-cell lymphomas. Mariano G. Cardenas, Matt
R. Teater, Nieves Calvo-Vidal, Shao Ning Yang, J F.
Glickman, Ari Melnick, Leandro Cerchietti.
4233
Mef2C enhances 1,25-dihydroxyvitamin D3induced monocytic differentiation of human myeloid
leukemia cells by regulating C/EBP␤ expression. Ruifang
Zheng, Xuening Wang, George P. Studzinski.
4234
Identification of molecular targets for retinoid
signaling to regulate human hepatocellular carcinoma
development: contribution of OTUD7B, a negative
regulator of NF-␬B signaling, in antitumor effect of
retinoic acid. Goshi Shiota, Keita Kanki.
4235
Anti-proliferative effect of (19Z)halichondramide from the sponge Chondrosia corticata
via G2/M cell cycle arrest and suppression of mTOR
signaling in human lung cancer cells. Song Yi Bae,
Jayoung Song, Yoonho Shin, Won Kyung Kim, Jedo Oh, Tae
Joon Choi, Eun Ju Jeong, So Hyun Park, Eun Jeong Jang, Ji
In Kang, Hyen Joo Park, Ji-Young Hong, Gi Dae Kim, Ju-eun
Jeon, Jongheon Shin, Sang Kook Lee.
4236
Antitumor activity of a novel (-)-antofine analog
in human lung cancer cells and paclitaxel-resistant lung
cancer cells. Jayoung Song, Song Yi Bae, Yoonho Shin,
Won Kyung Kim, Jedo Oh, Tae Joon Choi, Eun Ju Jeong, So
Hyun Park, Eun Jeong Jang, Ji In Kang, Hyen Joo Park,
Ji-Young Hong, Hwa-Jin Chung, Yongseok Kwon, Sanghee
Kim, Sang Kook Lee.
Poster Abstract
Board Number
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4237
Antitumor activity of 2-hydroxycinnamaldehyde
against human colorectal cancer cells is mediated by
the Wnt/␤-catenin signaling pathway. Won Kyung Kim,
Jedo Oh, Song Yi Bae, Jayoung Song, Yoonho Shin, Tae
Joon Choi, Eun Ju Jeong, So Hyun Park, Eun Jeong Jang, Ji
In Kang, Hyen Joo Park, Ji-Young Hong, Min Ai Lee, HwaJin Chung, Sang Kook Lee.
4238
Exploring the therapeutic potential of IR and
IGF-1R/IR (co-)targeting in ovarian cancer. Jolanda A.
Visser, Roelien A. Meijering, Anne K. Reyners, Ate G. van
der Zee, Steven de Jong.
4239
Differentiation and apoptosis induced by alltrans retinoic acid is associated with downregulation of
peroxiredoxin 1 in myeloid leukemia cells. Eric J. Norris,
Yogin C. Patel, Michaela B. Reinhart, Ram N. Ganapathi,
Mahrukh K. Ganapathi.
4240
Targeting Galectin-3 to reverse tumor stemness
and drug resistance. Shumei Kato, Laetitia Seguin,
Aleksandra Franovic, Hisashi Kato, Maria Camargo, Jay
Desgrosellier, Sudarshan Anand, Sara Weis, Sanford Shattil,
David A. Cheresh.
4241
Preclinical studies of brain/brain tumor
disposition and antitumor efficacy of the aromatase
inhibitor letrozole. Nimita Dave, Pankaj B. Desai, Gary A.
Gudelsky, Kathleen LaSance, Lionel M. Chow, Xiaoyang Qi.
4242
Effects of dual inhibition of EGFR and Aurora A
kinase in a lung cancer model. Tetyana Bagnyukova,
Xiaofan Pan, Jiping Zhang, Brian Egleston, Igor Astsaturov,
Erica Golemis, Hossein Borghaei.
4243
EGFR inhibition causes growth delay and
induces apoptosis in HPV-positive head and neck
cancer. Alexandra D. Torres Law, Grace C. Blitzer, Molly A.
Smith, Eric A. Armstrong, Randall J. Kimple.
4244
Inhibition of HER2 and IGF2 triggers cell death
in trastuzumab-resistant HER2 positive JIMT1 cells.
Xousaen M. Helu, Daisy De Leon.
4245
A comparative analysis of PI3K inhibitors in
human tumor primary culture microspheroids. Robert A.
Nagourney, Paula J. Bernard, Federico Francisco, Steven S.
Evans.
4246
Probing the inhibitor selectivity site of class II
PI3KC2␤. Krithika Sundaram, Ian Jennings, Alexandre
Arcaro, Philip Thompson.
4247
Characterization of the selective pan-RAF
inhibitor TAK-632 with antitumor activity in BRAF
inhibitor-resistant melanoma. Akito Nakamura, Takeo
Arita, Shuntarou Tsuchiya, Jill Donelan, Jouhara Chouitar,
Elizabeth Carideo, Katherine Galvin, Masanori Okaniwa,
Tomoyasu Ishikawa, Sei Yoshida.
4248
Predictive signature of response to EGFR
tyrosine kinase inhibitors in non-small-cell lung cancer
cells by tyrosine kinase activity profiling. Naoki Izawa,
Masakuni Serizawa, Faris Naji, Rik D. Wijn, Riet Hilhorst,
Rob Ruijtenbeek, Hirofumi Yasui, Takako Nakajima, Narikazu
Boku, Yasuhiro Koh.
4249
The Pi3K␤/␦ inhibitor AZD8186 has potential to
treat tumours in combination with key signalling
pathway inhibitors. Simon T. Barry, Kathryn Cronin, Marie
Cumberbatch, Rebecca Ellston, Emily Foster, Urs Hancox,
Lyndsey Hanson, Liz Harrington, Carol Lenaghan, Stefan
Symeonides, Cath Trigwell, Lara Ward.
4250
Nitric oxide synthase activity and its
modulation in the treatment of colorectal cancer. Asim
Alam, Chris Rabender, Li Wang, Sundaresan Gobalakrishnan,
Jamal Zweit.
17
17
519
POSTER SESSION
Poster
Section
18
18
520
Gene Expression and Transcriptional Control 5
Poster Abstract
Board Number
1.
4251
Identification of expression quantitative trait
loci at lung cancer and COPD risk genes in normal
bronchial epithelial cells. Erin L. Crawford, Jiyoun Yeo,
Xiaolu Zhang, Karan Padda, Taylor Arend, Thomas M.
Blomquist, Albert M. Levin, Mei Lu, James C. Willey.
2.
4252
Regulation of the oncogene ZNF217 by
localization in breast cancer. Matthew J. Messana, Chao
Yang, Laurie E. Littlepage.
4.
4254
ESE1 binds to beta catenin and modulates its
expression. Xu-yu Yang, Kui Jin Kim, Hong Jun Shao,
Seong-Ho Lee.
5.
4255
Rational targeting of the Androgen receptor
interactome in prostate cancer. Preethi Ravindranathan,
Wayne Tilley, Ganesh V. Raj.
Poster Abstract
Board Number
6.
4256
Characterization of the cellular inhibitor of
apoptosis 1 (cIAP1) IRES trans-acting factors and their
contribution to apoptotic resistance in
rhabdomyosarcomas. Mame Daro Faye, Tyson E. Graber,
Shawn Beug, Xiao Xiang, Benjamin Wild, Stephanie
Langlois, Kyle N. Cowan, Robert G. Korneluk, Martin Holcik.
7.
4257
The survival prediction after curative resection
with adjuvant chemotherapy and neo-adjuvant
chemotherapy in locally advance stage by gastric
mucosal IL-8 mRNA expression for Thai gastric cancer.
Sirikan Yamada.
POSTER SESSION
Genomic and Molecular Characterization of Cancer 2
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
4258 Benchmarking algorithms for mutation impact
prediction using functionally validated missense mutations.
Luciano G. Martelotto, Yan Zhang, Charlotte K. Ng, Salvatore
Piscuoglio, Jorge S. Reis-Filho, Britta Weigelt.
4259 The radiogenomic landscape of cancer. Mohamed
Abazeed, Drew Adams, Pablo Tamayo, Matthew Meyerson, Peter
Hammerman, Stuart Schreiber.
4260 Standardized decision support in next-generation
sequencing (NGS) reports of somatic cancer variants. Rodrigo
Dienstmann, Fei Dong, Darrell Borger, Dora Dias Santagata, Leif W.
Ellisen, Long P. Le, A. John Iafrate.
4261 Prospective next generation sequencing (NGS) of rare
or poor prognosis cancers. Kim M. Hirshfield, Siraj M. Ali, Vincent
A. Miller, Philip J. Stephens, Vassiliki Karantza, Robert S. DiPaola,
Lorna Rodriguez-Rodriguez, Shridar Ganesan.
4262 A pan-cancer proteomic analysis of The Cancer
Genome Atlas (TCGA) project. Rehan Akbani, Kwok-Shing Ng,
Henrica M. Werner, Fan Zhang, Zhenlin Ju, Wenbin Liu, Ji-Yeon
Yang, Yiling Lu, John N. Weinstein, Gordon B. Mills.
4263 Identifying somatic mutation hotspots across protein
family alignments. Marcin Imielinski, Charles Du, Matthew
Meyerson.
4264 Whole exome and targeted sequencing identified the
MAPK and PI3K pathways as the main targets in intracranial
and testicular germ cell tumors. Koichi Ichimura, Shintaro
Fukushima, Yasushi Totoki, Yuko Matsushita, Ayaka Otsuka, Arata
Tomiyama, Tohru Niwa, Ryuichi Sakai, Toshikazu Ushijima, Taishi
Nakamura, Tomonari Suzuki, Kouhei Fukuoka, Takaaki Yanagisawa,
Kazuhiko Mishima, Yoichi Nakazato, Fumie Hosoda, Yoshitaka Narita,
Soichiro Shibui, Akihiko Yoshida, Hirokazu Takami, Akitake Mukasa,
Koki Aihara, Nobuhito Saito, Toshihiro Kumabe, Masayuki Kanamori,
Teiji Tominaga, Keiichi Kobayashi, Saki Shimizu, Motoo Nagane,
Toshihiko Iuchi, Masahiro Mizoguchi, Koji Yoshimoto, Kaoru Tamura,
Taketoshi Maehara, Kazuhiko Sugiyama, Mitsutoshi Nakada, Keiichi
Sakai, Yonehiro Kanemura, Masahiro Nonaka, Kiyotaka Yokogami,
Hideo Takeshima, Nobutaka Kawahara, Tatsuya Takayama, Masahiro
Yao, Hiromi Nakamura, Natsuko Hama, Masao Matsutani, Tatsuhiro
Shibata, Ryo Nishikawa.
4265 The landscape of somatic hypermutation in human
cancer. Jocelyn S. Chapman, Matthew T. Chang, Saurabh Asthana,
Kriti Lall, Nikolaus Schultz, Barry S. Taylor.
4266 Moving beyond in vitro models and addressing the
challenges of pooled RNAi screens in mouse xenografts. Donato
Tedesco, Kyle Bonneau, Mikhail Makhanov, Debbie Deng, Paul Diehl,
Peiqing Sun, Alex Chenchik.
4267 Quantification of somatic hotspot mutations in KRAS,
HRAS, BRAF, and PIK3CA: Comparing normal human breast and
ductal carcinoma. Malathi Banda, Meagan B. Myers, Karen L.
McKim, Yiying Wang, Barbara L. Parsons.
4268 An unbiased survey of cancer-related rearrangements
in 5,917 solid tumors identifies therapeutically actionable
fusions across multiple disease subtypes. Juliann Chmielecki,
Garrett Frampton, Doron Lipson, Jie He, Geoff Otto, Siraj Ali, Jeffrey
S. Ross, Vincent A. Miller, Roman Yelensky, Philip J. Stephens.
4269 Exome sequencing of tumor cell lines: Optimizing for
cancer variants. Alex H. Ramos, Ruibang Luo, Jacob Feala,
Binghang Liu, Lara Gong, Markus Warmuth, Ping Zhu, Peter Smith,
Lihua Yu.
4270 The use of mutational signatures in identifying
carcinogen exposure. Song Ling Poon, See-Tong Pang, John R.
McPherson, Steven G. Rozen, Patrick Tan, Bin Tean Teh.
4271 The cBioPortal for Cancer Genomics as a clinical
decision support tool. JianJiong Gao, B. Arman Aksoy, Benjamin
Gross, Gideon Dresdner, Yichao Sun, S. Onur Sumer, Chris Sander,
Nikolaus Schultz.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
4272 Applying TCGA data for breast cancer diagnostics and
pathway analysis. Jannik Andersen, Parantu Shah, Konstanty
Korski, Matthew Ibbs, Violetta Filas, Michal Kosiedowski, Juliusz
Pukacki, Cezary Mazurek, Yuanqing Wu, Edward Chang, Carlo
Toniatti, Giulio Draetta, Maciej Wiznerowicz.
4273 An enhanced microRNA backbone for potent singlecopy RNAi. Christof Fellmann, Thomas Hoffmann, Vaishali Sridhar,
Barbara Hopfgartner, Dan Yu Lai, Johannes Zuber.
4274 High fidelity copy number analysis of formalin-fixed
and paraffin-embedded tissues using Affymetrix CytoScan HD
chip. Jian-Hua Luo, Amantha Michalopoulos, Ying Ding, Yan P. Yu.
4275 Identifying cancer driver mutations in clinical
sequencing data. Tenghui Chen, Hao Zhao, Yong Mao, Yuan Qi,
Agda Karina Eterovic, Kenna R. Mills Shaw, Stacy L. Moulder,
Michael A. Davies, John F. Degroot, Scott E. Kopetz, Funda MericBernstam, Gordon B. Mills, Ken Chen.
4276 T200: a high depth targeted exome sequencing
platform to identify actionable alterations in FFPE solid tumor
samples. Karina Eterovic, Ken Chen, Hao Zhao, Funda MericBernstam, Raja Luthra, Aldape Kenneth, Mark Routbort, Scott Kopetz,
Michael Davies, John de Groot, Stacy Moulder, Yong Mao, Chacha
Horombe, Lin-ya Tang, Song Ping, Zhang Qingxiu, Ezzeddine Nader,
Lan Zhang, Kenna M. Shaw, John Mendelsohn, Gordon B. Mills.
4277 Alternative splicing in cancer transcriptomes. Shihao
Shen, Ying Nian Wu, Yi Xing.
4278 International Cancer Genome Consortium (ICGC).
Thomas J. Hudson, Jennifer L. Jennings.
4279 Rapid biomarker discovery using large-scale, patientderived cancer genomic cohorts. Sandeep Sanga, Praveen Nair,
Cyrus Mirsaidi, Thomas Broudy.
4280 Integrative analyses of multi-omics sequencing data to
guide treatment decisions in a patient with double malignancy.
Wei Zhu, Jiaqi Huang, Brandon W. Higgs, Philip Brohawn, Shujun
Dai, Laura Richman, Bahija Jallal, Liyan Jiang, Yihong Yao.
4281 Targeted or whole genome sequencing of formalinfixed tissue samples. Sarah Munchel, Yen Hoang, Yue Zhao,
Joseph Cottrell, Brandy Klotzle, Andrew Godwin, Janelle Noel, Brooke
Fridley, Peter Beyerlein, Jian-Bing Fan, Marina Bibikova, Jeremy R.
Chien.
4282 High content multiparametric functional screen for
regulators of epithelial-mesenchymal transition identifies genes
associated with chemoresistance. Elizabeth D. Williams, Nur
Akmarina Said, Cathryn M. Gould, Erik W. Thompson, Kaylene J.
Simpson.
4283 Whole genome sequencing is superior to cancer
panels to aid in decision-making in patients with advanced
malignancies. Janessa J. Laskin, Yaoqing Shen, Howard Lim, Karen
A. Gelmon, Daniel Renouf, Stephen Yip, David Huntsman, Anna
Tinker, Cheryl Ho, Stephen Chia, Yvonne Li, Katayoon Kasaian, Peter
Eirew, Sreeja Leelakumari, Richard Moore, Samuel Aparicio, Yusanne
Ma, Steven Jones, Marco Marra.
4284 Evaluation of cancer-related mutations in tumorgraft
models. Mariana Brait, Luciane T. Kagohara, Evgeny Izumchenko,
Samuel Long, Tin Khor, Elizabeth Bruckheimer, David Sidransky.
4285 Structural variant breakpoint detection in advanced
colorectal cancer. E van den Broek, O Krijgsman, D Sie, JC Haan,
M Komor, J Traets, DAM Heideman, MA van de Wiel, ID Nagtegaal,
CJA Punt, B Carvalho, B Ylstra, GA Meijer, RJA Fijneman.
4286 Improved FFPE DNA extraction for next generation
sequencing using adaptive focused acoustics technology. Ling
Lin, Mikenah Vega, Robert T. Jones, Liuda Ziaugra, Deniz N. Dolcen,
Ashwini Sunkavalli, Laura Schubert, Jack R. Lepine, Aaron R.
Thorner, Matthew D. Ducar, William C. Hahn, Matthew L. Meyerson,
Laura E. MacConaill, Paul Van Hummelen.
Poster
Section
19
19
521
POSTER SESSION
Poster
Section
20
20
Imaging
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
522
4287
Novel method of liver tumor detection and
characterization using ultrasound-induced biomarker
release. Aloma L. D’Souza, Xinrui Yan, Sanjiv S. Gambhir.
4288
Molecular imaging of tumor-associated
cathepsins: implication for rapid detection of human
nonmelanoma skin cancer. Ethan Walker, Margaret Mann,
Galia Blum, Matthew Bogyo, James P. Basilion.
4289
Noninvasive monitoring of blood-brain barrier
permeability for antibodies by apoptosis imaging:
optimization of treatment strategies for maximal brain
delivery. Thomas G. Weber, Julia Mathejczyk, Stefanie
Galbán, Alnawaz Rehemtulla, Werner Scheuer.
4290
In vitro & in vivo analysis of indocyanine greenlabeled panitumumab for optical imaging: a cautionary
tale. Yang Zhou, Young-Seung Kim, Diane E. Milenic,
Kwamena E. Baidoo, Martin W. Brechbiel.
4291
A novel image-based cytometry method for
autophagy detection in living cells. Leo L. Chan, Dee
Shen, Alisha R. Wilkinson, Wayne Patton, Ning Lai, Eric
Chan, Dmitry Kuksin, Bo Lin, Jean Qiu.
4292
Fast and automated assessment of tumor
response: Infrared imaging. Hadrien D’inca, Florentina
Pascale, Saida Homayra Ghegediban, Michel Wassef, Cyril
Gobinet, Julien Namur, Alexandre Laurent, Michel Manfait.
4293
Whole-body bio-distribution of anti-5T4mcMMAF (anti-5T4-ADC) using fluorescence molecular
tomography (FMT) imaging in a non-small cell lung
cancer mice model. Anand Giddabasappa, Rand Norberg,
Mauricio Leal, David Paterson, Kush Lalwani, Ted Levkoff,
Stella Rapa, Puja Sapra, Michael Ritche, Joann Wentland,
Brian Rago, Jeetendra Eswaraka.
4294
Addressing the limitations of thyroid biopsies:
Using elastic scattering spectroscopy to improve the
assessment of indeterminate nodules. Jennifer E. Rosen,
Nicholas J. Giordano, Eladio Rodriguez-Diaz, Ousama M.
A’Amar, Irving J. Bigio, Stephanie L. Lee.
4295
A 3D culture model for screening of cancer
therapeutics. Kalpana Patel, Belinda O’Clair, Tim
O’Callaghan, Daniel M. Appledorn, Derek Trezise.
4296
Correlation of the apparent diffusion coefficient
of water assessed by diffusion-weighted imaging with
treatment outcome in refractory lymphoma patients.
Fernando Arias-Mendoza, Hamed Mojahed, Ahmed Sawas,
Owen A. O’Connor.
4297
Quantifying three-dimensional cellular
morphology and its heterogeneity in epithelial cancers
by single-cell optical tomography. Vivek Nandakumar,
Stephanie Helland, Jessica H. Han, Geriann Davis, Brian A.
Ashcroft, Thai H. Tran, Ting Li, Karen S. Anderson, Rahul
Pannala, Joseph R. Mikhael, David E. Fleischer, Roger H.
Johnson, Kimberly J. Bussey, Deirdre R. Meldrum.
4298
Comparison of dual labeling strategies for NIRF/
PET hybrid imaging. Sukhen C. Ghosh, Barrett R. Harvey,
Holly Robinson, Kenneth L. Pinkston, Nathaniel Wilganowski,
Banghe Zhu, Eva M. Sevick-Muraca, Ali Azhdarinia.
4299
Comparison of high-resolution 3D X-ray
microCT and tomosynthesis imaging: A breast phantom
study. Jolene M. Singh, Anthony H. Bui, James S.
Michaelson.
4300
Receptor occupancy and tumor penetration by
antibodies, peptides, and antibody fragments: Molecular
simulation of imaging assessment. Kelly D. Orcutt,
Gregory P. Adams, Anna M. Wu, Matthew Silva, Jack
Hoppin, Catey Harwell, Manabu Matsumura, Masakatsu
Kotsuma, Daniel Freeman, Archie Tse, Jonathan Greenberg,
Andrew Scott, Robert A. Beckman.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
4301
Detection and characterization of regions of
hypoxia within orthotopic pancreatic tumors using
multispectral optoacoustic tomography. Shanice V.
Hudson, Charles Kimbrough, Michael Egger, Anil Khanal,
Michelle E. Smith, William E. Grizzle, Lacey R. McNally.
4302
The development study of hypoxia responsive
chemiluminescent probe for tumor hypoxia imaging.
Kensuke Okuda, Toru Ban, Tasuku Hirayama, Hideko
Nagasawa.
4303
Bioimaging of multiple elements by Laser
Ablation Inductively Coupled Plasma Mass Spectrometry
(LA-ICP-MS) in penile carcinomas. Juan J. Muñoz, Sandra
A. Drigo, Fabio Marchi, Gustavo Pessoa, Cristovam S. Neto,
Gustavo Guimaraes, Marco A. Arruda, Silvia R. Rogatto.
4304
Evaluation of different near-infrared fluorescent
dyes. Maria P. Lambros, Antonio Sanchez, Surbhi Desai,
Labanya Kondapalli.
4305
Biodistribution and clearance of non-targeted
DyLight dyes in tumor-free nude mice for in vivo
imaging. Marie C. NLEND, Surbhi Desai, Suk J. Hong, Mary
Beth Anderson, Georgyi V. Los, Greg T. Hermanson, Justin
M. Diener, Warren M. Leevy, Peter A. Bell.
4306
Bioconjugation of near infrared dyes by
PEGylation improves pharmacokinetics and allows for
better labeling and imaging of human gastrointestinal
cancers. Ali A. Maawy, Yukihiko Hiroshima, George A.
Luiken, Yong Zhang, Robert M. Hoffman, Michael Bouvet.
4307
MRI characterization of OKN-007 efficacy in a
preclinical pediatric glioma model. Patricia COUTINHO DE
SOUZA, Nataliya Smith, Charity Njoku, Debra Saunders,
Krithika Balasubramanian, Rene Y. McNall, Xiao-Nan Li,
Rheal A. Towner.
4308
3D nuclear telomeric signatures define
circulating tumor cells (CTCs) and characterize CTC
subpopulations in intermediate risk prostate cancer
patients. Awe A. Julius, Adam Yan, Nidhi Shah, Klewes
Ludger, Alexandra Kuzyk, Michael Xu, Ramy Boles, Jeff
Saranchuk, Darrel Drachenberg, Sabine Mai.
4309
Whole slide image analysis quantification in a
mouse lung metastasis model. George E. Sandusky,
Ronne Surface, Eva Tonsing-Carter, jayne Silver, Tony Sinn,
Karen Pollok.
4310
Assessing PK parameters using dynamic
contrast enhanced multispectral optoacoustic
tomography (DCE-MSOT). Stefan Morscher, Wouter H.
Driessen, Neal C. Burton, Thomas Sardella, Daniel
Razansky, Vasilis Ntziachristos.
4311
Fluorescence-guided surgery of pancreatic
cancer using activatable cell penetrating peptides
(ACPPs) in orthotopic mouse models. Cristina A. Metildi,
Sharmeela Kaushal, Csilla N. Felsen, Quyen T. Nguyen,
Robert M. Hoffman, Roger Y. Tsien, Michael Bouvet.
4312
Seamless fluorescence guided surgery for
pancreatic cancer is facilitated by a hand held
electrocautery pencil with excitation light source. Ali A.
Maawy, Yukihiko Hiroshima, George A. Luiken, Yong Zhang,
Richard P. Fleenor, Robert M. Hoffman, Michael Bouvet.
4313
Efficacy of fluorescence-guided surgery on
primary human osteosarcoma. Shinji Miwa, Yukihiko
Hiroshima, Shuya Yano, Yasunori Matsumoto, Fuminari
Uehara, Mako Yamamoto, Hiroaki Kimura, Katsuhiro
Hayashi, Hiroyuki Tsuchiya, Robert M. Hoffman.
POSTER SESSION
Metabolic Pathways and Mitochondria
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
4314
Metabolic manipulation of hypoxia and
radiotherapy response by electron transport inhibitors.
Maria Jose Gandolfo, Alastair H. Kyle, Andrew I. Minchinton.
4315
System Xc- in glioma alters redox regulation,
energetics and morphology. Monika D. Polewski, Rosyli F.
Reveron, Karen S. Aboody.
4316
BNIP3 suppresses mammary tumorigenesis and
metastasis through negative regulation of Warburg
effect and HIF-1␣. Aparajita H. Chourasia, Kristin Tracy,
Michelle Boland, Marina Sharifi, Kay F. Macleod.
4317
Inhibiting the mitochondrial DNA polymerase
gamma (POLG) with 2=,3=-dideoxycytidine reduces
oxidative phosphorylation and increases apoptosis in
acute myeloid leukemia (AML) cells. Sanduni Liyanage,
Rose Hurren, Rebecca Laposa, Aaron Schimmer.
4318
Mycoplasma arginini infection shifts the energy
catabolism ratio of metastatic macrophages towards
fermentation and is associated with an increase in
primary tumor size, metastasis and malignancy. Roberto
Flores, Ashley K. Brown, Zeynep Akgoc, Thomas N.
Seyfried.
4319
Inability of putative ovarian cancer stem cells
to engage OXPHOS confer 2-deoxyglucose-mediated
prevention of in vivo recurrence. Ayesha B. Alvero,
Michele Montagna, Natalia J. Sumi, Won Duk Joo, Vinicius
Craveiro, Emma Graham, Gil Mor.
4320
Mitochondrial DNA copy number in peripheral
blood and the risk of clear-cell renal cell carcinoma:
Effect of age, gender, smoking, and history of
hypertension. Xin Wang, Stephanie Melkonian, Jian Gu,
David Chang, Nizar Tannir, Christopher Wood, Xifeng Wu.
4321
Effect of pretreatment, dose and route of
administration of BPM31510 (Coenyzme Q10 containing
proprietary formulation) alone or in combination with
gemcitabine improves survival in pancreatic cancer.
Niven Narain, Lucia Mauro, Assuan Lens, Viatcheslav
Akmaev, Rangaprasad Sarangarajan, Joaquin Jimenez.
4322
The landscape of mitochondrial DNA mutations
in human cancer. Young Seok Ju, Ludmil Alexandrov,
Moritz Gerstung, Inigo Martincorena, ICGC Breast Cancer
Group; ICGC Chronic Myeloid Disorders Group; ICGC Prostate
Cancer Group, Mike Stratton, Peter J. Campbell.
4323
Mitochondrial 22 tRNAs alterations in Iranian
breast cancer patients. Sara Eslamizadeh, Massoud
Ghaffarpour, Mohammad Arabzadeh, Massoud Houshmand.
4324
BNip3 connects energy sensing to hepatic lipid
metabolism and mitophagy. Michelle L. Boland, He Huang,
Ramilla Shah, Almas Ali, Yingming Zhao, Christopher J.
Rhodes, Kay F. Macleod.
4325
Overexpression of UCP2 is associated with
tumor progression in Iranian breast cancer patients.
Neda Maraghechi, Massoud Ghaffarpour, Golna Asaadi
Tehrani.
4326
Mitochondrial genetics and cellular metabolism
regulate tumorigenicity and metastatic potential. Kyle P.
Feeley, Alexander W. Bray, Jessica L. Fetterman, David G.
Westbrook, Larry W. Johnson, Robert A. Kesterson, Danny
R. Welch, Scott W. Ballinger.
4327
Mitochondrial reprogramming in triple negative
breast cancer progression. Junhyoung Park, Kavisha
Arora, Sajna A. Vithayathil, Taraka R. Donti, Chad Creighton,
Michael T. Lewis, Arun Sreekumar, Lee-Jun Wong, Benny A.
Kaipparettu.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4328
Marrow stromal cells promote mitochondrial
energy metabolism in primary CLL cells without
impacting cellular proliferation. Hima Venkata
Vangapandu, Kumudha Balakrishnan, William G. Wierda,
Michael J. Keating, Christine M. Stellrecht, Varsha Gandhi.
4329
Lipid droplets and associated proteins in
hepatocellular carcinoma tumour cells. Evette Yassa,
Hussam Alamri, Tommy Alain, Anthoula Lazaris, Peter Ghali,
Nahum Sonenberg, Peter Metrakos.
4330
Everolimus-induced hyperglycemia: Dual
efficacy of metformin. Gerke Ariaans, Steven de Jong,
Elisabeth G. de Vries, Mathilde Jalving.
4331
Lowering glucose increases nutlin-3 toxicity
against melanomas irrespective of BRAF,NRAS or p53
mutations. Manuel Rieber, Valery Chavez-Perez, Mary
Strasberg-Rieber.
4332
Diagnostic applications of fatty acid synthase
monoclonal antibodies. Walter P. Carney, Wendy Zhang,
David Jarosz, Patrick Muraca, Sunny TAM.
4333
Metabolite profiling reveals druggable metabolic
distinctions between basal-like and non-basal-like
triple-negative breast cancers. Alexander Beatty, Lauren
Fink, Ulrike Rennefahrt, Alexander Strigun, Erik Peter, Hajo
Schiewe, Regina Reszka, Jeffrey R. Peterson.
4334
Greater resistance of mutant p53 tumor cells to
hypoxia or chloroquine with glucose or pyruvate
supplementation is diminished under glucose starvation.
Manuel Rieber.
4335
A p53/HIF-1alpha-mediated metabolic response
to stress. Suthakar Ganapathy, Zhi-Min Yuan.
4336
Design of a chamber for studying glucose
metabolism by anoxic cancer cells. Jan Lankelma,
Mohamed Ahmed, Adrià López Nadal, Josephine C.
Dorsman, Hans Joenje, Hans V. Westerhoff.
4337
In vitro biotransformation of and inhibitory
effects of CZ48 in human liver microsomes. Xing Liu,
Albert DeJesus, Dana Vardeman, Zhisong Cao, Beppino
Giovanella.
4338
The lipogenic phenotype of HER2/neu-positive
breast cancer cells. Jan M. Baumann, Douglas S. Conklin.
4339
Acute lymphoblastic leukemia cells stimulate
adipocyte lipolysis and utilize adipocyte-derived freefatty acids for proliferation. Jonathan Tucci, Xia Sheng,
Steven D. Mittelman.
4340
The amino acid transporter SLC6A14 is an
effective drug target for treatment of pancreatic cancer.
Yangzom D. Bhutia, Veena Coothankandaswamy, Sha Cao,
Ying Xu, Vadivel Ganapathy.
4341
Metabolomic analysis of HER2-positive breast
cancer cells. Malika K. Sahni, Resmi K. Ravindran, Imran
H. Khan, Jason A. Bush, V. V. Krishnan.
4342
Crosstalk between initiating cells with different
metabolism in a murine model of malignant glioma.
Oltea Sampetrean, Isako Saga, Shunsuke Shibao, Jun
Okubo, Satoru Osuka, Nobuyuki Onishi, Hideyuki Saya.
4343
Inhibition of fatty acid synthase reduces
mitochondrial respiration and addiction of colorectal
cancer cells to glycolysis. Yekaterina Zaytseva, Mihail
Mitov, D. Allan Butterfield, Tianyan Gao, B. M. Evers.
21
21
523
POSTER SESSION
Poster
Section
22
22
MicroRNA Targets 1
Poster Abstract
Board Number
1.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
524
4344
Tumor suppressive miR-137 targets Aurora-A
and leads to apoptosis in colorectal cancer cells. YuChuan Huang, Liang-Yi Hung.
4345
Dysregulated miR-205 signaling promotes
symmetric division of self-renewing mammary stem
cells and mammary tumorigenesis. Meng-Ju Wu, ChiHong Chao, Chao-Ching Chang, Chun-Ju Chang.
4346
Novel discovery of miR-30e* regulating Bmi1
expression induced by tumor-associated macrophages
in gastrointestinal cancer. Hidetaka Sugihara, Takatsugu
Ishimoto, Daiauke Izumi, Hiroshi Sawayama, Yu Imamura,
Satoshi Ida, Shiro Iwagami, Yoshifumi Baba, Yasuo
Sakamoto, Yuji Miyamoto, Naoya Yoshida, Hideo Baba.
4347
Interphase reduction in ZEB1 and tubulin
isotypes in breast cancer cells associated with
antimitotic drug treatment. Sharon Lobert, Mary E.
Graichen.
4348
TGF-␤ enhances mir-455–5p expression that
regulates tumorigenesis through UBE2B in betel quidassociated oral cancer. Chao-Min Cheng, Shine-Gwo
Shiah, Ya-Wen Chen, Jang-Yang Chang.
4349
Regulation of proliferation and platelet-derived
growth factor expression in desmoid tumors by
microRNA-29. Mushriq Al-Jazrawe, Raymond Poon, Jessica
Liu, Benjamin Alman.
4350
Tumor-suppressive microRNA-29a inhibits
cancer cell migration and invasion via targeting HSP47
in cervical squamous cell carcinoma. Noriko Yamamoto,
Takashi Kinoshita, Nijiro Nohata, Akira Mitsuhashi, Hirokazu
Usui, Hirofumi Yoshino, Toshihiko Itesako, Hideki Enokida,
Masayuki Nakagawa, Makio Shozu, Naohiko Seki.
4351
Targeting miRNA-driven aggressive behavior of
pancreatic cancer stem cells by a novel drug. Evan Bao,
Asfar Azmi, Ellen Zhang, Shadan Ali, Aamir Ahmad, Feras
Zaiem, Bin Bao, Fazlul H. Sarkar.
4352
Tumor suppressive microRNAs (miR-29s/miR218) regulate laminin-integrin signaling in head and
neck squamous cell carcinoma. Takashi Kinoshita, Nijiro
Nohata, Toyoyuki Hanazawa, Naoko Kikkawa, Noriko
Yamamoto, Hirofumi Yoshino, Toshihiko Itesako, Hideki
Enokida, Masayuki Nakagawa, Yoshitaka Okamoto, Naohiko
Seki.
4353
microRNA-196b induces epithelial-tomesenchymal transition through targeting HOXA9 in
non-small cell lung cancer cells. Ji Woong Son, SeongLan Yu, Dong Chul Lee, Shin Yup Lee, Chang Gyo Park, Hoi
Young Lee, Jaeku Kang.
4354
miR-603 targets WIF1 to promote glioma
tumorigenesis via Wnt/␤-catenin pathway. Mian Guo,
Guangzhi Wang, Kevork Khadarian, Yongri Zheng, Albert D.
Ha, Jia Shen.
4355
A microRNA signature of response to erlotinib
is impacted by the EMT-inducing cytokine TGF␤1.
Madeline J. Krentz, Rebecca Astley, Andrew Stacy, Esther P.
Black.
4356
Tumor suppressive miRNA-145 inhibits IGF-1
and cell viability in prostate cancer cells. Sanchaika
Gaur, Gary Gallick.
4357
Long noncoding RNA HOTAIR is targeted and
regulated by microRNA-141 in renal carcinoma cells.
Takeshi Chiyomaru, Shinichiro Fukuhara1, Sharanjot Saini,
Shahana Majid, Guoren Deng, Varahram Shahryary, Inik
Chang, Yuichiro Tanaka, Hideki Enokida, Masayuki
Nakagawa, Rajvir Dahiya, Soichiro Yamamura.
4358
MicroRNA-198 inhibits non-small cell lung
cancer migration and invasion through targeting OTX1
and VCP. Jin-Ah Kim, Junguk Yang, Yeong Nang Jo, Chang
Woo Lee, Ok-Jun Lee, Song-Yi Choi, Jong Soon Kang, Jieun
Yun.
Poster Abstract
Board Number
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
29.
30.
4359
Elucidation of the role of microRNA-155 in a
murine model of non-alcoholic steatohepatitis. Tasneem
Motiwala, Mufaddal Mustafa, Huban Kutay, Rachael C.
Sullivan, Kun-Yu Teng, Vivek Chowdhary, Lianbo Yu,
Kalpana Ghoshal, Samson T. Jacob.
4360
Hypoxia-induced miR-372 targets p62 to affect
the progression of oral carcinoma. Li-Yin Yeh, Shu-Chun
Lin, Chung-Ji Liu, Yong-Kie Wong, Kuo-Wei Chang.
4361
Hypoxia-related microRNA, miR-199a-3p,
inhibits ovarian cancer progression through the
suppression of c-Met expression. Yasuto Kinose, Kenjiro
Sawada, Koji Nakamura, Seiji Mabuchi, Ken-ichirou
Morishige, Tadashi Kimura.
4362
miR-211 is contributive to the progression of
oral carcinoma through targeting transcription factor 12
(Tcf12). Yi-Fen Chen, Kuo-Wei K. Chang, Shu-Chun Lin.
4363
Macrophage migration inhibitory factor (MIF)
and miR-301b interactively enhance disease
aggressiveness by targeting NR3C2 in human pancreatic
cancer. Shouhui Yang, Peijun He, Jian Wang, Aaron
Schetter, Naotake Funamizu, Katsuhiko Yanaga, Jochen
Gaedcke, B. Michael Ghadimi, Matthias M. Gaida, Thomas
Ried, Nader Hanna, H. Richard Alexander, S. Perwez
Hussain.
4364
Posttranscriptional regulation of tetraspanins
CD151 & CD9 in breast & prostate cancers. Danielle R.
Bond, Crystal Passfield, Murray Cairns, Leonie K. Ashman,
Judith Weidenhofer.
4365
miR-106b modulates C1orf24 expression in
thyroid tumors. Bruno H. Nozima, Gianna M. Carvalheira,
Janete M. Cerutti.
4366
MicroRNA (miR) 199a-5p regulates mitogenactivated protein kinase 3–11 (MAP3K11) expression in
esophageal cancer cells by modulating mRNA stability.
Kimberly A. Byrnes, Pornima Phatak, Daniel Mansour,
Jaladanki N. Rao, Douglas Turner, Jian-Ying Wang, James
M. Donahue.
4367
Tumor suppressor miR-30a inhibits LOX
expression and progression in anaplastic thyroid
cancer. Myriem Boufraqech, Naris Nilubol, Lisa Zhang,
Samira Sadowski, Sudheer Kumar Gara, Mei He, Sean
Davis, Martha Quezado, Electron Kebebew.
4368
MicroRNAs miR-503 and -182 regulate FBXW7
contributing to the malignant transformation to colon
adenocarcinoma. Lihua Li, Aaron Sarver, Rohini Khatri,
Praveensingh Hajeri, Iris Kamenev, Stephen Thibodeau,
Clifford J. Steer, Subbaya Subramanian.
4369
The microRNA-218-survivin axis regulates
cervical cancer cell migration and invasion. Ryunosuke
Kogo, Christine How, Jeff Bruce, Willa Shi, Kenneth W. Yip,
Laurie Ailles, Fei-Fei Liu.
4370
miRNA profiles identify different subgroups of
triple negative tumors and reveal novel miRNA-mRNA
interactions in breast cancer tumorigenesis. Sandra L.
Romero-Cordoba, Rosa Rebollar-Vega, Valeria QuintanarJurado, Alfredo Hidalgo-Miranda, Sergio Rodriguez-Cuevas,
Veronica Bautista-Pina, Antonio Maffuz-Aziz.
4371
Tumor suppressive microRNA-218 inhibits
cancer cell migration and invasion via targeting LASP1
in prostate cancer. Rika Nishikawa, Yusuke Goto, Takashi
Kinoshita, Shinichi Sakamoto, Takeshi Chiyomaru, Hideki
Enokida, Satoko Kojima, Masayuki Nakagawa, Yukio Naya,
Tomohiko Ichikawa, Naohiko Seki.
4372
MiR-449a promotes breast cancer progression
by activating the NF-␬B pathway. Wei Shi, Matthew Lee,
Ryunosuke Kogo, Jeff Bruce, Christine How, Kenneth W. Yip,
Fei-Fei Liu.
POSTER SESSION
MicroRNAs and Therapeutics
Poster
Section
Poster Abstract
Board Number
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
4373
Integrated microRNA and mRNA signature
associated with the transition from the locally confined
to the metastasized renal cell carcinoma. Jean-Noel
Billaud.
4374
Genistein suppresses prostate cancer regulating
long non-coding RNA. Takeshi Chiyomaru, Soichiro
Yamamura, Shinichiro Fukuhara, Takashi Kinoshita, Shahana
Majid, Sharanjot Saini, Inik Chang, Yuichiro Tanaka, Hideki
Enokida, Naohiko Seki, Masayuki Nakagawa.
4375
UVC irradiation in combination with
fluorescence-guided surgery cures metastatic human
pancreatic cancer in orthotopic mouse models. Yukihiko
Hiroshima, Ali Maawy, Sho Sato, Takashi Murakami, Mako
Yamamoto, Fuminari Uehara, Shinji Miwa, Shuya Yano,
Masashi Momiyama, Takashi Chishima, Kuniya Tanaka,
Michael Bouvet, Itaru Endo, Robert M. Hoffman.
4376
Upregulation of miR-21 in cisplatin-resistant
ovarian cancer via JNK-1/c-Jun pathway. Ileabett M.
Echevarria, Joel Encarnacion, Fatma Valiyeva, Pablo Vivas.
4377
Novel RNAi agent can control HCV replication.
Masahiko Kuroda, Masakatsu Takanashi, Shinichiro Ohno,
Yoshiki Murakami.
4378
miR-100 mediates resistance to paclitaxel in
cervical cancer cells. Rina Kato, Hirotaka Nishi, Yuzo
Nagamitsu, Toru Sasaki, Keiichi Isaka.
4379
Identification and characterization of
therapeutic targets via microRNA profiling in HBVrelated hepatocellular carcinoma. Keon Uk Park, Jin
Young Kim, Ilseon Hwang, Hun Mo Ryoo, Sang-Woo Kim,
Yun-Han Lee.
4380
The miR-15 family members are therapeutic
candidates to treat chemoresistant neuroblastomas.
Aroa Soriano, Laia Paris-Coderch, Luz Jubierre, Ana
Almazán-Moga, Carla Molist, Josep Roma, Soledad Gallego,
José Sánchez de Toledo, Miguel F. Segura.
4381
MiR-205 and Trastuzumab: Potential as
adjuvant therapeutic tool and predictive biomarker.
Elvira D’Ippolito, Claudia Piovan, Ilaria Plantamura, Marta
Giussani, Patrizia Casalini, Manuela Campiglio, Elda
Tagliabue, Marilena V. Iorio.
4382
Relative expression of miR200 microRNAs and
ERBB family negative regulator Mig6 in estimation of
EMT status and erlotinib sensitivity. Eugene G.
Izumchenko, Xiaofei Chang, Christina Michailidi, Luciane
Kagohara, Rajani Ravi, Mariana Brait, Atul Bedi, David
Sidransky.
4383
Effects of inhibition of upregulated microRNAs
in canine histiocytic sarcoma. Emmalena J. GregoryBryson, Maciej Parys, Matti Kiupel, Vilma YuzbasiyanGurkan.
4384
Targeting miR-124 inhibits growth of prostate
cancer xenografts and sensitized prostate cancer cells
to anti-androgen. Xu-Bao Shi, Aihong Ma, Lingru Xue,
Ralph W. deVere White.
4385
Identification of the crucial microRNA, miR1246 related to the chemoresistance and stemness in
pancreatic cancer for new targeting therapy. Shinichiro
Hasegawa, Ishii Hideshi, Hidetoshi Eguchi, Shogo Kobayashi,
Hiroshi Wada, Naoki Hama, Yoshito Tomimaru, Kawamoto
Koichi, Masamitsu Konno, Hisataka Ogawa, Shimpei
Nishikawa, Yoshihiro Kano, Yoshihiro Kano, Takahito
Fukusumi, Atsushi Hamabe, Takenori Nishimura, Kunihiko
Hinohara, Taroh Satoh, Noriko Gotoh, Hiroaki Nagano,
Yuichiro Doki, Masaki Mori.
Poster Abstract
Board Number
15.
16.
17.
19.
20.
21.
23.
24.
26.
27.
28.
29.
30.
4386
Identification of microRNA which regulates
paclitaxel resistance of ovarian cancer cells - a
potential of miR-194 by attenuating paclitaxel
resistance through the down-regulation of oncogene
BMI-1. Koji Nakamura, Kenjiro Sawada, Yasuto Kinose, Kae
Hashimoto, Seiji Mabuchi, Tadashi Kimura.
4387
Up-regulation of VHL by miR-1273C inhibits
renal cell carcinoma. Chang Woo Lee, Moo Rim Kang,
Jieun Yun, Soo Jin Oh, Jong Soon Kang.
4388
Targeted VHL activation by RNAa inhibits renal
cell carcinoma. Jong Soon Kang, Moo Rim Kang, Jieun
Yun, Soo Jin Oh, Ki Hwan Park, Chang Woo Lee.
4389
Hypoxia-inducible HIF1␣-miR-210 signaling axis
enhances chemoresistance in human hepatocellular
carcinoma. Alan K. Kai, Regina C. Lo, Joyce M. Lee, Kwan
Man, Carmen C. Wong, Jack C. Wong, Irene O. Ng.
4390
Non-coding RNAs in EGFR therapy resistance in
breast cancer. Luis D. Borrero-García, Linette CastilloPichardo, Roxana S. Redis, George A. Calin, Suranganie
Dharmawardhane.
4391
Multi-modal nanomedicine for glioblastoma.
Paula Ofek, Marcelo Calderon, Fatemeh Sheikhi-Mehrabadi,
Shiran Ferber, Rainer Haag, Ronit Satchi-Fainaro.
4392
Tumor suppressor miR-339 –5p regulates PD-L1
expression in lung cancer. Rachel Heymach, Lixia Diao,
Lauren A. Byers, Monique Nilsson, Jing Wang, Maria A.
Cortez.
4393
miR-138 overexpression most effectively
enhanced efficacy of apigenin to impair cell cycle
progression and induce apoptosis in human malignant
neuroblastoma SK-N-DZ and SK-N-BE2 cells in vivo.
Mrinmay Chakrabarti, Walden Ai, Swapan K. Ray.
4394
Genistein downregulates onco-miR-1260b and
inhibits Wnt-signaling in renal cancer cells. Hiroshi
Hirata, Koji Ueno, Yuichiro Tanaka, Z.Laura Tabatabai, Koichi
Nakajima, Yuji Hinoda, Nobuhisa Ishii, Rajvir Dahiya.
4395
Modulation of circulating microRNAs in serum
of clear cell renal cell carcinoma (ccRCC) patients
treated with vorinostat and bevacizumab. Sreenivasulu
Chintala, Kiersten M. Miles, Remi Adelaiye, Roberto Pili.
4396
MicroRNA MIR551B amplified at 3q26.2 locus
activate c-KIT expression and causes resistance to
anoikis of ovarian cancer cells. Pradeep ChaluvallyRaghavan, Fan Zhang, Wenbin Liu, Moss Tyler, Shuangxing
Yu, Sunila Pradeep, Prahlad Ram, Yiling Lu, Anil Sood,
Gordon Mills.
4397
Therapeutic microRNA agaisnt KRAS mutant
colorectal cancer. Masayuki Hiraki, Junichi Nishimura,
Mamoru Uemura, Taishi Hata, Ichiro Takemasa, Tsunekazu
Mizushima, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori.
4398
MicroRNA-203 enhances radiosensitivity of
human malignant glioma cells. Yeohyeon Hwang, David J.
Lee, Eun Jung Choi, Bong Jun Cho, In-Ah Kim.
23
23
525
POSTER SESSION
Poster
Section
24
24
Oncogenes, Growth Factors, and Signal Transducers 1
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
526
4399
Somatic HIF2A mutations identified in a new
syndrome with multiple paragangliomas and
somatostatinomas associated with polycythemia.
Chunzhang Yang, Karel Pacak, Zhengping Zhuang.
4400
The let-7 microRNA binding site variant in the
KRAS 3’-UTR is not associated with the risk of head
and neck cancer. Nejat Dalay, Semra Demokan, Yusufhan
Suoglu, Rasim Yilmazer, Murat Ulusan.
4401
A novel drug suppresses proliferation of lung
cancer cells via increasing the CBL activity and downregulating epidermal growth factor receptor. Kuo-Yen
Huang, Szu-Hua Pan, Wen-Lung Wang, Ching-Shih Chen,
Tse-Ming Hong, Pan-Chyr Yang.
4402
Synergistic cell death in nedd8 and hrb27c
mutant cells under an rbf-negative background is
dependent on EGFR/MAPK signaling. Robin Zhang, Tianyi
Zhang, Zhentao Sheng, Wei Du.
4403
Preclinical evaluation of LY2801653, an orally
bioavailable small molecule oncokinase inhibitor, in
cholangiocarcinoma models. Sau-Chi B. Yan, Suzane L.
Um, Victoria L. Peek, Megan N. Thobe, Kelly M. Credille,
Jennifer R. Stephens, Jason R. Manro, Darryl W. Ballard,
Jessica A. Baker, Joel D. Cook, Bruce W. Konicek, Jeremy
R. Graff, Timothy R. Holzer, Richard A. Walgren.
4404
CSF-1R signaling drives mesothelioma
stemness and chemoresistance. Mario Cioce, Claudia
Canino, Chandra Goparaju, Haining Yang, Michele Carbone,
Harvey I. Pass.
4405
AXL receptor tyrosine kinase is associated with
the prognosis of patients with esophageal squamous
cell carcinoma. Pei-Wen Yang, Min-Shu Hsieh, Ya-Chuan
Huang, Tzu-Hsuan Chiang, Jang-Ming Lee.
4406
Role of KRAS in modulating the metabolomic
profile and the response of NSCLC cells to PI3K/mTOR
and AMPK interfering agents. Elisa Caiola, Laura Brunelli,
Mirko Marabese, Marina C. Garassino, Gabriella Farina,
Massimo Broggini, Roberta Pastorelli.
4407
A GNAS mutation found in pancreatic
intraductal papillary mucinous neoplasms changes
mucin gene expression and gene expression profiles.
Hirotake Komatsu, Naoaki Sakata, Takeshi Aoki, Fuyuhiko
Motoi, Takeshi Naitoh, Yu Katayose, Shinichi Egawa,
Michiaki Unno, Toru Furukawa.
4408
Her2 C terminal PDZ binding domain interacting
with DLG1 is required for radioresistance through
induction of EMT and loss of epithelial polarity. Dong
Lin, Xiaodi Zhang, Angela Eldridge, Ming Fan, Cheikh
Menaa, Jianjian Li.
4409
P-cadherin modulates signaling of multiple
growth factor receptors and cellular aggressiveness in
oral carcinoma cells. James Mar, Adam Robinson, Rachel
Neville, Desseree Lysne, Kathryn Lawson.
4410
KRAS mutation status is associated with
enhanced dependency on purine biosynthesis and
related pathways in non small cell lung cancer cells.
Diarmuid M. Moran, Patricia B. Trusk, Karen Pry, David
Sidransky, Keren Paz, Sarah S. Bacus.
4411
DRAK1 overexpressed in head and neck cancer
suppresses the TGF-␤1 tumor suppressor activity in
head and neck cancer cells. Kyung-Min Yang, WonJoo
Kim, Jeong-Mi Lee, Seong-Jin Kim.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4413
Mnk activity in diffuse large b-cell lymphoma:
targeting translation. Ari Landon, Parameswary A.
Muniandy, Ronald B. Gartenhaus.
4414
Neuropilin2 is a novel target gene of Wnt
signaling pathway regulating angiogenesis, metastasis
and growth of osteosarcoma. Tao Ji, Yi Guo, Carol Lin,
Cheng-Fong Chen, Xiaolin Zi, Bang H. Hoang.
4415
Discoidin domain receptor 1 (DDR1) and IGF-I
system crosstalk in bladder cancer progression. Alaide
Morcavallo, Simone Buraschi, Shi-Qiong Xu, Leonard G.
Gomella, Antonino Belfiore, Renato V. Iozzo, Andrea
Morrione.
4416
IKBKE is a key mediator of Ras activation of
NF-␬B and Ras oncogenic function. Donghwa Kim,
Jianping Guo, Sridevi Challa, Domenico Coppola, Jin Q.
Cheng.
4417
Targeting Ras with small molecules that
activate SOS-mediated nucleotide exchange. Olivia W.
Rossanese, Michael C. Burns, Qi Sun, R. N. Daniels,
DeMarco V. Camper, J. P. Kennedy, Jason Phan, Edward T.
Olejniczak, Taekyu Lee, Alex G. Waterson, Stephen W.
Fesik.
4418
Oncogenic activation of RAS and RAF induce
distinct ERK activation in the colon. Shingo Miyamoto,
David A. Drew, Daniel W. Rosenberg.
4420
Matriptase-mediated proteolytic regulation of
biological activity and spatial distribution of PDGF-D.
Wei Huang, Hyeong-Reh C. Kim.
4421
PTEN-deficient tumors depend on Akt2 for
maintenance. Rebecca Chin, Steve P. Balk, Alex Toker.
4422
A Hippo-independent pathway modulates YAPinduced resistance of cancer cells to antitubulin drugs.
Yulei Zhao, Prem Khanal, Xiaolong Yang.
4423
Somatic mutations in the insulin-like growth
factor-1 and insulin receptors found in cancer genomes
result in constitutive activation of the receptor kinases.
Ann Greer, Stephen Hillerman, Han Chang, Tai W. Wong.
4424
Analysis of 1115 patients tested for MET
amplification and therapy response in the MD Anderson
phase I clinic. Chad Tang, Denis Jardim, Debora Gagliato,
Gerald Falchook, Kenneth Hess, Siqing Fu, Jennifer Wheler,
Ralph Zinner, Aung Naing, Apostolia Tsimberidou, Funda
Meric-Bernstam, David Hong.
4425
Drug resistance via feedback activation of Stat3
in oncogene-addicted cancer cells. Ho-June Lee,
Guanglei Zhuang, Yi Cao, Pan Du, Hyo-Jin Kim, Jeff
Settleman.
4426
Tumor suppressive effects of wild-type Hras on
oncogenic Kras-driven pancreatic tumorigenesis. Jamie
D. Weyandt, Christopher M. Counter.
4427
Copper is required for oncogenic BRAF
signaling and tumorigenesis. Donita C. Brady, Matthew S.
Crowe, Michelle L. Turski, G A. Hobbs, Apirat Chaikuad,
Stefan Knapp, Sharon L. Campbell, Dennis J. Thiele,
Christopher M. Counter.
4428
Oncogenic ERBB3 mutations in human cancers.
Bijay S. Jaiswal, Noelyn M. Kljavin, Eric Stawiski, Steffen
Durinck, Subhra Chaudhuri, Charles Eigenbrot, Gabriele
Schaefer, Frederic J. de Sauvage, Somasekar Seshagiri.
POSTER SESSION
Ubiquitin and Ubiquitin-like Proteins / GTPases and Their Regulators and
Targets
Poster Abstract
Board Number
1.
4429
Loss of function Cbl-c mutations in solid
tumors. Stephen C. Kales, Philip E. Ryan, Marion M. Nau,
Jeffrey E. Green, Stanley Lipkowitz.
2.
4430
Veratridine induces cell death through a
ubiquitin-like (UBX) domain containing protein, UBXN2A.
Ammara Abdullah.
3.
4431
N-terminal portion of ␤-catenin is important in
ISGylation of ␤-catenin by 90K glycoprotein in
colorectal cancer cells. Somy Yoon, Jeong A Bae, Hangun
Kim, Kyung-Sub Moon, Kyung Keun Kim.
4.
4432
The involvement of suppressor of cytokine
signaling 6 (SOCS6) in the ECS E3 ubiquitin ligase
complex. Shu-Chuan Chen, Huan-Yu Lin, Shiu-Ting Lin,
Mei-Jung Wang, Jeou-Yuan Chen.
5.
4433
Fbxw11 promotes leukemia development by
activating the NF-␬B signaling pathway. Lina Wang,
Jinfeng Liao, Xiao Yang, Wenli Feng, Shayan Chen,
Guoguang Zheng.
6.
4434
Role of Deubiquitinase Usp9x in pancreatic
cancers: Tumor promoter or tumor suppressor. Anupama
Pal, Marina Pasca di Magliano, Moshe Talpaz, Michelle
Dziubinski, Diane Simeone, Nicholas J. Donato.
7.
4435
Deubiquitinases Usp9x and Usp5 control
tumorigenicity and apoptotic responsiveness in
malignant melanoma. Harish Potu, Anupama Pal, Hanshi
Sun, Luke Peterson, Moshe Talpaz, Monique Verhaegen,
Juxiang Cao, Ugur Eskiocak, Sean Morrison, Nicholas J.
Donato.
Poster Abstract
Board Number
16.
4444
The role of small GTPase Rab7 in the secretion
of extracellular microvesicles by head and neck
squamous cells carcinoma. Fernanda S. Giudice, Bruna R.
Rodrigues, Marcos V. S. Dias, Antuani R. Baptistella, Tonielli
Cristina S. Lacerda, Luiz P. Kowalski, Vilma R. Martins.
17.
4445
RhoA is required for lung adenocarcinoma
progression but is dispensable for K-Ras-induced tumor
initiation. Inuk Zandvakili, Yi Zheng.
18.
4446
The allelic variants of Dock9 contribute to
urethane-induced lung tumor susceptibility. Yan Lu,
Pengyuan Liu, Haris Vikis.
19.
4447
Generation of a conditional S194A mutant RalA
allele in mice. Matthew S. Crowe, Christopher M. Counter.
20.
4448
Overexpression of ECT2 promotes proliferation
and metastasis of UPSC. Claire M. Mach, Thomas J.
Magliaro, Matthew L. Anderson.
21.
4449
Tissue- and isoform-specific Ras expression
during development. Anna U. Newlaczyl, Judy M. Coulson,
Ian A. Prior.
22.
4450
Comparison of structural elements in RasGRP3
and RasGRP1 controlling membrane interaction. Agnes
Czikora, Noemi Kedei, Peter M. Blumberg.
23.
4451
Novel orphan G-protein-coupled receptor is
oncogenic and mediates anti-estrogen resistance in
human mammary carcinoma. Yu Jin Lee, Kyeong Jin
Shin, Soo-Ah Park, Sung Ho Ryu, Pann-Ghill Suh.
24.
4452
Regulation of histone deacethylase 8 expression
by inhibitory GTP binding proteins signaling via JNK
pathway in H1299 non-small-cell lung cancer cells.
Hwa-jeong Hahn, Yong-Sung Juhnn.
25.
4453
Synergistic anticancer effect of combination of
AZD6244 and BYL719 targeting KRAS mutant in nonsmall cell lung cancer. Eun Hye Jho, Sin Il Kang, YeonHee Bae, Young Mee Park, Jong-Mu Sun, Jin Seok Ahn,
Keunchil Park, Myung-Ju Ahn.
26.
4454
SRJ09, a semisynthetic anticancer agent,
targets Ras-MAPK signaling pathway: assessment in
breast and colon cancer cell lines. Johnson Stanslas,
Charng Choon Wong, Sreenivasa R. Sagineedu, Shiran M.
Sidik, Shariful H. Sumon, Roger Phillips, Nordin H. Lajis.
8.
4436
Neddylation of ribosomal protein S27-like and
RPS27 regulates survival of breast cancer cells.
Yongchao Zhao, Xiufang Xiong, Yi Sun.
9.
4437
Fbxw8 targets hematopoietic progenitor kinase
1 for proteasomal degradation. Hua Wang, Yue Chen,
Ping Lin, Lei Li, Guisheng Zhou, Guangchao Liu, Craig
Logsdon, Jianping Jin, James L. Abbruzzese, Tse-Hua Tan,
Huamin Wang.
10.
4438
Changes in Nrdp1 regulation of ErbB3 in
androgen-dependent vs. independent prostate cancer.
Rosalinda M. Savoy, Salma Siddiqui, William H. Fry, Kermit
L. Carraway, Paramita Ghosh.
11.
4439
Proteomic analysis of SIAH2 E3 ligase complex
in oncogenic K-Ras-driven cell transformation and
oncogenesis. Monicah M. Njogu, Ming Lei Bian, Amy H.
Tang.
27.
4440
TRAF4 is a key molecule for lung cancer
through regulating AKT ubiquitination and activation.
Cong Peng, Wei Li, Xiang Chen, Zigang Dong.
4455
Targeting a novel kras-integrin-linked kinase
regulatory circuitry in pancreatic cancer. Po-Chen Chu,
Ming-Chen Yang, Samuel K. Kulp, Ching-Shih Chen.
28.
4456
Aurora-A is a downstream target of RAS and
forms a positive feedback regulation loop with NF-␬B in
non-small cell lung cancer. Donghwa Kim, Masayuki
Kanai, Xiangqian Zheng, Dali Zheng, Domenico Coppola, Jin
Q. Cheng.
12.
13.
4441
Ube2e inhibits the ubiquitination and
degradation of EGFR mediated by Cbl and Ube2d. Ke Ma,
Stanley Lipkowitz, Rachel Klevit, Mariya S. Liyasova.
14.
4442
Inhibition of SIAH E3 ligase function leads to
increased cell death in metastatic human cancer cells.
Zena M. Urban, Lauren van Reesema, Minglei Bian, Thomas
C. Smyrk, Gloria Peterson, Amy H. Tang.
29.
4457
Regulation of GRM1 by estrogen receptor in
breast cancer. Sonia C. Dolfi, Madhura S. Mehta, David
Kornblum, Andrew Boughton, Hussein Rahim, Daniel
Medina, Kim M. Hirshfield.
15.
4443
The tumor suppressive small GTPase DiRas1
binds the RhoGEF SmgGDS and antagonizes RhoA
activation. Andrew D. Hauser, Kristen M. Barr, Anne C.
Frei, Patrick Gonyo, Ellen L. Lorimer, Carol L. Williams,
Carmen Bergom.
30.
4458
PDLIM2 is essential for feedback regulation of
the B1 integrin-FAK-RhoA signalling pathway to
maintain epithelial cell polarity and suppress
transformation. Ravi Kiran-Deevi, Orla T. Cox, Rosemary
O’Connor.
Poster
Section
25
25
527
POSTER SESSION
Chemistry 7
Poster
Section
26
26
Drug Delivery
Poster Abstract
Board Number
1.
2.
4460
Super carbonate apatite as simplified systemic
nanoparticle carrier for therapy of solid tumors. Hirofumi
Yamamoto, Xin Wu, Susumu Miyazaki, Mamoru Uemura,
Taishi Hata, Junichi Nishimura, Ichiro Takemasa, Tsunekazu
Mizushima, Yuichiro Doki, Masaki Mori.
3.
4461
Anti-cancer activity of immunoliposomes
encapsulated effective amount of glycosylated paclitaxel
with novel loading strategy. Tsukasa Shigehiro, Tomonari
Kasai, Akifumi Mizutani, Hiroshi Murakami, Katsuhiko
Mikuni, Tadakatsu Mandai, Hiroki Hamada, Masaharu Seno.
4.
4462
Structure-activity relationship studies for
PSMA-targeted tubulysin conjugates. Kevin Wang,
Spencer Hahn, Hari Santhapuram, Longwu Qi, Paul Kleindl,
Jeremy Vaughn, Fei You, Joe Reddy, Ryan Dorton,
Christopher Leamon, Iontcho Vlahov.
5.
4463
Targeting SN38 delivery to gastrointestinal
cancer cells using a fucose-bound nanoparticle
approach. Junji Kato, Rishu Takimoto, Takahiro Osuga,
Michihiro Ono, Masahiro Hirakawa, Makoto Yoshida, Yasushi
Sato, Fumito Tamura.
6.
4464
Growth inhibitory effect of combination of
sorafenib and IFN␣ using a new drug delivery system.
Kosuke Ueda, Jun Akiba, Sachiko Ogasawara, Keita
Todoroki, Masamichi Nakayama, Akiko Sumi, Hironori
Kusano, Sakiko Sanada, Shigetaka Suekane, Keming Xu,
Motoichi Kurisawa, Kei Matsuoka, Hirohisa Yano.
7.
4465
Differential MMAE delivery from ADCs utilizing
the valine-citrulline-PAB and ␤-glucuronide cleavable
linker systems. Nicole M. Okeley, Heather A. VanEpps,
Xinqun Zhang, Jocelyn R. Setter, Patrick J. Burke, Joseph Z.
Hamilton, Robert P. Lyon.
8.
528
4459
Characterization of a novel magnetic
nanoparticles formulation for cancer therapeutic
applications. Murali M. Yallapu, Neeraj Chauhan, Shadi F.
Othman, Vahid Khalilzad-Sharghi, Meena Jaggi, Subhash C.
Chauhan.
4466
Surface-functionalized nanoparticles for
inhalation delivery of chemotherapeutics to lung cancer.
Ameya R. Kirtane, Timothy Wiedmann, Jayanth Panyam.
9.
4467
Treating brain tumors with targeted-micelles
containing rapamycin. Ann-Marie Broome, Suraj K. Dixit,
Kayla Miller, Alfred Moore, Amy-Lee Bredlau.
10.
4468
Tumor vasculature targeting using cell-specific
thioaptamer decorated chitosan nanoparticle. Dahai
Jiang, Lingegowda S. Mangala, Hongyu Wang, Sherry Wu,
Lokesh G. Rao, Cristian Rodriguez-Aguayo, Sunila Pradeep,
David E. Volk, Gabriel Lopez-Berestein, Anil K. Sood.
Poster Abstract
Board Number
11.
4469
An evaluation of the role of mucin in nano drug
delivery. Musaed A. Alkholief, Robert Campbell.
12.
4470
Elucidating the role of drug-linker
hydrophobicity in the disposition of antibody-drug
conjugates. Svetlana O. Doronina, Jocelyn R. Setter, Tim D.
Bovee, Martha E. Anderson, Mechtild Jonas, Steven Daniho,
Heather Kostner, Peter D. Senter, Robert P. Lyon.
13.
4471
AD-O64.4 - a novel bioconjugate for tumortargeted drug delivery. Wojciech Strozek, Anna
Pieczykolan, Bartlomiej Zerek, Michal Szymanik, Albert
Jaworski, Marlena Galazka, Katarzyna Bukato, Piotr Rozga,
Sebastian Pawlak, Katarzyna Poleszak, Malgorzata TeskaKaminska, Jerzy Pieczykolan.
14.
4472
Targeted multifunctional lipid-PLGA hybrid
nanosystems for metastatic breast cancer imaging and
therapy. Amalendu P. Ranjan, Anindita Mukerjee, Jamboor
K. Vishwanatha.
15.
4473
Development of ceramide liposomes for tumor
interstitial and vascular drug targeting. Shaohua Cheng,
William Crall, Bryan Nguyen, Charles Dang, Musaed
Alkholief, Robert B. Campbell.
16.
4474
Protein-photosensitizer nanoparticles for the
treatment of cancer. Marimar Benitez, Anna M. Molina, Kai
Griebenow.
17.
4475
IL-4 receptor-targeted delivery of liposomal
doxorubicin and siRNA to tumor. Poongkavithai Vadevoo
Sri Murugan, Gunassekaran Gowri Rangaswamy, Lianhua
Chi, Guruprasath Padmanaban, Moon-Chang Baek, In-San
Kim, Rang-Woon Park, Byung-Heon Lee.
18.
4476
Targeted delivery of curcumin to improve
therapeutic outcome in breast cancer. Rajesh Singh,
James W. Lillard.
19.
4477
pH-responsive PEG-HPAH micelles for drug
delivery and their potential in cancer therapy. Qin Xu,
Jingshuang Yu, Bangshang Zhu.
20.
4478
Biopharmaceutic studies of novel nucleoside
transporter inhibitor prodrugs that can protect against
nucleoside drug-induced mitochondrial toxicity. Shan
Sun, Hilaire C. Playa, Hemantkumar S. Deokar, Wenwei Lin,
John K. Buolamwini.
21.
4479
Influence of the blood-brain barrier on drug
distribution and efficacy of PI3K/mTOR inhibitors.
Rajneet K. Oberoi, William F. Elmquist, Rajendar Mittapalli,
Jenny Pokorny, Jann Sarkaria.
POSTER SESSION
Chemistry 8
Enhanced Drug Delivery through Nanotechnology and Conjugation Strategies
Poster Abstract
Board Number
1.
4480
Double targeting nanoscale drug delivery
system for treatment and imaging of metastatic solid
cancers. Md Shakir U. Ahmed, Mohamed O. Abdalla,
Timothy Turner.
2.
4481
Genetically encoded chimeric polypeptide
nanoparticles for gemcitabine delivery to solid tumors.
Jayanta Bhattacharyya, Ashutosh Chilkoti.
3.
4482
Development of localized cisplatin
chemotherapy: from benchside to investigational new
drug application. Shuang Cai, Jeffrey Bryan, Daniel Aries,
Laird Forrest.
4.
4483
IO125, a novel Pt-based supramolecular
therapeutic exhibits increased anti-cancer efficacy
compared with oxaliplatin. Monideepa Roy, Sk Samad
Hossain, Arindam Sarkar, Aniruddha Sengupta, Nimish
Gupta, Sajid Hussain, Aasif Ansari, Sanghamitra Mylavarapu,
Shiladitya Sengupta.
5.
4484
Anti-cancer treatments delivered by antibody
guided PLGA nanoparticles. Shuta Wu, Anthony Fowler,
Craig Ogle, Pinku Mukherjee.
6.
4485
Synthesis of targeted docetaxel-polymer
conjugate and its anti-tumor efficacy. Young Bok Lee,
Deog Joong Kim, Miyoung Yang, Chang-Ho Ahn, Anjan Nan.
Poster Abstract
Board Number
7.
4486
Stromal depletion by a docetaxel nanoparticle
for enhanced therapy of breast and pancreatic cancer.
Mark Ernsting, Mami Murakami, Elijus Undzys, Shyh-Dar Li.
8.
4487
Targeting trastuzumab-resistant HER2ⴙ breast
cancer with a HER3-targeting nanoparticle. Jessica Sims,
Michael Taguaim, Chris Hanson, Xiaojiang Cui, Lali K.
Medina-Kauwe.
9.
4488
Multi-functional, miR-205 complexed,
gemcitabine conjugated nanomedicines for effective
treatment of chemo-resistant pancreatic
adenocarcinoma. Deepak Chitkara, Anupama Mittal,
Stephen W. Behrman, Ram I. Mahato.
10.
4489
Targeting cancer cells and antitumor effects of
brucine immunonanoparticles on hepatocellular
carcinoma in vivo. Jianmin Qin.
11.
4490
A novel tumor-targeting construct aimed at cMet. mitra mastali, Jessica D Sims, Jan M Taguiam, Chris
Hanson, Felix Alonso Valenteen, Lali K. Medina-Kauwe.
Poster
Section
27
27
529
POSTER SESSION
Poster
Section
29
29
Biologic Therapy 3
Poster Abstract
Board Number
1.
2.
3.
4.
5.
4492
Blockade of angiopoietin-2 or Tie2 is equally
effective at inhibiting tumor growth and reducing tumor
vessel density in most human tumor xenograft models.
Alexander P. Adler, Christopher Daly, Asma A. Parveen,
Thomas Nevins, Jing Shan, Jeanette Fairhurst, Tammy
Huang, Joel Martin, Nicholas Papadopoulos, George D.
Yancopoulos, Gavin Thurston, Gavin Thurston, Alexandra
Eichten.
4493
Medi-573 alone or in combination with
mammalian target of rapamycin inhibitors, targets the
insulin-like growth factor pathway in sarcomas. Haihong
Zhong, Christine Fazenbaker, Shannon Breen, Cui Chen,
Jiaqi Huang, Morehouse Chris, Yihong Yao, Robert
Hollingsworth.
4494
A clinical candidate anti-mesothelin-MMAE
antibody-drug conjugate (ADC) for therapy of
mesothelin-expressing cancers. Suzie J. Scales, Nidhi
Gupta, Glenn Pacheco, Ron Firestein, Dorothy M. French,
Josefa Chuh, Yin Zhang, Leanne Berry, Jenny Bostrom,
Elizabeth Luis, Aimee Fourie O’Donohue, Katherine R. Kozak,
Sarajane Ross, Mark S. Dennis, Jay Tibbitts, Susan D.
Spencer.
4495
Sym013, novel pan-HER monoclonal antibody
mixture, augments radiation response in human lung
and head and neck tumors. David Francis, Shyhmin
Huang, Lauryn Werner, Johan Lantto, Ivan D. Horak,
Michael Kragh, Paul M. Harari.
7.
4497
Therapeutic benefit of targeting ERK in mutant
KRAS pancreatic ductal adenocarcinoma. Tikvah K.
Hayes.
8.
4498
Afatinib, an irreversible ErbB family inhibitor,
demonstrates activity against HER2 mutated cervical
cancer in vitro. Salvatore Lopez, Emiliano Cocco, Bellone
Stefania, Ileana Bortolomai, Elena Bonazzoli, Roberta
Nicoletti, Carlton Schwab, Diana P. English, Corrado
Terranova, Roberto Angioli, Alessandro D. Santin.
9.
4499
Activation of PI3-kinase pathway and tumor
response to everolimus in patient-derived xenografts of
triple-negative breast cancer. Elisabetta Marangoni, Rana
Hatem, Rania El Botty, Ludmilla De Plater, Dalila Labiod,
Sophie Vacher, Sophie Chateau-Joubert, Ivan Bièche.
10.
4500
An AR-regulated kinase CCRK activates a
tumor-initiating circuitry through dual regulation of
EZH2. Alfred S. Cheng, Hai Feng, Zhuo Yu, Ying-Ying Lee,
May S. Li, Yue-Sun Cheung, Paul B. Lai, Joseph J. Sung.
11.
12.
530
4491
FGFR2-ADC potently and selectively inhibits
growth of gastric and breast cancer xenograft models.
Anette Sommer, Carl F. Nising, Christoph Mahlert, Charlotte
C. Kopitz, Hans-Georg Lerchen, Simone Greven, Beatrix
Stelte-Ludwig, Joachim Schuhmacher, Ruprecht Zierz,
Sabine Wittemer-Rump, Christoph Schatz, Frank Reetz,
Heiner Apeler, Rolf Jautelat, Bertolt Kreft, Karl Ziegelbauer.
4501
Sensitivities of kinase inhibitors of BCR
signaling are correlated with the BCR signaling pathway
activities in DLBCL and CLL. Joyce O. Obidi, Patricia
Burke, Laura Richman, Dirk Mendel, Haifeng Bao.
4502
Nonclinical characterization and tolerability of a
surrogate anti-mesothelin-MMAE antibody-drug
conjugate. Nidhi Gupta, Willy A. Solis, Reina N. Fuji, Amy
Oldendorp, Glenn Pacheco, Elizabeth Luis, Josefa Chuh,
Dorothy M. French, Elizabeth Drake, Mark S. Dennis,
Katherine R. Kozak, Sarajane Ross, Jay Tibbitts, Susan D.
Spencer, Suzie J. Scales.
Poster Abstract
Board Number
13.
4503
A small molecule glycomimetic antagonist of
E-selectin (GMI-1271) prevents pancreatic tumor
metastasis and offers a novel treatment for improved
efficacy of chemotherapy. Maria M. Steele, Prakash
Radhakrishnan, John L. Magnani, Michael A. Hollingsworth.
14.
4504
Urokinase plasminogen activator-dependent tumor
penetrating peptide. Tambet Teesalu, Kazuki N. Sugahara,
Gary B. Braun, Venkata Ramana Kotamraju, Erkki Ruoslahti.
15.
4505
Anti-tumor activity in pancreatic cancer of a
low immunogenic and clinically optimized antimesothelin immunotoxin RG7787. Ira Pastan, Kevin
Hollevoet, Emily Mason-Osann, Christine Alewine, Xiu-Fen Liu.
16.
4506
Targeting stepwise HER2 and VEGF can
overcome multidrug resistance in small cell lung
cancer. Toshiyuki Minami, Takashi Kijima, Osamu
Morimura, Yuhei Kinehara, Masayoshi Higashiguchi, Kotaro
Miyake, Haruhiko Hirata, Yoshiko Takeuchi, Kiyoharu
Fukushima, Yoshitomo Hayama, Koji Inoue, Izumi Nagatomo,
Yoshito Takeda, Hiroshi Kida, Atsushi Kumanogoh.
17.
4507
SL-501, a next-generation targeted therapy
directed to IL-3R, inhibits the growth of tyrosine kinase
inhibitor-resistant CML cells. Christopher Brooks, Kenneth
Hoberman, Ivan Bergstein, Eric Rowinsky.
18.
4508
Engineering a single ubiquitin ligase for the
selective degradation of all activated ErbB receptor
tyrosine kinases. Hui Li.
19.
4509
The fully human, proapoptotic fusion protein
Granzyme B/VEGF121 targets tumor vasculature and
inhibits tumor growth. Khalid A. Mohamedali, Lawrence H.
Cheung, Yu Cao, Walter N. Hittelman, Michael G.
Rosenblum.
20.
4510
RG7787 - a novel de-immunized PE based
fusion protein for therapy of mesothelin-positive solid
tumors. Gerhard Niederfellner, Frieder Bauss, Sabine ImhofJung, Friederike Hesse, Sven Kronenberg, Roland Staak,
Martin Lechmann, Ben Krippendorff, Wolfgang Richter, Rita
Mateus, Gwendlyn Kollmorgen, Ulli Brinkmann, Masanori
Onda, Ira Pastan, Klaus Bosslet.
21.
4511
Differential effects of GA201 and cetuximab on
EGFR expression and endosomal recycling in non-small
cell lung cancer cell lines. Arjan Kol, Steven de Jong,
Martin Pool, Elisabeth G. de Vries, Christian A. Gerdes,
Anton G. Terwisscha van Scheltinga.
22.
4512
Construction and characterization of novel,
human serine protease granzyme B-based cancer
therapeutics targeting the TNFR family member Fn14.
Hong Zhou, Khalid A. Mohamedali, Yu Cao, Mary Migliorini,
Lawrence H. Cheung, Walter N. Hittelman, Jeffrey A.
Winkles, Michael G. Rosenblum.
23.
4513
IMGN289, an EGFR-targeting antibody-drug
conjugate, is effective against tumor cells that are
resistant to EGFR tyrosine kinase inhibitors. Yulius Y.
Setiady, Ling Dong, Anna Skaletskaya, Jan Pinkas, Robert J.
Lutz, John M. Lambert, Thomas Chittenden.
24.
4514
Studies on growth response of a panel of
human ovarian tumor cell lines to treatment with
afatinib, erlotinib, crizotinib and cytotoxic drugs.
Soozana Pivanenthiran, Sharadah Essapen, Alan M. Seddon,
Helmout Modjtahedi.
25.
4514A
Antibody to Progranulin (Anti-GP88)
potentiates tamoxifen and letrozole effect in estrogen
receptor positive breast cancer cells. Ginette Serrero,
Jianping Dong, Jorge Marquez, Binbin Yue, Jun Hayashi.
POSTER SESSION
Cell Cycle and PI3K/AKT Inhibitors
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
4515
SPR965: an oral PI3K/ mTOR C1/C2 inhibitor for
the treatment of solid tumors. Reena Arora, Bakul K.
Dutta, Ravinder Goel, Frank P. Hollinger, Bilash Kulia,
Dinesh Mahajan, Amal R. Mahapatra, Milind Sagar,
Somdutta Sen, Amit Sharma, Sundeep Dugar.
4516
Evaluation of p70S6K/Akt inhibitor
MSC2363318A in patient derived xenograft (PDX) models
of breast cancer. Bayard R. Huck, H Tian, Sakeena Syed,
Jing Lin, Jianguo Ma, Anderson Clark, Remiguisz Kaleta,
Andreas Machl, Erik Wilker, Marc Lecomte.
4517
Evaluation of the TOR kinase inhibitor CC214 –2
in a mouse model of hormone-refractory prostate
cancer. Wenqing Yang, Jing Jiu, Rama Krishna Narla,
Heather K. Raymon.
4518
The PI3K-␦ inhibitor TGR-1202 induces
cytotoxicity and inhibits phosphorylation of AKT in 17p
deleted and non-17p deleted CLL cells in vitro. Daphne
R. Friedman, Tiffany Simms, Sallie D. Allgood, Danielle M.
Brander, Peter Sportelli, Hari P. Miskin, Swaroop
Vakkalanka, Srikant Viswanadha, J. Brice Weinberg, Mark C.
Lanasa.
4519
Targeting of cyclin D/Rb/E2F and PI3K/AKT/
MTOR pathways with ON 123300 as a therapeutic
strategy for mantle cell lymphoma. E. Premkumar Reddy,
Saikrishna A. Divakar, M.V. Ramana Reddy, Stephen C.
Cosenza, Stacey J. Baker, Balaiah Akula, Samir Parekh.
4520
Inhibition of melanoma growth by small
molecules that attenuate PI3K/PDK1 signaling and
promote ATF2 mitochondrial localization. Tal Varsano,
Yongmei Feng, Giuseppina Claps, Marzia Scortegagna, Eric
Lau, Marilyn Leonard, Anthony Pinkerton, Maurizio
Pellecchia, Michael Davies, Marcus Bosenberg, Ze’ev Ronai.
4521
P7170, a novel inhibitor of phosphoinositide
3-kinase (PI3K)-mammalian target of rapamycin (mTOR)
and activin receptor-like kinase 1 (ALK1) shows antitumor activity in triple negative breast cancer. Veena R.
Agarwal, Dimple Bhatia, Asavari Joshi, Prabha Mishra,
Kalyani G. Bharadwaj, Aurelio S. lobo, Pranoy Menon, Payal
Dhar, Prashant Pandey, Sreesha Srinivasa, vinay sonawane.
4522
Akt2 and acid ceramidase cooperate to induce
malignant transformation. Said M. Sebti, Norbert Berndt,
Ronil Patel, Hua Yang, Maria Balasis.
4523
Chaetoglobosin K, a dual Akt and JNK inhibitor,
modulates Akt phosphorylation in an mTORC2
independent manner. Amna Ali, Diane F. Matesic.
4524
Combined inhibition of PIM and PI3 kinases
shows an enhanced efficacy in a number of solid
tumour cell lines. Michael O’Neil, C. Blanco Aparicio, S.
Jiang, S. Martinez, A. McKenzie, Martin Page, J. Pastor.
4525
mTOR complex inhibition as a novel therapeutic
strategy in high-grade papillary serous ovarian cancer.
Fernanda Musa, Amandine Alard, Gizelka David-West, Iulia
Giuroiu, Stephanie Blank, Bhavana Pothuri, John P. Curtin,
Robert Schneider.
4526
BIBF1120, an investigational triple angiokinase
inhibitor, in combination with inhibitors of mTOR
signaling shows potent antitumor activity in preclinical
models of sarcoma. Parag P. Patwardhan, Elgilda Musi,
Kathryn S. Ivy, Natalie Giovino, Gary K. Schwartz.
4527
Oral multi-pathway inhibitors for the treatment
of triple negative breast cancer. Cathy A. Swindlehurst,
Kyle W. Chan, Leah Fung, Robert W. Sullivan, Sabine Ottilie,
Sergey V. Slepenkov, Shile Huang, Robert E. Rhoads.
4528
Comparison of anti-proliferation activity of BEZ
235, a multi-step inhibitor of mTOR pathway, vs.
BKM120, a pan PI3K inhibitor, in lung cancer cell lines
(LCCL). Chao H. Huang, Christopher Beaudoin, Peter V.
Veldhuizen, Faris Farassati.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
4529
The PI3K␦ inhibitor, idelalisib, inhibits
transcription and translation through PI3K/Akt pathway
in mantle cell lymphoma. Qingshan Yang, Lisa S. Chen,
Sattva S. Neelapu, Varsha Gandhi.
4530
Mechanism-based combination therapy of PI3
kinase delta-specific inhibitor Idelalisib with
Bendamustine in chronic lymphocytic leukemia. Prexy
Shah, Kumudha Balakrishnan, William Wierda, Varsha
Gandhi.
4531
INCB40093 is a selective PI3K␦ inhibitor with
potent antiproliferative activity against human B-cell
tumors. Niu Shin, Kathy Wang, Leslie Hall, Qian Wang,
Gengjie Yang, Yanlong Li, Yun-Long Li, Maryanne Covington,
Jordan Fridman, Robert Newton, Peggy Scherle.
4532
New tolfenamic acid’s derivatives inhibit cancer
cells growth and tumor progression: Pre-clinical studies
update. Maen Abdelrahim, Mehmet Asim Bilen, Stephen
Safe, Ala Abudayyeh.
4533
Mechanism of anti-proliferative effects of
sanguinarine in pancreatic cancer cells: A label-free
quantitative proteomics approach. Chandra K. Singh,
Satwinderjeet Kaur, Jasmine George, Molly C. PellitteriHahn, Cameron O. Scarlett, Nihal Ahmad.
4534
In vivo antitumor activity of PM060184 in
patient-derived xenografted tumors (avatar). Manuel
Hidalgo, M. José Guillén, Pedro Pablo López-Casas,
Francesca Sarno, Oscar Cataluña, Mandy Palomares,
Carmen Cuevas, Pablo M. Aviles.
4535
Inhibition of cell proliferation by (R,R’)-4’methoxy-1-naphthylfenoterol in breast cancer cell lines.
Rajib K. Paul, Artur Wnorowski, Michel Bernier, Irving W.
Wainer.
4536
ABT-737 and ABT-199 complement the
multikinase inhibitor TG02 to induce apoptosis in acute
myeloid leukemia cells. Amina Abdul-Aziz, Francis
Burrows, Ning Yu, Nigel H. Russell, Claire H. Seedhouse,
Monica Pallis.
4537
Pharmacokinetics of PLK2 inhibitor GBO-006 –1,
developed as a novel first-in-class molecule to treat
triple negative breast cancer. ARNAB ROYCHOWDHURY,
ATHISAYAMANI JEYARAJ DURAISWAMY, SRINIVASARAO
MADDI, CHANDRA DEB, SAYAN MITRA, RAMANA REDDY,
MANOJ MANIAR, SHASHIDHAR JATIANI, STEPHEN C.
COSENZA, AMOL PADGAONKAR, PREMKUMAR REDDY.
4538
BAY 1112054, a highly selective, potent and
orally available inhibitor of PTEFb/CDK9, shows
convincing anti-tumor activity. Arne Scholz, Ulrich
Lücking, Gerhard Siemeister, Philip Lienau, Knut Eis, Antje
Wengner, Kirstin Petersen, Ulf Bömer, Peter Nussbaumer,
Axel Choidas, Gerd Rühter, Jan Eickhoff, Carsten SchultzFademrecht, Bert Klebl, Stuart Ince, Franz von Nussbaum,
Dominik Mumberg, Michael Brands, Karl Ziegelbauer.
4539
NMS-P862, a novel orally available selective
small molecule Cdc7 inhibitor with antitumor efficacy in
breast cancer. Alessia Montagnoli, Maria Menichincheri,
Nadia Amboldi, Dario Ballinari, Marina Ciomei, Francesco
Fiorentini, Rosita Lupi, Daniele Pezzetta, Sonia Rainoldi,
Daniele Pezzetta, Eduard Felder, Antonella Isacchi, Enrico
Pesenti, Arturo Galvani.
4540
SAC abrogation by MPS1 kinase inhibition:
preclinical proof of concept of a novel approach to
tumor treatment. Dominik Mumberg, Gerhard Siemeister,
Antje M. Wengner, Marcus Koppitz, Volker Schulze,
Benjamin Bader, Stefan Prechtl, Bertolt Kreft, Karl
Ziegelbauer.
4541
Dual targeting of CDK4 and MEK as a
combination treatment strategy for metastatic colorectal
cancer. Elizabeth Ziemke, Joseph Dosch, Amrith Shettigar,
Shanshan Wan, Theodore Welling, Karin Hardiman, Judith
Sebolt-Leopold.
30
30
531
POSTER SESSION
Poster
Section
31
31
Cell Cycle Mechanisms of Anticancer Drug Action
Poster Abstract
Board Number
1.
4542
Regulation of the cell cycle by metformin is
p21-dependent in lung cancer. Amanda Templeton,
Rajagopal Ramesh.
14.
4555
Inhibition of CDK1/2 but not CDK4/6 cooperates
with tamoxifen to induce apoptosis. Gary K. Scott, Daniel
Rothschild, Ravneet Kaur, Christopher Benz.
2.
4543
Identification of downstream targets of pololike kinase 1 in melanoma by large-scale label-free
comparative proteomics profiling. Brian D. Cholewa, Molly
P. Hahn, Cameron O. Scarlett, Nihal Ahmad.
15.
3.
4544
Induction of KLF4 by LOR-253 as an innovative
therapeutic approach to induce apoptosis in acute
myeloid leukemia. Ronnie Lum, Mojib Javadi, Tiffany
Cheng, Robert Peralta, Howard Cukier, Jeff Lightfoot, Yoon
Lee, Aiping Young, William G. Rice.
4556
A therapeutic strategy combining the Wee1
inhibitor MK1775 with HDAC inhibitors targets both p53
wild-type or mutant AML cells. Yu Zhang, Liang Zhou,
Shuang Chen, Maciej Kmieciak, Hui Lin, Yun Dai, Steven
Grant.
16.
4557
Expression of p16 in colon cancer and cyclin
D1 in gastric cancer predicts response to CDK4/6
inhibition in vitro. Zev A. Wainberg, Ann Yufa, Adrian
Anghel, Amy M. Rogers, Tin Manivong, Shahriar Adhami,
Habib Hamidi, Dylan Conklin, Richard S. Finn, Dennis J.
Slamon.
17.
4558
Resveratrol alters the kinase activity of PKG-I␣
and Src family in A2780cp cells (ovarian cancer cell line
with mutated p53) resulting in growth inhibition.
Priyatham Gorjala, Janica C. Wong, Benjamin F.
Constantino, Mary G. Johlfs, Renee Coffman, Harry
Rosenberg, Ronald Fiscus.
18.
4559
Knockdown of cyclin G2 expression hinders the
cell cycle arrest response of MCF-7 cells to estrogen
receptor signaling-antagonists and treatment with the
antidiabetic metformin. Mary C. Horne, Maike Zimmerman,
Aruni S. Arachchige Don, Michaela Donaldson, Tommaso
Patriarchi.
19.
4560
Effects of cisplatin, vorinostat, and their
combinations on EGFR-overexpressing cell lines. Asmaa
E. El-Kenawi, John K. Cowell.
20.
4561
The antihistamine cyproheptadine induces cell
apoptosis through inhibition of ␤-catenin signaling
pathways in urothelial carcinoma. Hsiao-Yen Hsieh, YuanHung Wang, Cheng-Huang Shen, Shiu-Yi Chen, Michael W.
Chan, Cheng-Da Hsu.
4550
Differential PARP inhibitors’ effects on cell
cycle and consequently homologous DNA damage
repair. Petar Jelinic, Douglas A. Levine.
21.
4562
Ginkgetin inhibits the growth of cancer cells via
the cell cycle arrest at G2-phase. Byoung-Mog Kwon,
Yu-Jin Lee.
10.
4551
Emerging effects of Chinese herbal medicines
on human cancer cells proliferation. Xufei Zhang, Hao Li,
Herschel A. Espiritu, Anita Kim, Li Zhong.
22.
4563
Mechanism of action of Ibrutinib in mantle cell
lymphoma. Zhijian Sun, Dongping Zhou, Min Wei, Lusong
Luo.
11.
4552
Trimethoxy-cis-stilbene exhibits potent antitumor activities via suppression of AKT signaling and
cell cycle arrest in virus-induced hepatocellular
carcinoma. Charles Nguyen, Hari Kotturi, Sripathi Sureban,
Randal J. May, Parthasarathy Chandrakesan, Nathaniel
Weygant, Dongfeng Qu, Courtney Houchen, Naushad Ali.
23.
4564
Inhibitory effects of the BTK inhibitor, ibrutinib,
on Her2 amplified breast cancer growth, cell cycle
progression and clonogenicity. Jun Chen, Betty Y. Chang,
Laurence Elias.
24.
4565
Bet bromodomain inhibitors affects replication
& cell cycle progression. Somsundar Veppil Muralidharan,
Joydeep Bhadury, Lydia Green, Lisa M. Nilsson, Kevin G.
Mclure, Jonas A. Nilsson.
25.
4566
Fusarochromanone inhibits cell proliferation
and induces cell death in COS7 cells. Ying Gu, Shanxiang
Jiang, Elahe Mahdavian, Shile Huang.
26.
4566A
Effect of the anti-histaminic cyproheptadine
on cell cycle of hepatocellular carcinoma cells and its
mechanisms. Cheng-Da Hsu, Yu-Min Feng, Syue-Yi Chen,
Jing-Wen Feng.
4.
4545
Anticancer effects and mechanism of VR23, a
novel chloroquine derivative. Hai-Yen T. Vu, Sheetal
Pundir, Raja V. Solomon, Hoyun Lee.
5.
4546
COX-2 inhibitors arrest prostate cancer cell
cycle progression by downregulation of kinetochore/
centromere proteins. Jared Bieniek, Chandra Childress,
Matthew Swatski, Wannian Yang.
6.
4547
Enhanced anti-tumor effect of WNT pathway
antagonists in combination with taxanes. Wan-Ching
Yen, Marcus M. Fischer, John Lewicki, Austin Gurney,
Timothy Hoey.
7.
4548
The anti-proliferative activity of TAS-108 (a
steroid anti-estrogen) is augmented by high ER␤ levels
in breast cancer cells. Ye-Hwang Cheong, Young J. Choi.
8.
4549
CDK2 inhibition causes anaphase catastrophe
through the centrosomal protein CP110. Shanhu Hu,
Alexey V. Danilov, Kristina M. Godek, Bernardo Orr, Laura J.
Tafe, Vincent A. Memoli, Fabrizio Galimberti, Saranya Ravi,
Andrew J. DeCastro, Yun Lu, Lisa Maria Mustachio, David J.
Sekula, Angeline S. Andrew, Sarah J. Freemantle, Duane A.
Compton, Ethan Dmitrovsky.
9.
12.
13.
532
Poster Abstract
Board Number
4553
Gedunin, a novel HSP-90 inhibitor, synergizes
with cisplatin and paclitaxel to inhibit growth of
chemoresistant ovarian cancer cell lines. Jessica
Johnson, Anand Venugopal, Deep Kwatra, Katherine Roby,
Andrew Godwin, Shrikant Anant.
4554
Downstream effects of rigosertib (ON 01910.Na)
in cancer cells involves impairment of protein
translation via eIF2 and eIF4. Salim Merali, Oscar PerezLeal, Carlos Barrero.
POSTER SESSION
Molecular Diagnostics
Poster
Section
Poster Abstract
Board Number
1.
2.
4567
Demonstration of pharmacodynamic effects of
Notch and PI3Kinase inhibitors using robust
immunohistochemical assays on human skin explant
models. Timothy R. Holzer, Leslie A. O’Neill, Angie D.
Fulford, Janet M. Grondin, Bradley L. Ackermann, Robert J.
Konrad, Kelly M. Credille, Aejaz Nasir.
4568
A new quantitative in-situ IHC method validation of analytical performance. Kristian Jensen,
Rikke M. Jørgensen, Kenneth H. Petersen, Jesper Lohse,
Helene Derand.
Poster Abstract
Board Number
3.
4569
Digitizing single-cell expression patterns in
urine for prostate cancer detection. Chun-Lin Lin, ChunLiang Chen, Chiou-Miin Wang, Joseph Liu, Susan Huang,
Tim Huang.
4.
4570
Role of ERRalpha in ovarian cancer. Ellen V.
Stevens, Regina Whitaker, Audrey Guinet, Ching-Yi Chang,
Carole Grenier, Jeffrey Marks, Donald P. McDonnell, Susan
K. Murphy, Andrew Berchuck, Stephanie Gaillard.
32
32
533
POSTER SESSION
Poster
Section
33
33
Novel Drug Discovery and Delivery Systems
Poster Abstract
Board Number
1.
4571
Antitumor effects of an antibody (cetuximab)targeted nanoparticle containing siRNA against EGFR.
Dorothy W. Pan, Mark E. Davis.
2.
4572
Bioorthogonal, two-component drug delivery in
HER2(ⴙ) breast cancer mouse models. Sudath
Hapuarachchige, Wenlian Zhu, Yoshinori Kato, Dmitri
Artemov.
3.
534
4573
A novel bispecific Fap-Dr5 antibody inducing
potent and tumor-specific death receptor 5 (Dr5)
activation by fibroblast activation protein (Fap)dependent crosslinking. Katharina Wartha, Barbara Weiser,
Thomas Friess, Meher Majety, Valeria Runza, Frank Herting,
Thomas Weber, Werner Scheuer, Suzana Vega Harring,
Hadassah Sade, Huifeng Niu, Peter Bruenker.
Poster Abstract
Board Number
14.
4584
A novel drug-eluting platform for localized
treatment of pancreatic cancer. Matteo Ligorio, Laura
Indolfi, David T. Ting, Kristina Xega, Nicola Aceto, Francesca
Bersani, Cristina R. Ferrone, Daniel A. Haber, Robert Langer,
Elazer R. Edelman, Jeffrey W. Clark.
15.
4585
Crocin-supplemented cisplatin is highly
effective in killing breast cancer cells than cisplatin
alone. Sachin Gupta, Bhawna Jhamb, Sanjay Katiyar.
16.
4586
The Leukosome: A biomimetic liposome for the
targeting of inflamed tumor vasculature. Roberto
Molinaro, Alessandro Parodi, Nima Taghipour, Brandon
Brown, Dickson Kirui, Michael Evangelopoulos, Francesca
Taraballi, Claudia Corbo, Ennio Tasciotti.
4.
4574
Polo box-targeted PLK1 inhibitors: structure
activity relationships and activity in cells resistant to
ATP-based inhibitors. Merissa Baxer, Sandra Craig,
Campbell McInnes, Michael Wyatt.
17.
4587
Combined administration of Voluven® 10% and
anti-cancer drugs increases anti-tumor efficacy. Silke
Baasner, Corinna Lupp, Stefanie Honndorf, Johannes
Hermle, Martin Westphal.
5.
4575
Structure-based design, synthesis and
biological testing of highly potent semi-synthetic
epipodophyllotoxin-derived hybrid etoposide analogs.
Brian B. Hasinoff.
18.
4588
Polylysine linker for successful manufacturing
of hydrophobic peptides. Firuz Shakoori.
19.
4589
Impact of tumor microenvironment on tumor
growth, metastasis and response to combination
therapy via microenvironment-responsive dual drugloaded nanoparticles and radiation. Pallavi Sethi, Amar
Jyoti, Elden Swindell, Ulrich W. Langner, William H. Clair,
Ronald C. McGarry, Thomas V. O’Halloran, Meenakshi
Upreti.
20.
4590
Cisplatin-RNAi nanotherapeutics for synergistic
anti-tumor activity. Xiaoyang Xu, Xueqing Zhang, Kun Xie,
Graham Walker, Omid Farokhzad.
21.
4591
The folate receptor-targeted agents, vintafolide
and etarfolatide, are not substrates for the reduced
folate carrier or the proton-coupled folate transporter.
Nikki Parker, Christina Cherian, Larry Matherly, Christopher
P. Leamon.
22.
4592
Etirinotecan pegol accumulates in breast cancer
brain metastases and prolongs survival in an
experimental model of brain metastases of human triple
negative breast cancer. Mohamed Nounou, Ute Hoch,
Chris E. Adkins, Tori B. Terrell, Heidi Villalba, Michael E.
Eldon, Paul R. Lockman.
23.
4593
Targeted therapy of pancreatic cancer by
intraperitoneal delivery of uPAR-targeted theranostic
nanoparticles. Ning Gao, Erica Bozeman, Weiping Qian,
Charles Staley, Andrew Wang, Hui Mao, Lily Yang.
24.
4594
Reversal of Warburg effect by Apigenin and
5-Fluorouracil loaded dual drug liposomes result in
enhanced colorectal chemotherapy. Kacoli Sen,
Shubhadeep Banerjee, Mahitosh Mandal.
6.
4576
Development of thermochemotherapy using
cisplatin and ferucarbotran (Resovist®) in head and
neck cancer. Itaru Sato, Masanari Umemura, Kenji Mitsudo,
Xianfeng Feng, Hideyuki Nakashima, Mitomu Kioi, Akiyoshi
Miyajima, Haruki Eguchi, Iwai Tohnai, Yoshihiro Ishikawa.
7.
4577
Telomere oligonucleotides induce DNA damage
responses in cancer cells: Mechanism of action and
novel nanocomplex delivery system. Luke M. Wojdyla,
Srijayaprakash B. Uppada, Neelu Puri.
8.
4578
A novel polymer-anticancer drug micelle
formulation showing enhanced efficacy over Abraxane.
Wenbin Ying, Jihua Liu, Kwok Yin Tsang, Li Wang, Haiqing
Yin, Hao Bai, Yuwei Wang, Liping Wang, Yoshiro Niitsu.
9.
4579
Pathogen-derived targets for the delivery of
chemotherapeutics to the brain. Rebecca L. McCall, Kyle
T. Householder, Eugene P. Chung, Rachael W. Sirianni.
11.
4581
A novel modular polymer platform for the
treatment of oral and head and neck carcinoma. Yuan
Lin, Sherven Sharma, Steven M. Dubinett, Ben Wu, Maie St.
John.
12.
4582
CRLX522, a novel dynamic tumor-targeted
cabazitaxel nanopharmaceutical. Douglas Lazarus, Sujan
Kabir, Scott Eliasof.
13.
4583
In situ photocontrolled intratumoral depot for
combined photodynamic therapy and brachytherapy for
solid tumor. Wenge Liu, Ratul Mukerji, Xinghai Li, Jeff
Schaal, Jayanta Bhattacharyya, Michael Zalutsky, Ashutosh
Chilkoti.
POSTER SESSION
Novel Therapeutic Targets
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
4595 RPL18A as putative target of rigosertib. Irina Oussenko,
Saikrishna Divakar, M. V. Ramana Reddy, James F. Holland, E.
Premkumar Reddy, Takao Ohnuma.
4596 An integrated genomic characterization of the target
of a small molecule identifies a novel cancer dependency. Luc
M. de Waal, Tim A. Lewis, Lara Gechijian, Aviad Tsherniak, Willmen
Youngsaye, Matthew Rees, Oliver Mikse, Mark Hickey, Patrick
Faloon, Nicola Tolliday, Angela Koehler, Monica Schenone, Kwok
Wong, Alykhan Shamji, Benito Munoz, Stuart L. Schreiber, Heidi
Greulich, Matthew L. Meyerson.
4597 Characterization and targeting of radiation-inducible
neoantigens in multiple cancer types. Lincoln Muhoro, Heping
Yan, Jeremy Hunn, Dinesh Thotala, Daniel Ferraro, Dennis Hallahan.
4598 GP130 as a novel therapeutic target in il-6-dependent
cancers. Hui Xiao, Yang Bian, Chengguang Zhao, Li Lin, David Jou,
Huameng Li, Chenglong Li, Jiayuh Lin.
4599 Negative feedback loop between serum response
factor and androgen receptor in castrate-resistant prostate
cancer. Maria Prencipe, Gillian O’Hurley, Amanda O’Neill, Dara
Lundon, Lan K. Nguyen, Susie Boyce, Colm Morrissey, Helmut
Klocker, Elaine W. Kay, William Gallagher, William Watson.
4600 P-TEFb is a therapeutic target in human bortezomibresistant multiple myeloma cells. Yun Dai, Shuang Chen, Liang
Zhou, Yu Zhang, Yun Leng, Xin-Yan Pei, Hui Lin, Robert Z. Orlowski,
Steven Grant.
4601 Astrocytic elevated gene 1 (AEG1) a target for
pharmacological anticancer intervention. Jose M. Jimeno, Gerardo
Acosta, Miguel Ángel Molina, Nicky Karachaliou, Cristina Teixidó,
Carlos Obiol, Oriol Villacañas, Jordi Bertran, María Sánchez Rouco,
Ana Giménez Capitán, Santiago Ramón y Cajal, Miquel Taron, Rafael
Rosell, Fernando Albericio.
4602 Blocking of p14/ARF and DX2 binding by novel small
chemical can improve the chemo-sensitivity of small cell lung
cancer and non-small cell lung carcinoma. Ah Young Oh, YounSang Jung, Su-Jin Lee, Jung Hyun Jo, Ho Young Chun, Bum-Joon
Park.
4603 Targeted treatment of metastatic melanoma through
interference with Pin1-FOXM1 signaling. Flore Kruiswijk,
Sebastian E. Hasenfuss, Renuka Sivapatham, Niels J. van den Broek,
Wim Kruit, Arjan B. Brenkman, Judith Campisi, Boudewijn M.
Burgering, Jan H. Hoeijmakers, Peter L. de Keizer.
4604 PTP4A3 is oncogenic and modulates triple negative
breast cancer growth. Hamid H. Gari, Rahul Ray, Scott Lucia,
Christopher C. Porter, Christy M. Gearheart, Susan Fosmire, Gregory
D. DeGala, Zeying Fan, Yuanbin Ru, Ann D. Thor, James R. Lambert.
4605 STK17A is a potential therapeutic target in
glioblastoma. Pingping Mao, Mary P. Jardine, Gilbert J. Rahme, Eric
C. Yang, Janice Tam, Anita Kodali, Bijesh Biswal, Camilo E. Fadul,
Arti B. Gaur, Mark A. Israel, Alexandre Pletnev, Michael Spinella.
4606 Involvement of an angiotensin II type 2 receptor
(AT2R) signalling in human pancreatic ductal adenocarcinoma
(PDAC): a novel AT2R agonist effectively attenuates growth of
PDAC grafts in mice. Susumu Ishiguro, Kiyoshi Yoshimura, Sonshin
Takao, Atsushi Kawabata, Terrahn Wall, Ryouichi Tsunedomi,
Masaaki Oka, Makoto Inui, Charalambos Pappas, Andreas G. Tzakos,
Masaaki Tamura.
4607 Stathmin is involved in the maternal embryonic
leucine zipper kinase pathway and impacts in the outcome of
glioblastoma. Miyuki Uno, Sueli M. Oba-Shinjo, Roseli Silva, Marcela
Gimenez, Jose C. Rosa, Suely K. Marie.
4608 Exploring anti-oncogenic properties of riluzole in
breast cancer. Miriam A. Bukhsh, Cecilia L. Speyer, Ali A. Hachem,
Mahdy Nassar, Ali A. Assi, David H. Gorski.
4609 MEF2 plays a critical role in RENCA macrobeadinduced tumor cell growth inhibition. Prithy C. Martis, Atira
Dudley, Melissa A. Laramore, Barry H. Smith, Lawrence S. Gazda.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4610 A drug repositioning approach identifies tricyclic
antidepressants as inhibitors of small cell lung cancer and
other neuroendocrine tumors. Nadine S. Jahchan.
4611 Novel lysosomotrophic agent inhibits in vivo tumor
formation and triggers calcium-dependent cell death in a variety
of human cancer cell lines. Dan Liu, Gregory L. Bellot, Sanjiv K.
Yadav, Mark Fivaz, Charnjit Kaur, Gautam Sethi, Shazib Pervaiz.
4612 JQ1 suppresses tumor growth in tumorgraft models of
pancreatic ductal adenocarcinoma. Patrick L. Garcia, Tracy
Gamblin, Leona N. Council, John D. Christein, J. Pablo Arnoletti,
Martin J. Heslin, Joseph H. Richardson, Jun Qi, Jay E. Bradner,
Karina J. Yoon.
4613 Identification of tumor necrosis factor receptor II as a
regulatory T cell target for cancer immunotherapy using
designed ankyrin repeat protein phenotypic selections. Geoff
Williams, Judith Anderton, Vahe Bedian, Jane Coates Ulrichsen,
Andrea Gonzalez-Munoz, Sandrine Guillard, Olivia Harris, James Hair,
Andrew Leishman, Arthur Lewis, Jacques Moissan, Ralph Minter,
Bina Mistry, Julie Parmentier, Edmund Poon, Amy Popple, Steve
Rust, Alan Sandercock, Ross Stewart, Viia Valge-Archer, Robert W.
Wilkinson.
4614 Identification of two salinomycin binding targets in
neuroblastoma. Shuang Zhou, Fengfei Wang, Shi-Hua Xiang, Eric T.
Wong, Wallace W. Muhonen, Ekokobe Fonkem, Tze-chen Hsieh,
David W. Li, Ruiwen Zhang, John B. Shabb, Joseph M. Wu, Min Wu,
Erxi Wu.
4615 Influence of SF3B1 gene mutation is different from
that of Sf3B1 inhibitor in colorectal cancer. Tomoki Yamano, Shuji
Kubo, Nagahide Matsubara, Aya Yano, Naohiro Tomita.
4616 Chemo-sensitisation in epithelial ovarian cancer cell
lines by targeting Ankyrin Repeat Domain 1 (ANKRD1). Ying Lei,
Beric R. Henderson, Catherine Emmanuel, Paul Harnett, Anna de
Fazio.
4617 Targeting interferon-induced transmembrane protein 1:
a novel strategy to treat inflammatory breast cancer. Joshua W.
Ogony, Joan Lewis-Wambi.
4618 Therapeutic targeting for sphingosine kinase 1 in
epithelial ovarian cancer. Jeong-Won Lee, Ji Yoon Ryu, Hye-Kyung
Jeon, Young-Ae Park, Young-Jae Cho, Jung-Joo Choi, Yoo-Young
Lee, Tae-Joong Kim, Chel Hun Choi, Byoung-Gie Kim, Duk-Soo Bae.
4619 Protein palmitoylation in non-small cell lung cancer
(NSCLC): DHHC5 palmitoyltransferase as a potential therapeutic
target. Hui Tian, Jui-Yun Lu, Chunli Shao, Kenneth Huffman, Ryan
Carstens, John D. Minna, Sandra L. Hofmann.
4620 Wild-type IDH1: A molecular target in IDH1 mutant
cancers. Julie A. Wickenden, Paul Russell, Amy Smith, Tom Henley,
Jane Elliott, Dan Gitterman, Mark Stockdale, Christine Schofield,
Chris Torrance, Jonathan D. Moore.
4621 Hedgehog acyltransferase as a novel target in breast
cancer. Armine Matevossian, Marilyn Resh.
4622 Discovery of a novel target for monoclonal antibody
therapy of breast and ovary cancers. Alberto Grandi, Susanna
Campagnoli, Matteo Parri, Elisa De Camilli, Boquan Jin, Paolo
Sarmientos, Guido Grandi, Luigi Terracciano, Giuseppe Viale, Piero
Pileri, Renata Maria Grifantini.
4623 HDAC6 inhibition is a novel strategy to selectively
impact inflammatory breast cancer cell survival. Preeti Putcha,
Jiyang Yu, Andrea Califano, Jose Silva.
4624 Molecular target identification of quinolinone based
anticancer compounds. Gabriela Rylova, Petr Dzubak, Anna
Janostakova, Ivo Frydrych, Petr Konecny, Dusan Holub, Tomas
Ozdian, Dalibor Dolezal, Miroslav Soural, Jan Hlavac, Marian
Hajduch.
34
34
535
POSTER SESSION
Poster
Section
35
35
Pharmacokinetics and Pharmacodynamics
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
536
4625 Age dependence of doxorubicin pharmacokinetics in
pediatric cancer patients; results of an FP7-funded clinical
study. Alan V. Boddy, Nicolas Andre, Gianni Bisogno, Joachim Boos,
Maurizio D’Incalci, Nina Kontny, Miriam Krischke, Swantje Voeller,
Georg Hempel.
4626 Evaluating the pharmacodynamics and
pharmacokinetic effects of MM-398, a nanoliposomal irinotecan
(nal-IRI) in subcutaneous xenograft tumor models of human
squamous cell carcinoma and small cell lung cancers. Daniel C.
Chan, Ashish Kalra, Zhiyong Zhang, Nancy Paz, Dmitri Kirpotin, Daryl
Drummond, Ulrik Nielsen, Paul A. Bunn, Jonathan Fitzgerald.
4627 Fasting reduces the systemic exposure to irinotecan
and its active metabolite SN-38. Sander A. Huisman, P de Bruijn,
I.M. Ghobadi Moghaddam-Helmantel, J.N.M. IJzermans, E Wiemer,
A.H.J. Mathijssen, R.W.F. de Bruin.
4628 Acid suppression therapy impairs sunitinib efficacy in
renal cell cancer (RCC). Michael P. Chu, Vincent Ha, Margaret Ngo,
Sunita Ghosh, Carole R. Chambers, Michael B. Sawyer.
4629 Physiologically based pharmacokinetic model and
correlative in vitro assessment of metabolism-based interaction
between Everolimus and PI3K/mTOR inhibitor BEZ235. Ganesh P.
Moorthy, Bilal Abuasal, Larry Sallans, John C. Morris, George
Thomas, Pankaj B. Desai.
4630 Population pharmacokinetic-pharmacodynamic (PPD)
modeling of masitinib administered in combination with
gemcitabine to pancreatic cancer patients. Keyvan Rezai, Saik
Urien, Sophie Weill, Lise Barbin, Alain Moussy, François Lokiec.
4631 Pharmacokinetics and in vivo metabolism of
Z-endoxifen: Results from two phase I studies in women with
ERⴙ breast cancer, gynecologic malignancies and desmoids.
Joel M. Reid, Matthew P. Goetz, Shivaani Kumar, Renee M.
McGovern, Sarah A. Buhrow, Stephanie L. Safgren, Vera J. Suman,
Travis J. Docktor, Charles Erlichman, Howard Streicher, James H.
Doroshow, Jerry Collins, Matthew M. Ames.
4632 Plasma and tumor pharmacokinetics of IV LMP400, a
novel indenoisoquinoline topoisomerase I inhibitor, in a canine
phase I study. Julie L. Eiseman, Julianne Holleran, David L.
McCormick, Miguel Muzzio, Joseph M. Covey, Chand Khanna,
Christina Mazcko, Yves Pommier, Melissa Paoloni, James D.
Doroshow, Joseph E. Tomaszewski, Jan H. Beumer.
4633 Pharmacokinetics, metabolism and excretion of
idelalisib. Feng Jin, Michelle Robeson, Huafeng Zhou, Ellen Kwan,
Srini Ramanathan.
4634 Population pharmacokinetic model of ibrutinib, a
Bruton’s tyrosine kinase inhibitor, for the treatment of B-cell
malignancies. Eleonora Marostica, Juthamas Sukbuntherng, David
Loury, Jan De Jong, Xavier Woot de Trixhie, An Vermeulen, Giuseppe
de Nicolao, Susan O’Brien, John C. Byrd, Ranjana Advani, Jesse
McGreivy, Italo Poggesi.
4635 Relative bioavailability of dovitinib (TKI258)
formulations. Samira Garonzik, Jerry Nedelman, Jeffrey Scott,
Jeffrey Cramer, Eugene Tan.
4636 Pharmacokinetic (PK) food effect study of immediaterelease onapristone and its primary metabolite (M1) in healthy
female subjects: implications for design of a new formulation.
Keyvan Rezai, Stefan Proniuk, Alex Zukiwski, Erard Gilles, Didier
Chassard, Caroline Denot, Haydee L. Ramos, Alice S. Bexon,
François Lokiec.
4637 Evaluation of the pharmacokinetics and food effect of
oral ibrutinib in healthy subjects and chronic lymphocytic
leukemia patients. Jan de Jong, Juthamas Sukbuntherng, Donna
Skee, Joe Murphy, Susan O’Brien, John C. Byrd, Danelle James,
Peter Hellemans, Juhui James Jiao, Vijay Chauhan, Italo Poggesi,
Erik Mannaert.
4638 NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting
potent antitumor activity in mouse models of human cancer.
Stéphane Ferretti, Marjorie Berger, Ramona Rebmann, Francesca
Santacroce, Dario Sterker, Michael Jensen, Keiichi Masuya,
Sébastien Jeay.
4639 Do cation-selective transporters help or hurt the
antitumor efficacy of metformin in breast cancer. Hao Cai,
Muhammad Wahajuddin, Ruth Everett, Dhiren R. Thakker.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4640 Randomized, phase 1 crossover study assessing the
bioequivalence of tablet and capsule formulations of dovitinib
(TKI258). John Sarantopoulos, Sanjay Goel, Vincent Chung, Pamela
Munster, Shubham Pant, Manish Patel, Jeffrey Infante, Hussein
Tawbi, Carlos Becerra, Justine Bruce, Fairooz Kabbinavar, Howard
Kaufman, A. Craig Lockhart, Eugene Tan, Shu Yang, Mariama Diallo,
Jeffrey Scott, Sunil Sharma.
4641 Development of modified dosing approaches to
achieve specific pharmacokinetic (PK) objectives in the first-inhuman phase I clinical trial of IMGN853, a folate receptor ␣targeting antibody drug conjugate. Jose F. Ponte, Kelli L. Running,
Maurice Kirby, Julie Chan, Jan Pinkas, James J. O’Leary, Robert J.
Lutz.
4642 Model-based alternative clinical trial designs and
evaluations for SGN-CD19A, a novel antibody-drug conjugate.
Baiteng Zhao, Tina M. Albertson, Che-Leung Law, Megan M.
O’Meara, Ana Kostic, Tae H. Han.
4643 Phase I pharmacokinetics and pharmacodynamics of a
novel indenoisoquinoline topoisomerase 1 (TOP1) inhibitor,
LMP400, administered on a daily x 5 schedule. Jan H. Beumer,
Julianne Holleran, James Doroshow, Alice Chen, Deborah Allen,
Joseph Covey, Joseph Tomaszewski, Yves Pommier, Shivaani Kumar,
Julie L. Eiseman.
4644 Efficacy, pharmacokinetics and tissue distribution of
celastrol analogues SBI 064601, SBI 0640599 and SBI 0069272
in C.B-17 SCID mice bearing Daudi Burkitt’s lymphoma
xenografts. Jianxia Guo, Kathleen Paul, Edward V. Prochownik,
Nicholas Cosford, Robert A. Parise, Jan H. Beumer, Julie L. Eiseman.
4645 Clofarabine, a potent anticancer compound with
limited penetration in an orthotopic murine model of
ependymoma. Yogesh T. Patel, Megan O. Jacus, Abigail D. Davis,
Pradeep Vuppala, Jason D. Dapper, Burgess B. Freeman, Nidal
Boulos, Stacy L. Throm, Richard J. Gilbertson, Clinton F. Stewart.
4646 PK studies of the taccalonolides. Jing Li, John Kuhn,
Jiangnan Peng, April Risinger, Susan Mooberry.
4647 Investigation of the pharmacokinetic profile of the
novel PIM2 inhibitor, JP_11646. Laura B. Pitzonka, Allison Gaudy,
Sarah Schihl, Leslie Curtin, Sandra Sexton, Carmen M. Baldino,
Justin Caserta, Yvonne Flanders, Stephane Dumas, Gerald Fetterly.
4648 Development and validation of an HPLC-UV method for
Sirolimus (sir) quantification in human blood and application to
cancer patients in routine clinical practice. Vanesa EscuderoOrtiz, Belen Valenzuela, Joseba Rebollo, Manuel Sureda, Antonio
Brugarolas.
4649 Using pharmacokinetic/efficacy modeling to identify
the optimal schedule for MLN0264, an anti- guanylyl cyclase C
(GCC) antibody-drug conjugate, in a range of xenograft models.
Shu-Wen Teng, Christopher Zopf, Johnny Yang, Brad Stringer, Julie
Zhang, Wen Chyi Shyu, Arijit Chakravarty, Petter Veiby, Jerome
Mettetal.
4650 Pharmacokinetic and pharmacodynamic study of
adjuvant gemcitabine therapy of biliary tract cancer following
major hepatectomy (KHBO1101). Yutaka Fujiwara, Shogo
Kobayashi, Hiroaki Nagano, Masashi Kanai, Etsuo Hatano, Masanori
Toyoda, Tetsuo Ajiki, Yuki Takashima, Akinobu Hamada, Hironobu
Minami, Tatsuya Ioka.
4651 Characterization of the clinical pharmacokinetics of
actinomycin D and the influence of pharmacogenetic variation
in children with cancer. Gareth J. Veal, Christopher R. Hill, Michael
Cole, Julie Errington, Ghada Malik, Alan V. Boddy.
4652 Cerebrospinal fluid pharmacokinetics and
pharmacodynamics following high-dose erlotinib treatment in
brain cancer patients. Sandra Pastorino, Sandeep C. Pingle, Emma
Langley, Phillip Kim, Tiffany Juarez, Pengfei Jiang, Christopher
Tucker, Txheng Yang, Marlon Saria, Sharat Singh, Santosh Kesari.
4653 Pharmacokinetics and biodistribution of eribulin
mesylate, paclitaxel, and ixabepilone in mouse. Krystyna
Wozniak, Ying Wu, Kenichi Nomoto, Bruce A. Littlefield, Christopher
DesJardins, Edgar Schuck, Phil Saxton, Nancy Wong, Barbara S.
Slusher.
4654 Plasma, tissue and tumor pharmacokinetics of
PM060184 in NSCL xenograft mouse model. Tiziana Pernice, Alan
Bishop, Oscar Cataluña, Mandy Palomares, Raquel Lopez, Práxedes
Núñez, Carmen Cuevas, Maria José Guillén, Pablo M. Aviles.
POSTER SESSION
Next Generation Profiling, Clinical Therapeutics, and Survivorship Research
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
4655 Molecular Inversion Probe analysis using OncoScan™
FFPE Assay Kit to detect copy number aberrations and somatic
mutations in lung tumor DNA samples from formalin-fixed
paraffin-embedded (FFPE) tissue. Ron Sapolsky, Anju Shukla,
Sumathi Venkatapathy, Chuan Chen, Carsten Bruckner, Vicky Huynh,
Liansen Liu, Xuan Shen, Kent Suyenaga, Patrick Weaver, Wai Wu,
Bitao Liu, Matt Ghent, Benjamin Bolstad, Farooq Siddiqui, Diana
Abdueva, Mirjana Alvi, Eric Fung, Jeanette Schmidt, Lawrence
Greenfield.
4656 The novel mRNA in situ hybridization method for the
detection of ALK, RET, ROS1 and NTRK1 mRNA in non-small cell
lung cancer. Noriko Hirai, Takaaki Sasaki, Yoshinori Minami,
Yoshinobu Ohsaki.
4657 Evaluation of genomic profiling in the GALAXY-1
(NCT01348126), a randomized Phase 2b study of ganetespib in
combination with docetaxel versus docetaxel alone as second
line therapy in patients with advanced NSCLC. Dean Fennell,
Alexey Antonov, Miguel L. Martins, Sanjay Popat, Suresh S.
Ramalingam, James Spicer, Vojislav M. Vukovic, Iman El-Hariry,
Vienna Reichert, Rafael Rosell.
4658 Use of a defined oleander extract by advanced cancer
patients: Case reports on toxicity and tumor-related outcomes.
Keith I. Block, Charlotte Gyllenhaal, Robert A. Newman.
4659 Point of care PK quantitation device for
pharmacokinetic guided dosing of paclitaxel as a companion
diagnostic device. Cynthia Lee, Chulho Park, Chao Hsiao.
4660 Temporal interrogation of EGFR signaling in head and
neck cancer reveals highly distinct phosphorylation waves for
individual EGFR inhibitors. Gopal Iyer.
4661 The regulatory mechanism of fibronectin in EGFR and/
or HER2 positive breast cancer. Myeongjin Jeon.
4662 Prognostic value of total lesion glycolysis from 18Ffluorodeoxyglucose positron emission tomography patients with
gastric neuroendocrine carcinoma. Minkyu Jung, Beodeul Kang, Ji
Soo Park, Sun Min Lim, Hyo Song Kim, Sun Young Rha, Joong Bae
Ahn, Hyun Cheol Chung, Mijin Yun, Arthur Cho.
4663 KRAS, BRAF, and EGFR mutational analysis in ovarian,
colon, and lung cancers by highly multiplex PCR/barcodedmagnetic-bead (BMB) suspension-array assays. Jason Lei, Julia
Hsu, Peggy Jen, Daniel Huang, Andre Chung, Lloyd Kao, Miller
Chang, Chiou-Chung Yuan, Wei-Hwa Lee, Chi-Tai Yeh, Dean Tsao.
4664 Single-cell transcriptome analysis on lung squamous
cell carcinoma derived from a patient. Kyu-Tae Kim, Hye-Won
Lee, Kyeung Min Joo, Sang-Chul Kim, Jin-Ku Lee, Nakho Chang,
Jason K. Sa, Yu Jin Cho, Do-Hyun Nam, Hae-Ock Lee, Woong-Yang
Park.
4665 Quantitative in situ biomarker analysis via
ultrasensitive RNA in situ hybridization and automated image
analysis. Hongwei Wang, Laurent Lessard, Nan Su, Yuling Luo, Dave
Hoon, Xiao-Jun Ma.
4666 Profiling mesothelin protein expression by
immunohistochemistry and gene expression in adenocarcinoma
and squamous cell carcinoma of lung. Jackson Wong, Dana
Gaffney, Michael Sharp, Brenda Hertzog, Jayaprakash Karkera, Suso
Platero, John Alvarez.
4667 The impact of IASLC/ATS/ERS classification of lung
adenocarcinoma on survival after recurrence in resected
adenocarcinoma. Jung-Jyh Hung, Teh-Ying Chou, Wen-Hu Hsu,
Yu-Chung Wu.
4668 A next generation sequencing assay to detect the
fusion products of ALK, ROS1 and RET with any fusion partner
genes and hotspot mutations in FFPE samples. Qiang Xu, Guan
Wang, Bo Li, Maoxiang Qian, Douglas Fang, Lele Sun, Yundi Chen,
Hongye Sun.
4669 Prevalence of high risk human papillomavirus infection
in different cervical cytological features among health
examination of women in National Cancer Institute, Thailand.
Suleeporn Sangrajrang, Piyawat Laowahutanont, Anant Kalalak,
Paphawin Jamsri.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4670 Characterization of Met signaling in urothelial cancer
of the bladder. Young H. Lee, Andrea Apolo, Piyush K. Agarwal,
Donald P. Bottaro.
4671 Dual mutational changes of ALK gene fusion combined
with EGFR or K-ras oncogenes in lung adenocarcinomas. Jieun
Lee, Suk Hee Hong, Eun Kyung Jeon, Jung Oh Kim, Seung Joon
Kim, Young Kyoon Kim, Jae Gil Park, Sook-Whan Sung, Tae-Jung
Kim, Jin Hyoung Kang.
4672 MicroRNA expression signature of gastric carcinoma
patients treated with neoadjuvant chemotherapy. Michelle M.
Barcelos Baldoni, Cláudia M. Coutinho Camillo, Maria Dirlei F.
Begnami.
4673 ARID1A expression and its relation with microsatellite
instability and clinicopathological characteristics in colorectal
and gastric cancers of Korean patients. Soo Young Lee, DuckWoo Kim, Hye Seung Lee, Myong Hoon Ihn, Heung-Kwon Oh, SungBum Kang.
4674 Finding cancer biomarkers in platelets. Lee-Ann TjonKon-Fat, Marie Lundholm, Thomas Wurdinger, Camilla Thellenberg,
Anders Widmark, Pernilla Wikström, Jonas Nilsson.
4675 Detection of ALK, ROS1, and RET translocations in
non-small cell lung cancer (NSCLC) patients by intragenic
differential expression analysis. Shih-Min Cheng, Cindy Barlan,
Feras Hantash, Heather R. Sanders, Patricia H. Chan, Vladimira
Sulcova, Marc A. Sanidad, Kevin Qu, Joann C. Kelly, Fatih Z. Boyar,
Anthony D. Sferruzza, Frederic M. Waldman.
4676 In-vitro adenosine triphosphate-based chemotherapy
response assay (ATP-CRA) results comparison between primary
and recurrent gynecologic cancer using a unique cohort. Eun Ji
Nam, Young Tae Kim, Sang Wun Kim, Sunghoon Kim, Ga Won Yim.
4677 Niclosamide analogs for treatment of ovarian cancer.
Christen L. Walters Haygood, Rebecca C. Arend, Pui-Kai Li, Yonghe
Li, Chandrika Kurpad, Abhishek Gangrade, John M. Straughn, Donald
Buchsbaum.
4678 Application of the EGFR in squamous lung cancer and
its relationship between p63. Yiping Han, Bibo Wang, Ling Huang,
Li Qiang.
4679 Novel pathway mutations in malignant mesothelioma
revealed by high-throughput DNA and RNA sequencing. Akihiko
Miyanaga, Mari Masuda, Koji Tsuta, Yuka Nakamura, Hisao Asamura,
Akihiko Gemma, Tesshi Yamada.
4680 Effect of various anticoagulants on the bioanalysis of
drugs in rat blood: Implications for pharmacokinetic studies of
anticancer drugs. Preeti Kulkarni, Kamal Pathak, Murari Gurjar,
Sagar Dhoble, Arvind Naik, Bhaskar Gavitre, Bhaskar Vidhun, Vikram
Gota.
4681 The use of patient derived malignant effusions as in
vitro models for a personalized healthcare-approach in
anticancer therapy. Christian Ruiz, Tatjana Vlajnic, Leila Arabi, Sina
Wyttenbach, Betty Baschiera, Sacha Rothschild, Stefan Kustermann,
Alfred Zippelius, Adrian Roth, Lukas Bubendorf.
4682 Recurrence risk factors for advanced gastric cancer
after D2 gastrectomy followed by adjuvant chemotherapy. JunEul Hwang, Min-Jee Kim, Hyun-Jeong Shim, Woo-Kyun Bae, SangHee Cho, Ik-Joo Chung.
4683 Neuropathic pain in breast cancer patients undergoing
radiotherapy. Eunkyung Lee, Cristiane Takita, Jean L. Wright, Wei
Zhao, Isildinha Reis, Omar L. Nelson, Jennifer J. Hu.
4684 Medical providers perceive a lack of trust in the
medical system leads to suboptimal esophageal cancer care for
African American patients. Sumaiya Sarwar, Michael T. Kemp,
Sha’Shonda L. Revels, Benjamin M. Eilender, Steven R. Houtschilt,
Clifford Akateh, Rishindra M. Reddy.
Poster
Section
36
36
537
POSTER SESSION
Poster
Section
37
37
Preclinical to Clinical Translational Research
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
538
4685 Caffeine and caffeic acid inhibit growth and modify
estrogen receptor (ER)-␣ and insulin-like growth factor I receptor
(IGF-IR) levels in human breast cancer. Ann H. Rosendahl, Claire M.
Perks, Andrea Markkula, Maria Simonsson, Carsten C. Rose, Christian
Ingvar, Jeff M. Holly, Helena Jernström.
4686 MicroRNA mir-93 activates oncogenic c-Met/PI3K/Akt
pathway targeting PTEN in hepatocellular carcinoma. Katsuya Ohta,
Hiromitsu Hoshino, Keisuke Hata, Jinhua Wang, Sharon Huang, Vijay
Menon, Steven Colquhoun, Dave S. Hoon.
4687 The PI3K inhibitor GDC-0941 is synergistic with
lapatinib, and mediates endocrine sensitivity in uterine papillary
serous carcinoma. Kelly S. Levano, Alicia Rodriguez-Gabin, Gary L.
Goldberg, Susan B. Horwitz, June Y. Hou.
4688 Novel prognostic subtype of hepatocellular carcinoma
reflecting stem/maturational status of the tumor defined by GdEOB-DTPA-enhanced MRI and serum AFP. Taro Yamashita, Masao
Honda, Shuichi Kaneko.
4689 Pre-clinical investigation of the wee1 inhibitor MK-1775
using pharmacodynamic and mechanistic markers in diverse
cancer models in vivo. Deborah F. Wilsker, Allison M. Marrero,
Melinda Hollingshead, Scott M. Lawrence, Alice Chen, Shivaani
Kummar, Joseph M. Covey, Ralph E. Parchment, Robert J. Kinders,
Joseph E. Tomaszewski, James H. Doroshow.
4690 A multimodality imaging end-point study of everolimus
and ganetespib in treatment of pancreatic cancer: A pre-clinical
PET/MRI/MRS study. Justin Y. Lee, Lora A. Wilson, Jerry Choi, Kendra
M. Huber, Andrea L. Merz, Colin D. Weekes, Natalie J. Serkova.
4691 Overactivation of poly (ADP-ribose) polymerase (PARP)
in localised non-small cell lung cancer (NSCLC) predicts dismal
prognosis. Judith Michels, Aïcha Goubar, Julien Adam, Lorenzo
Galluzzi, Ken André Olaussen, Angélique Robin, Philippe Girard, Isabelle
Kremer, Maria Castedo, Jean-Charles Soria, Guido Kroemer.
4692 Relationships between somatic genomic alterations,
tumor stage and progression-free survival in cervical cancer.
Akinyemi I. Ojesina, Bradley Murray, Line Bjorge, Kathrine Woie,
Camilla Krakstad, Lee Lichtenstein, Chandra Sekhar Pedamallu, Amaro
Taylor-Weiner, Samuel S. Freeman, Andrew D. Cherniack, Michael S.
Lawrence, Kristian Cibulskis, Scott L. Carter, Heather Walline, Thomas
E. Carey, Olav K. Vintermyr, Bjorn Bertelsen, Christopher P. Crum, Gad
Getz, Matthew Meyerson, Helga B. Salvesen.
4693 Inhibition of BET bromodomain targets PTEN positive
endometrioid endometrial cancers. Haifeng Qiu, Amanda Jackson,
Joshua Kilgore, Chunxiao Zhou, Victoria L. Bae-Jump.
4694 Indices of actionability and clinical utility in a CLIAenabled study of whole genome/exome/RNA sequencing in 33
cancer patients: Actionable vs. utility. Jan B. Egan, Alan H. Bryce,
Mia D. Champion, Winnie S. Liang, Rafael Fonseca, Ann E. McCullough,
Michael T. Barrett, Katherine Hunt, Rachel M. Condjella, Robert R.
McWilliams, Stephen D. Mastrian, Janine LoBello, Daniel Von Hoff,
David W. Craig, A. K. Stewart, John D. Carpten, Mitesh J. Borad.
4695 Role of KITENIN in malignant gliomas in relation to
tumor invasiveness. Kyung-Hwa Lee, Kyung-Sub Moon, Eun-Jeong
Ahn, Se-Jeong Oh, Sang-Hee Cho, Jae-Hyuk Lee, Shin Jung, Kyung
Keun Kim.
4696 Identification of driver mutations and gene
amplifications in resected asophageal adenocarcinoma: Impact on
clinical care. Haiyu Zhou, Luis Tapias Vargas, Justin Elliot, Douglas J.
Mathisen, Michael Lanuti.
4697 Quantitation of BRAF V600E alleles predicts papillary
thyroid cancer progression. Chan Kwon Jung, Min Hee Kim, Ja
Seong Bae, Dong Jun Lim, Hyoungnam Lee, So Ra Jeon, Gyeong Sin
Park.
4698 Gene expression profiling distinguishes between
endometrial stromal tumors subtypes. Joanna Przybyl, Magdalena
Kowalewska, Anna Quattrone, Barbara Dewaele, Vanessa Vanspauwen,
Julio Finalet-Ferreiro, Michal Swierniak, Elwira Bakula-Zalewska,
Janusz A. Siedlecki, Mariusz Bidzinski, Jan Cools, Maria DebiecRychter.
4699 Analytical validation of solid tumor fusion gene detection
in a comprehensive NGS-based clinical cancer genomic test.
Roman Yelensky, Amy Donahue, Geoff Otto, Michelle Nahas, Jie He,
Frank Juhn, Sean Downing, Garrett M. Frampton, Juliann Chmielecki,
Jeffrey S. Ross, Maureen Zakowski, Marc Ladanyi, Vincent A. Miller,
Philip J. Stephens, Doron Lipson.
Poster Abstract
Board Number
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
4700 One size does not fit all: Fingerprinting advanced
carcinoma of unknown primary through comprehensive profiling
identifies aberrant activation of the PI3K and MAPK signaling
cascades in concert with impaired cell cycle arrest. Ishwaria M.
Subbiah, Gauri Varadhachary, Apostolia M. Tsimberidou, Jennifer J.
Wheler, Vivek Subbiah, Filip Janku, Sinchita Roy Chowdhury, Ralph
Zinner, Funda Meric-Bernstam, David S. Hong.
4701 Acquisition of Oct-4 upregulation transactivates MDR1
and is associated with increased tumor recurrence in bladder
cancer. Chia-Sing Lu, Ai-Li Shiau, Gia-Shing Shieh, Bing-Hua Su, WuChou Su, Wen-Horng Yang, Chao-Liang Wu.
4702 Caveolin-1 confers a multi-modality therapy resistance
phenotype in pancreatic cancer cells. Moumita Chatterjee, Terence
M. Williams.
4703 Genome & exome analysis of early colon cancers reveals
new targets. Avijit Majumdar, Jian Chen, Sue H. Lin, Lior Katz,
Gottumukkala S. Raju, Kirti Shetty, Jon White, Xifeng Wu, Asif Rashid,
John S. McMurray, Kenna R. Shaw, Xiaoping Su, Brian Weston, Selvi
Thirumurthi, Aiwu R. He, Lopa Mishra.
4704 Prognostic significance of T gene SNP s2305089 in
individuals with spinal column chordoma. Peter Varga, Charles
Fisher, Lawrence Rhines, Ziya Gokaslan, Stefano Boriani, Áron Lazary,
Wei-Lien Wang, Niccole Germscheid, Stephen Yip, Chetan Bettegowda.
4705 Integrating germline cancer predisposition gene testing
into routine clinical practice - The Mainstreaming Cancer Genetic
programme. Nazneen Rahman, The Mainstreaming Cancer Genetics
Consortium.
4706 Biomarker selection defines a subgroup of hepatocellular
carcinoma (HCC) patients with poor prognosis who are candidates
for MET inhibition strategy. Annemilai Tijeras-Raballand, Miguel
Albuquerque, Cindy Neuzillet, Nathalie Colnot, Friedhelm Bladt, Christian
Ihling, Manfred Klevesath, Hongxia Zheng, Eric Raymond, Armand de
Gramont, Sandrine Faivre, Valérie Paradis.
4707 Comprehensive integrated genomic analysis. Catherine K.
Foo, John St. John, Nicholas Hahner, Oscar Westesson, Mitchell E.
Skinner, Urvish Parikh, Kimberly Lung, Aleah F. Cauhlin, Jeffrey P.
Catalano, Anne S. Wellde, Jonathan K. Barry, George W. Wellde, Patrick
Ma, Rafael Rosell, Andres F. Cardona Zorilla, William R. Polkinghorn,
Trever G. Bivona, Jonathan S. Weissman, Petros Giannikopoulos.
4708 Treatment-associated changes in whole-body metabolic
tumor volume on 18F-fluorocholine PET/CT: potential prognostic
value in castrate-resistant prostate cancer. Sandi Kwee, John Lim,
Kathleen Kromer-Baker, Kyle Miyazaki, Miles Sato, Dayna LucuabFegurgur, Marc N. Coel.
4709 ERK1/2 regulates hepatocellular carcinoma through
proinflammatory homeobox gene, ISX. Shen-Nien Wang, Shih-Hsien
Hsu.
4710 Innovative technologies to overcome disparities in
prostate cancer research: Using snap-frozen prostate biopsy tissue
prints to expand patient representation in biorepository collections
used for molecular biomarker research. Sandra M. Gaston, Gary P.
Kearney, Rick Kittles, Peter N. Kolettis, George W. Adams, William E.
Grizzle.
4711 The PI3K-␦ inhibitor TGR-1202 in combination with
Brentuximab Vedotin (SGN-35) synergistically induces G2/M phase
arrest and cell death via inhibition of tubulin polymerization in
Hodgkin lymphoma cell lines. Silvia L. Locatelli, Silvia Tartari, Luca
Castagna, Luca Rubino, Srikant Viswanadha, Peter Sportelli, Armando
Santoro, Carmelo Carlo-Stella.
4712 Personalized ovarian cancer surveillance and detection
of a therapeutic drug target in circulating tumor DNA. John A.
Martignetti, Olga Camacho-Vanegas, Nolan Priedigkeit, Catalina
Camacho-Vanegas, Elena Pereira, Li Lin, Bojan Losic, hardik Shah, Jun
Liao, Jian Ma, Pratik Lahiri, Mark Chee, Eric Schadt, Peter Dottino.
4713 High-throughput multiplex Sequenom MassARRAY
clinical diagnostic assay for the identification of actionable
genetic variants in hematologic malignancies. Mahadeo A. Sukhai,
Mariam Thomas, Tong Zhang, Cuihong Wei, Suzanne Trudel, Karen
Yee, Mark D. Minden, Andre Schuh, Tracy Stockley, Suzanne KamelReid.
4714 The association of glioma germline risk SNPs with
mutation-based molecular subgroups. Jeanette E. Eckel-Passow,
Thomas M. Kollmeyer, Gobinda Sarkar, Anisha Chada, Paul A. Decker,
Matthew L. Kosel, Alissa A. Caron, Hugues Sicotte, Kannabiran
Nandakumar, Naresh Prodduturi, Brian P. O’Neill, Daniel H. Lachance,
Robert B. Jenkins.
POSTER SESSION
Prognostic Markers and Cancer Biology
Poster
Section
Poster Abstract
Board Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
4715 OX40 expression improves the prognostic value of
CD8 positive lymphocyte density in colorectal carcinoma.
Benjamin Weixler, Raoul A. Droeser, Roberto Sorge, Tarik Delko,
Christian A. Nebiker, Giandomenica Iezzi, Giulio C. Spagnoli,
Christoph Kettelhack, Urs W. von Holzen, Daniel Oertli, Luigi
Terracciano, Luigi Tornillo, Giuseppe Sconocchia.
4716 Discovery of biomarkers from highly enriched
prostate cancer microparticles for prognostication of
prostate cancer. Colleen N. Biggs, Quiquan Guo, Jun Yang,
Ann F. Chambers, Joseph L. Chin, Nicholas Power, Hon S.
Leong.
4717 Detection of the Cyclin J (CCNJ) as a new cancerrelated gene in human hepatocellular carcinoma by using a
method of triple combination array analysis. Nao Takano,
Shuji Nomoto, Mitsuhiro Hishida, Yoshikuni Inokawa, Masamichi
Hayashi, Mitsuro Kanda, Yukiyasu Okamura, Yoko Nishikawa,
Chie Tanaka, Daisuke Kobayashi, Suguru Yamada, Goro
Nakayama, Tsutomu Fujii, Hiroyuki Sugimoto, Masahiko Koike,
Michitaka Fujii, Shin Takeda, Yasuhiro Kodera.
4718 ERO1L, a novel prognostic marker of gastric
cancer patient survival, mediates cancer cell invasion and
chemoresistance. So-Young Seol, Jae Yun Lim, Sun Och Yoon,
Soon Won Hong, Jong Won Kim, Seung Ho Choi, Jae Yong Cho.
4719 Associations between IL-6 genotype and IL-6related tumor alterations in ERⴙ breast cancer: results
from ECOG2190/Int0121. Angela M. Demichele, Michelle
Donelson, Sara Komrokian, Christopher Colameco, Jinbo Chen,
Lu Chen, Robert Gray, Jennifer Nnoli, William Vaughan, Karen
Anderson, Jacqueline Bromberg.
4720 Evaluation of a genomic classifier (Decipher®) in
subsets of primary tumors with common prostate cancer
genomic alterations. Mohammed Alshalalfa, Ismael Vergara,
Nicholas Erho, Elai Davicioni, Robert Jenkins, Kollmeyer
Thomas.
4721 Polymorphisms in cancer-related genes and
survival in early stage non-small cell lung cancer. Shin Yup
Lee, Yi Young Choi, Hyo-Sung Jeon, Jin Eun Choi, Hyo-Gyoung
Kang, Seung Soo Yoo, Eung Bae Lee, Won Kee Lee, Jaehee
Lee, Seung Ick Cha, Chang Ho Kim, Ji Woong Son, Jae Yong
Park.
4722 Transcription factor PAX6 is expressed in human
soft tissue sarcomas and confers negative impact on
patients’ survival. Yury Kiselev, Andrej Valkov, Ingvild Mikkola,
Igor Snapkov, Sveinung Sorbye, Roy Bremnes, Lill-Tove Busund.
4723 Prognostic significance of EGFR expression in
localized gastric cancer. Ji Soo Park, Hyo Song Kim, Yoon
Sung Bae, Sung Hoon Noh, Hyunki Kim.
4724 Adverse prognostic significance of TNFAIP8 protein
expression in non small cell lung cancer. Bhaskar V.
Kallakury, Usha N. Kasid, Olga Voronel, Christopher B. Sheehan,
Christine E. Sheehan, Jeffrey S. Ross.
4725 Elevated co-expression of CCL2 and CX3CL1 is
associated with apoptosis and good prognosis in soft tissue
sarcoma patients. Elke Nolte, Astrid Kehlen, Thomas Greither,
Sven Wach, Matthias Kappler, Matthias Bache, Hans-Jürgen
Holzhausen, Christine Lautenschläger, Steffen Göbel, Peter Würl,
Uta-Dorothee Immel, Abbas Agaimy, Bernd Wullich, Helge
Taubert.
4726 Virus-guided fluorescence imaging of
intraperitoneal free gastric cancer cells as a potential
clinical biomarker. Megumi Watanabe, Shunsuke Kagawa,
Michihiro Ishida, Naoto Hori, Satoru Kikuchi, Shinji Kuroda,
Hiroyuki Kishimoto, Masahiko Nishizaki, Hiroshi Tazawa,
Toshiyoshi Fujiwara.
4727 Prognostic roles of DDB2 and XPC mRNA
expressions in treatment responses and overall survivals of
head and neck cancer patients. Chang-Shen Lin, Ka-Wo Lee,
Jau-Ling Huang, Yu-Chu Wang, Yi-Shan Tsai.
4728 FGFR1 gene amplification in small cell lung cancer.
Ji Soo Park, Jae-Seok Lee, Hyo Sup Shim, Hye Ryun Kim, Sun
Min Lim, Joo Hang Kim, Byoung Chul Cho.
Poster Abstract
Board Number
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
4729 Expression of lumican is negatively associated
with the risk of biochemical recurrence in human prostate
cancer. Marco A. De Velasco, Yuji Hatanaka, Takashi Oki, Yurie
Kura, Yutaka Yamamoto, Kazuhiro Yoshimura, Nobutaka
Shimizu, Masahiro Nozawa, Kazuhiro Yoshikawa, Kazuto Nishio,
Hirotsugu Uemura.
4730 Identification of novel prognostic signatures in
rhabdomyosarcoma by whole transcriptome expression
profiling: A discovery and validation study. Anirban P. Mitra,
Sheetal A. Mitra, Jonathan D. Buckley, Philipp Kapranov, James
R. Anderson, Stephen X. Skapek, Douglas S. Hawkins, Timothy
J. Triche.
4731 High level of nuclear heat-shock factor 1 is
associated with aggressive disease and suggests targets
for therapy in endometrial carcinoma. Hilde Engerud, Ingvild
Løberg Tangen, Anna Berg, Kanthida Kusonmano, Ingunn
Stefansson, Helga B. Salvesen, Camilla Krakstad.
4732 Vasohibine-1 negative and EZH2 positive may
predict the prognosis of cholangiocarcinoma. Shigeki
Nakagawa, Yasuo Sakamoto, Ryuma Tokunaga, Takaaki Higashi,
Keita Sakamoto, Akira Chikamoto, Takatoshi Ishiko, Toru Beppu,
Hideo Baba.
4733 p62/sequestosome 1, a potent prognostic factor,
enhance cell proliferation in human colorectal carcinoma.
Shun Nakayama, Takashi Suzuki, Shinichi Yabuuchi, Kiyoshi
Takagi, Yoshiaki Onodera, Yasuhiro Nakamura, Mika Watanabe,
Fumiyoshi Fujishima, Hiroshi Yoshida, Takanori Morikawa,
Hideaki Karasawa, Tomohiko Sase, Takeshi Naitoh, Yu Katayose,
Shinichi Egawa, Michiaki Unno, Hironobu Sasano.
4734 Activation of yap1 is significantly associated with
poor prognosis and cetuximab resistance in colorectal
cancer patients. Keun-Wook Lee, Sung Sook Lee, Sang-Bae
Kim, Yun-Yong Park, Bo Hwa Sohn, Hyun-Sung Lee, Ju-Seog
Lee.
4735 Stem cells like phenotype of inflammatory breast
cancer and locally advanced breast cancer: increased
expression of sox2 and oct3/4 contributes to poor response
to treatment and reduced survival rates. Abdel-Rahman N.
Zekri, Abeer Bahnassy, Ahmed E. El-Bastawisy, Hanan R.
Nassar, Neveen M. Elhady, John Effat.
4736 Inhibition of STAT3 sensitizes neuroblastoma
xenografts cells to Etoposide. Shuang Yan, Carol Thiele.
4737 Role of hypoxia-inducible factor-1␣, carbonic
anhydrase-IX and glucose transporter-1 in cervical cancer.
Keita Iwasaki, Hiromitsu Yabushita, Taiki Ueno, Akihiko
Wakatsuki.
4738 Clinicopathological roles of adiponectin receptor
and leptin receptor in endometrial carcinoma. Hiromitsu
Yabushita, Keita Iwasaki, Taiki Ueno, Akihiko Wakatsuki.
4739 Nutrient depletion caused by PKR induces
phosphorylation of AMPK in lung cancer. Apar Pataer,
Chengcheng Guo, Ruping Shao, Arlene M. Correa, Carmen
Behrens, Bingliang Fang, Jack A. Roth, Ignacio I. Wistuba,
Stephen G. Swisher.
4740 Real-time impedance analysis of triple negative
breast cancer cells from African Americans demonstrates
oncogenic mutant p53 (mtp53) is a promoter of cellular
deformability. Nataly Shtraizent, Menglu Shi, Alla Polotskaya,
Hiroshi Matsui, Jill Bargonetti.
4741 SerpinA1 promotes gastric cancer progression
through regulation of snail. Chae Hwa Kwon, Hye Ji Park,
Hyun Jung Moon, Ja-Rang Lee, Do Youn Park.
4742 Comprehensive analysis of the PI3K-Akt-mTOR
pathway in epithelial ovarian carcinoma. Tetsuro Oishi,
Hiroaki Itamochi, Nao Oumi, Misaki Kato, Tadahiro Shoji,
Yasushi Saga, Hiroyuki Fujiwara, Muneaki Shimada, Toru
Sugiyama, Mitsuaki Suzuki, Junzo Kigawa, Tasuku Harada.
4743 Analysis of a protein expression biomarkers in HPV
negative SCCHN. Ranee Mehra, Donghua Yang, Elizabeth
Handorf, Ilya Serebriiskii, Eric Ross, Miriram Lango, John A.
Ridge, Erica Golemis, Barbara Burtness.
38
38
539
LATE-BREAKING POSTER SESSIONS
Tuesday, 1:00 p.m.-5:00 p.m.
Hall A-E, San Diego Convention Center
Abstracts will be available online and in the Proceedings Part 2 beginning Friday, April 4.
Poster Section 39
Late-Breaking Research: Prevention
Poster Section 41
Late-Breaking Research: Immunology
540
Tuesday, 1:30 p.m.-3:30 p.m.
Technology Transfer and Intellectual Property: Financial and Career
Opportunities for Researchers
Chairperson: Phuong Kim Pham, National Institutes of Health, Bethesda, MD
Technology transfer (TT) is the licensing or sale of intellectual property (IP), including patents,
patent applications, know-how, and trade secrets, from one party to another in exchange for
financial compensation and further development of the technology.
What do scientists need to know about IP/TT? What kind of financial consideration as well as
career opportunities can scientists receive from getting involved in TT as an inventor or with a
career in TT? Come and join representatives from Cooley Law Firm, Merck, The Salk Institute of
Biological Studies, University of Southern California, and National Institutes of Health for a lively
discussion on their IP/TT experiences and career paths, and discover new opportunities.
Speakers:
Michelle Booden, The Salk Institute, La Jolla, CA
Jennifer Dyer, University of Southern California, Los Angeles, CA
Bonnie Weiss McLeod, Cooley LLP, Washington, DC
Phuong Kim Pham, National Institutes of Health, Bethesda, MD
541
CAREER CONVERSATIONS
Tuesday, 2:30 p.m.-3:30 p.m.
Balancing Research and Clinical Responsibilities: What Every
Physician-Scientist Should Know
Career Conversations, organized by the Associate Member Council, are informal networking and
discussion sessions designed to allow early-career scientists the opportunity to interact with junior
faculty and scientists. This session will address the best strategies for physician-scientists to
balance clinical duties with a strong research program. Open to all graduate students, medical
students, residents, and clinical and postdoctoral fellows, this session will take place in the
Associate Member Resource and Career Center located in AACRcentral; limited seating is
available on a first-come, first-served basis. #AACR14 #AACRCC
Speakers:
Manish K. Aghi, University of California, San Francisco, CA
Yael P. Mosse, Children’s Hospital of Philadelphia, Philadelphia, PA
MEET AND GREET
Tuesday, 2:30 p.m.-3:30 p.m.
Meet the Mentor: Undergraduate Focus
This session will feature a leading scientist, who will engage undergraduate students in an informal
discussion about cancer research. Key answers will also be provided to important questions to
help guide students in their professional development throughout their cancer research career. All
undergraduate student attendees at the Annual Meeting are invited to participate in this session.
542
AACR CICR AWARD LECTURE
Tuesday, 3:00 p.m.-4:00 p.m.
Eighth Annual AACR Award for Outstanding Achievement in
Chemistry in Cancer Research
Uniquely Effective Synthetic Analogs of the Complex
Antitumor Natural Products Vinblastine and the Duocarmycins
Dale L. Boger, PhD
Chairman and Richard & Alice Cramer Professor of Chemistry
Department of Chemistry, The Scripps Research Institute, La Jolla, CA
The AACR and its Chemistry in Cancer Research Working
Group established the Outstanding Achievement in
Chemistry in Cancer Research Award in 2007 to
recognize the importance of chemistry in advancing
cancer research. The Award is presented for outstanding,
novel chemistry research that has led to significant
contributions to the fields of basic or translational cancer
research, cancer diagnosis, prevention, or clinical cancer
treatments and therapeutics.
extraction techniques to isolate and purify libraries. His
work led to the founding of CombiChem, a successful
combinatorial chemistry company sold to DuPont. He
provided a total synthesis of distamycin A and library of
its analogs through the solution-phase approach. He
then developed rapid, high-throughput screens for
determining relative DNA binding affinity and DNA
binding sequence selectivity of the libraries that revealed
novel DNA binding agents.
Dr. Dale L. Boger, currently Richard and Alice Cramer
Professor and Chair of the Department of Chemistry at
The Scripps Research Institute in La Jolla, California, is
honored for his development of elegant and highly
dependable synthetic methods to construct numerous
naturally ocurring highly potent anticancer agents. His
work is characterized by the pursuit of detailed structurefunction relationships of natural or designed agents in
order to understand the fundamental structural bases of
their anticancer properties. In these studies Dr. Boger’s
group addresses the challenging problem of
understanding the beautiful solutions and subtle design
elements that nature has provided in the form of a natural
product and endeavors to extend the solution through
rational design elements to provide more selective, more
efficacious, or more potent agents designed specifically
for the problem or target under investigation.
Dr. Boger has received numerous awards including the
1988 American Chemical Society A.C. Cope Scholar
Award, 2002 Paul Janssen Prize for Creativity in Organic
Synthesis, 2003 Royal Society of Chemistry Adrien
Albert Medal, 2007 American Chemical Society Ernest
Guenther Award in the Chemistry of Natural Products,
and the 2013 American Chemical Society Hirschmann
Award in Peptide Chemistry. He was elected to the
American Academy of Arts and Sciences, named a
Fellow of the Royal Society of Chemistry (2009), and is a
Fellow of the American Chemical Society (2010).
Dr. Boger’s group is particularly recognized for his many
contributions to unravelling the complex properties of the
sequence-specific DNA alkylating natural products such
as CC-1065, duocarmycins, bleomycin A2, sandramycin,
luzopeptins, and isochrysohermidin. A number of the
potent antitumor agents he has synthesized are being
used in antibody-drug conjugates, which are finding
widespread use in cancer drug discovery.
Dr. Boger’s seminal contributions to combinatorial
chemistry include the use of solution-phase library
synthesis. He devised liquid-liquid and liquid-solid
Beyond Dr. Boger’s specific contributions to the cancer
research community, the broader scientific community
has benefitted: He has educated over 50 PhD students
and over 150 postdoctoral associates who now conduct
important work in their own right, and he was the
founder and remains the Editor-in-Chief of Bioorganic &
Medicinal Chemistry Letters, a journal where important
findings in cancer research are presented.
Dr. Boger earned his BSc at the University of Kansas in
1975 and earned his PhD in Organic Chemsitry with E.J.
Corey at Harvard in 1980. Following his PhD, he returned
to the University of Kansas in the Department of
Medicinal Chemistry from 1979-1985. He then moved his
research group to the Chemistry Department at Purdue
University from 1985-1990 when he moved to The
Scripps Research Institute.
543
AACR-ACS AWARD LECTURE
Tuesday, 3:00 p.m.-4:00 p.m.
Twenty-Third Annual AACR-American Cancer Society Award for Research
Excellence in Cancer Epidemiology and Prevention
Integration of Cancer Epidemiology and Biomarkers in
Precision Cancer Medicine
Curtis C. Harris, MD
Chief, Laboratory of Human Carcinogenesis
National Cancer Institute, Bethesda, MD
The AACR and the American Cancer Society established
this Award in 1992 to honor outstanding research
accomplishments in the fields of cancer epidemiology,
biomarkers, and prevention.
Dr. Curtis C. Harris is honored for his exceptional career
in molecular cancer epidemiology, cancer biomarkers,
and cancer prevention.
Among his contributions to molecular cancer
epidemiology is the first molecular link between an
environmental carcinogen, aflatoxin B1, and a specific
mutation at codon 249 of the TP53 gene in
hepatocellular carcinoma. This discovery was selected
by the AACR as a Centennial Landmark in Cancer
Research. He pioneered investigation of carcinogen
metabolism, DNA damage, and DNA repair among
humans and their tissues, and explored the quantitative
analysis of p53 mutations in human tissues and plasma
prior to cancer in tobacco smokers and in chronic
inflammation. His work on p53 function in the regulation
of DNA repair, apoptosis, and cellular senescence is
particularly important. These and other contributions
made by Dr. Harris’ studies substantially contributed to
the concepts of cancer risk assessment and geneenvironment interactions in cancer epidemiology and
were crucial in the development of molecular cancer
epidemiology as a mature discipline.
One particularly important aspect of Dr. Harris’ studies is
chronic inflammation. He showed that increased levels of
circulating interleukin 6, interleukin 8, C-reactive protein,
and MBL2 (all markers of inflammation) were associated
with risk, diagnosis, and prognosis of lung cancer
patients. He identified microRNAs associated with both
diagnosis and prognosis of lung cancer and the
diagnosis, prognosis, and therapeutic outcome of colon
cancer. In addition, he was first to discover that
544
expression of combinations of microRNAs and proteincoding genes (e.g., inflammation-related) produced by
human lung, colon, and esophageal carcinomas are
robust cancer prognostic classifiers. These studies
identified early-stage lung and colon cancers that have
poor prognoses due to the likelihood of undetected
micrometastasis. In parallel to these biomarker studies,
he and collaborators investigated inflammatory
mediators in cellular and animal model studies and in
clinical studies.
Dr. Harris’ exceptional record of research
accomplishment includes over 60,000 citations, and an
H-factor of over 115. He was awarded the AACR
Princess Takamatsu Award, the Ochsner Award relating
Smoking and Health from the American College of
Physicians, the Deichmann Award from the International
Union of Toxicology, and the Distinguished Service
Medal - the highest honor of the U.S. Public Health
Service. He has served in leadership posts in the
scientific community, such as: Chairman of the Program
Committee of the AACR Annual Meeting; member of the
AACR’s Board of Directors, Chairman of the Board of
Directors; and Chairman of the Scientific Program
Advisory Board for the Keystone Symposia of Molecular
and Cellular Biology. He is also the Editor-in Chief of the
journal Carcinogenesis. He has successfully mentored
more than 100 young scientists and received the NCI
Outstanding Mentor Award.
MAJOR SYMPOSIUM
Tuesday, 3:00 p.m.-5:00 p.m.
AACR-JCA Joint Symposium: Inflammation in Gastric Cancer
Co-Chairpersons: James G. Fox, Massachusetts Institute of Technology, Cambridge, MA, and
Masanori Hatakeyama, University of Tokyo, Tokyo, Japan
The AACR and the Japanese Cancer Association (JCA) are pleased to jointly present this
symposium focused on inflammation and gastric cancer. Gastric cancer continues to contribute
significantly to cancer mortality, being the fourth most common malignancy and the secondleading cause of cancer-related deaths, accounting for 10% of total cancer deaths worldwide.
Like other cancers, gastric cancer develops through a multistep process, the progression of which
is variably influenced by host genetic factors and environmental factors. Among those, the gastric
pathogen Helicobacter pylori is the strongest risk factor, playing a critical role in the development
of non-cardia gastric cancer, both intestinal and diffuse types. Recently, considerable attention
has been focused on the role of inflammation in promoting carcinogenesis and, indeed, there is
little doubt about the role of chronic inflammation as a driving force of gastric carcinogenesis. This
session will highlight new findings that provide molecular and functional links between
inflammation and gastric cancer, particularly focusing on H. pylori factors, host immune
responses, the intestinal microbiome, and genetic/epigenetic changes that underlie gastric
carcinogenesis.
3:00 p.m.
Role of Helicobacter pylori CagA in inflammation and carcinogenesis
Masanori Hatakeyama, University of Tokyo, Tokyo, Japan
3:25 p.m.
Discussion
3:30 p.m.
COX-2/PGE2 pathway-associated inflammation in gastric tumorigenesis
Masanobu Oshima, Kanazawa University Cancer Research Institute,
Kanazawa, Japan
3:55 p.m.
Discussion
4:00 p.m.
The gastric cancer connection: Helicobacter pylori, helminths, and the
intestinal microbiome
James G. Fox, Massachusetts Institute of Technology, Cambridge, MA
4:25 p.m.
Discussion
4:30 p.m.
Emerging insights from the TCGA study of gastric cancer
Adam J. Bass, Dana-Farber Cancer Institute, Boston, MA
4:55 p.m.
Discussion
545
CLINICAL TRIALS MINISYMPOSIUM
Tuesday, 3:00 p.m.-5:00 p.m.
Tumor-Specific Early Phase Clinical Trials
Co-Chairpersons: Gary K. Schwartz, Columbia University Irving Comprehensive Cancer Center,
New York, NY, and Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN
3:00 p.m.
Introduction
3:05 p.m.
CT337 Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with
carboplatin (C) in triple-negative breast cancer (TNBC) at low genetic
risk (NCT00647062)
Victoria L. Chiou, Elise C. Kohn, Christina M. Annunziata, Lori Minasian,
JoAnne Zujewski, Minshu Yu, Jay Ji, James Doroshow, Nicolas Gordon,
Nicole Houston, Jung-Min Lee
3:20 p.m.
CT338 Combination of a PI3K- and a PARP-inhibitor to treat high-grade serous
ovarian or triple-negative breast cancer
Gerburg M. Wulf, Ashish Juvekar, Costas A. Lyssiotis, Hai Hu, Sina
Yadegarynia, Hui Liu, Baek Kim, Eric Winter, Ralph Scully, John Asara,
Lewis C. Cantley, Ursula Matulonis
3:35 p.m.
CT339 Prospective molecular identification of ovarian cancer patients
benefiting from PARP inhibitor (PARPi, rucaparib) maintenance therapy:
Reaching beyond germline BRCA mutations
Elizabeth Swisher, Iain McNeish, Robert L. Coleman, James D. Brenton,
Scott H. Kaufmann, Andrew Allen, Mitch Raponi, Heidi Giordano, Lara
Maloney, Jeffrey Isaacson, Jonathan A. Ledermann
3:50 p.m.
CT340 Phase Ib/IIa study of the nanopharmaceutical CRLX101 with
bevacizumab (bev) in the treatment of patients (pts) with refractory
metastatic renal cell carcinoma (mRCC): Results from the planned
interim analysis
Stephen M. Keefe, Meliessa Hennessy, Orvar Gunnarsson, Ronac Mamtani,
David Vaughn, Jean Hoffman-Censits, Katherine Nathanson, Priti Lal, Priti Lal,
Daniel Pryma, Scott Eliasof, Edward Garmey, Roger B. Cohen, Naomi B. Haas
4:05 p.m.
CT341 AFM13, an antigen-specific immunotherapy for the treatment of CD30+
malignancies: Results of first-in-man study in relapsed/refractory (R/R)
Hodgkin lymphoma (HL)
Achim Rothe, Katrin S. Reiners, Max S. Topp, Anas Younes, Bastian von
Tresckow, Horst Dieter Hummel, Joerg Kessler, Miroslav Ravic,
Jens-Peter Marschner, Elke Pogge von Strandmann, Andreas Engert
4:20 p.m.
CT342 Phase I/II study of gefitinib in combination with vorinostat in patients
with advanced non-small cell lung cancer (NSCLC) who progressed on
prior chemotherapy
Ji-Youn Han, Soo Hyun Lee, Tak Yun, Young Jooo Lee, Kum Hui Hwang,
Sunah Ryu, Heung Tae Kim, Jin Soo Lee
4:35 p.m.
CT343 Phase II study of low-dose rate thoracic radiotherapy for treatment of
intrathoracic relapsed or progressive small cell lung cancer
Guy C. Jones, James B. Mitchell, Bruce E. Johnson, Kevin Camphausen,
Eli Glatstein, Charles B. Simone II
4:50 p.m.
Discussion
546
LATE-BREAKING MINISYMPOSIUM
Tuesday, 3:00 p.m.-5:00 p.m.
Novel Drug Targets, Compounds, and Signatures of
Response and Resistance
Chairperson: Steven Grant, VCU Massey Cancer Center, Richmond, VA
3:00 p.m.
Introduction
3:05 p.m.
LB-324 First isoform selective inhibitor of FGFR4 for the treatment of
genomically defined patients with hepatocellular carcinoma
Margit Hagel, Chandra Miduturu, Mike Sheets, Weifan Weng, Nooreen
Rubin, Neil Bifulco, Lucian DiPietro, Joseph Kim, Natasja Brooijmans,
Nicolas Stransky, Christopher Winter, Christoph Lengauer, Timothy Guzi
3:20 p.m.
LB-325 Global analysis of the phosphoproteome of human blasts reveals
predictive phosphorylation markers for the treatment of acute myeloid
leukemia with quizartinib
Christoph Schaab, Felix Oppermann, Martin Klammer, Heike Pfeifer,
Andreas Tebbe, Thomas Oellerich, Juergen Krauter, Mark Levis, Alexander
Perl, Henrik Daub, Bjoern Steffen, Klaus Godl, Hubert Serve
3:35 p.m.
LB-326 Structural basis of lipid-binding and regulation in PI3Kα
Michelle S. Miller, Oleg Schmidt-Kittler, David M. Bolduc, Evan T. Brower,
Daniele Chaves-Moreira, Marc Allaire, Kenneth W. Kinzler, Ian G. Jennings,
Philip E. Thompson, Philip A. Cole, L. Mario Amzel, Bert Vogelstein,
Sandra B. Gabelli
3:50 p.m.
LB-327 Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719
and provides evidence of convergent evolution under selective
therapeutic pressure
Pau Castel, Dejan Juric, Helen Won, Benjamin Ainscough, Haley Ellis, Saya
Ebbesen, Malachi Griffith, Obi Griffith, Iyer Gopakumar, Dennis Sgroi,
Steven Isakoff, Elaine Mardis, David Solit, Scott Lowe, Cornelia Quadt,
Malte Peters, Michael Berger, Maurizio Scaltriti, José Baselga
4:05 p.m.
LB-328 SHP-1, p53 and Y674/Y675-phosphorylated-trkA: A molecular pathway
and prognostic marker for neuroblastoma
Gehad Youssef, Cheryl Gillet, Dyanne Rampling, Mirza Chagtay, Alex
Virasami, Neil Sebire, John Anderson, Ximena Montano
4:20 p.m.
LB-329 Identification of alternative mechanisms of resistance to FGFR
inhibitor treatment in FGFR1-amplified large cell compared to FGFR1amplified small cell lung cancer models
Eleonora Jovcheva, Souichi Ogata, Kelly Van De Ven, Caroline Paulussen,
Inez Van de Weyer, Hans De Wolf, Hugo Ceulemans, Steve McClue, Jorge
Vialard, Timothy Perera
4:35 p.m.
LB-330 Four individually druggable Met hotspots mediate HGF-driven tumor
progression
Anna Hultberg, Cristina Basilico, Cristophe Blanchetot, Natalie De Jonge,
Valérie Hanssens, Gitte De Boeck, Alessia Mira, Manuela Cazzanti, Virginia
Morello, Torsten Dreier, Michael Saunders, Hans De Haard, Paolo Michieli
4:50 p.m.
Discussion
547
MAJOR SYMPOSIUM
Tuesday, 3:00 p.m.-5:00 p.m.
CIMT-AACR-CIMM Joint Session on Deciphering and Modulating
T Cell Specificity in Clinically Effective Antitumor Responses
Co-Chairpersons: Cedrik M. Britten, BioNTech AG, Mainz, Germany, and Sjoerd H. Van Der Burg,
Leiden University Medical Center, Leiden, The Netherlands
Currently there are a number of immunotherapeutic approaches delivering clinical success in the
treatment of cancer (Adoptive Cell Transfer = ACT, immune modulatory antibodies, vaccines,
immune-receptor-engineered lymphocytes), which in fact all are based on naturally occurring or
“synthetic/engineered” T cell responses. Good evidence accumulates that tumor-specific T cell
responses (mutations, newly expressed antigens, viral antigens) or synthetically engineered T cell
responses (CARs or affinity matured TCs) rather than naturally occurring T cell responses to
typically shared tumor-associated antigens may be more potent. This session focuses on
modulation and deciphering tumor-specific T cells in clinically active therapies. This session is
being jointly sponsored by the AACR Cancer Immunology (CIMM) Working Group and the
Association for Cancer Immunotherapy (CIMT).
3:10 p.m.
Cell therapy targeting unique cancer mutations
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD
3:25 p.m.
Discussion
3:30 p.m.
Linking cancer exome to immune therapy
Pia Kvistborg, University of Copenhagen, Copenhagen, Denmark
3:45 p.m.
Discussion
3:50 p.m.
mRNA-based personalized cancer immunotherapy
Ugur Sahin, BioNTech AG, Mainz, Germany
4:05 p.m.
Discussion
4:10 p.m.
Chemo-immunotherapy to modulate myeloid cells and boost vaccine efficacy
Sjoerd H. Van Der Burg, Leiden University Medical Center, Leiden, The Netherlands
4:25 p.m.
Discussion
4:30 p.m.
Fine-tuned T cell receptors for cancer immunotherapy
Bent Jakobsen, Immunocore, Abingdon, United Kingdom
4:45 p.m.
Discussion
4:50 p.m.
Panel Discussion
548
MINISYMPOSIA
Tuesday, 3:00 p.m.-5:00 p.m.
Chemistry 9
Endocrinology 3
Small Molecule Design and Optimization
Preclinical and Molecular Advances in
Hormone-responsive Cancers
Chairpersons: Timothy M. Ramsey and Kevin Koch
Chairpersons: Karen E. Knudsen and Peter S. Nelson
3:00
Introduction
3:05
4744
Structure-based development of covalent inhibitors of
the activating and T790M gatekeeper mutant forms of the
epidermal growth factor receptor (EGFR) leading to the
discovery of AZD9291. Richard A. Ward, Susan Ashton, Mark
Anderton, Pete G. Ballard, Rob H. Bradbury, Sam Butterworth,
Nicola Colclough, Darren A. Cross, M Ray V. Finlay, Heather L.
McFarland, Martine Mellor, Mike J. Waring.
3:20
3:35
3:50
4745
Discovery of potent and selective Ros1 inhibitors with
a unique DFG-out binding mode. Laurence Mevellec, Berthold
Wroblowski, Ron Gilissen, Sophie Descamps, Elisabeth Pasquier,
Christophe Adelinet, Marine Bourgeois, Guillaume Mercey,
Matthieu Jeanty, Thierry Jousseaume, Aurélie Luguern, Javier
Astray Gandara, Said Akzinnay, Etienne Daras, Inge Boeckx, Nele
Van Slycken, Mariette Bekkers, Jeroen Van De Ven, Tinne
Verhulst, Lieven Meerpoel, Jorge Vialard.
4746
Selective inhibition of mutant IDH1 via small molecule
binding to the dimer interface. Gejing Deng, Stuart Licht,
Junqing Shen, Ming Yin, Jessica McManus, Patricia Gee, Tim He,
Giang Gao, Bailin Zhang, Magali Mathieu, Alexey Rak, Olivier
Bedel, Chaomei Shi, Stefan Gross, Dietmar Hoffmann, Eamonn
Rooney, Aurelie Vassort, Walter Englaro, Yi Li, Dmitri
Wiederschain, Vinod Patel, Francisco Adrian, Hong Cheng.
4747
Design and synthesis of a series highly potent and
bioavailable FASN KR domain inhibitors for cancer. Tianbao
Lu, Richard Alexander, Gilles Bignan, James Bischoff, Peter
Connolly, Max Cummings, Sabine De Breucker, Norbert Esser,
Erwin Fraiponts, Ron Gilissen, Bruce Grasberger, Boudewijn
Janssens, Donald Ludovici, Lieven Meerpoel, Christophe Meyer,
Michael Parker, Danielle Peeters, Carsten Schubert, Karine Smans,
Luc Van Nuffel, Peter Vermeulen.
4:05
4748
Discovery of JNJ-42756493, a potent fibroblast
growth factor receptor (FGFR) inhibitor using a fragment
based approach. Patrick R. Angibaud, Laurence Mevellec, Gordon
Saxty, Christophe Adelinet, Rhalid Akkari, Valerio Berdini, Pascal
Bonnet, Marine Bourgeois, Xavier Bourdrez, Anne Cleasby, Helene
Colombel, Imre Csoka, Werner Embrechts, Eddy Freyne, Ronaldus
Gilissen, Eleonora Jovcheva, Peter King, Jean Lacrampe, Delphine
Lardeau, Yannick Ligny, Steve Mcclue, Lieven Meerpoel, David R.
Newell, Martin Page, Alexandra Papanikos, Elisabeth Pasquier,
Isabelle Pilatte, Virginie Poncelet, Olivier Querolle, David C. Rees,
Sharna Rich, Bruno Roux, Elodie Sement, Yvan Simonnet, Matthew
Squires, Virginie Tronel, Tinne Verhulst, Jorge Vialard, Marc
Willems, Steven J. Woodhead, Berthold Wroblowski, Christopher
W. Murray, Timothy Perera.
4:20
4749
New benzazepine BET-inhibitors with improved oral
bioavailability. Norbert Schmees, Bernard Haendler, Pascale
Lejeune, Antje Stresemann, Roland Neuhaus, Stephan Siegel,
Amaury Ernesto Fernandez-Montalvan, Hilmar Weinmann, Volker
Gekeler.
4:35
4750
Development of potent NADPH oxidase inhibitors with
significant activity against colon cancer. Jiamo Lu, Prabhakar
Risbood, Charles T. Kane, Md Tafazzal Hossain, Yongzhong Wu,
Smitha Antony, Jennifer L. Meitzler, Agnes Juhasz, Han Liu,
Guojian Jiang, Krishnendu Roy, James H. Doroshow.
4:50
Discussion
3:00
Introduction
3:05
4751
25-hydroxyvitamin D3 induces vitamin D signaling
independent of CYP27B1 in non-small cell lung cancer cells.
Alissa R. Verone, Suzanne Shoemaker, Robert Parise, Jan H.
Beumer, Pamela A. Hershberger.
3:20
4752
Targeting senescence-induced pro-survival pathways
in PRⴙ ovarian cancer cells. Caroline H. Diep, Carol A. Lange.
3:35
4754
Androgen receptor acquires an oncogenic role in the
AI resistance mechanism in breast cancer. Rika Fujii, Toru
Hanamura, Toshifumi Niwa, Yuri Yamaguchi, Takanori Ishida,
Hironobu Sasano, Noriaki Ohuchi, Shin-ichi Hayashi.
3:50
4755
Estrogen receptor mediates novel mechanisms of
estrogen-induced growth and tamoxifen resistance in invasive
lobular carcinoma. Matthew J. Sikora, Amir Bahreini, Steffi
Oesterreich.
4:05
4756
In vivo efficacy of combined targeting of CDK4/6, ER
and PI3K signaling in ERⴙ breast cancer. Neil A. O’Brien,
Emmanuelle Di Tomaso, Raul Ayala, Luo Tong, Shawnt
Issakhanian, Ronald Linnartz, Richard S. Finn, Samit Hirawat,
Dennis J. Slamon.
4:20
4757
A novel class of selective estrogen receptors
degraders regresses tumors in pre-clinical models of
endocrine-resistant breast cancer. James D. Joseph, Beatrice
Darimont, Steven Govek, Dan Brigham, Jing Qian, John
Sensintaffar, Gang Shao, Anna Aparicio, Mehmet Kahraman,
Andiliy Lai, Kyoung-Jin Lee, Nhin Lu, Johnny Nagasawa, Michael
Moon, Peter Rix, Nick Smith, Jeff Hager.
4:35
Discussion
549
MINISYMPOSIA
Tuesday, 3:00 p.m.-5:00 p.m.
Mechanisms of Cellular Response to
Anticancer Drugs in Solid and
Hematologic Malignancies
Novel Biologics as Targeted Cancer
Therapy
Chairpersons: Fernando Vidal-Vanaclocha and Edward
A. Sausville
3:00
Introduction
3:05
4758
Disruption of CRAF-mediated MEK activation is
required for effective MEK inhibition in KRAS mutant tumors.
Piro Lito, Anna Saborowski, Jingyin Yue, Martha Solomon, Eric
Joseph, Christof Fellman, Kazuhiro Ohara, Kenji Morikami, Takaaki
Miura, Christine Lucas, Nobuya Ishii, Scott Lowe, Neal Rosen.
3:20
4759
Integral role of the PI3K-AKT-mTOR pathway in DDRmediated antitumor actions of PARP inhibitor in triplenegative breast carcinogenesis. Brian Leyland-Jones, Jennifer
Carlson, Yuliang Sun, Lori Friedman, Pradip De, Nandini Dey.
3:35
4760
ER-␤/Sp/NF␬B/FLIP axis: Potential therapeutic target
in prostate cancer. Huiyoung Yun, Jianping Xie, Izhar S. Batth,
Rong Li, Rita Ghosh, Addanki P. Kumar.
3:50
4761
Defining the adaptive kinome response to BRAF and
MEK inhibition in melanoma. Steven P. Angus, Timothy J.
Stuhlmiller, Rachel Reuther, Trang T. Pham, Deborah A. Granger,
David B. Darr, Jamie L. Jordan, Stergios J. Moschos, Gary L.
Johnson, Norman E. Sharpless.
4:05
4762
Deficient double strand breaks repair of bone marrow
plasma cells correlates with better clinical outcome of
multiple myeloma patients. Maria Gkotzamanidou, Masood
Shammas, Evangelos Terpos, Sathees C. Raghavan, Kenneth C.
Anderson, Nikhil C. Munshi, Meletios - Athanasios Dimopoulos,
Vassilis L. Souliotis.
4:20
4763
The tyrosine kinase inhibitor axitinib targets T315I
gatekeeper-mutant Philadelphia chromosome-positive
leukemias in vitro and in vivo. Tea Pemovska, Mika Kontro,
Gretchen A. Repasky, Kimmo Porkka, Krister Wennerberg.
4:35
4764
Transfer of regulatory protein networks via
extracellular vesicles as a candidate mechanism of apoptosisresistance in acute myeloid leukemia. Anna Wojtuszkiewicz,
Jacqueline Cloos, Floortje L. Kessler, Sander Piersma, Jako Knol,
Gerrit Jansen, Yehuda G. Assaraf, Gertjan L. Kaspers, Sonja
Zweegman, Gerrit J. Schuurhuis, Connie R. Jimenez.
4:50
Discussion
550
Chairpersons: Jonathan M. Yingling and Avi Ashkenazi
3:00
Introduction
3:05
4765
Drug synergies observed for antibody and toxin
components of SAR3419 ADC contribute to overall conjugate
efficacy and can be combination drug or tumor cell line
dependent. Richard J. Rickles, Thomas P. Giordano, Shakira F.
Cotard, Jill M. Grenier, Angela Romanelli, Ti Cai.
3:20
4766
Pharmacodynamic and stratification biomarker for the
anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC.
Christoph A. Schatz, Charlotte Kopitz, Sabine Wittemer-Rump,
Anette Sommer, Lars Lindbom, Motonobu Osada, Hiroshi
Yamanouchi, Hung Huynh, Thomas Krahn, Khusru Asadullah.
3:50
4768
Novel peptidic CXCR4 antagonist LY2510924 disrupts
the SDF-1␣/CXCR4 axis resulting in anti-AML efficacy in vivo.
Byung Sik Cho, Zhihong Zeng, Hong Mu, Teresa McQueen, Marina
Protopopova, Jorge Cortes, Joe Marszalek, Sheng-Bin Peng,
Donald E. Thornton, Michael Andreeff, Marina Konopleva.
4:05
4769
Ex-vivo and in-vitro combination strategies with
ibrutinib in chronic lymphocytic leukemia. Fabiola CervantesGomez, Kumudha Balakrishnan, William G. Wierda, Michael J.
Keating, Varsha Gandhi.
4:20
4770
Anti-ROR1 monoclonal antibodies induce apoptosis in
pancreatic cancer cells via the PI3-kinase/AKT/mTOR
pathway. Amir Hossein Daneshmanesh, Mohammad HojjatFarsangi, Ali Moshfegh, Eva Mikaelsson, Abdul Salam Khan,
Anders Österborg, Håkan Mellstedt.
4:35
4771
Identification of inhibitors of TWIST1 as a treatment
for lung cancer. Sarah N. Chatley, Jessica Cades, Neil Neumann,
Lucia Mazzacurati, Zachary Yochum, Katriana Nugent, Yoon-Jae
Cho, Andrew Ewald, Charles Rudin, Phuoc Tran, Timothy F. Burns.
4:50
Discussion
MINISYMPOSIA
Tuesday, 3:00 p.m.-5:00 p.m.
EGFR Family, PI3K, AKT, and NF-␬B
Signaling
Chairpersons: Antonio Di Cristofano and Hossein
Borghaei
3:00
Introduction
3:05
4772
Novel transforming ErbB2 mutations in leukemia.
Jamie Keck, Brian Druker.
3:20
4773
Inhibition of mutant EGFR in lung cancer cells
triggers SOX2-FOXO6 dependent survival pathways. Stephen
M. Rothenberg, Kyle Concannon, Sarah Cullen, Alexa B. Turke,
Anthony C. Faber, Jeffrey A. Engelman, Shyamala Maheswaran,
Daniel A. Haber.
3:35
4774
The antitumor effects of PI3K beta inhibitors in PTEN
negative prostate cancer are enhanced by inhibition of
reactivated PI3K alpha signaling. Sarit Schwartz, Brett S.
Carver, John Wongvipat, Vanessa Rodrik-Outmezguine, Elisa De
Stanchina, Cath Trigwell, Simon Barry, Jose Baselga, Sarat
Chandarlapaty, Howard I. Scher, Charles L. Sawyers, Neal Rosen.
3:50
4775
PI3K-p110␤ is required for leukemic transformation
and HSC depletion in the absence of Pten. Haluk Yuzugullu,
Lukas Baitsch, Allison Steiner, Linda K. Clayton, Kira Gritsman,
Jean J. Zhao.
4:05
4776
PDK1-dependent activation of AGC kinases is an
absolute requirement for AKT oncogenic activity. Arturo
Orlacchio, Valeria Antico Arciuch, Antonio Di Cristofano.
4:20
4777
A phosphoproteomics analysis reveals Akt isoformspecific signals that link RNA splicing to non-small cell lung
cancer. Ioannis Sanidas, Christos Polytarchou, Maria
Hatziapostolou, Scott A. Ezell, Filippos Kottakis, Lan Hu, Ailan Guo,
Jianxin Xie, Michael J. Comb, Dimitrios Iliopoulos, Philip N.
Tsichlis.
4:35
4:50
LB-323
Control of DNA repair and genome stability by the
colon microbiome: The EPEC bacterially encoded NLEE
virulence effector protein methylates and inactivates the
human ZRANB3 DNA repair helicase. Jayashree Karar,
Hongzhuang Peng, Li Zhang, Qing Yao, Ilan Rosenshine,
Feng Shao, Frank J. Rauscher III.
Epigenetics 4
Chairpersons: Cigall Kadoch and Alex Kentsis
3:00
Introduction
3:05
4779
DNMT3B (a de novo DNA methyltransferase)
epigenetically regulates gene expression, independent of its
DNA methyltransferase activity. Khadijah A. Mitchell, Hariharan
Easwaran, Stephen B. Baylin.
3:20
4780
The effects of the global loss of DNA methylation on
the functional organization of the epigenome. Fides D. Lay,
Yaping Liu, Theresa K. Kelly, Heather Witt, Adam Blattler, Peggy J.
Farnham, Ben P. Berman, Peter A. Jones.
3:35
4781
Integrated epigenomic profiling reveals widespread
demethylation in melanoma and reveals CSF-1 receptor as an
aberrant regulator of malignant growth and invasion. Yongkai
Mo, Orsolya Giricz, Caroline H. Hu, Kimberly B. Dahlman, Sanchari
Bhattacharyya, Hoa Nguyen, Bernice Matusow, Tushar Bhagat,
Rafe Shellooe, Elizabeth Burton, James Tsai, Chao Zhang, Gaston
Habets, Yu Shyr, John Greally, Yiting Yu, Gideon E. Bollag, Richard
Stanley, Jeffrey Trent, Paraic A. Kenny, Brian L. West, Jeffrey
Sosman, Amit K. Verma.
3:50
4782
Epigenetic resistance to Notch inhibition in T cell
acute lymphoblastic leukemia. Birgit Knoechel, Justine Roderick,
Kaylyn Williamson, Jiang Zhu, Jens Lohr, Matthew Cotton, Shawn
Gillespie, Daniel Fernandez, Manching Ku, Hongfang Wang,
Federica Piccioni, Serena Silver, Mohit Jain, Daniel Pearson,
Michael Kluk, Christopher Ott, Dale Greiner, Michael Brehm,
Leonard Shultz, Alejandro Gutierrez, Kimberly Stegmaier, Marian
Harris, Lewis Silverman, Stephen Sallan, Andrew Kung, David
Root, James Bradner, Jon Aster, Michelle Kelliher, Bradley
Bernstein.
4:05
4783
Amplification of distant estrogen response elements
epigenetically deregulates target genes in ER␣-mediated
breast tumorigenesis. PEI-YIN HSU, HANG-KAI HSU, Victor X. Jin,
Zelton D. Sharp, Tim H.-M. Huang.
4:20
4784
Selective bioluminogenic HDAC activity assays for
profiling HDAC inhibitors. Kevin R. Kupcho, Nathan J. Evans,
Andrew L. Niles, Thomas A. Kirkland, Dan F. Lazar.
4:35
Discussion
Discussion
551
MINISYMPOSIA
Tuesday, 3:00 p.m.-5:00 p.m.
Tumor Biology 42
Noncoding RNAs as Drivers of Malignant
Transformation
Elucidation and Niche Targeting of
Cancer Stem Cell Epigenetic and
Metabolic Alterations
Chairpersons: Muller Fabbri and George A. Calin
3:00
Introduction
3:05
4785
miR-125b targets erythropoietin and its receptor and
their expression correlates with metastatic potential and
ERBB2/HER2 expression. Manuela Ferracin, Cristian Bassi,
Massimo Pedriali, Sara Pagotto, Lucilla D’Abundo, Barbara Zagatti,
Stefano Volpato, Patrizia Querzoli, Massimo Negrini.
3:20
3:35
4786
Circulating miR-21, miR-146a and miR-210 levels in
plasma are associated with clinical outcome in breast cancer.
Ioanna S. Sourvinou, Athina Markou, Nikolaos Malamos, Vasilis
Georgoulias, ⌭vi S. Lianidou.
4787
Targeting miR-21 in hepatocellular carcinoma. Sonya
Zabludoff, Timothy Wagenaar, Francisco Adrian, Charles Allerson,
Heike Arlt, Raffaele Baffa, Bal Bhat, Hui Cao, Scott Davis, Carlos
Garcia-Echeverria, Kathrin Heermeier, Shih-Min Huang, Lan Jiang,
Eric Marcusson, Christiane Metz-Weidmann, Adam Pavlicek, Jack
Pollard, Jennifer Rocnik, Sabine Scheidler, Chaomei Shi, Fangxian
Sun, Tatiana Tolstykh, Qunyan Yu, Gang Zheng, Dmitri
Wiederschain.
Chairpersons: Catriona H. M. Jamieson and John E.
Dick
3:00
Introduction
3:05
4792
Elucidating stem cell-specific metabolic pathways in
normal and malignant hematopoiesis to target human acute
myeloid leukemia stem cells. Stephanie Z. Xie, Elisa Laurenti,
John E. Dick.
3:20
4793
The M2 isoform of pyruvate kinase (PKM2)
contributes to leukemia stem cell persistence by maintaining
oxidative homeostasis and promoting glycolysis. Eric M.
Sturgill, Monica L. Guzman.
3:35
4794
NANOG represses mitochondrial energy production
and promotes fatty acid synthesis to promote self-renewal in
tumor-initiating cells. Chia-Lin Chen, Vasu Punj, Linda Sher,
Lydia Petrovic, Keigo Machida.
3:50
4795
CCK2R marks gastric antral stem cell and mediates
antral carcinogenesis. Hayakawa Yoku, Guanchun Jin, Hongshan
Wang, Xiaowei Chen, Christoph B. Westphalen, Samuel Asfaha,
Daniel L. Worthley, Bernhard Renz, Hiroshi Ariyama, Zinaida A.
Dubeykovskaya, Yoshihiro Takemoto, Ashlesha Mulay, Yagnesh
Tailor, Duan Chen, Sureshkumar Muthupalani, James G. Fox,
Shigeo Takaishi, Timothy C. Wang.
3:50
4788
MiR-509 inhibits human leukemia cell growth. Yee
Sun Tan, Wen-Chih Cheng, Curt I. Civin.
4:05
4789
In vitro and vivo activity against multiple myeloma
cells of a novel locked nucleic acid (LNA)-miR-221 inhibitor.
Maria T. Di Martino, Maria E. Gallo Cantafio, Annamaria Gullà,
Emanuela Altomare, Eugenio Morelli, Nicola Amodio, Emanuela
Leone, Cirino Botta, Niels M. Frandsen, Pierosandro Tagliaferri,
Pierfrancesco Tassone.
4:05
4790
Overexpression of miR-3151 leads to direct
deregulation of the TP53 pathway and is associated with
BRAF mutations in malignant melanoma. Malori Lankenau, Ravi
Patel, Joseph Markowitz, William E. Carson, Albert de la Chapelle,
Ann-Kathrin Eisfeld.
4796
Cancer stem cell vaccine inhibits metastases of
primary tumors and induces humoral immune responses
against cancer stem cells. Lin Lu, Huimin Tao, Yang Xia, John
Owen, Jeffrey S. Moyer, Mark E. Prince, Alfred E. Chang, Max S.
Wicha, Qiao Li.
4:20
4791
The role of microRNA-15a/16 in early B1 cell
development in a mouse model of chronic lymphocytic
leukemia. Chingiz Underbayev, Siddha Kasar, Heba Degheidy,
Gerald Marti, Marilyn Lightfoote, Elizabeth Raveche.
4797
VS-6063 (defactinib) targets cancer stem cells
directly and through inhibition of tumor-associated
macrophages and cytokine production. Jonathan A. Pachter,
Jennifer E. Ring, Vihren N. Kolev, Irina M. Shapiro, Christian M.
Vidal, Mahesh V. Padval, Qunli Xu.
4:35
4798
The niche specific role of CD44 splice isoform
expression in blast crisis leukemia stem cell generation. Frida
L. Holm, Eva Hellqvist, Cayla Mason, Christian Barrett, Kelly A.
Frazer, Anil Sadarangani, Catriona H. Jamieson.
4:50
Discussion
4:20
4:35
4:50
552
Discussion
MINISYMPOSIA
Tuesday, 3:00 p.m.-5:00 p.m.
Tumor Biology 43
Tumor Biology 44
Stromal Importance in Modulating
Tumor Progression
Tumor Angiogenesis
Chairpersons: Sendurai A. Mani and Michael M.
Ittmann
3:00
Introduction
3:05
4799
Identification and characterization of stromal factors
with clinical significance in the ovarian tumor
microenvironment. Tsz-Lun Yeung, Cecilia S. Leung, KwongKwok Wong, Samuel C. Mok.
3:20
4800
Heterogeneity of cancer associated fibroblasts in
non-small cell lung cancer is defined by the level of collagen
gel contraction activity. Roya Navab.
3:35
4801
Stromal-mediated collagen I signal in promoting
bladder cancer progression. Antonina V. Kurtova, Jing Xiao,
Erica J. Lay, Qianxing Mo, Seth P. Lerner, David R. Rowley, Keith
S. Chan.
3:50
4802
Human breast carcinoma-associated mesenchymal
stem cells from primary breast cancer metastasis promote
proliferation, invasion and mammosphere formation in breast
cancer. Maria E. Gonzalez, Kathy A. Toy, Celina G. Kleer.
4:05
4803
Cancer-associated fibroblast promotes gastric cancer
invasion and epithelial-mesenchymal transition via the IL-6/
JAK/STAT3 signaling pathway. Liping Su, Xiongyan Wu, Quan
Zhou, Chenchen Wang, Bingya Liu.
4:20
4804
Metastatic breast cancer cells induce an osteoblastTAF-like phenotype and communicate with osteoblasts via
gap junctions and exosomal crosstalk to facilitate breast
cancer cell quiescence in bone. Karen M. Bussard, Frank C.
Marini.
4:35
4805
Carcinogenesis by stem cell misplacement–a novel
cancer theory and its implications. Rui-An Wang.
4:50
Discussion
Chairpersons: James P. Quigley and Luisa Iruela-Arispe
3:00
Introduction
3:05
4806
Angiogenesis is independently influenced by
interstitial flow and concentration gradients of tumor secreted
morphogens. Venktesh S. Shirure, Steven C. George.
3:20
4807
Zoledronic acid overcomes the resistance to the antiangiogenic therapy and normalizes tumor vessels by
switching from a M2- to a M1-like macrophages phenotype in
a mouse model of spontaneous cervical cancer. Stefania
Capano, Federica Maione, Oriol Casanovas, Federico Bussolino,
Enrico Giraudo.
3:35
4808
Aflibercept is highly active in clinically relevant,
patient derived xenografts of colorectal cancer. Rebecca G.
Bagley, Zakia Amalou, Marielle Chiron, Vincent Vuaroqueaux, Anne
Caron, Nina Baltes, Heinz H. Fiebig.
3:50
4809
Enhanced activity of aflibercept compared to
bevacizumab in a patient-derived xenograft colorectal cancer
model is associated with reduced tumor vascularity in
humanized VEGF mice. Cristina L. Abrahams, Laura D. Winters,
Baosheng Li, Asma A. Parveen, Tatjana Kloss, Rebecca G. Bagley,
Donald A. Bergstrom, Gavin Thurston, Marielle Chiron.
4:05
4810
Identification of molecular markers of pathological
vascular subtypes with differential sensitivity to therapies
targeting the VEGF pathway. Beverly L. Falcon, Marguerita
O’Mahony, Julie Stewart, Jiangang Liu, Janice A. Nagy, Qi Xue,
Yong Pan, Cynthia Jeffries, Emma Hatten, Tim R. Holzer, Harold F.
Dvorak, Aejaz Nasir, Bronek Pytowski, Laura Benjamin, Mark T.
Uhlik.
4:20
4811
Soluble biomarkers identify mCRC patients subgroups
showing increased benefit from the VEGF signaling inhibitor
cediranib in combination with chemotherapy. Aurelien J.C.
Pommier, Stuart Spencer, Shethah Morgan, Chris Womack, Juliane
M. Jurgensmeier, Susan Critchlow, Simon T. Barry.
4:35
4812
A novel EGFL7-derived peptide, E7C13, is a potent
anti-tumor agent that inhibits angiogenesis in a beta 1
integrin- and thrombospondin-dependent manner. Choi-Fong
Cho, Laura A. Fung, Tienabe Nsiama, Lihai Yu, Alisha Kadam,
Daniela F. Quail, Katia Carmine-Simmen, Desmond Pink, LynneMarie Postovit, Leonard G. Luyt, John D. Lewis.
4:50
Discussion
553
REGULATORY SCIENCE
AND POLICY SESSION
Tuesday, 3:00 p.m.-5:00 p.m.
Room 6E, San Diego Convention Center
Successful Oncology Drug Development: Balancing Knowledge,
Speed, and Risk
Co-Chairpersons: Mace L. Rothenberg, Pfizer, Inc., New York, NY, and Tatiana Prowell, U.S. Food
and Drug Administration, Silver Spring, MD, and Johns Hopkins Kimmel Cancer Center,
Baltimore, MD
This session will discuss common errors in oncology drug development and present suggestions
on how to avoid them. Topics will include attention to dose selection, choice of diseases for study,
pursuit of a broad indication versus indication in a biomarker-defined subset, appropriate use of
interim analyses, endpoint selection, deciding when to pursue accelerated approval, premature
abandonment of products due to lack of efficacy or safety signals, and the pitfalls of decision
making based on another product’s development plan or timeline. Anonymized case studies of
development failures along with examples of overcoming mistakes in development will be
presented. Expert advice on how to avoid errors in development will be offered from the
perspective of regulatory, academic, industry, and cooperative group thought leaders. Panel
discussions will include:
• Operational issues such as best practices for timely protocol writing and implementation, which
is increasingly important with multi-site studies
• Identification of critical research questions in the setting of limited resources
• Biostatistical considerations in trial design, especially for biomarker-driven studies of targeted
therapies
• Parallel development plans for submission to both U.S. and international regulatory agencies
• Payor considerations for successful drug reimbursement strategies
Introduction and framework of the session and industry perspective
Mace L. Rothenberg, Pfizer, Inc., New York, NY
Pitfalls in oncology drug development: A consultant’s view
Gwendolyn A. Fyfe, Independent Consultant, San Francisco, CA
Pitfalls in oncology drug development: A regulator’s view
Tatiana Prowell, U.S. Food and Drug Administration, Silver Spring, MD, and
Johns Hopkins Kimmel Cancer Center, Baltimore, MD
Biostatistical considerations in drug development
Elizabeth S. Garrett-Mayer, Medical University of SC Hollings Cancer Center,
Charleston, SC
Translational researcher and biomarker-based drug development expert
Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, New York, NY
Cooperative group and collaborative clinical trials expert
Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY
Payor considerations for successful drug reimbursement strategies
Michael A. Kolodziej, Aetna Foundation, Hartford, CT
554
MEET AND GREET
Tuesday, 3:30 p.m.-4:30 p.m.
Meet the Director and Staff of the NCI-Center to Reduce
Cancer Health Disparities
Organized by the Minorities in Cancer Research (MICR) Council
The Center to Reduce Cancer Health Disparities (CRCHD) is central to NCI’s efforts to reduce the
unequal burden of cancer in our society and train the next generation of competitive researchers in
cancer and cancer health disparities research. All MICR members and Annual Meeting attendees
are invited to this informal meet and greet with the director and staff.
Director:
Sanya A. Springfield, NCI-CRCHD, Bethesda, MD
Deputy Director:
H. Nelson Aguila, NCI-CRCHD, Rockville, MD
Acting Chief, Diversity Training Branch:
Peter O. Ogunbiyi, NCI-CRCHD, Bethesda, MD
555
Tuesday, 3:30 p.m.-5:30 p.m.
Funding Opportunities for Cancer Research at Multiple NIH Institutes
and Centers with NIH Experts
Chairperson: Phuong Kim Pham, National Institutes of Health, Bethesda, MD
Did you know that your cancer research could be funded by many other NIH Institutes and
Centers in addition to the National Cancer Institute? Would you like to maximize your chance of
getting NIH funding from NIH experts? Then come to our workshop to explore all possibilities with
the insiders.
We will provide you with an overview of the NIH grant process and tips on how to work with the
system and staffs to increase your chances. A summary of cancer funding sources and contacts at
multiple NIH Institutes and Centers including Center for Scientific Review (CSR), National Cancer
Institute (NCI), National Institute of General Medical Sciences (NIGMS), National Institute of Allergy
and Infectious Diseases (NIAID), National Institute on Alcohol Abuse and Alcoholism (NIAAA),
National Institute of Environmental Health Sciences (NIEHS) as well as National Institute of Dental
and Craniofacial Research (NIDCR), and National Institute of Mental Health (NIMH) will be provided.
Slides for the NIAID and NIEHS presentation were provided by Drs. Helen Quill and Kimberly
McAllister, respectively.
Speakers:
Rajeev K. Agarwal, National Cancer Institute, Bethesda, MD
Philip J. Brooks, NIH-National Institute on Alcohol Abuse and Alcoholism, Rockville, MD
Pamela Anne Marino, NIH-National Institute of General Medical Sciences, Bethesda, MD
Phuong Kim Pham, National Institutes of Health, Bethesda, MD
Syed Musaddaq Quadri, Center for Scientific Review, Bethesda, MD
Sundar Venkatachalam, NIH-National Institute of Dental and Craniofacial Research, Bethesda, MD
556
AACR BURCHENAL AWARD LECTURE
Tuesday, 4:00 p.m.-5:00 p.m.
Nineteenth Annual AACR Joseph H. Burchenal Memorial Award for Outstanding
Achievement in Clinical Cancer Research
GvHD vs. GvL… and the Winner Is?
John F. DiPersio, MD, PhD
Chief, Division of Oncology
Deputy Director, Siteman Cancer Center
Washington University School of Medicine, St. Louis, MO
The Joseph H. Burchenal Memorial Award was
established in 1996 to recognize outstanding
achievements in the field of clinical cancer research. It is
named for the late Dr. Joseph H. Burchenal, honorary
member and past president of the American Association
for Cancer Research and pioneer in the development of
chemotherapeutics for the treatment of cancer.
Dr. John F. DiPersio is honored for his outstanding
clinical-translational research that has produced multiple
advances related to understanding and treating acute
myelogenous leukemia (AML). Dr. DiPersio is the Virginia
E. and Sam J. Golman, Professor of Medicine and Chief
of Oncology at Washington University School of
Medicine, and the Deputy Director of Siteman Cancer
Center.
Dr. DiPersio has approached treatment of AML from
several aspects. He has studied mechanisms of
resistance to chemotherapy in AML, focusing on the role
of the microenvironment. He has identified factors in the
microenvironment that contribute to chemoresistance
and worked on an approach to release leukemia cells
from that microenvironment by blocking the chemokine
receptor CXCR4. His studies have shown that
mobilization of AML cells using plerixafor (AMD3100)
increases senstivity to chemotherapy. A Phase I/II clinical
trial testing this hypothesis is ongoing, combining
plerixafor with mitoxantrone, etoposide, and cytarabine.
In a second important aspect of his research, Dr.
DiPersio has supported and been a Project Leader in the
Washington University “Genomics of AML” program,
which has accomplished so much in unlocking the
molecular origins of leukemia. A series of mutations have
been identified in sequencing studies of AML samples.
Dr. DiPersio has particularly focused on genomic and
transcriptional aberrations in chemotherapy and
allogeneic T cell resistant AML cells. It is hoped that
these studies will identify mutations or alterations in
gene expression that confer resistance alone or in
combination with other factors. Identification of specific
targets raises the hope of developing small molecules or
antibodies against those targets.
Finally, Dr. DiPersio studied in clinical trials a series of
small molecules for their activity in AML and the related
myelodysplastic syndrome. These molecules include,
among others, epigenetic agents, mTOR inhibitors, and
kinase inhibitors. He has also studied graft vs. host
disease, in an effort to mitigate that complication of
allogeneic stem-cell transplantation. These different
approaches to improving the therapy of AML represent a
body of work that has moved the field forward,
identifying new targets for treatment, and studies to
reduce toxicity of therapy.
Dr. DiPersio received his medical degree from The
University of Rochester, and completed his residency in
Internal Medicine at Parkland Memorial Hospital in
Dallas, TX, and then completed a fellowship in the
Division of Hematology/Oncology at the UCLA School of
Medicine. He has received multiple honors and awards,
and has served on numerous review panels, study
sections, and advisory boards. He was chosen to speak
in the NIH Great Teacher Series. Dr. DiPersio, a member
of the AACR, is also known as an excellent teacher and
mentor. He has trained numerous students and fellows,
and has consistently obtained NCI and other
organizational grant funding.
Together, these efforts at bringing new ideas and
discoveries to the clinic emulate the work of Dr.
Burchenal in persistently translating basic research to
the bedside.
557
AACR ROSENTHAL AWARD LECTURE
Tuesday, 4:00 p.m.-5:00 p.m.
Thirty-Eighth Annual AACR Richard and Hinda Rosenthal Memorial Award
Realizing the Potential of Cancer Immunotherapy
Jedd D. Wolchok, MD, PhD
Lloyd J. Old/Ludwig Chair in Clinical Investigation
Chief, Melanoma and Immunotherapeutics Service
Memorial Sloan-Kettering Cancer Center, New York, NY
The American Association for Cancer Research and the
Rosenthal Family Foundation originally established this
award in 1977 to recognize research that has made
notable contributions to improving clinically based
cancer care. In an effort to honor and provide incentive
to early investigators, the foundation has restricted
award recipients to the age of 50 years at the time the
award is presented.
Dr. Jedd D. Wolchok is honored for his contributions to
the development of progressively effective
immunotherapies for the treatment of melanoma.
After studying fundamental mechanisms of antitumor
immunity, autoimmunity, and self-tolerance with Alan
Houghton, Dr. Wolchok embarked on a career in the
experimental immunotherapy of cancer. He led clinical
trials of anticancer vaccine immunotherapy, using DNAencoding xenogenic proteins, like tyrosinase present in
most melanoma cells, to evade tumor antigen tolerance.
Based on his work, this strategy garnered approval by
the United States Department of Agriculture (USDA) for
the treatment of melanoma in dogs, representing the first
therapeutic cancer vaccine.
for cytotoxic chemotherapy drugs proved inadequate for
immunotherapy. The trial design and results were
described in what has become a landmark paper in the
New England Journal of Medicine.
He has continued his work to improve anticancer
immunotherapy, undertaking a trial of ipilumumab given
along with nivolumab, an immune checkpoint inhibitor
with a different target. Early trial results hint that this
combination may be even more effective that
ipilumumab alone, leading to a global phase 3 trial to be
directed by Dr. Wolchok.
Dr. Wolchok received a Bachelor’s degree from Princeton
in 1987, and earned a Master’s degree in 1991, a Doctor
of Philosophy degree in 1993, and a medical degree in
1994 from New York University. He completed Internal
Medicine residency training at NYU in 1996 and a
fellowship in Hematology/Oncology at the Memorial
Sloan-Kettering Cancer Center (MSKCC) in 2000.
Dr. Wolchok earned international recognition for his
critical role in the clinical development of ipilumumab, an
antibody that undermines immune “checkpoints” to
allow more robust activation of T cell responses to
growing cancers. He served as the Principal Investigator
for the pivotal phase 3 trial comparing ipilumumab and
dacarbazine versus dacarbazine alone for metastatic
melanoma that formed the basis for the approval of
ipilumumab (as Yervoy(r)) by the Food and Drug
Administration (FDA). Conduct of the trial necessitated
changes in the way subjects with metastatic melanoma
were monitored for treatment efficacy versus treatment
failure; the antitumor response criteria historically used
558
FORUMS
How to Achieve a Cancer
Knowledge Commons Database of
Cancer Genetics
Moderator: Thomas J. Hudson, Ontario Institute for
Cancer Research, Toronto, ON, Canada
The advent of next-generation sequencing technologies,
large-scale surveys of cancer genomes, and targeted
therapies are driving rapid changes in how cancer is
diagnosed and treated. As the implementation of clinical
sequencing is rolling out in clinical research and health
care organizations, many challenges are being identified
related to the management and interpretation of the
data. The research community believes that it would be
useful to prospectively archive all mutation data in
databases along with clinical information to accelerate
the expansion of knowledge regarding clinical and
functional significance of these new mutations. In this
session, speakers will discuss emerging solutions in
data analysis pipelines, data storage, and computer
technologies, integration of clinical and sequence
datasets and models for data sharing among research
and healthcare organizations to enable secure and
responsible sharing of genomic and clinical data.
Panel:
David Haussler, Howard Hughes Medical Institute,
Santa Cruz, CA
Gad Getz, Broad Institute of MIT and Harvard,
Cambridge, MA
Putting Molecular Science into
Clinical Trials
Moderator: James H. Doroshow, National Cancer
Institute-DCTD, Bethesda, MD
The focus of the session is on understanding the role of
identifying a range of molecular lesions, including
genetic mutations, amplifications, and translocations, as
well as other measures of cancer gene function, in
predicting the therapeutic efficacy of molecularly
targeted anticancer agents. It will provide specific
examples of several ongoing clinical studies that are
attempting to match patient treatment with specific
drugs based on molecular testing, including DNA
sequencing of tumors, as well as the role of the
Tuesday, 5:00 p.m.-6:30 p.m.
multidisciplinary teams needed for these efforts. The
session will also review the regulatory requirements for
developing new diagnostic platforms that play a central
role in support of clinical trials that use the techniques of
precision medicine to speed the evaluation of novel
targeted cancer therapeutics.
Panel:
Jeffrey M. Trent, Translational Genomics Research
Institute, Phoenix, AZ
Pamela L. Bradley, U.S. Food and Drug Administration,
Silver Spring, MD
Screening for Lung Cancer: Do We
Know the Way Forward?
Moderator: Robert Smith, American Cancer Society,
Atlanta, GA
In 2010, the National Lung Screening Trial (NLST)
demonstrated the efficacy of lung cancer screening with
low-dose computed tomography (LDCT) for individuals
at very high risk of the disease. Since then a growing
number of organizations have issued guidelines
supportive of lung cancer screening in adults that
approximate the participation requirements of the NLST.
Although the evidence is convincing, it needs to be
appreciated that organizations issuing new lung cancer
screening guidelines are doing so with limited
information from the NLST and incomplete data from
ongoing randomized controlled trials in Europe and
elsewhere. This early in the implementation phase of
lung cancer screening, there is uncertainty about cost
effectiveness, capacity, expertise, the prevalence of
expert, multispecialty groups in the U.S. to provide lung
cancer screening and follow up, and to do so with a high
level of quality. Finally, there is no broad consensus that
the NLST target population is the appropriate group to
invite to screening, with some arguing that it is too
constrained, and others too inclusive. The forum will
address these issues, and highlight what they share in
common with other cancer screening tests.
Panel:
Christine Dorothy Berg, George Mason University,
Bethesda, MD
Peter P. Bach, Memorial Sloan-Kettering Cancer Center,
New York, NY
559
FORUMS
Tuesday, 5:00 p.m.-6:30 p.m.
Room 29A-D, San Diego Convention Center
Stereotactic Body Radiotherapy: Dose
(Physics) or Biology?
Moderator: David R. Gius, Northwestern University,
Chicago, IL
Stereotactic body radiation therapy (SBRT) is a new
technique that allows for the delivery of very high (or
ablative) doses of radiation, usually in several large
fractions (hypofractionated) that is delivered using by
multiple coplanar and non-coplanar treat beams that are
aligned using a small CT scanner that is directly attached
to the linear accelerator, referred to as a cone beam CT
(CBCT). This irradiation technique allows for the delivery
of ablative doses of focused radiation that also allows of
the maximal sparing of normal tissues. However, this
precise method to treat lung, as well as other tumors,
involves very different treatment techniques and the
biology of ionizing radiation-induced tumor cell
cytotoxicity is different than conventional fractionated
irradiation. These issues will be discussed as well as the
potential to use SBRT to treat other tumors that should
allow for local control while decrease long-term
radiation-induced side effects.
Panel:
J. Martin Brown, Stanford University School of Medicine,
Palo Alto, CA
Richard N. Kolesnick, Memorial Sloan-Kettering Cancer
Center, New York, NY
560
SPECIAL SESSION
Tuesday, 5:00 p.m.-6:30 p.m.
RAS Pathway Social Interactome
Following upon the success of the inaugural RAS Interactome Session at the 2013 Annual
Meeting, Drs. Frank McCormick and Stephen Friend will be returning to host a session focused on
community building for RAS/RAF researchers. Through text mining of abstracts and a survey sent
to AACR attendees, the interactome application will provide a visual map of research within RAS
and highlight areas of interest within this community—enabling attendees of this session to
identify potential collaborators working in adjacent areas.
Annual Meeting attendees focused on RAS are welcome to attend this session to view a
demonstration of the interactome and to provide feedback.
561
CIMM TOWN MEETING
Tuesday, 6:00 p.m.-8:30 p.m.
Grand Ballroom A-C, Level 4, Omni San Diego Hotel
Cancer Immunology (CIMM) Town Meeting and
Networking Reception
This co-sponsored session is an opportunity for all interested to hear from our colleagues in the
AACR-Cancer Immunology (CIMM) Working Group and Society for Immunotherapy of Cancer
(SITC) speak on “Therapeutic Cancer Vaccines: Dinosaurs or Key Components?” Drs. Elizabeth
Jaffee, from Johns Hopkins University and CIMM Past Chairperson, will speak on “Vaccines: The
ignitors of antitumor immunity”; Francesco M. Marincola, Chief Research Officer, Sidra Medical
and Research Center and President of SITC, will speak on “Basic concept for the understanding
of cancer-mediated immune rejection”; and Howard L. Kaufman, from Rutgers Cancer Institute of
New Jersey and Vice-President of SITC, will speak on “The role of oncolytic viruses in tumor
immunotherapy.” Additionally, Dr. Glenn Dranoff, Editor-in-Chief of Cancer Immunology Research
will be providing an update on this journal. After this exciting program, a networking reception will
follow. Come learn about these and other important CIMM initiatives, meet members of the
working group and steering committee, in addition to taking advantage of the opportunity to join
the CIMM Working Group.
6:00 p.m.
Chairperson: Opening remarks
Robert H. Vonderheide, Abramson Cancer Center of the University of
Pennsylvania, Philadelphia, PA
6:15 p.m.
Chairperson-Elect: Remarks
Nina Bhardwaj, Mt. Sinai Medical Center, New York, NY
6:30 p.m.
Editor-in-Chief, Cancer Immunology Research
Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA
6:40 p.m.
Program’s opening remarks
6:45 p.m.
Introduction, SITC President
Francesco M. Marincola, Sidra Medical and Research Center, Doha, Qatar
6:50 p.m.
The role of oncolytic viruses in tumor immunotherapy
Howard L. Kaufman, Rutgers Cancer Institute of New Jersey,
New Brunswick, NJ
7:05 p.m.
Basic concept for the understanding of cancer-mediated immune rejection
Francesco M. Marincola, Sidra Medical and Research Center, Doha, Qatar
7:20 p.m.
Vaccines: The ignitors of antitumor immunity
Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, MD
7:35 p.m.
Closing remarks
562
NOTES
563
NOTES
564

Detailed Schedule - Tuesday, April 8

Transcription

Similar documents

Universal Health Care and Interdisciplinar y Research in Asia

TUMORI UTERINI MESENCHIMALI

donor report - American-Italian Cancer Foundation

TUMOR LAMBUNG

Prostate Biopsy - Facoltà di Medicina e Chirurgia

biobanking for cancer research: rules and roles

DeFlora - Tumori_professionali

Donor Report - American-Italian Cancer Foundation

Immunotherapy meets Lung Cancer: New treatments for

Nuovi farmaci per terapia in uso clinico: Ra-223